1. Li Y, Wang X, Shen XR, et al. A 1-year longitudinal study on COVID-19 convalescents reveals persistence of anti-SARS-CoV-2 humoral and cellular immunity. *Emerg Microbes Infect* 2022; **11**(1): 902-13.

2. Giesen N, Busch E, Schalk E, et al. AGIHO guideline on evidence-based management of COVID-19 in cancer patients: 2022 update on vaccination, pharmacological prophylaxis and therapy in light of the omicron variants. *Eur J Cancer* 2023; **181**: 102-18.

3. Moody R, Sonda S, Johnston FH, et al. Antibodies against Spike protein correlate with broad autoantigen recognition 8 months post SARS-CoV-2 exposure, and anti-calprotectin autoantibodies associated with better clinical outcomes. *Front Immunol* 2022; **13**: 945021.

4. Pozzi C, Sarti R, Levi R, et al. Association between duration of SARS-CoV-2 positivity and long COVID. *Clin Infect Dis* 2023.

5. Erickson MA, Logsdon AF, Rhea EM, et al. Blood-brain barrier penetration of non-replicating SARS-CoV-2 and S1 variants of concern induce neuroinflammation which is accentuated in a mouse model of Alzheimer's disease. *Brain Behav Immun* 2023; **109**: 251-68.

6. Sunada N, Nakano Y, Otsuka Y, et al. Characteristics of Sleep Disturbance in Patients with Long COVID: A Retrospective Observational Study in Japan. *J Clin Med* 2022; **11**(24).

7. Kang YR, Huh JY, Oh JY, et al. Clinical Characteristics of Post-COVID-19 Persistent Cough in the Omicron Era. *Allergy Asthma Immunol Res* 2023; **15**(3): 395-405.

8. Herting A, Jahnke-Triankowski J, Harberts A, et al. Clinical Outcomes of SARS-CoV-2 Breakthrough Infections in Liver Transplant Recipients during the Omicron Wave. *Viruses* 2023; **15**(2).

9. Russell L, Jeffreys M, Churchward M, et al. Cohort profile: Ngā Kawekawe o Mate Korona | Impacts of COVID-19 in Aotearoa - a prospective, national cohort study of people with COVID-19 in New Zealand. *BMJ Open* 2023; **13**(7): e071083.

11. Du M, Ma Y, Deng J, Liu M, Liu J. Comparison of Long COVID-19 Caused by Different SARS-CoV-2 Strains: A Systematic Review and Meta-Analysis. *Int J Environ Res Public Health* 2022; **19**(23).

12. Matveeva O, Shabalina SA. Comparison of vaccination and booster rates and their impact on excess mortality during the COVID-19 pandemic in European countries. *Front Immunol* 2023; **14**: 1151311.

13. Lippi G, Sanchis-Gomar F, Henry BM. COVID-19 and its long-term sequelae: what do we know in 2023? *Pol Arch Intern Med* 2023; **133**(4).

14. Zhu F, Ang JY. COVID-19 Infection in Children: Diagnosis and Management. *Curr Infect Dis Rep* 2022; **24**(4): 51-62.

16. Wise J. Covid-19: Long covid risk is lower with omicron than delta, researchers find. *Bmj* 2022; **377**: o1500.

17. Jeong YJ, Wi YM, Park H, Lee JE, Kim SH, Lee KS. Current and Emerging Knowledge in COVID-19. *Radiology* 2023; **306**(2): e222462.

18. Fu L, Gilham D, Stotz SC, et al. Dual mechanism: Epigenetic inhibitor apabetalone reduces SARS-CoV-2 Delta and Omicron variant spike binding and attenuates SARS-CoV-2 RNA induced inflammation. *Int Immunopharmacol* 2023; **117**: 109929.

19. Seghatchian J. Editorial: Time to explore the missing links: the cross-talk between COVID infection and cancer cells; lingering questions on the longitudinal efficacy of the front line immunotherapies against unpredictable "Omicron ghosts" and insights from CAR-T cell therapy pointing toward better clinical outcomes. *Transfus Apher Sci* 2022; **61**(4): 103490.

20. Goel RR, Painter MM, Lundgreen KA, et al. Efficient recall of Omicron-reactive B cell memory after a third dose of SARS-CoV-2 mRNA vaccine. *Cell* 2022; **185**(11): 1875-87.e8.

21. Ioannidis JPA, Zonta F, Levitt M. Estimates of COVID-19 deaths in Mainland China after abandoning zero COVID policy. *Eur J Clin Invest* 2023; **53**(4): e13956.

24. Su Y, Xing H, Shen W, Li M, Xu Y, Li Y. Fatal multisystem inflammatory syndrome in a 78-year-old adult after severe COVID-19 pneumonia during 2022 Omicron variant epidemic in Shanghai, China. *J Infect Public Health* 2023; **16**(3): 418-21.

25. Percze AR, Nagy A, Polivka L, et al. Fatigue, sleepiness and sleep quality are SARS-CoV-2 variant independent in patients with long COVID symptoms. *Inflammopharmacology* 2023: 1-7.

26. Bechor Ariel T, Ariel B, Ben-Acon M, Sharon N. Focal and generalized onset seizures in children post-COVID (Omicron) recovery: 3 clinical case reports. *Epilepsy Behav Rep* 2023; **23**: 100608.

27. van Dorp C, Goldberg E, Ke R, Hengartner N, Romero-Severson E. Global estimates of the fitness advantage of SARS-CoV-2 variant Omicron. *Virus Evol* 2022; **8**(2): veac089.

28. Fernández-de-Las-Peñas C, Cuadrado ML, Gómez-Mayordomo V, García-Azorín D, Arendt-Nielsen L. Headache as a COVID-19 onset symptom or Post-COVID symptom according to the SARS-CoV-2 Variant. *Expert Rev Neurother* 2023; **23**(2): 179-86.

29. Howe S, Szanyi J, Blakely T. The health impact of long COVID during the 2021-2022 Omicron wave in Australia: a quantitative burden of disease study. *Int J Epidemiol* 2023; **52**(3): 677-89.

30. Malkan UY, Haznedaroglu IC. Hematological aspects of the COVID-19 syndrome. *Eur Rev Med Pharmacol Sci* 2022; **26**(12): 4463-76.

31. Ham RE, Smothers AR, Che R, Sell KJ, Peng CA, Dean D. Identifying SARS-CoV-2 Variants of Concern through Saliva-Based RT-qPCR by Targeting Recurrent Mutation Sites. *Microbiol Spectr* 2022; **10**(3): e0079722.

32. Di Fusco M, Sun X, Moran MM, et al. Impact of COVID-19 and effects of booster vaccination with BNT162b2 on six-month long COVID symptoms, quality of life, work productivity and activity impairment during Omicron. *J Patient Rep Outcomes* 2023; **7**(1): 77.

33. Bauer L, Rissmann M, Benavides FFW, et al. In vitro and in vivo differences in neurovirulence between D614G, Delta And Omicron BA.1 SARS-CoV-2 variants. *Acta Neuropathol Commun* 2022; **10**(1): 124.

34. Shan D, Liu C, Li S, Zheng Y. Increased anxiety from fear of Omicron in China as compared to North America and Western Europe: A cross-sectional Kendall's tau-b analysis using the generalized anxiety disorder 7-item questionnaire. *Front Psychiatry* 2022; **13**: 977361.

35. Amir O, Goldberg Y, Mandel M, et al. Initial protection against SARS-CoV-2 omicron lineage infection in children and adolescents by BNT162b2 in Israel: an observational study. *Lancet Infect Dis* 2023; **23**(1): 67-73.

36. Teng L, Chang W. The Investigation of Kidney Involvement in 430 Hospitalized Patients with Omicron COVID-19 in Tianjin, China. *Blood Purif* 2023; **52**(5): 437-45.

37. Chen Q, Allot A, Leaman R, et al. LitCovid in 2022: an information resource for the COVID-19 literature. *Nucleic Acids Res* 2023; **51**(D1): D1512-d8.

38. Jarupan M, Jantarabenjakul W, Jaruampornpan P, et al. Long COVID and Hybrid Immunity among Children and Adolescents Post-Delta Variant Infection in Thailand. *Vaccines (Basel)* 2023; **11**(5).

40. Fernández-de-Las-Peñas C, Notarte KI, Peligro PJ, et al. Long-COVID Symptoms in Individuals Infected with Different SARS-CoV-2 Variants of Concern: A Systematic Review of the Literature. *Viruses* 2022; **14**(12).

42. Olschewski H, Eber E, Bucher B, et al. Management of patients with SARS-CoV-2 infections with focus on patients with chronic lung diseases (as of 10 January 2022) : Updated statement of the Austrian Society of Pneumology (ASP). *Wien Klin Wochenschr* 2022; **134**(9-10): 399-419.

43. Mesias VSD, Zhu H, Tang X, et al. Moderate Binding between Two SARS-CoV-2 Protein Segments and α-Synuclein Alters Its Toxic Oligomerization Propensity Differently. *J Phys Chem Lett* 2022; **13**(45): 10642-8.

45. Carmona-Rivera C, Zhang Y, Dobbs K, et al. Multicenter analysis of neutrophil extracellular trap dysregulation in adult and pediatric COVID-19. *JCI Insight* 2022; **7**(16).

46. Seehusen F, Clark JJ, Sharma P, et al. Neuroinvasion and Neurotropism by SARS-CoV-2 Variants in the K18-hACE2 Mouse. *Viruses* 2022; **14**(5).

47. Henri J, Minder L, Mohanasundaram K, et al. Neuropeptides, New Ligands of SARS-CoV-2 Nucleoprotein, a Potential Link between Replication, Inflammation and Neurotransmission. *Molecules* 2022; **27**(22).

48. Kubota T, Kuroda N, Sone D. Neuropsychiatric aspects of long COVID: A comprehensive review. *Psychiatry Clin Neurosci* 2023; **77**(2): 84-93.

49. Couzin-Frankel J. New Long Covid cases decline with Omicron. *Science* 2023; **379**(6638): 1174-5.

50. Ahn B, Choi SH, Yun KW. Non-neuropsychiatric Long COVID Symptoms in Children Visiting a Pediatric Infectious Disease Clinic After an Omicron Surge. *Pediatr Infect Dis J* 2023; **42**(5): e143-e5.

51. Yang C, Zhao H, Shannon CP, Tebbutt SJ. Omicron variants of SARS-CoV-2 and long COVID. *Front Immunol* 2022; **13**: 1061686.

52. Barie PS, Brindle ME, Khadaroo RG, Klassen TL, Huston JM. Omicron, Long-COVID, and the Safety of Elective Surgery for Adults and Children: Joint Guidance from the Therapeutics and Guidelines Committee of the Surgical Infection Society and the Surgery Strategic Clinical Network, Alberta Health Services. *Surg Infect (Larchmt)* 2023; **24**(1): 6-18.

53. Kanaan CN, Iskandar JP, Gad MM, et al. Outcomes Associated With COVID-19 Hospitalization in Heart Transplantation Patients. *Transplant Proc* 2022; **54**(10): 2688-91.

54. Teng L, Song X, Zhang M, et al. The pattern of cytokines expression and dynamic changes of renal function at 6 months in patients with Omicron COVID-19. *J Med Virol* 2023; **95**(2): e28477.

55. Jung YH, Ha EH, Choe KW, Lee S, Jo DH, Lee WJ. Persistent Symptoms After Acute COVID-19 Infection in Omicron Era. *J Korean Med Sci* 2022; **37**(27): e213.

56. Ballouz T, Menges D, Kaufmann M, et al. Post COVID-19 condition after Wildtype, Delta, and Omicron SARS-CoV-2 infection and prior vaccination: Pooled analysis of two population-based cohorts. *PLoS One* 2023; **18**(2): e0281429.

57. Morioka S, Tsuzuki S, Suzuki M, et al. Post COVID-19 condition of the Omicron variant of SARS-CoV-2. *J Infect Chemother* 2022; **28**(11): 1546-51.

59. Bhandari S, Rankawat G, Joshi S, Tiwaskar M, Lohmror A, Bhandari S. Post-COVID Syndrome: The Stranger Ghost of Culprit COVID-19. *J Assoc Physicians India* 2023; **71**(2): 11-2.

60. Iqbal P, Ata F, Chaudhry H, et al. Post-COVID-19-associated multiorgan complications or "long COVID" with literature review and management strategy discussion: A meta-analysis. *Health Sci Rep* 2023; **6**(4): e1211.

62. Chen H, Zhang L, Zhang Y, et al. Prevalence and clinical features of long COVID from omicron infection in children and adults. *J Infect* 2023; **86**(4): e97-e9.

65. Ratcliffe NA, Castro HC, Gonzalez MS, Mello CB, Dyson P. Reaching the Final Endgame for Constant Waves of COVID-19. *Viruses* 2022; **14**(12).

66. Zhang HP, Sun YL, Wang YF, et al. Recent developments in the immunopathology of COVID-19. *Allergy* 2023; **78**(2): 369-88.

67. Chiang CY, Lin YJ, Weng WT, et al. Recuperative herbal formula Jing Si maintains vasculature permeability balance, regulates inflammation and assuages concomitants of "Long-Covid". *Biomed Pharmacother* 2023; **163**: 114752.

69. Mazzitelli M, Trunfio M, Sasset L, et al. Risk of hospitalization and sequelae in patients with COVID-19 treated with 3-day early remdesivir vs. controls in the vaccine and Omicron era: A real-life cohort study. *J Med Virol* 2023; **95**(3): e28660.

70. Antonelli M, Pujol JC, Spector TD, Ourselin S, Steves CJ. Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2. *Lancet* 2022; **399**(10343): 2263-4.

72. Nathanielsz J, Toh ZQ, Do LAH, Mulholland K, Licciardi PV. SARS-CoV-2 infection in children and implications for vaccination. *Pediatr Res* 2023; **93**(5): 1177-87.

73. AlBahrani S, AlBarrak A, AlGubaisi N, et al. Self-reported long COVID-19 symptoms are rare among vaccinated healthcare workers. *J Infect Public Health* 2023; **16**(8): 1276-80.

74. Gottlieb M, Wang RC, Yu H, et al. Severe Fatigue and Persistent Symptoms at 3 Months Following Severe Acute Respiratory Syndrome Coronavirus 2 Infections During the Pre-Delta, Delta, and Omicron Time Periods: A Multicenter Prospective Cohort Study. *Clin Infect Dis* 2023; **76**(11): 1930-41.

75. Muleme M, McNamara BJ, Ampt FH, et al. Severity of COVID-19 among Residents in Aged Care Facilities in Victoria, Australia: A Retrospective Cohort Study Comparing the Delta and Omicron Epidemic Periods. *J Am Med Dir Assoc* 2023; **24**(4): 434-40.e5.

76. Wacharapluesadee S, Hirunpatrawong P, Petcharat S, et al. Simultaneous detection of omicron and other SARS-CoV-2 variants by multiplex PCR MassARRAY technology. *Sci Rep* 2023; **13**(1): 2089.

77. Taquet M, Dercon Q, Harrison PJ. Six-month sequelae of post-vaccination SARS-CoV-2 infection: A retrospective cohort study of 10,024 breakthrough infections. *Brain Behav Immun* 2022; **103**: 154-62.

78. Seghatchian J, Pereira P, Lanza F. Spotlights on the latest opinions on identification, prevention, and management of newer CoV-2 variants: A roundup appraisal on innovative ideas and designer vaccines for Omicron. *Transfus Apher Sci* 2022; **61**(6): 103499.

79. Servier C, Porcher R, Pane I, Ravaud P, Tran VT. Trajectories of the evolution of post-COVID-19 condition, up to two years after symptoms onset. *Int J Infect Dis* 2023; **133**: 67-74.

80. Nakano Y, Otsuka Y, Honda H, et al. Transitional Changes in Fatigue-Related Symptoms Due to Long COVID: A Single-Center Retrospective Observational Study in Japan. *Medicina (Kaunas)* 2022; **58**(10).

81. Sakurada Y, Otsuka Y, Tokumasu K, et al. Trends in Long COVID Symptoms in Japanese Teenage Patients. *Medicina (Kaunas)* 2023; **59**(2).

82. Zhao J, Zhu J, Huang C, et al. Uncovering the information immunology journals transmitted for COVID-19: A bibliometric and visualization analysis. *Front Immunol* 2022; **13**: 1035151.

83. Avery RK. Update on COVID-19 Therapeutics for Solid Organ Transplant Recipients, Including the Omicron Surge. *Transplantation* 2022; **106**(8): 1528-37.

84. Florentino PTV, Alves FJO, Cerqueira-Silva T, et al. Vaccine effectiveness of CoronaVac against COVID-19 among children in Brazil during the Omicron period. *Nat Commun* 2022; **13**(1): 4756.

85. Murillo E, Palacio-Rua K, Afanador-Ayala C, García-Correa JF, Zuluaga AF. [Validation of a new strategy for the identification of SARS-CoV-2 variants by sequencing the spike gene by Sanger]. *Enferm Infecc Microbiol Clin* 2023; **41**(5): 284-9.

4. Goh GKM, Dunker AK, Foster JA, Uversky VN. A Study on the Nature of SARS-CoV-2 Using the Shell Disorder Models: Reproducibility, Evolution, Spread, and Attenuation. *Biomolecules* 2022; **12**(10).

5. Leahy J, Bajracharya R, Altonen BL, Ferreira-Ortiz M, Silvera L, Astua AJ. The Omicron Surge Outpaces Previous Surges in Post-COVID Hospitalization Healthcare Usage. *American Journal of Respiratory and Critical Care Medicine* 2023; **207**(1).

6. Maffia-Bizzozero S, Cevallos C, Lenicov FR, et al. Viable SARS-CoV-2 Omicron sub-variants isolated from autopsy tissues. *Frontiers in Microbiology* 2023; **14**.

8. Akhtardanesh B, Jajarmi M, Shojaee M, et al. Molecular screening of SARS-CoV-2 in dogs and cats from households with infected owners diagnosed with COVID-19 during Delta and Omicron variant waves in Iran. *Vet Med Sci* 2023; **9**(1): 82-90.

9. Al-Fattah Yahaya AA, Khalid K, Lim HX, Poh CL. Development of Next Generation Vaccines against SARS-CoV-2 and Variants of Concern. *Viruses* 2023; **15**(3).

10. Alves R, Wang YT, Mikulski Z, et al. SARS-CoV-2 Omicron (B.1.1.529) shows minimal neurotropism in a double-humanized mouse model. *Antiviral Res* 2023; **212**: 105580.

11. Andrade SA, Batalha-Carvalho JV, Curi R, et al. Equine Anti-SARS-CoV-2 Serum (ECIG) Binds to Mutated RBDs and N Proteins of Variants of Concern and Inhibits the Binding of RBDs to ACE-2 Receptor. *Front Immunol* 2022; **13**: 871874.

12. Armando F, Beythien G, Kaiser FK, et al. SARS-CoV-2 Omicron variant causes mild pathology in the upper and lower respiratory tract of hamsters. *Nat Commun* 2022; **13**(1): 3519.

13. Ayass MA, Tripathi T, Griko N, et al. Highly efficacious and safe neutralizing DNA aptamer of SARS-CoV-2 as an emerging therapy for COVID-19 disease. *Virol J* 2022; **19**(1): 227.

15. Becker M, Cossmann A, Lürken K, et al. Longitudinal cellular and humoral immune responses after triple BNT162b2 and fourth full-dose mRNA-1273 vaccination in haemodialysis patients. *Front Immunol* 2022; **13**: 1004045.

16. Bloom JD, Beichman AC, Neher RA, Harris K. Evolution of the SARS-CoV-2 Mutational Spectrum. *Mol Biol Evol* 2023; **40**(4).

17. Borghi M, Gallinaro A, Pirillo MF, et al. Different configurations of SARS-CoV-2 spike protein delivered by integrase-defective lentiviral vectors induce persistent functional immune responses, characterized by distinct immunogenicity profiles. *Front Immunol* 2023; **14**: 1147953.

18. Bowden-Reid E, Ledger S, Zhang Y, et al. Novel siRNA therapeutics demonstrate multi-variant efficacy against SARS-CoV-2. *Antiviral Res* 2023; **217**: 105677.

19. Cacciottolo M, Nice JB, Li Y, et al. Exosome-Based Multivalent Vaccine: Achieving Potent Immunization, Broadened Reactivity, and Strong T-Cell Responses with Nanograms of Proteins. *Microbiol Spectr* 2023; **11**(3): e0050323.

20. Chen Y, Wu Y, Chen S, et al. Sertraline Is an Effective SARS-CoV-2 Entry Inhibitor Targeting the Spike Protein. *J Virol* 2022; **96**(24): e0124522.

21. Chi X, Guo Y, Zhang G, et al. Broadly neutralizing antibodies against Omicron-included SARS-CoV-2 variants induced by vaccination. *Signal Transduct Target Ther* 2022; **7**(1): 139.

23. Deng K, Nemser SM, Frost K, et al. Successful Detection of Delta and Omicron Variants of SARS-CoV-2 by Veterinary Diagnostic Laboratory Participants in an Interlaboratory Comparison Exercise. *J Appl Lab Med* 2023; **8**(4): 726-41.

24. Deng S, Liu Y, Tam RC, et al. An intranasal influenza virus-vectored vaccine prevents SARS-CoV-2 replication in respiratory tissues of mice and hamsters. *Nat Commun* 2023; **14**(1): 2081.

25. Deng Y, Li J, Sun C, et al. Rational Development of a Polysaccharide-Protein-Conjugated Nanoparticle Vaccine Against SARS-CoV-2 Variants and Streptococcus pneumoniae. *Adv Mater* 2022; **34**(21): e2200443.

26. Dwivedi R, Sharma P, Eilts F, et al. Anti-SARS-CoV-2 and anticoagulant properties of Pentacta pygmaea fucosylated chondroitin sulfate depend on high molecular weight structures. *Glycobiology* 2023; **33**(1): 75-85.

28. Esmagambetov IB, Ryabova EI, Derkaev AA, et al. rAAV expressing recombinant antibody for emergency prevention and long-term prophylaxis of COVID-19. *Front Immunol* 2023; **14**: 1129245.

30. Frumkin LR, Lucas M, Scribner CL, et al. Egg-Derived Anti-SARS-CoV-2 Immunoglobulin Y (IgY) With Broad Variant Activity as Intranasal Prophylaxis Against COVID-19. *Front Immunol* 2022; **13**: 899617.

31. Gao SY, Amaro-Mugridge NB, Madrid-Weiss J, et al. Nanocell COVID-19 vaccine triggers a novel immune response pathway producing high-affinity antibodies which neutralize all variants of concern. *Front Immunol* 2022; **13**: 1038562.

32. Gao Y, Wang W, Yang Y, et al. Developing Next-Generation Protein-Based Vaccines Using High-Affinity Glycan Ligand-Decorated Glyconanoparticles. *Adv Sci (Weinh)* 2023; **10**(2): e2204598.

34. Goldberg EE, Lin Q, Romero-Severson EO, Ke R. Swift and extensive Omicron outbreak in China after sudden exit from 'zero-COVID' policy. *Nat Commun* 2023; **14**(1): 3888.

35. Gregory DA, Trujillo M, Rushford C, et al. Genetic diversity and evolutionary convergence of cryptic SARS- CoV-2 lineages detected via wastewater sequencing. *PLoS Pathog* 2022; **18**(10): e1010636.

36. Hamill V, Noll L, Lu N, et al. Molecular detection of SARS-CoV-2 strains and differentiation of Delta variant strains. *Transbound Emerg Dis* 2022; **69**(5): 2879-89.

37. He P, Xia K, Song Y, et al. Synthesis of multivalent sialyllactose-conjugated PAMAM dendrimers: Binding to SARS-CoV-2 spike protein and influenza hemagglutinin. *Int J Biol Macromol* 2023; **246**: 125714.

38. He Q, Mao Q, Peng X, et al. Immunogenicity and protective efficacy of a recombinant protein subunit vaccine and an inactivated vaccine against SARS-CoV-2 variants in non-human primates. *Signal Transduct Target Ther* 2022; **7**(1): 69.

39. He X, Aid M, Chandrashekar A, et al. A homologous or variant booster vaccine after Ad26.COV2.S immunization enhances SARS-CoV-2-specific immune responses in rhesus macaques. *Sci Transl Med* 2022; **14**(638): eabm4996.

40. Honda-Okubo Y, Li L, André G, et al. An Advax-CpG55.2™ adjuvanted recombinant spike protein vaccine protects cynomolgus macaques from a homologous SARS-CoV-2 virus challenge. *Vaccine* 2023; **41**(32): 4710-8.

41. Huang HC, Wang SH, Fang GC, et al. Upregulation of PD-L1 by SARS-CoV-2 promotes immune evasion. *J Med Virol* 2023; **95**(2): e28478.

42. Inoue T, Shinnakasu R, Kawai C, et al. Antibody feedback contributes to facilitating the development of Omicron-reactive memory B cells in SARS-CoV-2 mRNA vaccinees. *J Exp Med* 2023; **220**(2).

43. Kaewchim K, Glab-Ampai K, Mahasongkram K, et al. Neutralizing and Enhancing Epitopes of the SARS-CoV-2 Receptor-Binding Domain (RBD) Identified by Nanobodies. *Viruses* 2023; **15**(6).

44. Kaur L, Ahirwar AK. Omicron variant of SARS-CoV-2: a review of existing literature. *Horm Mol Biol Clin Investig* 2023; **44**(1): 73-7.

45. Khandia R, Singhal S, Alqahtani T, et al. Emergence of SARS-CoV-2 Omicron (B.1.1.529) variant, salient features, high global health concerns and strategies to counter it amid ongoing COVID-19 pandemic. *Environ Res* 2022; **209**: 112816.

46. Kibria KMK, Faruque MO, Islam MSB, et al. A conserved subunit vaccine designed against SARS-CoV-2 variants showed evidence in neutralizing the virus. *Appl Microbiol Biotechnol* 2022; **106**(11): 4091-114.

47. Kim E, Khan MS, Ferrari A, et al. SARS-CoV-2 S1 Subunit Booster Vaccination Elicits Robust Humoral Immune Responses in Aged Mice. *Microbiol Spectr* 2023; **11**(3): e0436322.

48. Kim TY, Jeon S, Ko M, et al. Lancemaside A from Codonopsis lanceolata: Studies on Antiviral Activity and Mechanism of Action against SARS-CoV-2 and Its Variants of Concern. *Antimicrob Agents Chemother* 2022; **66**(12): e0120122.

49. Lawal-Ayinde BM, Morita T, Oda K, et al. Virus purification highlights the high susceptibility of SARS-CoV-2 to a chlorine-based disinfectant, chlorous acid. *PLoS One* 2023; **18**(7): e0288634.

50. Lei H, Alu A, Yang J, et al. Intranasal administration of a recombinant RBD vaccine induces long-term immunity against Omicron-included SARS-CoV-2 variants. *Signal Transduct Target Ther* 2022; **7**(1): 159.

51. Linkowska K, Bogiel T, Lamperska K, et al. Commercially available SARS-CoV-2 RT-qPCR diagnostic tests need obligatory internal validation. *Sci Rep* 2023; **13**(1): 6991.

52. Liu H, Wu L, Liu B, et al. Two pan-SARS-CoV-2 nanobodies and their multivalent derivatives effectively prevent Omicron infections in mice. *Cell Rep Med* 2023; **4**(2): 100918.

53. Liu S, Selvaraj P, Sangare K, Luan B, Wang TT. Spike protein-independent attenuation of SARS-CoV-2 Omicron variant in laboratory mice. *Cell Rep* 2022; **40**(11): 111359.

54. Lloren KKS, Jawalagatti V, Hewawaduge C, Chandran S, Park JY, Lee JH. Salmonella-mediated oral delivery of multiple-target vaccine constructs with conserved and variable regions of SARS-CoV-2 protect against the Delta and Omicron variants in hamster. *Microbes Infect* 2023; **25**(5): 105101.

55. Long J, Yu C, Zhang H, et al. Novel Ionizable Lipid Nanoparticles for SARS-CoV-2 Omicron mRNA Delivery. *Adv Healthc Mater* 2023; **12**(13): e2202590.

56. Machado RRG, Walker JL, Scharton D, et al. Immunogenicity and efficacy of vaccine boosters against SARS-CoV-2 Omicron subvariant BA.5 in male Syrian hamsters. *Nat Commun* 2023; **14**(1): 4260.

57. Mathez G, Pillonel T, Bertelli C, Cagno V. Alpha and Omicron SARS-CoV-2 Adaptation in an Upper Respiratory Tract Model. *Viruses* 2022; **15**(1).

58. Ong CP, Ye ZW, Tang K, et al. Comparative analysis of SARS-CoV-2 Omicron BA.2.12.1 and BA.5.2 variants. *J Med Virol* 2023; **95**(1): e28326.

59. Panzera Y, Mirazo S, Baz M, et al. Detection and genome characterisation of SARS-CoV-2 P.6 lineage in dogs and cats living with Uruguayan COVID-19 patients. *Mem Inst Oswaldo Cruz* 2023; **117**: e220177.

60. Paulino-Ramírez R, López P, Mueses S, Cuevas P, Jabier M, Rivera-Amill V. Genomic Surveillance of SARS-CoV-2 Variants in the Dominican Republic and Emergence of a Local Lineage. *Int J Environ Res Public Health* 2023; **20**(8).

61. Peled Y, Afek A, Kreiss Y, et al. Kinetics of cellular and humoral responses to third BNT162B2 COVID-19 vaccine over six months in heart transplant recipients - implications for the omicron variant. *J Heart Lung Transplant* 2022; **41**(10): 1417-25.

62. Planchais C, Fernández I, Bruel T, et al. Potent human broadly SARS-CoV-2-neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2. *J Exp Med* 2022; **219**(7).

63. Primard C, Monchâtre-Leroy E, Del Campo J, et al. OVX033, a nucleocapsid-based vaccine candidate, provides broad-spectrum protection against SARS-CoV-2 variants in a hamster challenge model. *Front Immunol* 2023; **14**: 1188605.

65. Salgado-Benvindo C, Leijs AA, Thaler M, et al. Honokiol Inhibits SARS-CoV-2 Replication in Cell Culture at a Post-Entry Step. *Microbiol Spectr* 2023; **11**(3): e0327322.

68. Shirato K, Ujike M, Kawase M. Trends of Mismatches in Real-Time RT-PCR Assays Developed by the National Institute of Infectious Diseases, Japan for Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2. *Jpn J Infect Dis* 2023; **76**(3): 204-6.

69. Shiwa-Sudo N, Sakai Y, Iwata-Yoshikawa N, et al. Impact of Reinfection with SARS-CoV-2 Omicron Variants in Previously Infected Hamsters. *J Virol* 2023; **97**(1): e0136622.

70. Smyth DS, Trujillo M, Gregory DA, et al. Tracking cryptic SARS-CoV-2 lineages detected in NYC wastewater. *Nat Commun* 2022; **13**(1): 635.

71. Solforosi L, Costes LMM, Tolboom J, et al. Booster with Ad26.COV2.S or Omicron-adapted vaccine enhanced immunity and efficacy against SARS-CoV-2 Omicron in macaques. *Nat Commun* 2023; **14**(1): 1944.

72. Song SJ, Kim H, Jang EY, et al. SARS-CoV-2 spike trimer vaccine expressed in Nicotiana benthamiana adjuvanted with Alum elicits protective immune responses in mice. *Plant Biotechnol J* 2022; **20**(12): 2298-312.

73. Stravalaci M, Pagani I, Paraboschi EM, et al. Recognition and inhibition of SARS-CoV-2 by humoral innate immunity pattern recognition molecules. *Nat Immunol* 2022; **23**(2): 275-86.

74. Subramoney K, Mtileni N, Giandhari J, et al. Molecular Epidemiology of SARS-CoV-2 during Five COVID-19 Waves and the Significance of Low-Frequency Lineages. *Viruses* 2023; **15**(5).

75. Tada T, Minnee J, Landau NR. Vectored immunoprophylaxis and treatment of SARS-CoV-2 infection in a preclinical model. *Proc Natl Acad Sci U S A* 2023; **120**(23): e2303509120.

76. Telenti A, Hodcroft EB, Robertson DL. The Evolution and Biology of SARS-CoV-2 Variants. *Cold Spring Harb Perspect Med* 2022; **12**(5).

77. Upadhyay V, Suryawanshi RK, Tasoff P, et al. Mild SARS-CoV-2 infection results in long-lasting microbiota instability. *mBio* 2023; **14**(4): e0088923.

78. Wang J, Wen Y, Zhou SH, et al. Self-Adjuvanting Lipoprotein Conjugate αGalCer-RBD Induces Potent Immunity against SARS-CoV-2 and its Variants of Concern. *J Med Chem* 2022; **65**(3): 2558-70.

79. Xie T, Lu S, He Z, et al. Three doses of prototypic SARS-CoV-2 inactivated vaccine induce cross-protection against its variants of concern. *Signal Transduct Target Ther* 2022; **7**(1): 61.

80. Yang J, Xiao Y, Lidsky PV, et al. Fluorogenic reporter enables identification of compounds that inhibit SARS-CoV-2. *Nat Microbiol* 2023; **8**(1): 121-34.

81. Yogesh R, Srivastava N, Abbas Bukhari SN. COVID-19 Challenge: A Quest for Effective Vaccine Strategies Against Circulating and Emerging SARS-CoV-2 Variants. *Curr Pharm Des* 2022; **28**(35): 2901-13.

82. Zhang RY, Zhou SH, He CB, et al. Adjuvant-Protein Conjugate Vaccine with Built-In TLR7 Agonist on S1 Induces Potent Immunity against SARS-CoV-2 and Variants of Concern. *ACS Infect Dis* 2022; **8**(7): 1367-75.

83. Zhang Y, Lv Q, Qi F, et al. Comparison of the replication and neutralization of different SARS-CoV-2 Omicron subvariants in vitro. *Animal Model Exp Med* 2023; **6**(1): 51-6.

84. Zhang YN, Zhang HQ, Wang GF, et al. Intranasal delivery of replicating mRNA encoding hACE2-targeting antibody against SARS-CoV-2 Omicron infection in the hamster. *Antiviral Res* 2023; **209**: 105507.

85. Zhou B, Cheng L, Song S, et al. Identification and application of a pair of noncompeting monoclonal antibodies broadly binding to the nucleocapsid proteins of SARS-CoV-2 variants including Omicron. *Virol J* 2022; **19**(1): 96.

1. Barrière J, Zalcman G, Fignon L, Peiffer-Smadja N, Audigier-Valette C, Carles M. Recommendations to protect patients with cancer against the Omicron variant. *Bull Cancer* 2022; **109**(2): 115-8.

3. D'Acremont V, Chambaz G, Genton B. Covid-19 crisis: testing and vaccination in the light of diminishing returns. *Rev Med Suisse* 2022; **18**(780): 904-8.

4. de San Segundo Reyes M, Granizo Martínez JJ, Veiga Crespo MC, Sanchís Ruiz A, Camacho Muñoz I, Sánchez-Uriz M. Factors associated with the duration of SARS-CoV-2 infection in healthcare professionals at a second-level public hospital in the Community of Madrid (Spain) during the sixth wave.. *Rev Esp Salud Publica* 2023; **97**.

5. Du J, Wang JM, Wang J, Gao YL, Pang XH, Li G. Study of transmissibility of 2019-nCoV Omicron variant in Beijing. *Zhonghua Liu Xing Bing Xue Za Zhi* 2022; **43**(9): 1364-9.

6. Feng Q, Wang Z, Yu H, Shi L, Xu L. Analysis of clinical characteristics of 362 vaccinated or unvaccinated patients infected by novel coronavirus Omicron variant. *Zhonghua Wei Zhong Bing Ji Jiu Yi Xue* 2022; **34**(5): 459-64.

7. Guo X, Luo X, Wu B, Wang W, Wang Y. Retrospective observation and analysis of autoimmune-related indicators in 317 patients with acute Omicron variant infection. *Zhonghua Wei Zhong Bing Ji Jiu Yi Xue* 2022; **34**(6): 581-5.

8. Hagihara M, Hayashi H, Nakajima S, et al. Outcomes of COVID-19 due to omicron variant infection complicated with hematological disorders. *Rinsho Ketsueki* 2023; **64**(1): 3-8.

9. Han Y, Liu Q. Rapid identification of SARS-CoV-2 main variants using real-time quantitative PCR assay. *Sheng Wu Gong Cheng Xue Bao* 2022; **38**(6): 2224-35.

11. Hu CC, Xu P, Xu L, et al. Short-term persistent symptoms in preschool children with mild/common coronavirus disease 2019 caused by Omicron variant infection after discharge: a follow-up study. *Zhongguo Dang Dai Er Ke Za Zhi* 2022; **24**(12): 1289-94.

13. Jiang XL, Qiu Y, Zhang YP, et al. Latent period and incubation period with associated factors of COVID-19 caused by Omicron variant. *Zhonghua Yu Fang Yi Xue Za Zhi* 2023; **57**(5): 659-66.

14. Kim T, Ha B, Yang JI, Kim MJ, Seo KW. Descriptive analysis of the incidence rate of postacute COVID-19 syndrome in the Republic of Korea Army. *Journal of the Korean Medical Association* 2023; **66**(3): 200-8.

15. Korózs D, Jenőfi N, Szabó BG, Szlávik J, Mikala G. "When it rains, it pours" - de novo diagnosed multiple myeloma with invasive Streptococcus pneumoniae infection in severe COVID-19 complicated with cytokine storm. *Orv Hetil* 2023; **164**(20): 763-9.

16. Li SJ, Zhang L, Yuan H, et al. Management and short-term outcomes of neonates born to mothers infected with SARS-CoV-2 Omicron variant. *Zhonghua Er Ke Za Zhi* 2022; **60**(11): 1163-7.

17. Li WX, Cao L, Zhang DH, et al. Study of incubation period of infection with 2019-nCoV Omicron variant BA.5.1.3. *Zhonghua Liu Xing Bing Xue Za Zhi* 2023; **44**(3): 367-72.

19. Liu MF, Ma RX, Cao XB, et al. Incidence and prognosis of olfactory and gustatory dysfunctions related to infection of SARS-CoV-2 Omicron strain: a national multi-center survey of 35 566 population. *Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi* 2023; **58**(6): 579-88.

20. Liu X, Chen M, Zhou Z, Chen D, Mo J, Liu J. Epidemiological characteristics of 17 imported patients infected with SARS-CoV-2 Omicron variant. *Zhong Nan Da Xue Xue Bao Yi Xue Ban* 2022; **47**(3): 344-51.

21. Liu X, Hu Q, Yao M, Chen W, Zhang Q, Huang J. Five patients with novel coronavirus Omicron variant of concern infection. *Zhonghua Wei Zhong Bing Ji Jiu Yi Xue* 2022; **34**(5): 471-4.

22. Lu WY, Chen XH, Zheng N, Yu HJ. Prediction of protection probability against Omicron BA.1, BA.4 and BA.5 variants in symptomatic infections with prototype strain based on neutralization antibody levels. *Zhonghua Yi Xue Za Zhi* 2023; **103**(18): 1429-34.

23. Madruga Flores M, Corrales López M, Gómez-Pavón J. The impact of the first pandemic waves of COVID-19 in older people with dementia. *Aten Primaria* 2023; **55**(6): 102622.

24. Markina UA, Fomina DS, Lebedkina MS, et al. Efficacy and safety of regdanvimab in patients with mild/moderate COVID-19 and high risk of progression of the disease: a retrospective study in a short-term stay unit. *Ter Arkh* 2022; **94**(5): 675-82.

25. Meylan P. Not Available. *Rev Med Suisse* 2023; **19**(N° 809-10): 90-1.

26. Mo Y, Mo J, Liang RY, Xiao GY, Li Y, Wei QF. A case report of neonatal severe coronavirus disease 2019. *Zhongguo Dang Dai Er Ke Za Zhi* 2022; **24**(11): 1266-8.

28. Nehme M, Ducrot A, Salmon D, Guessous I. Post-Covid: 2022 updates and next steps. *Revue Medicale Suisse* 2023; **19**(812): 160-6.

29. Quickert S, Stallmach A, Reuken P. Sequelae of SARS-CoV-2 infection including post-COVID syndrome. *Gastroenterologie* 2023; **18**(2): 136-42.

30. Ren B, Liao BY, Wang JN, Peng X, Zhou XD. Omicron Variant of SARS-CoV-2 and Its Potential Impact on Dental Practice. *Sichuan Da Xue Xue Bao Yi Xue Ban* 2022; **53**(2): 175-80.

31. Shang FQ, Chen H, Yang X, Wu MJ, Wang FY, Ren F. Clinical characteristics of patients infected with 2019-nCoV Omicron variants BA.2 and BA.5 in Xi'an city, China. *Zhonghua Jie He He Hu Xi Za Zhi* 2022; **45**(12): 1199-203.

32. Shi YY, Lu YM, Yan GF, et al. Severe pneumonia caused by coinfection of SARS-CoV-2 Omicron variant and Mycoplasma pneumoniae in a child. *Zhonghua Er Ke Za Zhi* 2022; **60**(6): 600-2.

34. Vigotti FN, Bianco S, Alfieri V, et al. COVID-19 recurrence due to reinfection with SARS-CoV-2 in a hemodialysis patient: there and back again. *G Ital Nefrol* 2022; **39**(2).

38. Wang Z, Feng Q, Yu H, Shi L, Xu L. Clinical study of awake prone positioning treatment in patients with common coronavirus disease 2019 caused by Omicron variant. *Zhonghua Wei Zhong Bing Ji Jiu Yi Xue* 2022; **34**(6): 576-80.

39. Weinberger B. Vaccination against coronavirus disease 2019 (COVID-19). *Z Gerontol Geriatr* 2022; **55**(7): 558-63.

40. Wu SS, Sun Y, Dou XF, et al. Analysis on infection sources and transmission chains of three outbreaks caused by 2019-nCoV Omicron variant in Beijing, China. *Zhonghua Liu Xing Bing Xue Za Zhi* 2023; **44**(3): 373-8.

41. Xu H, Wang J, Gao H, Wang Y. Analysis of clinical characteristics of patients with different vaccines and underlying diseases infected with novel coronavirus Omicron variant. *Zhonghua Wei Zhong Bing Ji Jiu Yi Xue* 2022; **34**(6): 571-5.

42. Xu X, Sun D, Cao M, et al. Analysis of clinical characteristics and prognosis of 4 264 patients with asymptomatic and mild novel coronavirus infections in Shanghai. *Zhonghua Wei Zhong Bing Ji Jiu Yi Xue* 2022; **34**(5): 449-53.

43. Yin R, Lu Q, Jiao JL, et al. Characteristics and related factors of viral nucleic acid negative conversion in children infected with Omicron variant strain of SARS-CoV-2. *Zhonghua Er Ke Za Zhi* 2022; **60**(12): 1307-11.

44. Yu YC, Song Y. Etiology, clinical features, infection control and therapy of SARS-CoV-2 Omicron variant. *Medical Journal of Chinese People's Liberation Army* 2022; **47**(11): 1063-72.

45. Yuan W, Lyu Y, Shi DL, et al. Analysis of liver function injury associated with 2019-nCoV Omicron mutant strains. *Zhonghua Gan Zang Bing Za Zhi* 2022; **30**(5): 513-9.

46. Zhang YF, Liang SS, Wu PL, et al. Clinical features of severe acute respiratory syndrome coronavirus 2 Omicron variant infection in children: an analysis of 201 cases. *Zhongguo Dang Dai Er Ke Za Zhi* 2023; **25**(1): 5-10.

1. Ballouz T, Menges D, Kaufmann M, et al. Post COVID-19 condition after Wildtype, Delta, and Omicron variant SARS-CoV-2 infection and vaccination: pooled analysis of two population-based cohorts. 2022.

4. Iqbal P, Ata F, Chaudhry H, et al. Post-COVID-19-associated multiorgan complications or “long COVID” with literature review and management strategy discussion: A meta-analysis. *Health Science Reports* 2023; **6**(4).

7. Piechotta V, Siemens W, Thielemann I, et al. Safety and effectiveness of vaccines against COVID-19 in children aged 5–11 years: a systematic review and meta-analysis. *The Lancet Child and Adolescent Health* 2023; **7**(6): 379-91.

8. Human vaccines & immunotherapeutics news: January 2022. *Human Vaccines and Immunotherapeutics* 2022; **18**(1).

9. Anastassopoulou C, Hatziantoniou S, Boufidou F, Patrinos GP, Tsakris A. The Role of Oral Antivirals for COVID-19 Treatment in Shaping the Pandemic Landscape. *Journal of Personalized Medicine* 2022; **12**(3).

12. Bailey J, Phillips A, Herzog K, Sala MA, Carnethon M, Kalhan R. Compared to the Wuhan Variant, Infection With Omicron and Delta Variants of SARS-CoV-2 Are Associated With Decreased Odds of Developing Post-Acute Sequelae of COVID-19. *American Journal of Respiratory and Critical Care Medicine* 2023; **207**(1).

14. Blann AD, Heitmar R. SARS-CoV-2 and COVID-19: A Narrative Review. *British Journal of Biomedical Science* 2022; **79**.

15. Brainard J. News at a glance. *Science* 2021; **374**(6575): 1540.

16. Buonsenso D. A call to invest in immunological determinants of pediatric post-COVID conditions: Insights from a post-COVID pANCA+ diffuse alveolar hemorrhage in an adolescent. *Pediatric Pulmonology* 2022; **57**(11): 2861-2.

18. Chew-Graham CA, Briggs TA, Kane B. Long COVID in children and young people: uncertainty and contradictions. *British Journal of General Practice* 2022; **72**(719): 253-4.

19. Cooper S, Waisbourd-Zinman O. Reply to: Severe Hepatitis in Children Likely Caused by HAdV-41 Following SARS-CoV-2. *Journal of Pediatric Gastroenterology and Nutrition* 2023; **76**(3): E70.

22. Dela Cruz P, Wargowsky R, Gonzalez A, et al. BLOOD RNA BIOMARKERS DISTINGUISH IMMUNE RESPONSES TO COVID-19 VIREMIA VERSUS COMORBID INFECTIONS. *Critical Care Medicine* 2023; **51**(1): 186.

23. Desai P, Rojas J, Chen YS, et al. CLINICAL OUTCOMES BY SARS-CoV-2 VARIANT AT A SINGLE ACADEMIC MEDICAL CENTER. *Topics in Antiviral Medicine* 2023; **31**(2): 356.

25. Gross R, Lo Re V. Disentangling the Postacute Sequelae of SARS-CoV-2: E Unibus Pluram (From One, Many). *JAMA* 2023; **329**(22): 1918-9.

26. Gumowski P, Diaz-Badial P, Cereda C. SARS-CoV-2 Vaccinations do not confer protection against Omicron variants: COVID naïve, naturally immunized and vaccinated patients have the same symptoms. *Swiss Medical Weekly* 2022; **152**: 29S.

27. Gunst JD, Cajander S. Editorial: COVID-19: From bedside to follow-up. *Frontiers in Medicine* 2023; **10**.

28. Hagiya H, Otsuka Y, Otsuka F. Call for correction: Mid and long-term neurological and neuropsychiatric manifestations of post-COVID-19 syndrome: A meta-analysis. *Journal of the Neurological Sciences* 2022; **436**.

29. Harrison S, Davies E, Shelton C. Aerosol-generating procedures: research, guidance and implementation. *Anaesthesia* 2023; **78**(2): 150-4.

30. Heald-Sargent T. Increasing Understanding of SARS-CoV-2 Infection in Young Children - Would They Benefit from Immunization? *JAMA Network Open* 2022; **5**(6).

31. Huang L, Gu X, Zhang H, Cao B. A glimpse into long COVID and symptoms – Authors' reply. *The Lancet Respiratory Medicine* 2022; **10**(9): e82.

32. Imzil A, Essaid Y, Moubachir H, Serhane H. Post covid-19 manifestations in the omicron wave. *European Respiratory Journal* 2022; **60**.

34. Kalyansundaram K, Chang G, Dickson J, Linnane S. EFFECT OF SARS-CoV-2 VARIANT ON LONG COVID SYMPTOMOLOGY. *Irish Journal of Medical Science* 2023; **192**: S38.

35. Kizhikkilot V. Sars-Cov2 Infection and Its Impact on Cystic Fibrosis Patients - An Indian Study. *American Journal of Respiratory and Critical Care Medicine* 2023; **207**(1).

36. Lai JB, Kong LZ, Chen J, Hu SH. From strict quarantine to an optimized policy: Are we psychologically prepared? *Asian Journal of Psychiatry* 2023; **81**.

38. Lechner-Scott JS, Davis JS, Hawkes C, Giovannoni G, Levy M, Yeh A. Vaccine hesitancy in people with multiple sclerosis. *Multiple Sclerosis and Related Disorders* 2022; **65**.

39. Leppkes M, Neurath MF. Rear Window—What Can the Gut Tell Us About Long-COVID? *Gastroenterology* 2022; **163**(2): 376-8.

41. Magnusson JM, Oltean M. Impact of COVID-19 on lung transplant recipients: Only time will tell. *Transplant Infectious Disease* 2022; **24**(6).

43. McGrath L, Scott A, Surinach A, Chambers R, Benigno M, Malhotra D. Use of the new ICD-10-CM diagnosis code for post COVID-19 condition in routine clinical practice in the United States. *Pharmacoepidemiology and Drug Safety* 2022; **31**: 82-3.

44. Mendes D, Chapman R, Aruffo E, et al. EPH257 Public Health Impact of UK COVID-19 Booster Vaccination during Omicron Predominance. *Value in Health* 2023; **26**(6): S209.

45. Mortazavi SA, Bevelacqua JJ, Welsh JS, et al. The Paradox of COVID-19 in Sub-Saharan Africa: Why it is More Unethical Not to Investigate Low Dose Radiotherapy for COVID-19. *Journal of Biomedical Physics and Engineering* 2022; **12**(5): 539-42.

46. Pagel C, Squires A. Schools: Still a gaping hole in the English covid strategy. *The BMJ* 2021; **375**.

47. Phyland DJ. Singing in and out of COVID. *Respirology* 2023; **28**(1): 17-9.

48. Pierce CA, Herold KC, Herold BC, et al. COVID-19 and children. *Science* 2022; **377**(6611): 1144.

49. Prendki V, Tiseo G, Falcone M. Caring for older adults during the COVID-19 pandemic. *Clinical Microbiology and Infection* 2022; **28**(6): 785-91.

52. Rhee DK. COVID-19 infection and ginseng: Predictive influenza virus strains and non-predictive COVID-19 vaccine strains. *Journal of Ginseng Research* 2023; **47**(2): 347-8.

54. Satta S, Shahabipour F, Gao W, et al. Engineering viral genomics and nano-liposomes in microfluidic platforms for patient-specific analysis of SARS-CoV-2 variants. *Theranostics* 2022; **12**(10): 4779-90.

55. Savytskyi IV, Pruc M, Malysz M, Maslyukov A, Szarpak L. Post-COVID-19 postural orthostatic tachycardia syndrome. *Cardiology Journal* 2022; **29**(3): 531-2.

56. Scarpellini E, Tack J. Post-COVID-19 Gastro-Intestinal Disturbances. *Reviews on Recent Clinical Trials* 2023; **18**(1): 34-40.

57. Seghatchian J. Editorial: Time to explore the missing links: the cross-talk between COVID infection and cancer cells; lingering questions on the longitudinal efficacy of the front line immunotherapies against unpredictable “Omicron ghosts” and insights from CAR-T cell therapy pointing toward better clinical outcomes. *Transfusion and Apheresis Science* 2022; **61**(4).

59. Siddiqui T, Doultani PR, Tayyaba. Beating Corona Virus Disease (COVID-19) in Newborns, Infants and Toddlers. *Journal of the Pakistan Medical Association* 2023; **73**(3): 742.

60. Sin DD. Is long COVID an autoimmune disease? *European Respiratory Journal* 2023; **61**(1).

61. Singhal T. Looking Back at the COVID-19 Pandemic in Children. *Indian Journal of Pediatrics* 2023; **90**(2): 114-5.

62. Skegg DCG, Brewerton M, Hill PC, Iosua E, Murdoch DR, Turner N. Vaccine mandates in the time of Omicron. *New Zealand Medical Journal* 2022; **135**(1552): 11-5.

63. Slawson DC. Likelihood of Long COVID Varies by Variant, Sex, and Vaccination Status. *American Family Physician* 2023; **107**(2): 199.

64. Spiers N. Life & Times Recognising and bearing the burden of long COVID-related disability. *British Journal of General Practice* 2022; **72**(715): 70.

65. Stevens MA, Melnick ER, Savitz S, Jeffery MM, Nath B, Janke A. National Trends in Emergency Conditions Through the Omicron COVID-19 Wave. *Academic Emergency Medicine* 2023; **30**: 291-2.

66. Tan L, Quizon AI, Santiago MT. Effect of Acute COVID-19 Infection on Control, Quality of Life and Pulmonary Function in Children With Asthma. *American Journal of Respiratory and Critical Care Medicine* 2023; **207**(1).

67. The Lancet Regional Health – Western P. The end of zero-COVID-19 policy is not the end of COVID-19 for China. *The Lancet Regional Health - Western Pacific* 2023; **30**.

68. Tosi D, Tang F, Brito Y, Sarasua A, Ruiz J, Hammel IS. Vaccination as a protective factor for PASC in Frail, Pre-frail, and Robust Veterans During the Omicron Wave. *Journal of the American Geriatrics Society* 2023; **71**: S158-S9.

69. Trapani G, Verlato G, Bertino E, et al. Response to commentary ‘long COVID-19/post-COVID condition in children: do we all speak the same language? *Italian Journal of Pediatrics* 2022; **48**(1).

70. Tudas RA, Stalker GW, Carmo DS, et al. Long-COVID Is Associated With Residual Functional Small Airway Disease and Parenchymal Changes Regardless of SARS-CoV-2 Variant. *American Journal of Respiratory and Critical Care Medicine* 2023; **207**(1).

71. Vaira LA, Lechien JR, De Riu G, Saussez S. The Trajectories of Olfactory Dysfunction from the First to the Omicron Wave: Are We Getting over it? *Pathogens* 2023; **12**(1).

72. Ward H. The unrecovered. *Science* 2023; **379**(6628): 145.

73. Werneke U, van Der Feltz-Cornelis C, Löwe B, Ventriglio A, Bhugra D. Editorial: Outbreak Investigation: Mental Health in the Times of Coronavirus (COVID-19). *Frontiers in Psychiatry* 2022; **13**.

76. Zisis SN, Durieux JC, Perez JA, et al. INCIDENT NEW ONSET DIABETES AFTER COVID-19 INFECTION: A NATIONAL MULTICENTER COHORT. *Topics in Antiviral Medicine* 2023; **31**(2): 282-3.

77. Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis. *Lancet* 2023; **401**(10379): 833-42.

78. Abbasi HQ. Comments on: Clinical characteristics of unvaccinated or incompletely vaccinated children with neurological manifestations due to SARS-CoV-2 Omicron infection. *J Med Virol* 2023; **95**(8): e29008.

79. AbdelMassih A, Sedky A, Shalaby A, et al. From HIV to COVID-19, Molecular mechanisms of pathogens' trade-off and persistence in the community, potential targets for new drug development. *Bull Natl Res Cent* 2022; **46**(1): 194.

80. Abdelrahim M, Esmail A, Al Saadi N, et al. Thymoquinone's Antiviral Effects: It is Time to be Proven in the Covid-19 Pandemic Era and its Omicron Variant Surge. *Front Pharmacol* 2022; **13**: 848676.

81. Abubaker Bagabir S, Ibrahim NK, Abubaker Bagabir H, Hashem Ateeq R. Covid-19 and Artificial Intelligence: Genome sequencing, drug development and vaccine discovery. *J Infect Public Health* 2022; **15**(2): 289-96.

82. Aghamirza Moghim Aliabadi H, Eivazzadeh-Keihan R, Beig Parikhani A, et al. COVID-19: A systematic review and update on prevention, diagnosis, and treatment. *MedComm (2020)* 2022; **3**(1): e115.

83. Ahmad Malik J, Ahmed S, Shinde M, et al. The Impact of COVID-19 On Comorbidities: A Review Of Recent Updates For Combating It. *Saudi J Biol Sci* 2022; **29**(5): 3586-99.

85. Alam MS. Insight into SARS-CoV-2 Omicron variant immune escape possibility and variant independent potential therapeutic opportunities. *Heliyon* 2023; **9**(2): e13285.

86. Alcendor DJ, Matthews-Juarez P, Smoot D, Edwards A, Hildreth JEK, Juarez PD. Vaccine Confidence and Uptake of the Omicron Bivalent Booster in Tennessee: Implications for Vulnerable Populations. *Vaccines (Basel)* 2023; **11**(5).

87. Alcendor DJ, Matthews-Juarez P, Smoot D, et al. Breakthrough COVID-19 Infections in the US: Implications for Prolonging the Pandemic. *Vaccines (Basel)* 2022; **10**(5).

88. Alhamid G, Tombuloglu H, Rabaan AA, Al-Suhaimi E. SARS-CoV-2 detection methods: A comprehensive review. *Saudi J Biol Sci* 2022; **29**(11): 103465.

89. Amani B, Akbarzadeh A, Amani B, et al. Comparative efficacy and safety of nirmatrelvir/ritonavir and molnupiravir for COVID-19: A systematic review and meta-analysis. *J Med Virol* 2023; **95**(6): e28889.

90. Amiral J, Seghatchian J. Autoimmune complications of COVID-19 and potential consequences for long-lasting disease syndromes. *Transfus Apher Sci* 2023; **62**(1): 103625.

92. Arabi M, Al-Najjar Y, Mhaimeed N, et al. Severity of the Omicron SARS-CoV-2 variant compared with the previous lineages: A systematic review. *J Cell Mol Med* 2023; **27**(11): 1443-64.

93. Arabi M, Al-Najjar Y, Sharma O, et al. Role of previous infection with SARS-CoV-2 in protecting against omicron reinfections and severe complications of COVID-19 compared to pre-omicron variants: a systematic review. *BMC Infect Dis* 2023; **23**(1): 432.

94. Atuire CA, Hassoun N. Rethinking solidarity towards equity in global health: African views. *Int J Equity Health* 2023; **22**(1): 52.

95. Balloux F, Tan C, Swadling L, et al. The past, current and future epidemiological dynamic of SARS-CoV-2. *Oxf Open Immunol* 2022; **3**(1): iqac003.

96. Banerjee S, Banerjee D, Singh A, Saharan VA. A Comprehensive Investigation Regarding the Differentiation of the Procurable COVID-19 Vaccines. *AAPS PharmSciTech* 2022; **23**(4): 95.

99. Bauer L, van Riel D. Do SARS-CoV-2 Variants Differ in Their Neuropathogenicity? *mBio* 2023; **14**(1): e0292022.

100. Berenguer J. Neutralizing antibodies for SARS-CoV-2 infection. *Rev Esp Quimioter* 2022; **35 Suppl 3**(Suppl 3): 16-9.

101. Bergeri I, Whelan MG, Ware H, et al. Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: A systematic review and meta-analysis of standardized population-based studies. *PLoS Med* 2022; **19**(11): e1004107.

102. Bhardwaj P, Mishra SK, Behera SP, Zaman K, Kant R, Singh R. Genomic evolution of the SARS-CoV-2 Variants of Concern: COVID-19 pandemic waves in India. *Excli j* 2023; **22**: 451-65.

103. Blom K, Havervall S, Marking U, et al. Infection Rate of SARS-CoV-2 in Asymptomatic Healthcare Workers, Sweden, June 2022. *Emerg Infect Dis* 2022; **28**(10): 2119-21.

104. Bova SM, Serafini L, Serati I, Fiori L, Veggiotti P. Seizures may be an early sign of acute COVID-19, and the Omicron variant could present a more epileptogenic profile. *Acta Paediatr* 2022; **111**(9): 1814-5.

105. Brand M, Keşmir C. Evolution of SARS-CoV-2-specific CD4(+) T cell epitopes. *Immunogenetics* 2023; **75**(3): 283-93.

106. Brogna B, Bignardi E, Megliola A, et al. A Pictorial Essay Describing the CT Imaging Features of COVID-19 Cases throughout the Pandemic with a Special Focus on Lung Manifestations and Extrapulmonary Vascular Abdominal Complications. *Biomedicines* 2023; **11**(8).

107. Buonsenso D, Cusenza F, Passadore L, Bonanno F, De Guido C, Esposito S. Duration of immunity to SARS-CoV-2 in children after natural infection or vaccination in the omicron and pre-omicron era: A systematic review of clinical and immunological studies. *Front Immunol* 2022; **13**: 1024924.

108. Cao L. AI in Combating the COVID-19 Pandemic. *IEEE Intell Syst* 2022; **37**(2): 3-13.

109. Caputo E, Mandrich L. Structural and Phylogenetic Analysis of SARS-CoV-2 Spike Glycoprotein from the Most Widespread Variants. *Life (Basel)* 2022; **12**(8).

111. Carvajal J, Casanello P, Toso A, et al. Functional consequences of SARS-CoV-2 infection in pregnant women, fetoplacental unit, and neonate. *Biochim Biophys Acta Mol Basis Dis* 2023; **1869**(1): 166582.

112. Castaldo P, d'Alanno G, Biserni GB, et al. Exploring Factors Influencing Changes in Incidence and Severity of Multisystem Inflammatory Syndrome in Children. *Pathogens* 2023; **12**(8).

113. Catalano A, Iacopetta D, Ceramella J, et al. Are Nutraceuticals Effective in COVID-19 and Post-COVID Prevention and Treatment? *Foods* 2022; **11**(18).

114. Chang ZY, Alhamami F, Chin KL. Aptamer-Based Strategies to Address Challenges in COVID-19 Diagnosis and Treatments. *Interdiscip Perspect Infect Dis* 2023; **2023**: 9224815.

115. Chavda VP, Bezbaruah R, Deka K, Nongrang L, Kalita T. The Delta and Omicron Variants of SARS-CoV-2: What We Know So Far. *Vaccines (Basel)* 2022; **10**(11).

116. Chavda VP, Vuppu S, Mishra T, et al. Recent review of COVID-19 management: diagnosis, treatment and vaccination. *Pharmacol Rep* 2022; **74**(6): 1120-48.

117. Chen C, Dai L, Zheng C, et al. Antibody response to SARS-CoV-2 WT and Omicron BA.4/5 of inactivated COVID-19 vaccine in patients with lung cancer after second and booster immunization. *J Hematol Oncol* 2023; **16**(1): 47.

118. Chen CS, Chang CN, Hu CF, et al. Critical pediatric neurological illness associated with COVID-19 (Omicron BA.2.3.7 variant) infection in Taiwan: immunological assessment and viral genome analysis in tertiary medical center. *Int J Infect Dis* 2022; **124**: 45-8.

120. Chenchula S, Amerneni KC, Ghanta MK, et al. Clinical virology and effect of Covid-19 vaccination and monoclonal antibodies against highly infectious SARS- CoV-2 omicron sub variant BF.7 (BA.5.2.1.7): A systematic review. *Virology* 2023; **584**: 38-43.

121. Conklin J, Arroyo J, Kumar R, Patibandla S. Two SARS-CoV-2 serology assays detect antibodies in the sera of individuals diagnosed with SARS-CoV-2 Omicron variant. *Clin Biochem* 2022; **103**: 35-6.

122. Dadras O, SeyedAlinaghi S, Karimi A, et al. COVID-19 Vaccines' Protection Over Time and the Need for Booster Doses; a Systematic Review. *Arch Acad Emerg Med* 2022; **10**(1): e53.

123. Dal-Ré R, Becker SL, Bottieau E, Holm S. Availability of oral antivirals against SARS-CoV-2 infection and the requirement for an ethical prescribing approach. *Lancet Infect Dis* 2022; **22**(8): e231-e8.

125. de Souza AS, de Freitas Amorim VM, Guardia GDA, et al. Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern: A Perspective for Emerging More Transmissible and Vaccine-Resistant Strains. *Viruses* 2022; **14**(4).

126. Del Bello A, Marion O, Izopet J, Kamar N. Can the COVID-19 Pandemic Improve the Management of Solid Organ Transplant Recipients? *Viruses* 2022; **14**(9).

127. Deng J, Ma Y, Liu Q, Du M, Liu M, Liu J. Association of Infection with Different SARS-CoV-2 Variants during Pregnancy with Maternal and Perinatal Outcomes: A Systematic Review and Meta-Analysis. *Int J Environ Res Public Health* 2022; **19**(23).

128. Derdevet J, Ranque B, Khimoud D, et al. Efficacy of COVID-19 vaccination in adult patients with sickle cell disease during the Omicron wave in France. *Eur J Haematol* 2023; **111**(3): 509-12.

129. Diani S, Leonardi E, Cavezzi A, et al. SARS-CoV-2-The Role of Natural Immunity: A Narrative Review. *J Clin Med* 2022; **11**(21).

130. Dimopoulou D, Dasoula F, Liaska M, et al. Rise of Neurologic Manifestations During SARS-CoV-2 Omicron Wave in Children With COVID-19. *Pediatr Infect Dis J* 2023; **42**(4): e128-e9.

131. Ding Q, Zhao H. Long-term effects of SARS-CoV-2 infection on human brain and memory. *Cell Death Discov* 2023; **9**(1): 196.

132. Dong J, Chen R, Zhao H, Zhu Y. COVID-19 and ocular complications: A review of ocular manifestations, diagnostic tools, and prevention strategies. *Adv Ophthalmol Pract Res* 2023; **3**(1): 33-8.

133. Dorabawila V, Bassett MT, Rosenberg ES. Risk of Infection and Hospitalization Among Children and Adolescents in New York After Emergence of the SARS-CoV-2 Omicron Variant-Reply. *Jama* 2022; **328**(14): 1460-1.

134. Drożdżal S, Rosik J, Lechowicz K, et al. An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment. *Drug Resist Updat* 2021; **59**: 100794.

136. Dutta D, Liu J, Xiong H. NLRP3 inflammasome activation and SARS-CoV-2-mediated hyperinflammation, cytokine storm and neurological syndromes. *Int J Physiol Pathophysiol Pharmacol* 2022; **14**(3): 138-60.

137. Eid J, Post S, Guhde H, et al. Increasing rates of sars-cov-2 infection in newborns during the omicron variant epoch. *Am J Reprod Immunol* 2023; **90**(2): e13742.

138. El-Shabasy RM, Nayel MA, Taher MM, Abdelmonem R, Shoueir KR, Kenawy ER. Three waves changes, new variant strains, and vaccination effect against COVID-19 pandemic. *Int J Biol Macromol* 2022; **204**: 161-8.

139. Eyssette-Guerreau S, Khimoud D, Michaux K, et al. Severe cases of COVID-19 in children with sickle cell disease during the Omicron wave in France: a plea for vaccination. *Br J Haematol* 2022; **199**(2): e8-e11.

140. Fang FF. As the virus evolves, so too must we: a drug developer's perspective : We need a new paradigm in searching for next-generation countermeasures. *Virol J* 2022; **19**(1): 159.

141. Feikin DR, Higdon MM, Abu-Raddad LJ, et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. *Lancet* 2022; **399**(10328): 924-44.

143. Ferretti S, Chiaretti A, Gatto A, Curatola A. Incidence of MIS-C during the Omicron wave: Authors' replay. *Acta Paediatr* 2022; **111**(9): 1821-2.

144. Flacco ME, Acuti Martellucci C, Baccolini V, et al. Risk of reinfection and disease after SARS-CoV-2 primary infection: Meta-analysis. *Eur J Clin Invest* 2022; **52**(10): e13845.

145. Flacco ME, Acuti Martellucci C, Baccolini V, et al. COVID-19 vaccines reduce the risk of SARS-CoV-2 reinfection and hospitalization: Meta-analysis. *Front Med (Lausanne)* 2022; **9**: 1023507.

146. Flaherty GT, Hamer DH, Chen LH. Travel in the Time of COVID: A Review of International Travel Health in a Global Pandemic. *Curr Infect Dis Rep* 2022; **24**(10): 129-45.

147. Fleming-Dutra KE, Zauche LH, Roper LE, et al. Safety and Effectiveness of Maternal COVID-19 Vaccines Among Pregnant People and Infants. *Obstet Gynecol Clin North Am* 2023; **50**(2): 279-97.

148. Focosi D, Casadevall A. A Critical Analysis of the Use of Cilgavimab plus Tixagevimab Monoclonal Antibody Cocktail (Evusheld™) for COVID-19 Prophylaxis and Treatment. *Viruses* 2022; **14**(9).

149. Focosi D, Franchini M, Pirofski LA, et al. COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes. *Clin Microbiol Rev* 2022; **35**(3): e0020021.

150. Frasca L, Ocone G, Palazzo R. Safety of COVID-19 Vaccines in Patients with Autoimmune Diseases, in Patients with Cardiac Issues, and in the Healthy Population. *Pathogens* 2023; **12**(2).

151. Fyntanidou B, Meletis G, Gkarmiri S, Gkeka I, Tychala A, Skoura L. Negative Predictive Value of the Rapid Test Ag 2019-nCoV During the Predominance of Omicron over the Delta Variant and Implications in the Emergency Department. *SN Compr Clin Med* 2022; **4**(1): 213.

152. Gabrielli M. COVID-19 in Older Adults at the Time of the Omicron Variant. *J Clin Med* 2022; **11**(18).

153. Ghosh N, Nandi S, Saha I. A review on evolution of emerging SARS-CoV-2 variants based on spike glycoprotein. *Int Immunopharmacol* 2022; **105**: 108565.

155. Gili R, Burioni R. SARS-CoV-2 before and after Omicron: two different viruses and two different diseases? *J Transl Med* 2023; **21**(1): 251.

156. Goodlad C, Davenport A. The changing pattern of COVID-19 infection in hemodialysis and peritoneal dialysis patients. *Artif Organs* 2023; **47**(7): 1202-7.

157. Gupta A, Singh AP, Singh VK, Sinha RP. Recent Developments and Future Perspectives of Vaccines and Therapeutic Agents against SARS-CoV2 Using the BCOV\_S1\_CTD of the S Protein. *Viruses* 2023; **15**(6).

158. Gupta SL, Tyagi R, Dhar A, Oswal N, Khandelwal A, Jaiswal RK. Children's SARS-CoV-2 Infection and Their Vaccination. *Vaccines (Basel)* 2023; **11**(2).

160. Harne R, Williams B, Abdelal HFM, Baldwin SL, Coler RN. SARS-CoV-2 infection and immune responses. *AIMS Microbiol* 2023; **9**(2): 245-76.

161. He J, Wei Z, Leng T, Bao J, Gao X, Chen F. Vaccination options for pregnant women during the Omicron period. *J Reprod Immunol* 2023; **156**: 103798.

162. He X, He C, Hong W, Yang J, Wei X. Research progress in spike mutations of SARS-CoV-2 variants and vaccine development. *Med Res Rev* 2023; **43**(4): 932-71.

163. Henning RJ. Cardiovascular complications of COVID-19 severe acute respiratory syndrome. *Am J Cardiovasc Dis* 2022; **12**(4): 170-91.

164. Hernández-Aceituno A, Larumbe Zabala E. Risk factors for mortality from COVID-19 Omicron variant: Retrospective analysis in elderly from the Canary Islands. *Rev Esp Geriatr Gerontol* 2023; **58**(4): 101381.

165. Hernández-Sampelayo T, Gómez-Pavón J, González Del Castillo J, et al. COVID in Pediatric Age: an opinion paper. *Rev Esp Quimioter* 2022; **35**(4): 333-43.

166. Holmer HK, Mackey K, Fiordalisi CV, Helfand M. Major Update 2: Antibody Response and Risk for Reinfection After SARS-CoV-2 Infection-Final Update of a Living, Rapid Review. *Ann Intern Med* 2023; **176**(1): 85-91.

167. Hossain A, Akter S, Rashid AA, Khair S, Alam A. Unique mutations in SARS-CoV-2 Omicron subvariants' non-spike proteins: Potential impacts on viral pathogenesis and host immune evasion. *Microb Pathog* 2022; **170**: 105699.

169. Huang Y, Zheng ZW, Chen C, et al. Epidemiological characteristics of two local COVID-19 outbreaks caused by 2019-nCoV Omicron variant in Guangzhou, China. *Zhonghua Liu Xing Bing Xue Za Zhi* 2022; **43**(11): 1705-10.

170. Hulme J. COVID-19 and Diarylamidines: The Parasitic Connection. *Int J Mol Sci* 2023; **24**(7).

172. Jia H, Wang H, Cao L, et al. Genetic analysis of a SARS-CoV-2 Omicron variant from a Chinese traveller returning from overseas. *Emerg Microbes Infect* 2022; **11**(1): 306-9.

174. John BV, Bastaich DR, Ferreira RD, et al. COVID-19 vaccine effectiveness and community prevalence of Alpha, Delta and Omicron variants in patients with cirrhosis. *Gut* 2023; **72**(9): 1800-2.

175. Jondreville L, D'Aveni M, Labussière-Wallet H, et al. Pre-exposure prophylaxis with tixagevimab/cilgavimab (AZD7442) prevents severe SARS-CoV-2 infection in recipients of allogeneic hematopoietic stem cell transplantation during the Omicron wave: a multicentric retrospective study of SFGM-TC. *J Hematol Oncol* 2022; **15**(1): 169.

176. Jung C, Kmiec D, Koepke L, et al. Omicron: What Makes the Latest SARS-CoV-2 Variant of Concern So Concerning? *J Virol* 2022; **96**(6): e0207721.

177. Karimian A, Behjati M, Karimian M. Molecular mechanisms involved in anosmia induced by SARS-CoV-2, with a focus on the transmembrane serine protease TMPRSS2. *Arch Virol* 2022; **167**(10): 1931-46.

178. Katoto PD, Tamuzi JL, Brand AS, et al. Effectiveness of COVID-19 Pfizer-BioNTech (BNT162b2) mRNA vaccination in adolescents aged 12-17 years: A systematic review and meta-analysis. *Hum Vaccin Immunother* 2023; **19**(1): 2214495.

179. Katz MJ, Jump RLP. Omicron infection milder in nursing home residents. *Lancet Healthy Longev* 2022; **3**(5): e314-e5.

181. Kedzierska K, Thomas PG. Count on us: T cells in SARS-CoV-2 infection and vaccination. *Cell Rep Med* 2022; **3**(3): 100562.

182. Kelleni MT. Evolution of SARS CoV-2 Omicron subvariants BF.7 and XBB.1.5: Time to follow Africa and abort all COVID restrictions. *J Infect* 2023; **86**(4): 405.

183. Khairnar P, Soni M, Handa M, Riadi Y, Kesharwani P, Shukla R. Recent highlights on Omicron as a new SARS-COVID-19 variant: evolution, genetic mutation, and future perspectives. *J Drug Target* 2022; **30**(6): 603-13.

184. Khalid N, Wheeler AM. SARS-CoV-2 in relation to global vaccination and booster doses: what is the future of vaccination in the battle against COVID-19? *Bratisl Lek Listy* 2022; **123**(9): 631-3.

186. Khemiri H, Ayouni K, Triki H, Haddad-Boubaker S. SARS-CoV-2 infection in pediatric population before and during the Delta (B.1.617.2) and Omicron (B.1.1.529) variants era. *Virol J* 2022; **19**(1): 144.

187. Kherabi Y, Launay O, Luong Nguyen LB. COVID-19 Vaccines against Omicron Variant: Real-World Data on Effectiveness. *Viruses* 2022; **14**(10).

188. Kim K, Cho K, Song J, et al. The case fatality rate of COVID-19 during the Delta and the Omicron epidemic phase: A meta-analysis. *J Med Virol* 2023; **95**(2): e28522.

189. Kim S, Nguyen TT, Taitt AS, et al. SARS-CoV-2 Omicron Mutation Is Faster than the Chase: Multiple Mutations on Spike/ACE2 Interaction Residues. *Immune Netw* 2021; **21**(6): e38.

190. Kohn M, Alsuliman T, Lamure S, et al. Characteristics of SARS-CoV-2 infection in lymphoma/chronic lymphocytic leukemia patients during the Omicron outbreak. *Leuk Lymphoma* 2022; **63**(11): 2686-90.

191. Kontoghiorghes GJ, Fetta S, Kontoghiorghe CN. The need for a multi-level drug targeting strategy to curb the COVID-19 pandemic. *Front Biosci (Landmark Ed)* 2021; **26**(12): 1723-36.

193. Krygier A, Szmajda-Krygier D, Świechowski R, et al. Molecular Pathogenesis of Fibrosis, Thrombosis and Surfactant Dysfunction in the Lungs of Severe COVID-19 Patients. *Biomolecules* 2022; **12**(12).

194. Kubo M, Kubo K, Kobayashi KI, Komiya N. Non-severe COVID-19 complicated by cytotoxic lesions of the corpus callosum (mild encephalitis/encephalopathy with a reversible splenial lesion): a case report and literature review. *Int J Infect Dis* 2022; **125**: 1-9.

196. Kulkarni AV, Metage CS, Gora BA, et al. SARS-CoV-2 Omicron variant infection was associated with higher morbidity in patients with cirrhosis. *Gut* 2023; **72**(10): 1995-6.

197. Külper-Schiek W, Piechotta V, Pilic A, et al. Facing the Omicron variant-how well do vaccines protect against mild and severe COVID-19? Third interim analysis of a living systematic review. *Front Immunol* 2022; **13**: 940562.

198. LaRotta J, Escobar O, Ávila-Aguero ML, et al. COVID-19 in Latin America: A Snapshot in Time and the Road Ahead. *Infect Dis Ther* 2023; **12**(2): 389-410.

199. Lauster D, Osterrieder K, Haag R, Ballauff M, Herrmann A. Respiratory viruses interacting with cells: the importance of electrostatics. *Front Microbiol* 2023; **14**: 1169547.

200. Lee HR, Choe YJ, Jang EJ, et al. Time from Exposure to Diagnosis among Quarantined Close Contacts of SARS-CoV-2 Omicron Variant Index Case-Patients, South Korea. *Emerg Infect Dis* 2022; **28**(4): 901-3.

202. Li Wan Po A. Omicron variant as nature's solution to the COVID-19 pandemic. *J Clin Pharm Ther* 2022; **47**(1): 3-5.

204. Liao CX, Wang B, Lyu J, Li LM. Progress in research of epidemiology of 2019-nCoV reinfection. *Zhonghua Liu Xing Bing Xue Za Zhi* 2023; **44**(3): 360-6.

205. Liew F, Efstathiou C, Openshaw PJM. Long COVID: clues about causes. *Eur Respir J* 2023; **61**(5).

206. Lim S, Sohn M. How to cope with emerging viral diseases: lessons from South Korea's strategy for COVID-19, and collateral damage to cardiometabolic health. *Lancet Reg Health West Pac* 2023; **30**: 100581.

207. Lin DY, Gu Y, Xu Y, et al. Association of Primary and Booster Vaccination and Prior Infection With SARS-CoV-2 Infection and Severe COVID-19 Outcomes. *Jama* 2022; **328**(14): 1415-26.

208. Lino A, Cardoso MA, Martins-Lopes P, Gonçalves HMR. Omicron - The new SARS-CoV-2 challenge? *Rev Med Virol* 2022; **32**(4): e2358.

210. Long B, Carius BM, Chavez S, et al. Clinical update on COVID-19 for the emergency clinician: Presentation and evaluation. *Am J Emerg Med* 2022; **54**: 46-57.

211. Lowe S, Xie R, Chen Y, Shen Y, Sun C. It is not the time to relax yet: masks are still needed for the Omicron variant of SARS-CoV-2. *Public Health* 2022; **205**: e21-e2.

213. Madewell ZJ, Yang Y, Longini IM, Jr., Halloran ME, Dean NE. Household Secondary Attack Rates of SARS-CoV-2 by Variant and Vaccination Status: An Updated Systematic Review and Meta-analysis. *JAMA Netw Open* 2022; **5**(4): e229317.

214. Madewell ZJ, Yang Y, Longini IM, Jr., Halloran ME, Vespignani A, Dean NE. Rapid review and meta-analysis of serial intervals for SARS-CoV-2 Delta and Omicron variants. *BMC Infect Dis* 2023; **23**(1): 429.

216. Mair MJ, Mitterer M, Gattinger P, et al. Enhanced SARS-CoV-2 breakthrough infections in patients with hematologic and solid cancers due to Omicron. *Cancer Cell* 2022; **40**(5): 444-6.

217. Malik JA, Ahmed S, Mir A, et al. The SARS-CoV-2 mutations versus vaccine effectiveness: New opportunities to new challenges. *J Infect Public Health* 2022; **15**(2): 228-40.

218. Mallakpour S, Azadi E, Hussain CM. Fabrication of air filters with advanced filtration performance for removal of viral aerosols and control the spread of COVID-19. *Adv Colloid Interface Sci* 2022; **303**: 102653.

219. Maniruzzaman M, Islam MM, Ali MH, et al. COVID-19 diagnostic methods in developing countries. *Environ Sci Pollut Res Int* 2022; **29**(34): 51384-97.

220. Manoharan R, Kore RA, Mehta JL. Mesenchymal stem cell treatment for hyperactive immune response in patients with COVID-19. *Immunotherapy* 2022; **14**(13): 1055-65.

221. Marchesi F, Salmanton-García J, Buquicchio C, et al. Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry. *J Hematol Oncol* 2023; **16**(1): 32.

223. Marta RA, Nakamura GEK, de Matos Aquino B, Bignardi PR. COVID-19 vaccines: Update of the vaccines in use and under development. *Vacunas* 2022; **23**: S88-s102.

224. Martín Sánchez FJ, Martínez-Sellés M, Molero García JM, et al. Insights for COVID-19 in 2023. *Rev Esp Quimioter* 2023; **36**(2): 114-24.

225. McLean G, Kamil J, Lee B, et al. The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines. *mBio* 2022; **13**(2): e0297921.

226. Menegale F, Manica M, Zardini A, et al. Evaluation of Waning of SARS-CoV-2 Vaccine-Induced Immunity: A Systematic Review and Meta-analysis. *JAMA Netw Open* 2023; **6**(5): e2310650.

228. Mohamed Y, El-Maradny YA, Saleh AK, Nayl AA, El-Gendi H, El-Fakharany EM. A comprehensive insight into current control of COVID-19: Immunogenicity, vaccination, and treatment. *Biomed Pharmacother* 2022; **153**: 113499.

229. Moore PL, Baden LR. Omicron - Decoupling Infection from Severe Disease. *N Engl J Med* 2022; **386**(14): 1361-2.

230. Moshabela M, Msomi N, Kalla GCM, Maimela G, Yombi JC, Mbopi-Keou FX. Hosting ICASA 2021 in South Africa amidst the global Omicron scare. *Pan Afr Med J* 2022; **41**: 91.

231. Moussaoui ME, Desmecht S, Tashkeev A, et al. Reduced T-cell response following a third dose of SARS-CoV-2 vaccine in infection-naïve people living with HIV. *J Infect* 2022; **85**(6): 702-69.

232. Mura M, Simon F, Pommier de Santi V, Tangy F, Tournier JN. Role and Limits of COVID-19 Vaccines in the Delicate Transition from Pandemic Mitigation to Endemic Control. *Vaccines (Basel)* 2022; **10**(9).

234. Naeimi R, Sepidarkish M, Mollalo A, et al. SARS-CoV-2 seroprevalence in children worldwide: A systematic review and meta-analysis. *EClinicalMedicine* 2023; **56**: 101786.

236. Ng TI, Correia I, Seagal J, et al. Antiviral Drug Discovery for the Treatment of COVID-19 Infections. *Viruses* 2022; **14**(5).

237. Ngai HW, Kim DH, Hammad M, Gutova M, Aboody K, Cox CD. Stem Cell-based therapies for COVID-19-related acute respiratory distress syndrome. *J Cell Mol Med* 2022; **26**(9): 2483-504.

238. Nguyen NN, Nguyen YN, Hoang VT, Million M, Gautret P. SARS-CoV-2 Reinfection and Severity of the Disease: A Systematic Review and Meta-Analysis. *Viruses* 2023; **15**(4).

239. Palalay H, Vyas R, Tafuto B. Real-world effectiveness of mRNA COVID-19 vaccines in the elderly during the Delta and Omicron variants: Systematic review. *World J Metaanal* 2023; **11**(5): 167-80.

240. Parihar A, Malviya S, Khan R, Kaushik A, Mostafavi E. COVID-19 associated thyroid dysfunction and other comorbidities and its management using phytochemical-based therapeutics: a natural way. *Biosci Rep* 2023; **43**(7).

241. Patel SK, Surve J, Parmar J, Ahmed K, Bui FM, Al-Zahrani FA. Recent Advances in Biosensors for Detection of COVID-19 and Other Viruses. *IEEE Rev Biomed Eng* 2023; **16**: 22-37.

242. Pather S, Madhi SA, Cowling BJ, et al. SARS-CoV-2 Omicron variants: burden of disease, impact on vaccine effectiveness and need for variant-adapted vaccines. *Front Immunol* 2023; **14**: 1130539.

243. Paul P, El-Naas A, Hamad O, et al. Effectiveness of the pre-Omicron COVID-19 vaccines against Omicron in reducing infection, hospitalization, severity, and mortality compared to Delta and other variants: A systematic review. *Hum Vaccin Immunother* 2023; **19**(1): 2167410.

244. Pecetta S, Kratochvil S, Kato Y, Vadivelu K, Rappuoli R. Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines. *Pharmacol Rev* 2022; **74**(1): 313-39.

246. Petráš M, Máčalík R, Janovská D, et al. Risk factors affecting COVID-19 vaccine effectiveness identified from 290 cross-country observational studies until February 2022: a meta-analysis and meta-regression. *BMC Med* 2022; **20**(1): 461.

247. Piechotta V, Siemens W, Thielemann I, et al. Safety and effectiveness of vaccines against COVID-19 in children aged 5-11 years: a systematic review and meta-analysis. *Lancet Child Adolesc Health* 2023; **7**(6): 379-91.

248. Polatoğlu I, Oncu-Oner T, Dalman I, Ozdogan S. COVID-19 in early 2023: Structure, replication mechanism, variants of SARS-CoV-2, diagnostic tests, and vaccine & drug development studies. *MedComm (2020)* 2023; **4**(2): e228.

249. Poydenot F, Lebreton A, Haiech J, Andreotti B. At the crossroads of epidemiology and biology: Bridging the gap between SARS-CoV-2 viral strain properties and epidemic wave characteristics. *Biochimie* 2023; **213**: 54-65.

250. Pratama NR, Wafa IA, Budi DS, et al. Effectiveness of COVID-19 Vaccines against SARS-CoV-2 Omicron Variant (B.1.1.529): A Systematic Review with Meta-Analysis and Meta-Regression. *Vaccines (Basel)* 2022; **10**(12).

251. Primorac D, Vrdoljak K, Brlek P, et al. Adaptive Immune Responses and Immunity to SARS-CoV-2. *Front Immunol* 2022; **13**: 848582.

252. Prüβ BM. Variants of SARS CoV-2: mutations, transmissibility, virulence, drug resistance, and antibody/vaccine sensitivity. *Front Biosci (Landmark Ed)* 2022; **27**(2): 65.

253. Rabaan AA, Al-Ahmed SH, Albayat H, et al. Variants of SARS-CoV-2: Influences on the Vaccines' Effectiveness and Possible Strategies to Overcome Their Consequences. *Medicina (Kaunas)* 2023; **59**(3).

254. Rahmati M, Yon DK, Lee SW, et al. Effects of COVID-19 vaccination during pregnancy on SARS-CoV-2 infection and maternal and neonatal outcomes: A systematic review and meta-analysis. *Rev Med Virol* 2023; **33**(3): e2434.

255. Rajpal VR, Sharma S, Kumar A, et al. "Is Omicron mild"? Testing this narrative with the mutational landscape of its three lineages and response to existing vaccines and therapeutic antibodies. *J Med Virol* 2022; **94**(8): 3521-39.

257. Rijnders BJA, Huygens S, Mitjà O. Evidence-based dosing of convalescent plasma for COVID-19 in future trials. *Clin Microbiol Infect* 2022; **28**(5): 667-71.

258. Rubin EJ, Baden LR, Morrissey S. Audio Interview: Covid-19 Vaccination and the Omicron Variant. *N Engl J Med* 2021; **385**(27): e102.

259. Rubio-Casillas A, Redwan EM, Uversky VN. SARS-CoV-2: A Master of Immune Evasion. *Biomedicines* 2022; **10**(6).

260. Sabu JM, Zahid I, Jacob N, Alele FO, Malau-Aduli BS. Effectiveness of the BNT162b2 (Pfizer-BioNTech) Vaccine in Children and Adolescents: A Systematic Review and Meta-Analysis. *Vaccines (Basel)* 2022; **10**(11).

261. Sahebkar A, Jamialahmadi T, Rahmoune H, Guest PC. Long-Term Vaccination and Treatment Strategies for COVID-19 Disease and Future Coronavirus Pandemics. *Adv Exp Med Biol* 2023; **1412**: 27-49.

263. Saravolatz LD, Depcinski S, Sharma M. Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs. *Clin Infect Dis* 2023; **76**(1): 165-71.

265. Schermerhorn J, Case A, Graeden E, et al. Fifteen days in December: capture and analysis of Omicron-related travel restrictions. *BMJ Glob Health* 2022; **7**(3).

266. Schmidt KH, Milger K, Pausch C, et al. Trends in COVID-19-associated mortality in patients with pulmonary hypertension: a COMPERA analysis. *Eur Respir J* 2023; **61**(4).

267. Scovino AM, Dahab EC, Vieira GF, Freire-de-Lima L, Freire-de-Lima CG, Morrot A. SARS-CoV-2's Variants of Concern: A Brief Characterization. *Front Immunol* 2022; **13**: 834098.

268. Seasely AR, Blanchard CT, Arora N, et al. Maternal and Perinatal Outcomes Associated With the Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection. *Obstet Gynecol* 2022; **140**(2): 262-5.

271. Seneff S, Kyriakopoulos AM, Nigh G, McCullough PA. A Potential Role of the Spike Protein in Neurodegenerative Diseases: A Narrative Review. *Cureus* 2023; **15**(2): e34872.

272. Shahin K, Zhang L, Mehraban MH, et al. Clinical and experimental bacteriophage studies: Recommendations for possible approaches for standing against SARS-CoV-2. *Microb Pathog* 2022; **164**: 105442.

274. Shao W, Chen X, Zheng C, et al. Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern in real-world: a literature review and meta-analysis. *Emerg Microbes Infect* 2022; **11**(1): 2383-92.

275. Shao W, Zhang W, Fang X, Yu D, Wang X. Challenges of SARS-CoV-2 Omicron Variant and appropriate countermeasures. *J Microbiol Immunol Infect* 2022; **55**(3): 387-94.

276. Sharma V, Rai H, Gautam DNS, Prajapati PK, Sharma R. Emerging evidence on Omicron (B.1.1.529) SARS-CoV-2 variant. *J Med Virol* 2022; **94**(5): 1876-85.

277. Shipovalov AV, Kudrov GA, Kartashov MY, et al. Antiviral activity of basidial fungus Inonotus obliquus aqueous extract against SARS-CоV-2 virus (Coronaviridae: Betacoronavirus: Sarbecovirus) in vivo in BALB/c mice model. *Vopr Virusol* 2023; **68**(2): 152-60.

278. Singh MB, Sharma R, Kumar D, et al. An understanding of coronavirus and exploring the molecular dynamics simulations to find promising candidates against the Mpro of nCoV to combat the COVID-19: A systematic review. *J Infect Public Health* 2022; **15**(11): 1326-49.

279. Singh R, Malik P, Kumar M, Kumar R, Alam MS, Mukherjee TK. Secondary fungal infections in SARS-CoV-2 patients: pathological whereabouts, cautionary measures, and steadfast treatments. *Pharmacol Rep* 2023; **75**(4): 817-37.

280. Singh RS, Singh A, Masih GD, et al. A comprehensive insight on the challenges for COVID-19 vaccine: A lesson learnt from other viral vaccines. *Heliyon* 2023; **9**(6): e16813.

281. Singhal T. The Emergence of Omicron: Challenging Times Are Here Again! *Indian J Pediatr* 2022; **89**(5): 490-6.

282. Smith BF, Graven PF, Yang DY, et al. Using Spike Gene Target Failure to Estimate Growth Rate of the Alpha and Omicron Variants of SARS-CoV-2. *J Clin Microbiol* 2022; **60**(4): e0257321.

283. Sommer I, Dobrescu A, Ledinger D, et al. Outpatient Treatment of Confirmed COVID-19: A Living, Rapid Review for the American College of Physicians. *Ann Intern Med* 2023; **176**(1): 92-104.

284. Soni V, Paital S, Raizada P, et al. Surveillance of omicron variants through wastewater epidemiology: Latest developments in environmental monitoring of pandemic. *Sci Total Environ* 2022; **843**: 156724.

285. Spinardi J, Dantas AC, Carballo C, et al. Narrative Review of the Evolution of COVID-19 Vaccination Recommendations in Countries in Latin America, Africa and the Middle East, and Asia. *Infect Dis Ther* 2023; **12**(5): 1237-64.

286. Strohl WR, Ku Z, An Z, Carroll SF, Keyt BA, Strohl LM. Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants. *BioDrugs* 2022; **36**(3): 231-323.

287. Stultz JS, Eiland LS. A Review of the Data Supporting Use of COVID-19 Vaccinations in the Pediatric Population. *Ann Pharmacother* 2023: 10600280231156625.

288. Su Z, McDonnell D, Bennett B, et al. Psychoneuroimmunology concerns of the Olympic boycotts. *Brain Behav Immun* 2022; **102**: 206-8.

289. Sullivan DJ, Focosi D, Hanley DF, et al. Outpatient regimens to reduce COVID-19 hospitalisations: a systematic review and meta-analysis of randomized controlled trials. *medRxiv* 2023.

290. Sun J, Yang ZD, Xie X, et al. Clinical application of SARS-CoV-2 antibody detection and monoclonal antibody therapies against COVID-19. *World J Clin Cases* 2023; **11**(10): 2168-80.

291. Suribhatla R, Starkey T, Ionescu MC, Pagliuca A, Richter A, Lee LYW. Systematic review and meta-analysis of the clinical effectiveness of tixagevimab/cilgavimab for prophylaxis of COVID-19 in immunocompromised patients. *Br J Haematol* 2023; **201**(5): 813-23.

292. Suzuki K, Hekmatikar AHA, Jalalian S, et al. The Potential of Exerkines in Women's COVID-19: A New Idea for a Better and More Accurate Understanding of the Mechanisms behind Physical Exercise. *Int J Environ Res Public Health* 2022; **19**(23).

293. Szpulak A, Garlak U, Ćwirko H, Witkowska B, Rombel-Bryzek A, Witkowska D. SARS-CoV-2 and its impact on the cardiovascular and digestive systems - The interplay between new virus variants and human cells. *Comput Struct Biotechnol J* 2023; **21**: 1022-9.

294. Takao H, Iijima H, Odagiri R, Hayakawa I, Ogimi C. Acute cerebellar ataxia during acute COVID-19: A case series and review of the literature. *J Infect Chemother* 2023; **29**(8): 792-5.

295. Tanase A, Manea A, Scurtu AD, et al. The "Invisible Enemy" SARS-CoV-2: Viral Spread and Drug Treatment. *Medicina (Kaunas)* 2022; **58**(2).

297. Terpos E, Musto P, Engelhardt M, et al. Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN). *Leukemia* 2023; **37**(6): 1175-85.

298. Thomas E, Delabat S, Carattini YL, Andrews DM. SARS-CoV-2 and Variant Diagnostic Testing Approaches in the United States. *Viruses* 2021; **13**(12).

299. Togha M, Hashemi SM, Yamani N, Martami F, Salami Z. A Review on Headaches Due to COVID-19 Infection. *Front Neurol* 2022; **13**: 942956.

300. Torresi J, Edeling MA, Nolan T, Godfrey DI. A Complementary Union of SARS-CoV2 Natural and Vaccine Induced Immune Responses. *Front Immunol* 2022; **13**: 914167.

301. Tulimilli SV, Dallavalasa S, Basavaraju CG, et al. Variants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Vaccine Effectiveness. *Vaccines (Basel)* 2022; **10**(10).

302. van der Straten K, van Gils MJ, de Taeye SW, de Bree GJ. Optimization of Anti-SARS-CoV-2 Neutralizing Antibody Therapies: Roadmap to Improve Clinical Effectiveness and Implementation. *Front Med Technol* 2022; **4**: 867982.

303. Vanker A, de Waal L, McGeer A, Morgan M. Severity of SARS-CoV-2 omicron infection in vaccinated and unvaccinated residents of long-term care homes. *Infect Control Hosp Epidemiol* 2023; **44**(2): 352-3.

304. Varasi I, Lai A, Fiaschi L, et al. Neutralizing antibodies response to novel SARS-CoV-2 omicron sublineages in long-term care facility residents after the fourth dose of monovalent BNT162b2 COVID-19 vaccination. *J Infect* 2023; **87**(3): 270-2.

305. Wan EYF, Mok AHY, Yan VKC, et al. Vaccine effectiveness of BNT162b2 and CoronaVac against SARS-CoV-2 Omicron BA.2 infection, hospitalisation, severe complications, cardiovascular disease and mortality in patients with diabetes mellitus: A case control study. *J Infect* 2022; **85**(5): e140-e4.

306. Wang BJ, Wang C, Dong N, et al. Clinical characteristics of children infected with SARS-CoV-2 Omicron variant combined with allergic disease. *Zhonghua Er Ke Za Zhi* 2023; **61**(1): 61-5.

307. Wang J, Dong W. COVID-19: the possibility, ways, mechanisms, and interruptions of mother-to-child transmission. *Arch Gynecol Obstet* 2023; **307**(6): 1687-96.

308. Wang X, Liu D, Chen D, et al. Clinical characteristics in patients with persistent positive pharyngeal swab of omicron variant and analysis on nucleic acid testing of anal swabs. *Zhonghua Wei Zhong Bing Ji Jiu Yi Xue* 2022; **34**(9): 905-8.

309. Wang XL, Zhai J, Zou YX. Clinical characteristics and vaccination status of SARS-CoV-2 Omicron variant infected children. *Zhonghua Er Ke Za Zhi* 2022; **60**(7): 671-5.

310. Wang Y, Long Y, Wang F, Li C, Liu W. Characterization of SARS-CoV-2 recombinants and emerging Omicron sublineages. *Int J Med Sci* 2023; **20**(1): 151-62.

311. Wang Y, Tan S, Yan Q, Gao Y. Sarcopenia and COVID-19 Outcomes. *Clin Interv Aging* 2023; **18**: 359-73.

312. Wang Y, Zhao D, Liu X, Chen X, Xiao W, Feng L. Early administration of Paxlovid reduces the viral elimination time in patients infected with SARS-CoV-2 Omicron variants. *J Med Virol* 2023; **95**(1): e28443.

313. Wei Z, He J, Wang C, Bao J, Leng T, Chen F. The importance of booster vaccination in the context of Omicron wave. *Front Immunol* 2022; **13**: 977972.

315. Wiegand T, Nemudryi A, Nemudraia A, et al. The Rise and Fall of SARS-CoV-2 Variants and Ongoing Diversification of Omicron. *Viruses* 2022; **14**(9).

316. Wolf JM, Wolf LM, Bello GL, Maccari JG, Nasi LA. Molecular evolution of SARS-CoV-2 from December 2019 to August 2022. *J Med Virol* 2023; **95**(1): e28366.

317. Wong SC, Au AK, Lo JY, et al. Evolution and Control of COVID-19 Epidemic in Hong Kong. *Viruses* 2022; **14**(11).

318. Wu N, Joyal-Desmarais K, Ribeiro PAB, et al. Long-term effectiveness of COVID-19 vaccines against infections, hospitalisations, and mortality in adults: findings from a rapid living systematic evidence synthesis and meta-analysis up to December, 2022. *Lancet Respir Med* 2023; **11**(5): 439-52.

320. Wu Y, Kang L, Guo Z, Liu J, Liu M, Liang W. Incubation Period of COVID-19 Caused by Unique SARS-CoV-2 Strains: A Systematic Review and Meta-analysis. *JAMA Netw Open* 2022; **5**(8): e2228008.

321. Wu Y, Long Y, Wang F, Liu W, Wang Y. Emergence of SARS-CoV-2 Omicron variant and strategies for tackling the infection. *Immun Inflamm Dis* 2022; **10**(12): e733.

322. Xu R, Wang W, Zhang W. As the SARS-CoV-2 virus evolves, should Omicron subvariant BA.2 be subjected to quarantine, or should we learn to live with it? *Front Public Health* 2022; **10**: 1039123.

323. Xu S, Li J, Wang H, Wang F, Yin Z, Wang Z. Real-world effectiveness and factors associated with effectiveness of inactivated SARS-CoV-2 vaccines: a systematic review and meta-regression analysis. *BMC Med* 2023; **21**(1): 160.

324. Yang G, Wang J, Sun P, et al. SARS-CoV-2 epitope-specific T cells: Immunity response feature, TCR repertoire characteristics and cross-reactivity. *Front Immunol* 2023; **14**: 1146196.

325. Yetmar ZA, Bhaimia E, Razonable RR. Antispike monoclonal antibodies for prevention and treatment of coronavirus disease-2019 in solid organ transplant recipients. *Curr Opin Organ Transplant* 2022; **27**(4): 269-76.

329. Zhang L, Zhao J, Li R, et al. Low risk of relapse in aplastic anemia patients after SARS-CoV-2 omicron infection: A prospective NICHE cohort. *Am J Hematol* 2023; **98**(10): E272-e5.

330. Zhang Y, Huang Z, Zhu J, et al. An updated review of SARS-CoV-2 detection methods in the context of a novel coronavirus pandemic. *Bioeng Transl Med* 2022; **8**(1): e10356.

331. Zhang Y, Luo MT, Wu Q, et al. Long-term and effective neutralization against omicron sublineages elicited by four platform COVID-19 vaccines as a booster dose. *Cell Discov* 2023; **9**(1): 17.

333. Zhao Y, Liu Q. Analysis of distribution characteristics of COVID-19 in America based on space-time scan statistic. *Front Public Health* 2022; **10**: 897784.

334. Zhou H, Møhlenberg M, Thakor JC, et al. Sensitivity to Vaccines, Therapeutic Antibodies, and Viral Entry Inhibitors and Advances To Counter the SARS-CoV-2 Omicron Variant. *Clin Microbiol Rev* 2022; **35**(3): e0001422.

336. Zou Y, Huang D, Jiang Q, Guo Y, Chen C. The Vaccine Efficacy Against the SARS-CoV-2 Omicron: A Systemic Review and Meta-Analysis. *Front Public Health* 2022; **10**: 940956.

1. Adachi E, Nagai E, Saito M, et al. Anti-spike protein antibody titer at the time of breakthrough infection of SARS-CoV-2 omicron. *J Infect Chemother* 2022; **28**(7): 1015-7.

2. Aggarwal NR, Molina KC, Beaty LE, et al. Real-world use of nirmatrelvir-ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study. *Lancet Infect Dis* 2023; **23**(6): 696-705.

3. Aiello TF, Puerta-Alcalde P, Chumbita M, et al. Current outcomes of SARS-CoV-2 Omicron variant infection in high-risk haematological patients treated early with antivirals. *J Antimicrob Chemother* 2023; **78**(6): 1454-9.

4. Al-Obaidi MM, Gungor AB, Kurtin SE, Mathias AE, Tanriover B, Zangeneh TT. The Prevention of COVID-19 in High-Risk Patients Using Tixagevimab-Cilgavimab (Evusheld): Real-World Experience at a Large Academic Center. *Am J Med* 2023; **136**(1): 96-9.

5. Ameratunga R, Leung E, Woon ST, et al. SARS-CoV-2 Omicron: Light at the End of the Long Pandemic Tunnel or Another False Dawn for Immunodeficient Patients? *J Allergy Clin Immunol Pract* 2022; **10**(9): 2267-73.

6. Anderson M, Stec M, Gosha A, et al. Longitudinal Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Antibody Responses and Identification of Vaccine Breakthrough Infections Among Healthcare Workers Using Nucleocapsid Immunoglobulin G. *J Infect Dis* 2022; **226**(11): 1934-42.

7. Andeweg SP, de Gier B, Eggink D, et al. Protection of COVID-19 vaccination and previous infection against Omicron BA.1, BA.2 and Delta SARS-CoV-2 infections. *Nat Commun* 2022; **13**(1): 4738.

8. Andrews N, Stowe J, Kirsebom F, et al. Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. *N Engl J Med* 2022; **386**(16): 1532-46.

9. Arbel R, Sergienko R, Friger M, et al. Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years. *Nat Med* 2022; **28**(7): 1486-90.

11. Arrospide A, Sagardui MG, Larizgoitia I, Iturralde A, Moreda A, Mar J. Effectiveness of the booster dose of COVID-19 vaccine in the Basque Country during the sixth wave: A nationwide cohort study. *Vaccine* 2023; **41**(29): 4274-9.

12. Atyeo C, Shook LL, Nziza N, et al. COVID-19 booster dose induces robust antibody response in pregnant, lactating, and nonpregnant women. *Am J Obstet Gynecol* 2023; **228**(1): 68.e1-.e12.

13. Azar JH, Evans JP, Sikorski MH, et al. Selective suppression of de novo SARS-CoV-2 vaccine antibody responses in patients with cancer on B cell-targeted therapy. *JCI Insight* 2023; **8**(6).

14. Bar-On YM, Goldberg Y, Mandel M, et al. Protection by a Fourth Dose of BNT162b2 against Omicron in Israel. *N Engl J Med* 2022; **386**(18): 1712-20.

15. Bartsch SM, O'Shea KJ, Chin KL, et al. Maintaining face mask use before and after achieving different COVID-19 vaccination coverage levels: a modelling study. *Lancet Public Health* 2022; **7**(4): e356-e65.

16. Baum U, Poukka E, Leino T, Kilpi T, Nohynek H, Palmu AA. High vaccine effectiveness against severe COVID-19 in the elderly in Finland before and after the emergence of Omicron. *BMC Infect Dis* 2022; **22**(1): 816.

17. Benny L, Mehta P, Ahmed S, et al. Correlates of breakthrough Omicron (B.1.1.529) infections in a prospective cohort of vaccinated patients with rheumatic diseases. *Rheumatol Int* 2023; **43**(6): 1033-9.

18. Bhandari S, Joshi S, Rankawat G, Tiwaskar M, Lohmror A, Singh A. Post-COVID-19 Arterial Thrombotic Events among Three Major Permutations of COVID-19. *J Assoc Physicians India* 2023; **71**(7): 11-2.

19. Birol Ilter P, Prasad S, Mutlu MA, et al. Maternal and perinatal outcomes of SARS-CoV-2 infection in unvaccinated pregnancies during Delta and Omicron waves. *Ultrasound Obstet Gynecol* 2022; **60**(1): 96-102.

20. Braeye T, Catteau L, Brondeel R, et al. Vaccine effectiveness against transmission of alpha, delta and omicron SARS-COV-2-infection, Belgian contact tracing, 2021-2022. *Vaccine* 2023; **41**(20): 3292-300.

21. Braeye T, van Loenhout JAF, Brondeel R, et al. COVID-19 vaccine effectiveness against symptomatic infection and hospitalisation in Belgium, July 2021 to May 2022. *Euro Surveill* 2023; **28**(26).

22. Brazete C, Brazete J, Alves F, et al. COVID-19 vaccines effectiveness against symptomatic disease and severe outcomes, 2021-2022: a test-negative case-control study. *Public Health* 2023; **218**: 84-91.

23. Briggs J, Takahashi S, Nayebare P, et al. Seroprevalence of Antibodies to SARS-CoV-2 in Rural Households in Eastern Uganda, 2020-2022. *JAMA Netw Open* 2023; **6**(2): e2255978.

24. Broketa M, Sokal A, Mor M, et al. Qualitative monitoring of SARS-CoV-2 mRNA vaccination in humans using droplet microfluidics. *JCI Insight* 2023; **8**(13).

25. Bubar KM, Middleton CE, Bjorkman KK, Parker R, Larremore DB. SARS-CoV-2 transmission and impacts of unvaccinated-only screening in populations of mixed vaccination status. *Nat Commun* 2022; **13**(1): 2777.

26. Buchan SA, Chung H, Brown KA, et al. Estimated Effectiveness of COVID-19 Vaccines Against Omicron or Delta Symptomatic Infection and Severe Outcomes. *JAMA Netw Open* 2022; **5**(9): e2232760.

27. Buisson Y. Covid-19, an unfinished story. *Presse Med* 2022; **51**(3): 104131.

28. Busà R, Miele M, Sorrentino MC, et al. Long-Term Effectiveness of BNT162b2 Pfizer-BioNTech mRNA-Based Vaccine on B Cell Compartment: Efficient Recall of SARS-CoV-2-Specific Memory B Cells. *Int J Mol Sci* 2022; **23**(23).

29. Campos C, Colomer-Castell S, Garcia-Cehic D, et al. The frequency of defective genomes in Omicron differs from that of the Alpha, Beta and Delta variants. *Sci Rep* 2022; **12**(1): 22571.

30. Canaday DH, Oyebanji OA, White E, et al. COVID-19 vaccine booster dose needed to achieve Omicron-specific neutralisation in nursing home residents. *EBioMedicine* 2022; **80**: 104066.

31. Canetti M, Barda N, Gilboa M, et al. Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up. *Nat Commun* 2022; **13**(1): 7711.

32. Cao L, Lou J, Chan SY, et al. Rapid evaluation of COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 variants by analysis of genetic distance. *Nat Med* 2022; **28**(8): 1715-22.

33. Carlson EC, Macsai M, Bertrand S, Bertrand D, Nau J. The SARS-CoV-2 Virus and the Cholinergic System: Spike Protein Interaction with Human Nicotinic Acetylcholine Receptors and the Nicotinic Agonist Varenicline. *Int J Mol Sci* 2023; **24**(6).

34. Cerqueira-Silva T, de Araujo Oliveira V, Paixão ES, et al. Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the Omicron period in Brazil. *Nat Commun* 2022; **13**(1): 4154.

35. Chalkias S, Harper C, Vrbicky K, et al. A Bivalent Omicron-Containing Booster Vaccine against Covid-19. *N Engl J Med* 2022; **387**(14): 1279-91.

36. Chemaitelly H, AlMukdad S, Ayoub HH, et al. Covid-19 Vaccine Protection among Children and Adolescents in Qatar. *N Engl J Med* 2022; **387**(20): 1865-76.

37. Chen CWS, So MKP, Liu FC. Assessing government policies' impact on the COVID-19 pandemic and elderly deaths in East Asia. *Epidemiol Infect* 2022; **150**: e161.

38. Chen X, Wang H, Ai J, et al. Identification of CKD, bedridden history and cancer as higher-risk comorbidities and their impact on prognosis of hospitalized Omicron patients: a multi-centre cohort study. *Emerg Microbes Infect* 2022; **11**(1): 2501-9.

39. Chen Y, Tong P, Whiteman N, et al. Immune recall improves antibody durability and breadth to SARS-CoV-2 variants. *Sci Immunol* 2022; **7**(78): eabp8328.

40. Chen Z, Li J, Zheng J, et al. Emerging Omicron subvariants evade neutralizing immunity elicited by vaccine or BA.1/BA.2 infection. *J Med Virol* 2023; **95**(2): e28539.

41. Cheung PK, Lapointe HR, Sang Y, et al. SARS-CoV-2 live virus neutralization after four COVID-19 vaccine doses in people with HIV receiving suppressive antiretroviral therapy. *Aids* 2023; **37**(5): F11-f8.

42. Choi H, Lee EJ, Ahn YS, Yoo YM. Effects of the Omicron variant on perinatal outcomes in full-term neonates. *BMC Pediatr* 2022; **22**(1): 625.

43. Choi MJ, Heo JY, Seo YB, et al. Six-month longitudinal immune kinetics after mRNA-1273 vaccination: Correlation of peak antibody response with long-term, cross-reactive immunity. *Front Immunol* 2022; **13**: 1035441.

44. Choi SE, Sima C, Colom LP, Nguyen GT, Giannobile WV. Evaluation of Comprehensive COVID-19 Testing Program Outcomes in a US Dental Clinical Care Academic Setting. *JAMA Netw Open* 2022; **5**(12): e2246530.

45. Cicchitto G, Cardillo L, Sequino D, et al. Effectiveness of Sotrovimab in the Omicron Storm Time: A Case Series. *Viruses* 2022; **15**(1).

46. Cloete J, Kruger A, Masha M, et al. Paediatric hospitalisations due to COVID-19 during the first SARS-CoV-2 omicron (B.1.1.529) variant wave in South Africa: a multicentre observational study. *Lancet Child Adolesc Health* 2022; **6**(5): 294-302.

47. Coelho DH, Reiter ER, French E, Costanzo RM. Decreasing Incidence of Chemosensory Changes by COVID-19 Variant. *Otolaryngol Head Neck Surg* 2023; **168**(4): 704-6.

49. Dang TQ, La DT, Tran TN. Myeloencephalitis as the only presentation of Omicron SARS-CoV-2 infection. *BMJ Case Rep* 2022; **15**(11).

50. de Michelena P, Olea B, Torres I, González-Candelas F, Navarro D. SARS-CoV-2 RNA load in nasopharyngeal specimens from outpatients with breakthrough COVID-19 due to Omicron BA.1 and BA.2. *J Med Virol* 2022; **94**(12): 5836-40.

51. de Souza Andrade A, Freitas EF, de Castro Barbosa E, et al. Potential use of high-resolution melting analyses for SARS-CoV-2 genomic surveillance. *J Virol Methods* 2023; **317**: 114742.

52. Diel R, Nienhaus A. Cost-Benefit of Real-Time Multiplex PCR Testing of SARS-CoV-2 in German Hospitals. *Int J Environ Res Public Health* 2023; **20**(4).

53. Dobaño C, Ramírez-Morros A, Alonso S, et al. Eleven-month longitudinal study of antibodies in SARS-CoV-2 exposed and naïve primary health care workers upon COVID-19 vaccination. *Immunology* 2022; **167**(4): 528-43.

54. Dowell AC, Lancaster T, Bruton R, et al. Immunological imprinting of humoral immunity to SARS-CoV-2 in children. *Nat Commun* 2023; **14**(1): 3845.

55. Durand GA, Amroun A, Grard G, Badaut C. Positive SARS-CoV-2 RT-qPCR of a nasal swab spot after 30 days of conservation on filter paper at room temperature. *J Med Virol* 2023; **95**(1): e28165.

56. Egia-Mendikute L, Bosch A, Prieto-Fernández E, et al. A flow cytometry-based neutralization assay for simultaneous evaluation of blocking antibodies against SARS-CoV-2 variants. *Front Immunol* 2022; **13**: 1014309.

57. Elliott P, Eales O, Steyn N, et al. Twin peaks: The Omicron SARS-CoV-2 BA.1 and BA.2 epidemics in England. *Science* 2022; **376**(6600): eabq4411.

58. Erazo D, Vincenti-Gonzalez MF, van Loenhout JAF, et al. Investigating COVID-19 Vaccine Impact on the Risk of Hospitalisation through the Analysis of National Surveillance Data Collected in Belgium. *Viruses* 2022; **14**(6).

59. Esman A, Dubodelov D, Khafizov K, et al. Development and Application of Real-Time PCR-Based Screening for Identification of Omicron SARS-CoV-2 Variant Sublineages. *Genes (Basel)* 2023; **14**(6).

60. Evans JP, Zeng C, Carlin C, et al. Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection. *Sci Transl Med* 2022; **14**(637): eabn8057.

61. Fasching CL, Servellita V, McKay B, et al. COVID-19 Variant Detection with a High-Fidelity CRISPR-Cas12 Enzyme. *J Clin Microbiol* 2022; **60**(7): e0026122.

62. Favresse J, Gillot C, Bayart JL, et al. Vaccine-induced binding and neutralizing antibodies against Omicron 6 months after a homologous BNT162b2 booster. *J Med Virol* 2023; **95**(1): e28164.

63. Fedele G, Trentini F, Schiavoni I, et al. Evaluation of humoral and cellular response to four vaccines against COVID-19 in different age groups: A longitudinal study. *Front Immunol* 2022; **13**: 1021396.

64. Feikin DR, Higdon MM, Andrews N, et al. Assessing COVID-19 vaccine effectiveness against Omicron subvariants: Report from a meeting of the World Health Organization. *Vaccine* 2023; **41**(14): 2329-38.

65. Fryer HA, Hartley GE, Edwards ESJ, O'Hehir RE, van Zelm MC. Humoral immunity and B-cell memory in response to SARS-CoV-2 infection and vaccination. *Biochem Soc Trans* 2022; **50**(6): 1643-58.

66. Fu JYL, Chong YM, Sam IC, Chan YF. SARS-CoV-2 multiplex RT-PCR to detect variants of concern (VOCs) in Malaysia, between January to May 2021. *J Virol Methods* 2022; **301**: 114462.

67. García-Pérez J, Bermejo M, Ramírez-García A, et al. Longer intervals between SARS-CoV-2 infection and mRNA-1273 doses improve the neutralization of different variants of concern. *J Med Virol* 2023; **95**(3): e28679.

68. Geisen UM, Rose R, Neumann F, et al. The long term vaccine-induced anti-SARS-CoV-2 immune response is impaired in quantity and quality under TNFα blockade. *J Med Virol* 2022; **94**(12): 5780-9.

69. Glatman-Freedman A, Bromberg M, Hershkovitz Y, et al. Effectiveness of BNT162b2 Vaccine Booster against SARS-CoV-2 Infection and Breakthrough Complications, Israel. *Emerg Infect Dis* 2022; **28**(5): 948-56.

70. Gordhan BG, Ealand CS, Kana BD. Survival and detection of SARS-CoV-2 variants on dry swabs post storage. *Front Cell Infect Microbiol* 2022; **12**: 1031775.

71. Govindaraj S, Cheedarla N, Cheedarla S, et al. COVID-19 vaccine induced poor neutralization titers for SARS-CoV-2 omicron variants in maternal and cord blood. *Front Immunol* 2023; **14**: 1211558.

72. Gram MA, Emborg HD, Schelde AB, et al. Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study. *PLoS Med* 2022; **19**(9): e1003992.

73. Grewal R, Kitchen SA, Nguyen L, et al. Effectiveness of a fourth dose of covid-19 mRNA vaccine against the omicron variant among long term care residents in Ontario, Canada: test negative design study. *Bmj* 2022; **378**: e071502.

74. Grewal R, Nguyen L, Buchan SA, et al. Effectiveness of mRNA COVID-19 vaccine booster doses against Omicron severe outcomes. *Nat Commun* 2023; **14**(1): 1273.

75. Guedalia J, Lipschuetz M, Calderon-Margalit R, et al. Effectiveness of a third BNT162b2 mRNA COVID-19 vaccination during pregnancy: a national observational study in Israel. *Nat Commun* 2022; **13**(1): 6961.

76. Hamid S, Woodworth K, Pham H, et al. COVID-19-Associated Hospitalizations Among U.S. Infants Aged <6 Months - COVID-NET, 13 States, June 2021-August 2022. *MMWR Morb Mortal Wkly Rep* 2022; **71**(45): 1442-8.

77. Hause AM, Marquez P, Zhang B, et al. Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Children Aged 5-11 Years - United States, October 12-January 1, 2023. *MMWR Morb Mortal Wkly Rep* 2023; **72**(2): 39-43.

78. Havers FP, Pham H, Taylor CA, et al. COVID-19-Associated Hospitalizations Among Vaccinated and Unvaccinated Adults 18 Years or Older in 13 US States, January 2021 to April 2022. *JAMA Intern Med* 2022; **182**(10): 1071-81.

79. Hawley L, Han LS. Acute macular neuroretinopathy following COVID-19 infection. *N Z Med J* 2022; **135**(1563): 105-7.

80. Hogan AB, Doohan P, Wu SL, et al. Estimating long-term vaccine effectiveness against SARS-CoV-2 variants: a model-based approach. *Nat Commun* 2023; **14**(1): 4325.

81. Huang Z, Xu S, Liu J, et al. Effectiveness of inactivated and Ad5-nCoV COVID-19 vaccines against SARS-CoV-2 Omicron BA. 2 variant infection, severe illness, and death. *BMC Med* 2022; **20**(1): 400.

82. Imaizumi Y, Ishige T, Fujikawa T, et al. Development of multiplex S-gene-targeted RT-PCR for rapid identification of SARS-CoV-2 variants by extended S-gene target failure. *Clin Chim Acta* 2022; **536**: 6-11.

83. Ioannou GN, Bohnert ASB, O'Hare AM, et al. Effectiveness of mRNA COVID-19 Vaccine Boosters Against Infection, Hospitalization, and Death: A Target Trial Emulation in the Omicron (B.1.1.529) Variant Era. *Ann Intern Med* 2022; **175**(12): 1693-706.

84. Iyaniwura SA, Musa R, Kong JD. A generalized distributed delay model of COVID-19: An endemic model with immunity waning. *Math Biosci Eng* 2023; **20**(3): 5379-412.

85. Jacobsen H, Strengert M, Maaß H, et al. Diminished neutralization responses towards SARS-CoV-2 Omicron VoC after mRNA or vector-based COVID-19 vaccinations. *Sci Rep* 2022; **12**(1): 19858.

86. Jäger M, Dichtl S, Bellmann-Weiler R, et al. Serum Neutralization Against SARS-CoV-2 Variants Is Heterogenic and Depends on Vaccination Regimen. *J Infect Dis* 2023; **227**(4): 528-32.

87. Jang KK, Kaczmarek ME, Dallari S, et al. Variable susceptibility of intestinal organoid-derived monolayers to SARS-CoV-2 infection. *PLoS Biol* 2022; **20**(3): e3001592.

88. Jara A, Undurraga EA, Zubizarreta JR, et al. Effectiveness of CoronaVac in children 3-5 years of age during the SARS-CoV-2 Omicron outbreak in Chile. *Nat Med* 2022; **28**(7): 1377-80.

89. Jayasena T, Bustamante S, Poljak A, Sachdev P. Assay of Fatty Acids and Their Role in the Prevention and Treatment of COVID-19. *Methods Mol Biol* 2022; **2511**: 213-34.

90. John BV, Ferreira RD, Doshi A, et al. Third dose of COVID-19 mRNA vaccine appears to overcome vaccine hyporesponsiveness in patients with cirrhosis. *J Hepatol* 2022; **77**(5): 1349-58.

91. Jones L, Naikare HK, Mosley YC, Tripp RA. Isothermal amplification using sequence-specific fluorescence detection of SARS coronavirus 2 and variants in nasal swabs. *Biotechniques* 2022; **72**(6): 263-72.

92. Jung SM, Jung J. The Possible Impact of Nationwide Vaccination on Outcomes of the COVID-19 Epidemic in North Korea: A Modelling Study. *J Korean Med Sci* 2022; **37**(41): e300.

93. Kahlert CR, Strahm C, Güsewell S, et al. Post-Acute Sequelae After Severe Acute Respiratory Syndrome Coronavirus 2 Infection by Viral Variant and Vaccination Status: A Multicenter Cross-Sectional Study. *Clin Infect Dis* 2023; **77**(2): 194-202.

94. Keyel AC, Russell A, Plitnick J, et al. SARS-CoV-2 Vaccine Breakthrough by Omicron and Delta Variants, New York, USA. *Emerg Infect Dis* 2022; **28**(10): 1990-8.

95. Khan K, Karim F, Cele S, et al. Omicron infection enhances Delta antibody immunity in vaccinated persons. *Nature* 2022; **607**(7918): 356-9.

97. Kheiroddin P, Gaertner VD, Schöberl P, et al. Gargle pool PCR testing in a hospital during medium and high SARS-CoV-2 incidence. *J Hosp Infect* 2022; **127**: 69-76.

98. Kim SR, Kang HJ, Jeong HR, et al. Relative Effectiveness of COVID-19 Vaccination in Healthcare Workers: 3-Dose Versus 2-Dose Vaccination. *J Korean Med Sci* 2022; **37**(35): e267.

99. Kitabatake M, Ouji-Sageshima N, Sonobe S, et al. Transition of Antibody Titers after SARS-CoV-2 mRNA Vaccination in Japanese Healthcare Workers. *Jpn J Infect Dis* 2023; **76**(1): 72-6.

100. Koets L, van Leeuwen K, Derlagen M, et al. Efficient SARS-CoV-2 Surveillance during the Pandemic-Endemic Transition Using PCR-Based Genotyping Assays. *Microbiol Spectr* 2023; **11**(3): e0345022.

101. Koh SWC, Liow Y, Loh VWK, Liew SJ, Chan YH, Young D. COVID-19 vaccine acceptance and hesitancy among primary healthcare workers in Singapore. *BMC Prim Care* 2022; **23**(1): 81.

102. Korves C, Izurieta HS, Smith J, et al. Relative effectiveness of booster vs. 2-dose mRNA Covid-19 vaccination in the Veterans Health Administration: Self-controlled risk interval analysis. *Vaccine* 2022; **40**(33): 4742-7.

103. Kumar D, Hu Q, Samson R, et al. Neutralization against Omicron variant in transplant recipients after three doses of mRNA vaccine. *Am J Transplant* 2022; **22**(8): 2089-93.

104. Kurhade C, Zou J, Xia H, et al. Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine. *Nat Commun* 2022; **13**(1): 3602.

105. Lapointe HR, Mwimanzi F, Cheung PK, et al. Serial infection with SARS-CoV-2 Omicron BA.1 and BA.2 following three-dose COVID-19 vaccination. *Front Immunol* 2022; **13**: 947021.

106. Lavezzo E, Pacenti M, Manuto L, et al. Neutralising reactivity against SARS-CoV-2 Delta and Omicron variants by vaccination and infection history. *Genome Med* 2022; **14**(1): 61.

107. Lewnard JA, Hong V, Kim JS, et al. Association of SARS-CoV-2 BA.4/BA.5 Omicron lineages with immune escape and clinical outcome. *Nat Commun* 2023; **14**(1): 1407.

108. Li J, Wen R, Li G, et al. Omicron variant of SARS-COV-2 in Shanghai: Clinical features and inactivated vaccine efficacy in 13,120 elderly patients. *Int J Med Sci* 2023; **20**(9): 1144-51.

109. Link-Gelles R, Ciesla AA, Fleming-Dutra KE, et al. Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection - Increasing Community Access to Testing Program, United States, September-November 2022. *MMWR Morb Mortal Wkly Rep* 2022; **71**(48): 1526-30.

110. Link-Gelles R, Ciesla AA, Roper LE, et al. Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5- and XBB/XBB.1.5-Related Sublineages Among Immunocompetent Adults - Increasing Community Access to Testing Program, United States, December 2022-January 2023. *MMWR Morb Mortal Wkly Rep* 2023; **72**(5): 119-24.

111. Link-Gelles R, Levy ME, Gaglani M, et al. Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated - VISION Network, 10 States, December 2021-June 2022. *MMWR Morb Mortal Wkly Rep* 2022; **71**(29): 931-9.

112. Liu Y, Bruine de Buin W, Kapteyn A, Szilagyi PG. Role of Parents' Perceived Risk and Responsibility in Deciding on Children's COVID-19 Vaccination. *Pediatrics* 2023; **151**(5).

113. Looi JC, Maguire PA, Kisely SR, Allison S. Psychiatrist and trainee moral injury during the organisational long COVID of Australian acute psychiatric inpatient services. *Australas Psychiatry* 2023; **31**(2): 121-3.

115. Malic L, Brassard D, Da Fonte D, et al. Automated sample-to-answer centrifugal microfluidic system for rapid molecular diagnostics of SARS-CoV-2. *Lab Chip* 2022; **22**(17): 3157-71.

116. Marchini A, Petrillo M, Parrish A, et al. New RT-PCR Assay for the Detection of Current and Future SARS-CoV-2 Variants. *Viruses* 2023; **15**(1).

117. McConeghy KW, Bardenheier B, Huang AW, et al. Infections, Hospitalizations, and Deaths Among US Nursing Home Residents With vs Without a SARS-CoV-2 Vaccine Booster. *JAMA Netw Open* 2022; **5**(12): e2245417.

118. McConeghy KW, White EM, Blackman C, et al. Effectiveness of a Second COVID-19 Vaccine Booster Dose Against Infection, Hospitalization, or Death Among Nursing Home Residents - 19 States, March 29-July 25, 2022. *MMWR Morb Mortal Wkly Rep* 2022; **71**(39): 1235-8.

119. McGrath LJ, Scott AM, Surinach A, Chambers R, Benigno M, Malhotra D. Use of the Postacute Sequelae of COVID-19 Diagnosis Code in Routine Clinical Practice in the US. *JAMA Netw Open* 2022; **5**(10): e2235089.

120. McNerney KO, Richards RM, Aguayo-Hiraldo P, et al. SARS-CoV-2 infections in pediatric and young adult recipients of chimeric antigen receptor T-cell therapy: an international registry report. *J Immunother Cancer* 2023; **11**(1).

121. Mentes A, Papp K, Visontai D, et al. Identification of mutations in SARS-CoV-2 PCR primer regions. *Sci Rep* 2022; **12**(1): 18651.

122. Miyamoto S, Arashiro T, Adachi Y, et al. Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variants. *Med* 2022; **3**(4): 249-61.e4.

123. Moat SJ, Hillier S, de Souza S, et al. Maternal SARS-CoV-2 sero-surveillance using newborn dried blood spot (DBS) screening specimens highlights extent of low vaccine uptake in pregnant women. *Hum Vaccin Immunother* 2022; **18**(5): 2089498.

124. Mohapatra RK, El-Shall NA, Tiwari R, et al. Need of booster vaccine doses to counteract the emergence of SARS-CoV-2 variants in the context of the Omicron variant and increasing COVID-19 cases: An update. *Hum Vaccin Immunother* 2022; **18**(5): 2065824.

125. Monto AS, Lauring AS, Martin ET. SARS-CoV-2 Vaccine Strain Selection: Guidance From Influenza. *J Infect Dis* 2022; **227**(1): 4-8.

126. Moore SC, Kronsteiner B, Longet S, et al. Evolution of long-term vaccine-induced and hybrid immunity in healthcare workers after different COVID-19 vaccine regimens. *Med* 2023; **4**(3): 191-215.e9.

127. Muhsen K, Maimon N, Mizrahi AY, et al. Association of Receipt of the Fourth BNT162b2 Dose With Omicron Infection and COVID-19 Hospitalizations Among Residents of Long-term Care Facilities. *JAMA Intern Med* 2022; **182**(8): 859-67.

128. Mupanomunda M, Fakih MG, Miller C, et al. Comparison of Severe Maternal Morbidities Associated With Delivery During Periods of Circulation of Specific SARS-CoV-2 Variants. *JAMA Netw Open* 2022; **5**(8): e2226436.

129. Murillo-Zamora E, Trujillo X, Huerta M, et al. First-generation BNT162b2 and AZD1222 vaccines protect from COVID-19 pneumonia during the Omicron variant emergence. *Public Health* 2022; **207**: 105-7.

130. Najjar-Debbiny R, Gronich N, Weber G, et al. Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients. *Clin Infect Dis* 2023; **76**(3): e342-e9.

131. Newcomb K, Bilal S, Michael E. Combining predictive models with future change scenarios can produce credible forecasts of COVID-19 futures. *PLoS One* 2022; **17**(11): e0277521.

132. Ng OT, Marimuthu K, Lim N, et al. Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore. *JAMA Netw Open* 2022; **5**(8): e2228900.

133. Ng RWY, Sze RKH, Chong KC, et al. Effectiveness of mRNA and inactivated COVID-19 vaccines: A test-negative study in an infection-naïve Hong Kong population. *J Infect* 2023; **87**(2): 136-43.

134. Nielsen KF, Moustsen-Helms IR, Schelde AB, et al. Vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance: A Danish nationwide study. *PLoS Med* 2022; **19**(11): e1004037.

135. Niha MA, Draper AD, Viegas ODS, et al. The epidemiology of the COVID-19 pandemic in the small, low-resource country of Timor-Leste, January 2020 - June 2022. *Commun Dis Intell (2018)* 2023; **47**.

136. Normandin E, Valizadeh N, Rudmann EA, et al. Neuropathological features of SARS-CoV-2 delta and omicron variants. *J Neuropathol Exp Neurol* 2023; **82**(4): 283-95.

137. Nugent C, Abul Y, White EM, et al. Second monovalent SARS-CoV-2 mRNA booster restores Omicron-specific neutralizing activity in both nursing home residents and health care workers. *Vaccine* 2023; **41**(22): 3403-9.

138. O'Shea KM, Schuler CFt, Chen J, et al. Wild-type SARS-CoV-2 neutralizing immunity decreases across variants and over time but correlates well with diagnostic testing. *Front Immunol* 2023; **14**: 1055429.

140. Ong DSY, de Man P, Verhagen T, et al. Airborne virus shedding of the alpha, delta, omicron SARS-CoV-2 variants and influenza virus in hospitalized patients. *J Med Virol* 2023; **95**(4): e28748.

141. Örtqvist AK, Magnus MC, Aabakke AJM, et al. Severe COVID-19 during pregnancy in Sweden, Norway, and Denmark. *Acta Obstet Gynecol Scand* 2023; **102**(6): 681-9.

142. Park K, Sung H, Kim MN. Prospective Evaluation of SARS-CoV-2 Rapid Antigen Test for Screening of Asymptomatic Caregivers. *Clin Lab* 2023; **69**(3).

143. Pascuale CA, Varese A, Ojeda DS, et al. Immunogenicity and reactogenicity of heterologous immunization against SARS CoV-2 using Sputnik V, ChAdOx1-S, BBIBP-CorV, Ad5-nCoV, and mRNA-1273. *Cell Rep Med* 2022; **3**(8): 100706.

144. Paton RS, Overton CE, Ward T. The rapid replacement of the SARS-CoV-2 Delta variant by Omicron (B.1.1.529) in England. *Sci Transl Med* 2022; **14**(652): eabo5395.

145. Perico L, Todeschini M, Casiraghi F, et al. Long-term adaptive response in COVID-19 vaccine recipients and the effect of a booster dose. *Front Immunol* 2023; **14**: 1123158.

146. Pettit R, Peng B, Yu P, et al. Optimized workplace risk mitigation measures for SARS-CoV-2 in 2022. *Sci Rep* 2023; **13**(1): 2779.

147. Piñana JL, López-Corral L, Martino R, et al. SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders. *J Hematol Oncol* 2022; **15**(1): 54.

148. Piñana JL, Vazquez L, Calabuig M, et al. One-year breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated hematological patients. *Blood Cancer J* 2023; **13**(1): 8.

149. Pinato DJ, Aguilar-Company J, Ferrante D, et al. Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study. *Lancet Oncol* 2022; **23**(7): 865-75.

150. Poh XY, Lee IR, Lim C, et al. Evaluation of the safety and immunogenicity of different COVID-19 vaccine combinations in healthy individuals: study protocol for a randomized, subject-blinded, controlled phase 3 trial [PRIBIVAC]. *Trials* 2022; **23**(1): 498.

151. Poisson M, Sibiude J, Mosnino E, et al. Impact of variants of SARS-CoV-2 on obstetrical and neonatal outcomes. *J Gynecol Obstet Hum Reprod* 2023; **52**(4): 102566.

152. Qasmieh SA, Robertson MM, Rane MS, et al. The Importance of Incorporating At-Home Testing Into SARS-CoV-2 Point Prevalence Estimates: Findings From a US National Cohort, February 2022. *JMIR Public Health Surveill* 2022; **8**(12): e38196.

154. Qi T, Jin Y, Wang H, et al. Nirmatrelvir-ritonavir therapy and COVID-19 vaccination improve clinical outcomes of SARS-CoV-2 Omicron variant infection. *J Med Virol* 2023; **95**(2): e28497.

155. Radcliffe C, Palacios CF, Azar MM, Cohen E, Malinis M. Real-world experience with available, outpatient COVID-19 therapies in solid organ transplant recipients during the omicron surge. *Am J Transplant* 2022; **22**(10): 2458-63.

156. Rader B, Gertz A, Iuliano AD, et al. Use of At-Home COVID-19 Tests - United States, August 23, 2021-March 12, 2022. *MMWR Morb Mortal Wkly Rep* 2022; **71**(13): 489-94.

157. Rasmussen LD, Richter SR, Midgley SE, Franck KT. Detecting SARS-CoV-2 Omicron B.1.1.529 Variant in Wastewater Samples by Using Nanopore Sequencing. *Emerg Infect Dis* 2022; **28**(6): 1296-8.

158. Raymenants J, Duthoo W, Stakenborg T, et al. Exhaled breath SARS-CoV-2 shedding patterns across variants of concern. *Int J Infect Dis* 2022; **123**: 25-33.

159. Rose O, Obarcanin E, Erzkamp S. Evaluating real-world data in COVID-19 antigen and PCR testing. *Int J Clin Pharmacol Ther* 2023; **61**(4): 172-7.

160. Rottenstreich A, Vorontsov O, Alfi O, et al. Maternal and Neonatal Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant Neutralization After Antenatal Messenger RNA Vaccination. *Clin Infect Dis* 2022; **75**(11): 2023-6.

161. Ruhl L, Kühne JF, Beushausen K, et al. Third SARS-CoV-2 vaccination and breakthrough infections enhance humoral and cellular immunity against variants of concern. *Front Immunol* 2023; **14**: 1120010.

162. Sankaranarayanan S, Mohkhedkar M, Janakiraman V. Mutations in spike protein T cell epitopes of SARS-COV-2 variants: Plausible influence on vaccine efficacy. *Biochim Biophys Acta Mol Basis Dis* 2022; **1868**(9): 166432.

163. Sasanami M, Fujimoto M, Kayano T, Hayashi K, Nishiura H. Projecting the COVID-19 immune landscape in Japan in the presence of waning immunity and booster vaccination. *J Theor Biol* 2023; **559**: 111384.

164. Seidel A, Zanoni M, Groß R, et al. BNT162b2 booster after heterologous prime-boost vaccination induces potent neutralizing antibodies and T cell reactivity against SARS-CoV-2 Omicron BA.1 in young adults. *Front Immunol* 2022; **13**: 882918.

165. Seymen AA, Gulten E, Ozgur E, et al. Clinical evaluation of DIAGNOVIR SARS-CoV-2 ultra-rapid antigen test performance compared to PCR-based testing. *Sci Rep* 2023; **13**(1): 4438.

166. Shete AM, Patil DY, Sahay RR, Sapkal GN, Deshpande GR, Yadav PD. Waning natural and vaccine-induced immunity leading to reinfection with SARS-CoV-2 Omicron variant. *Hum Vaccin Immunother* 2022; **18**(6): 2127289.

167. Shimizu J, Sasaki T, Koketsu R, et al. Reevaluation of antibody-dependent enhancement of infection in anti-SARS-CoV-2 therapeutic antibodies and mRNA-vaccine antisera using FcR- and ACE2-positive cells. *Sci Rep* 2022; **12**(1): 15612.

168. Shrestha S, Malla B, Angga MS, et al. Long-term SARS-CoV-2 surveillance in wastewater and estimation of COVID-19 cases: An application of wastewater-based epidemiology. *Sci Total Environ* 2023; **896**: 165270.

169. Sieber J, Mayer M, Schmidthaler K, et al. Long-Lived Immunity in SARS-CoV-2-Recovered Children and Its Neutralizing Capacity Against Omicron. *Front Immunol* 2022; **13**: 882456.

170. Sievers BL, Chakraborty S, Xue Y, et al. Antibodies elicited by SARS-CoV-2 infection or mRNA vaccines have reduced neutralizing activity against Beta and Omicron pseudoviruses. *Sci Transl Med* 2022; **14**(634): eabn7842.

171. Silva ARD, Jr., Villas-Boas LS, Tozetto-Mendoza TR, et al. Generation of neutralizing antibodies against Omicron, Gamma and Delta SARS-CoV-2 variants following CoronaVac vaccination. *Rev Inst Med Trop Sao Paulo* 2022; **64**: e19.

172. Simwanza J, Hines JZ, Sinyange D, et al. COVID-19 Vaccine Effectiveness during a Prison Outbreak when Omicron was the Dominant Circulating Variant-Zambia, December 2021. *Am J Trop Med Hyg* 2022; **107**(5): 1055-9.

173. Singanallur NB, van Vuren PJ, McAuley AJ, et al. At Least Three Doses of Leading Vaccines Essential for Neutralisation of SARS-CoV-2 Omicron Variant. *Front Immunol* 2022; **13**: 883612.

174. Skow RJ, Nandadeva D, Grotle AK, Stephens BY, Wright AN, Fadel PJ. Impact of breakthrough COVID-19 cases during the omicron wave on vascular health and cardiac autonomic function in young adults. *Am J Physiol Heart Circ Physiol* 2022; **323**(1): H59-h64.

175. Smith H, Mahon A, Moss A, Rao S. SARS-CoV-2 infection in children evaluated in an ambulatory setting during Delta and Omicron time periods. *J Med Virol* 2023; **95**(1): e28318.

176. Smoot K, Yang J, Tacker DH, et al. Persistence and Protective Potential of SARS-CoV-2 Antibody Levels After COVID-19 Vaccination in a West Virginia Nursing Home Cohort. *JAMA Netw Open* 2022; **5**(9): e2231334.

177. Sormani MP, Schiavetti I, Inglese M, et al. Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy. *EBioMedicine* 2022; **80**: 104042.

178. Stærke NB, Reekie J, Nielsen H, et al. Levels of SARS-CoV-2 antibodies among fully vaccinated individuals with Delta or Omicron variant breakthrough infections. *Nat Commun* 2022; **13**(1): 4466.

179. Stock SJ, Moore E, Calvert C, et al. Pregnancy outcomes after SARS-CoV-2 infection in periods dominated by delta and omicron variants in Scotland: a population-based cohort study. *Lancet Respir Med* 2022; **10**(12): 1129-36.

180. Sun K, Tempia S, Kleynhans J, et al. Rapidly shifting immunologic landscape and severity of SARS-CoV-2 in the Omicron era in South Africa. *Nat Commun* 2023; **14**(1): 246.

181. Svetlova J, Gustin D, Manuvera V, et al. Microarray Profiling of Vaccination-Induced Antibody Responses to SARS-CoV-2 Variants of Interest and Concern. *Int J Mol Sci* 2022; **23**(21).

182. Szanyi J, Wilson T, Scott N, Blakely T. A log-odds system for waning and boosting of COVID-19 vaccine effectiveness. *Vaccine* 2022; **40**(28): 3821-4.

183. Tan JY, Wee LE, Tan YH, et al. Favorable outcomes of COVID-19 in vaccinated hematopoietic stem cell transplant recipients: A single-center experience. *Transpl Infect Dis* 2023; **25**(3): e14024.

184. Tang L, Zhang Y, Wang F, et al. Relative vaccine effectiveness against Delta and Omicron COVID-19 after homologous inactivated vaccine boosting: a retrospective cohort study. *BMJ Open* 2022; **12**(11): e063919.

186. Terada M, Kondo N, Wanifuchi-Endo Y, et al. Efficacy and impact of SARS-CoV-2 vaccination on cancer treatment for breast cancer patients: a multi-center prospective observational study. *Breast Cancer Res Treat* 2022; **195**(3): 311-23.

187. Thenon N, Peyre M, Huc M, Touré A, Roger F, Mangiarotti S. COVID-19 in Africa: Underreporting, demographic effect, chaotic dynamics, and mitigation strategy impact. *PLoS Negl Trop Dis* 2022; **16**(9): e0010735.

188. Tonnara G, Piselli P, Cimaglia C, et al. The impact of COVID-19 vaccination programme in the Republic of San Marino: Focus on effectiveness of Gam-Covid-Vac. *Clin Microbiol Infect* 2022; **28**(12): 1636-43.

189. Trindade AJ, Chapin KC, Gannon WD, et al. Clinical course of SARS-CoV-2 infection and recovery in lung transplant recipients. *Transpl Infect Dis* 2022; **24**(6): e13967.

190. Tseng HF, Ackerson BK, Bruxvoort KJ, et al. Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5. *Nat Commun* 2023; **14**(1): 189.

191. Underwood AP, Sølund C, Fernandez-Antunez C, et al. Durability and breadth of neutralisation following multiple antigen exposures to SARS-CoV-2 infection and/or COVID-19 vaccination. *EBioMedicine* 2023; **89**: 104475.

192. van Doesum JA, Salmanton-García J, Marchesi F, et al. Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post-CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey. *Blood Adv* 2023; **7**(11): 2645-55.

193. Vangeti S, Periasamy S, Sun P, et al. Serum Fc-Mediated Monocyte Phagocytosis Activity Is Stable for Several Months after SARS-CoV-2 Asymptomatic and Mildly Symptomatic Infection. *Microbiol Spectr* 2022; **10**(6): e0183722.

194. Vasconcelos MW, de Barros FRO, Pilonetto JC, et al. Relationship between SARS-CoV-2 vaccination and cases, program breakthrough cases, and deaths in Dois Vizinhos, Paraná, Brazil. *J Med Virol* 2023; **95**(6): e28882.

195. Venekamp RP, Schuit E, Hooft L, et al. Diagnostic accuracy of SARS-CoV-2 rapid antigen self-tests in asymptomatic individuals in the omicron period: a cross-sectional study. *Clin Microbiol Infect* 2023; **29**(3): 391.e1-.e7.

196. Veneti L, Berild JD, Watle SV, et al. Effectiveness of BNT162b2 vaccine against SARS-CoV-2 Delta and Omicron infection in adolescents, Norway, August 2021 to January 2022. *Int J Infect Dis* 2023; **130**: 182-8.

197. Vietri MT, D'Elia G, Caliendo G, et al. Antibody levels after BNT162b2 vaccine booster and SARS-CoV-2 Omicron infection. *Vaccine* 2022; **40**(39): 5726-31.

198. Villar J, Soto Conti CP, Gunier RB, et al. Pregnancy outcomes and vaccine effectiveness during the period of omicron as the variant of concern, INTERCOVID-2022: a multinational, observational study. *Lancet* 2023; **401**(10375): 447-57.

199. Vogel E, Kocher K, Priller A, et al. Dynamics of humoral and cellular immune responses after homologous and heterologous SARS-CoV-2 vaccination with ChAdOx1 nCoV-19 and BNT162b2. *EBioMedicine* 2022; **85**: 104294.

200. Walker MR, Podlekareva D, Johnsen S, et al. SARS-CoV-2 RBD-Specific Antibodies Induced Early in the Pandemic by Natural Infection and Vaccination Display Cross-Variant Binding and Inhibition. *Viruses* 2022; **14**(9).

201. Wang J, Zhang Y, Dong S, et al. Bivalent mRNA vaccines against three SARS-CoV-2 variants mediated by new ionizable lipid nanoparticles. *Int J Pharm* 2023; **642**: 123155.

202. Wang JY, Li TN, Zhou CL, et al. Clinical and immunological features of convalescent pediatric patients infected with the SARS-CoV-2 Omicron variant in Tianjin, China. *Virol Sin* 2022; **37**(6): 850-9.

203. Wegrzynska K, Komiazyk M, Walory J, Kozinska A, Wasko I, Baraniak A. Differentiation of SARS-CoV-2 Variants Using RT-qPCRs by Targeting Recurrent Mutation Sites: A Diagnostic Laboratory Experience from Multi-Center Regional Study, August 2020-December 2021, Poland. *Int J Mol Sci* 2022; **23**(16).

204. Wei J, Matthews PC, Stoesser N, et al. Protection against SARS-CoV-2 Omicron BA.4/5 variant following booster vaccination or breakthrough infection in the UK. *Nat Commun* 2023; **14**(1): 2799.

205. Weng CH, Zhou S, Saal A, Hafferty M, McGuire DC, Chan PA. BNT162b2 and mRNA-1273 Vaccine Effectiveness against SARS-CoV-2 and Variants in the Urban Underserved Population. *R I Med J (2013)* 2023; **106**(1): 26-8.

206. Whittaker R, Greve-Isdahl M, Bøås H, Suren P, Buanes EA, Veneti L. COVID-19 Hospitalization Among Children <18 Years by Variant Wave in Norway. *Pediatrics* 2022; **150**(3).

207. Wing S, Thomas D, Balamchi S, et al. Effectiveness of Three Doses of mRNA COVID-19 Vaccines in the Hemodialysis Population during the Omicron Period. *Clin J Am Soc Nephrol* 2023; **18**(4): 491-8.

208. Woldemeskel BA, Garliss CC, Aytenfisu TY, et al. SARS-CoV-2-specific immune responses in boosted vaccine recipients with breakthrough infections during the Omicron variant surge. *JCI Insight* 2022; **7**(10).

209. Wolter N, Jassat W, Walaza S, et al. Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study. *Lancet* 2022; **399**(10323): 437-46.

210. Wong G, Rowlandson M, Sabanayagam D, et al. COVID-19 Infection With the Omicron SARS-CoV-2 Variant in a Cohort of Kidney and Kidney Pancreas Transplant Recipients: Clinical Features, Risk Factors, and Outcomes. *Transplantation* 2022; **106**(9): 1860-6.

211. Wong MTJ, Dhaliwal SS, Balakrishnan V, Nordin F, Norazmi MN, Tye GJ. Effectiveness of Booster Vaccinations on the Control of COVID-19 during the Spread of Omicron Variant in Malaysia. *Int J Environ Res Public Health* 2023; **20**(2).

212. Wu J, Wang L, Hua Y, et al. Trend and Co-occurrence Network of COVID-19 Symptoms From Large-Scale Social Media Data: Infoveillance Study. *J Med Internet Res* 2023; **25**: e45419.

213. Yang SL, Ripen AM, Lee JV, et al. Time from last immunity event against infection during Omicron-dominant period in Malaysia. *Int J Infect Dis* 2023; **128**: 98-101.

214. Yang Y, Nie J, Sun F, et al. The SARS-CoV-2 vaccination rate and hesitation in Shanghai older adults with dementia. *Front Public Health* 2023; **11**: 1172642.

215. Yotsuyanagi H, Ohmagari N, Doi Y, et al. A phase 2/3 study of S-217622 in participants with SARS-CoV-2 infection (Phase 3 part). *Medicine (Baltimore)* 2023; **102**(8): e33024.

216. Yu MKL, Chan SHS, Cheng S, et al. Hesitancy, reactogenicity and immunogenicity of the mRNA and whole-virus inactivated Covid-19 vaccines in pediatric neuromuscular diseases. *Hum Vaccin Immunother* 2023; **19**(1): 2206278.

217. Zapata-Cardona MI, Flórez-Álvarez L, Lopera TJ, et al. Neutralizing antibody titers to Omicron six months after vaccination with BNT162b2 in Colombia. *Front Immunol* 2022; **13**: 1102384.

218. Zhan H, Gao H, Liu Y, et al. Booster shot of inactivated SARS-CoV-2 vaccine induces potent immune responses in people living with HIV. *J Med Virol* 2023; **95**(1): e28428.

219. Zhang GF, Meng W, Chen L, et al. Neutralizing antibodies to SARS-CoV-2 variants of concern including Delta and Omicron in subjects receiving mRNA-1273, BNT162b2, and Ad26.COV2.S vaccines. *J Med Virol* 2022; **94**(12): 5678-90.

220. Zipfel CM, Paul P, Gowler CD, et al. Modeling the Effectiveness of Healthcare Personnel Reactive Testing and Screening for the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Omicron Variant Within Nursing Homes. *Clin Infect Dis* 2022; **75**(Suppl 2): S225-s30.

221. Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis. *Lancet* 2022; **399**(10344): 2351-80.

222. Abdalla M, Rabie AM. Dual computational and biological assessment of some promising nucleoside analogs against the COVID-19-Omicron variant. *Comput Biol Chem* 2023; **104**: 107768.

223. Abdin AD, Gärtner BC, Munteanu C, et al. Factors Associated With SARS-CoV-2 Infection at a German Medical Congress During the Omicron Wave. *JAMA Netw Open* 2023; **6**(6): e2318025.

224. Abeywardhana S, Premathilaka M, Bandaranayake U, Perera D, Peiris LDC. In silico study of SARS-CoV-2 spike protein RBD and human ACE-2 affinity dynamics across variants and Omicron subvariants. *J Med Virol* 2023; **95**(1): e28406.

225. Abullais SS, Arora S, Wahab S, et al. Convalescent Plasma Therapy against COVID-19: An Update on the Changing Facets of the ongoing Pandemic. *Curr Pharm Biotechnol* 2023; **24**(12): 1515-23.

226. Acosta N, Bautista MA, Waddell BJ, et al. Surveillance for SARS-CoV-2 and its variants in wastewater of tertiary care hospitals correlates with increasing case burden and outbreaks. *J Med Virol* 2023; **95**(2): e28442.

227. Adachi E, Saito M, Koga M, Tsutsumi T, Yotsuyanagi H. Favorable Outcome Following Sotrovimab Monoclonal Antibody in a Patient with Prolonged SARS-CoV-2 Omicron Infection with HIV/AIDS. *Intern Med* 2022; **61**(22): 3459-62.

228. Adeyemi OO, Ndodo ND, Sulaiman MK, et al. SARS-CoV-2 variants-associated outbreaks of COVID-19 in a tertiary institution, North-Central Nigeria: Implications for epidemic control. *PLoS One* 2023; **18**(1): e0280756.

229. Adhikari EH, MacDonald L, SoRelle JA, Morse J, Pruszynski J, Spong CY. COVID-19 Cases and Disease Severity in Pregnancy and Neonatal Positivity Associated With Delta (B.1.617.2) and Omicron (B.1.1.529) Variant Predominance. *Jama* 2022; **327**(15): 1500-2.

230. Agrawal U, Bedston S, McCowan C, et al. Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales. *Lancet* 2022; **400**(10360): 1305-20.

231. Ahn MJ, Kang JA, Hong SM, et al. Evaluation of a biotin-based surrogate virus neutralization test for detecting postvaccination antibodies against SARS-CoV-2 variants in sera. *Biochem Biophys Res Commun* 2023; **646**: 8-18.

232. Ahti J, Österback R, Keskitalo A, et al. Diagnostic Performance and Tolerability of Saliva and Nasopharyngeal Swab Specimens in the Detection of SARS-CoV-2 by RT-PCR. *Microbiol Spectr* 2023; **11**(3): e0532422.

233. Akerman A, Milogiannakis V, Jean T, et al. Emergence and antibody evasion of BQ, BA.2.75 and SARS-CoV-2 recombinant sub-lineages in the face of maturing antibody breadth at the population level. *EBioMedicine* 2023; **90**: 104545.

234. Al Hasan SM, Saulam J, Mikami F, Kanda K, Yokoi H, Hirao T. COVID-19 outbreak trends in South Africa: A comparison of Omicron (B.1.1.529), Delta (B.1.617.2), and Beta (B.1.351) variants outbreak periods. *J Infect Public Health* 2022; **15**(7): 726-33.

235. Al-Dury S, Waldenström J, Ringlander J, et al. Catch-up antibody responses and hybrid immunity in mRNA vaccinated patients at risk of severe COVID-19. *Infect Dis (Lond)* 2023; **55**(10): 744-50.

236. Al-Obaidi MM, Gungor AB, Murugapandian S, et al. The Impact of Nirmatrelvir-Ritonavir in Reducing Hospitalizations Among High-Risk Patients With SARS-CoV-2 During the Omicron Predominant Era. *Am J Med* 2023; **136**(6): 577-84.

237. Alcantara LCJ, Nogueira E, Shuab G, et al. SARS-CoV-2 epidemic in Brazil: how the displacement of variants has driven distinct epidemic waves. *Virus Res* 2022; **315**: 198785.

238. Aleshina OA, Zakurdaeva K, Vasileva AN, et al. Clinical Outcomes in Patients With COVID-19 and Hematologic Disease. *Clin Lymphoma Myeloma Leuk* 2023; **23**(8): 589-98.

239. Alfonso-Dunn R, Lin J, Lei J, et al. Humoral and cellular responses to repeated COVID-19 exposure in multiple sclerosis patients receiving B-cell depleting therapies: a single-center, one-year, prospective study. *Front Immunol* 2023; **14**: 1194671.

240. Alhuzali H, Zhang T, Ananiadou S. Emotions and Topics Expressed on Twitter During the COVID-19 Pandemic in the United Kingdom: Comparative Geolocation and Text Mining Analysis. *J Med Internet Res* 2022; **24**(10): e40323.

241. Alicandro G, Gerli AG, Remuzzi G, Centanni S, La Vecchia C. Updated estimates of excess total mortality in Italy during the circulation of the BA.2 and BA.4-5 Omicron variants: April-July 2022. *Med Lav* 2022; **113**(5): e2022046.

242. AlKalamouni H, Abou Hassan FF, Bou Hamdan M, et al. Genomic surveillance of SARS-CoV-2 in COVID-19 vaccinated healthcare workers in Lebanon. *BMC Med Genomics* 2023; **16**(1): 14.

243. Allen RA, Williams CL, Penrod Y, et al. A pyrosequencing protocol for rapid identification of SARS-CoV-2 variants. *J Med Virol* 2022; **94**(8): 3661-8.

244. Alves K, Plested JS, Galbiati S, et al. Immunogenicity and safety of a fourth homologous dose of NVX-CoV2373. *Vaccine* 2023; **41**(29): 4280-6.

245. Ameratunga R, Woon ST, Lea E, et al. The (apparent) antibody paradox in COVID-19. *Expert Rev Clin Immunol* 2022; **18**(4): 335-45.

246. Amir O, Goldberg Y, Mandel M, et al. Protection against Omicron BA.1/BA.2 severe disease 0-7 months after BNT162b2 booster. *Commun Biol* 2023; **6**(1): 315.

247. Anand U, Pal T, Zanoletti A, et al. The spread of the omicron variant: Identification of knowledge gaps, virus diffusion modelling, and future research needs. *Environ Res* 2023; **225**: 115612.

248. Anderson EJ, Creech CB, Berthaud V, et al. Evaluation of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age. *N Engl J Med* 2022; **387**(18): 1673-87.

249. Andrés C, González-Sánchez A, Jiménez M, et al. Emergence of Delta and Omicron variants carrying resistance-associated mutations in immunocompromised patients undergoing sotrovimab treatment with long-term viral excretion. *Clin Microbiol Infect* 2023; **29**(2): 240-6.

250. Anscombe C, Lissauer S, Thole H, et al. A comparison of four epidemic waves of COVID-19 in Malawi; an observational cohort study. *BMC Infect Dis* 2023; **23**(1): 79.

251. Aoki A, Adachi H, Mori Y, et al. Discrimination of SARS-CoV-2 Omicron Sublineages BA.1 and BA.2 Using a High-Resolution Melting-Based Assay: a Pilot Study. *Microbiol Spectr* 2022; **10**(4): e0136722.

252. Arashiro T, Arai S, Kinoshita R, et al. National seroepidemiological study of COVID-19 after the initial rollout of vaccines: Before and at the peak of the Omicron-dominant period in Japan. *Influenza Other Respir Viruses* 2023; **17**(2): e13094.

253. Arbel R, Peretz A, Sergienko R, et al. Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort study. *Lancet Infect Dis* 2023; **23**(8): 914-21.

254. Arbel R, Wolff Sagy Y, Hoshen M, et al. Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge. *N Engl J Med* 2022; **387**(9): 790-8.

255. Arnaout R, Arnaout R. Visualizing omicron: COVID-19 deaths vs. cases over time. *PLoS One* 2022; **17**(4): e0265233.

256. Assato PA, Clemente LG, Giovanetti M, et al. Retrospective Insights of the COVID-19 Epidemic in the Major Latin American City, São Paulo, Southeastern Brazil. *Viruses* 2023; **15**(2).

257. Assawasaksakul T, Sathitratanacheewin S, Vichaiwattana P, et al. Immunogenicity of the third and fourth BNT162b2 mRNA COVID-19 boosters and factors associated with immune response in patients with SLE and rheumatoid arthritis. *Lupus Sci Med* 2022; **9**(1).

258. Atanackovic D, Luetkens T, Omili D, et al. Vaccine-induced T-cell responses against SARS-CoV-2 and its Omicron variant in patients with B cell-depleted lymphoma after CART therapy. *Blood* 2022; **140**(2): 152-6.

259. Atkinson A, Albert A, McClymont E, et al. Canadian SARS-CoV-2 serological survey using antenatal serum samples: a retrospective seroprevalence study. *CMAJ Open* 2023; **11**(2): E305-e13.

260. Averbuch D, de la Camara R, Tridello G, et al. Risk factors for a severe disease course in children with SARS-COV-2 infection following hematopoietic cell transplantation in the pre-Omicron period: a prospective multinational Infectious Disease Working Party from the European Society for Blood and Marrow Transplantation group (EBMT) and the Spanish Group of Hematopoietic Stem Cell Transplantation (GETH) study. *Bone Marrow Transplant* 2023; **58**(5): 558-66.

261. Azami NAM, Perera D, Thayan R, et al. SARS-CoV-2 genomic surveillance in Malaysia: displacement of B.1.617.2 with AY lineages as the dominant Delta variants and the introduction of Omicron during the fourth epidemic wave. *Int J Infect Dis* 2022; **125**: 216-26.

262. Aziz MW, Mukhtar N, Anjum AA, et al. Genomic Diversity and Evolution of SARS-CoV-2 Lineages in Pakistan. *Viruses* 2023; **15**(7).

263. Babouee Flury B, Güsewell S, Egger T, et al. Risk and symptoms of COVID-19 in health professionals according to baseline immune status and booster vaccination during the Delta and Omicron waves in Switzerland-A multicentre cohort study. *PLoS Med* 2022; **19**(11): e1004125.

264. Bager P, Wohlfahrt J, Bhatt S, et al. Risk of hospitalisation associated with infection with SARS-CoV-2 omicron variant versus delta variant in Denmark: an observational cohort study. *Lancet Infect Dis* 2022; **22**(7): 967-76.

265. Bagutti C, Alt Hug M, Heim P, et al. Wastewater monitoring of SARS-CoV-2 shows high correlation with COVID-19 case numbers and allowed early detection of the first confirmed B.1.1.529 infection in Switzerland: results of an observational surveillance study. *Swiss Med Wkly* 2022; **152**: w30202.

266. Bajema KL, Berry K, Streja E, et al. Effectiveness of COVID-19 Treatment With Nirmatrelvir-Ritonavir or Molnupiravir Among U.S. Veterans: Target Trial Emulation Studies With One-Month and Six-Month Outcomes. *Ann Intern Med* 2023; **176**(6): 807-16.

267. Balasubramanian S, Dhanalakshmi K, Raj SL, Chandy S. MIS-C Triggered by Omicron Variant of SARS-CoV-2. *Indian Pediatr* 2022; **59**(5): 427-8.

268. Balkan İ, Dinc HO, Can G, et al. Waning immunity to inactive SARS-CoV-2 vaccine in healthcare workers: booster required. *Ir J Med Sci* 2023; **192**(1): 19-25.

269. Ban DK, Bodily T, Karkisaval AG, et al. Rapid self-test of unprocessed viruses of SARS-CoV-2 and its variants in saliva by portable wireless graphene biosensor. *Proc Natl Acad Sci U S A* 2022; **119**(28): e2206521119.

270. Banerjee A, Lew J, Kroeker A, et al. Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, Beta, Delta, and Omicron variants. *Med* 2022; **3**(6): 422-32.e3.

271. Banholzer N, Zürcher K, Jent P, et al. SARS-CoV-2 transmission with and without mask wearing or air cleaners in schools in Switzerland: A modeling study of epidemiological, environmental, and molecular data. *PLoS Med* 2023; **20**(5): e1004226.

272. Bar-Or I, Indenbaum V, Weil M, et al. National Scale Real-Time Surveillance of SARS-CoV-2 Variants Dynamics by Wastewater Monitoring in Israel. *Viruses* 2022; **14**(6).

273. Barro RJ. Vaccination rates and COVID outcomes across U.S. states. *Econ Hum Biol* 2022; **47**: 101201.

274. Bartsch YC, Atyeo C, Kang J, et al. Preserved recognition of Omicron spike following COVID-19 messenger RNA vaccination in pregnancy. *Am J Obstet Gynecol* 2022; **227**(3): 493.e1-.e7.

275. Batool R, Soler M, Colavita F, Fabeni L, Matusali G, Lechuga LM. Biomimetic nanoplasmonic sensor for rapid evaluation of neutralizing SARS-CoV-2 monoclonal antibodies as antiviral therapy. *Biosens Bioelectron* 2023; **226**: 115137.

276. Batra G, Murugesan DR, Raghavan S, et al. Trends of humoral immune responses to heterologous antigenic exposure due to vaccination & omicron SARS-CoV-2 infection: Implications for boosting. *Indian J Med Res* 2023; **157**(6): 509-18.

277. Bauer KA, Yu K, Moise PA, et al. Morbidity and mortality of hospitalised patients with candidemia during the various severe acute respiratory syndrome coronavirus 2 pandemic waves: A multicentre evaluation of 248 US hospitals. *Mycoses* 2023; **66**(6): 483-7.

278. Bbosa N, Ssemwanga D, Namagembe H, et al. Rapid Replacement of SARS-CoV-2 Variants by Delta and Subsequent Arrival of Omicron, Uganda, 2021. *Emerg Infect Dis* 2022; **28**(5): 1021-5.

279. Beaton B, Sasson SC, Rankin K, et al. Patients with treated indolent lymphomas immunized with BNT162b2 have reduced anti-spike neutralizing IgG to SARS-CoV-2 variants, but preserved antigen-specific T cell responses. *Am J Hematol* 2023; **98**(1): 131-9.

280. Beccia F, Lontano A, Rossi MF, et al. Three-year COVID-19 and flu vaccinations among medical residents in a tertiary hospital in Italy: The threat of acceptance decline in seasonal campaigns. *Hum Vaccin Immunother* 2023; **19**(2): 2252708.

281. Beesley LJ, Moran KR, Wagh K, et al. SARS-CoV-2 variant transition dynamics are associated with vaccination rates, number of co-circulating variants, and convalescent immunity. *EBioMedicine* 2023; **91**: 104534.

282. Bendall EE, Callear AP, Getz A, et al. Rapid transmission and tight bottlenecks constrain the evolution of highly transmissible SARS-CoV-2 variants. *Nat Commun* 2023; **14**(1): 272.

283. Beraud G, Bouetard L, Civljak R, et al. Impact of vaccination on the presence and severity of symptoms in hospitalized patients with an infection of the Omicron variant (B.1.1.529) of the SARS-CoV-2 (subvariant BA.1). *Clin Microbiol Infect* 2023; **29**(5): 642-50.

284. Beretta S, Cristillo V, Camera G, et al. Incidence and Long-term Functional Outcome of Neurologic Disorders in Hospitalized Patients With COVID-19 Infected With Pre-Omicron Variants. *Neurology* 2023; **101**(9): e892-e903.

285. Bertels X, Hanoteaux S, Janssens R, et al. Time series modelling for wastewater-based epidemiology of COVID-19: A nationwide study in 40 wastewater treatment plants of Belgium, February 2021 to June 2022. *Sci Total Environ* 2023; **899**: 165603.

286. Bezerra MF, Silva LCA, Pessoa ESR, et al. Real-life evaluation of a rapid antigen test (DPP SARS-CoV-2 Antigen) for COVID-19 diagnosis of primary healthcare patients, in the context of the Omicron-dominant wave in Brazil. *Clin Microbiol Infect* 2023; **29**(3): 392.e1-.e5.

287. Bieber A, Brikman S, Novack L, et al. SARS-CoV-2 infection among patients with autoimmune rheumatic diseases; comparison between the Delta and Omicron waves in Israel. *Semin Arthritis Rheum* 2023; **58**: 152129.

288. Birabaharan M, Martin TCS. Acute pulmonary emboli following rebound phenomenon after Nirmatrelvir/Ritonavir treatment for COVID-19. *Am J Emerg Med* 2022; **61**: 235.e5-.e6.

289. Blanquart F, Abad C, Ambroise J, et al. Temporal, age, and geographical variation in vaccine efficacy against infection by the Delta and Omicron variants in the community in France, December 2021 to March 2022. *Int J Infect Dis* 2023; **133**: 89-96.

290. Blanquart F, Hozé N, Cowling BJ, Débarre F, Cauchemez S. Selection for infectivity profiles in slow and fast epidemics, and the rise of SARS-CoV-2 variants. *Elife* 2022; **11**.

291. Blomquist PB, Bridgen J, Bray N, et al. Enhancing epidemiological surveillance of the emergence of the SARS-CoV-2 Omicron variant using spike gene target failure data, England, 15 November to 31 December 2021. *Euro Surveill* 2022; **27**(11).

292. Boeckel GR, Hölscher SD, Bürger C, et al. Comprehensive Treatment of Hematological Patients with SARS-CoV-2 Infection Including Anti-SARS-CoV-2 Monoclonal Antibodies: A Single-Center Experience Case Series. *Curr Oncol* 2022; **29**(4): 2312-25.

293. Bonnet G, Vassall A, Jit M. Is there a role for RDTs as we live with COVID-19? An assessment of different strategies. *BMJ Glob Health* 2023; **8**(1).

294. Bordoy AE, Saludes V, Panisello Yagüe D, et al. Monitoring SARS-CoV-2 variant transitions using differences in diagnostic cycle threshold values of target genes. *Sci Rep* 2022; **12**(1): 21818.

295. Borillo GA, Kagan RM, Marlowe EM. Rapid and Accurate Identification of SARS-CoV-2 Variants Using Real Time PCR Assays. *Front Cell Infect Microbiol* 2022; **12**: 894613.

296. Boulware DR, Murray TA, Proper JL, et al. Impact of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccination and Booster on Coronavirus Disease 2019 (COVID-19) Symptom Severity Over Time in the COVID-OUT Trial. *Clin Infect Dis* 2023; **76**(3): e1-e9.

297. Bouton TC, Atarere J, Turcinovic J, et al. Viral Dynamics of Omicron and Delta Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants With Implications for Timing of Release from Isolation: A Longitudinal Cohort Study. *Clin Infect Dis* 2023; **76**(3): e227-e33.

298. Brooks-Pollock E, Northstone K, Pellis L, et al. Voluntary risk mitigation behaviour can reduce impact of SARS-CoV-2: a real-time modelling study of the January 2022 Omicron wave in England. *BMC Med* 2023; **21**(1): 25.

299. Burkholz S, Rubsamen M, Blankenberg L, Carback RT, 3rd, Mochly-Rosen D, Harris PE. Analysis of well-annotated next-generation sequencing data reveals increasing cases of SARS-CoV-2 reinfection with Omicron. *Commun Biol* 2023; **6**(1): 288.

300. Cai M, Em Karniadakis G, Li C. Fractional SEIR model and data-driven predictions of COVID-19 dynamics of Omicron variant. *Chaos* 2022; **32**(7): 071101.

301. Cai W, Yang Z, Liang J, et al. How fast and how well the Omicron epidemic was curtailed. A Guangzhou experience to share. *Front Public Health* 2022; **10**: 979063.

302. Callaghan CJ, Curtis RMK, Mumford L, et al. Vaccine Effectiveness Against the SARS-CoV-2 B.1.1.529 Omicron Variant in Solid Organ and Islet Transplant Recipients in England: A National Retrospective Cohort Study. *Transplantation* 2023; **107**(5): 1124-35.

303. Callaway E. Beyond Omicron: what's next for COVID's viral evolution. *Nature* 2021; **600**(7888): 204-7.

304. Callebaut K, Stoefs A, Stylemans D, et al. Healthcare-Associated SARS-CoV-2 Reinfection after 3 Months with a Phylogenetically Distinct Omicron Variant: A Case Report. *Viruses* 2022; **14**(9).

305. Calvaresi V, Wrobel AG, Toporowska J, et al. Structural dynamics in the evolution of SARS-CoV-2 spike glycoprotein. *Nat Commun* 2023; **14**(1): 1421.

306. Calvet G, Ogrzewalska M, Tassinari W, et al. Accuracy of saliva for SARS-CoV-2 detection in outpatients and their household contacts during the circulation of the Omicron variant of concern. *BMC Infect Dis* 2023; **23**(1): 295.

307. Camacho J, Giménez E, Albert E, et al. Cumulative incidence of SARS-CoV-2 infection in the general population of the Valencian Community (Spain) after the surge of the Omicron BA.1 variant. *J Med Virol* 2023; **95**(1): e28284.

308. Canaday DH, Oyebanji OA, White EM, et al. SARS-CoV-2 Antibody Responses to the Ancestral SARS-CoV-2 Strain and Omicron BA.1 and BA.4/BA.5 Variants in Nursing Home Residents After Receipt of Bivalent COVID-19 Vaccine - Ohio and Rhode Island, September-November 2022. *MMWR Morb Mortal Wkly Rep* 2023; **72**(4): 100-6.

309. Cao L, Xu T, Liu X, et al. The Impact of Accumulated Mutations in SARS-CoV-2 Variants on the qPCR Detection Efficiency. *Front Cell Infect Microbiol* 2022; **12**: 823306.

310. Cao Y, Jian F, Zhang Z, et al. Rational identification of potent and broad sarbecovirus-neutralizing antibody cocktails from SARS convalescents. *Cell Rep* 2022; **41**(12): 111845.

311. Capraru ID, Romanescu M, Anghel FM, et al. Identification of Genomic Variants of SARS-CoV-2 Using Nanopore Sequencing. *Medicina (Kaunas)* 2022; **58**(12).

312. Carattini YL, Griswold A, Williams S, et al. Combined Use of RT-qPCR and NGS for Identification and Surveillance of SARS-CoV-2 Variants of Concern in Residual Clinical Laboratory Samples in Miami-Dade County, Florida. *Viruses* 2023; **15**(3).

313. Carazo S, Skowronski DM, Brisson M, et al. Effectiveness of previous infection-induced and vaccine-induced protection against hospitalisation due to omicron BA subvariants in older adults: a test-negative, case-control study in Quebec, Canada. *Lancet Healthy Longev* 2023; **4**(8): e409-e20.

314. Carazo S, Skowronski DM, Brisson M, et al. Estimated Protection of Prior SARS-CoV-2 Infection Against Reinfection With the Omicron Variant Among Messenger RNA-Vaccinated and Nonvaccinated Individuals in Quebec, Canada. *JAMA Netw Open* 2022; **5**(10): e2236670.

315. Cardoso CC, Rossi Á D, Galliez RM, Faffe DS, Tanuri A, Castiñeiras T. Olfactory Dysfunction in Patients With Mild COVID-19 During Gamma, Delta, and Omicron Waves in Rio de Janeiro, Brazil. *Jama* 2022; **328**(6): 582-3.

316. Carlsen E, Magnus MC, Oakley L, et al. Association of COVID-19 Vaccination During Pregnancy With Incidence of SARS-CoV-2 Infection in Infants. *JAMA Intern Med* 2022; **182**(8): 825-31.

317. Casado JL, Vizcarra P, Martín-Colmenarejo S, et al. Lower T cell response against SARS-CoV-2 variants of concern after mRNA vaccine and risk of breakthrough infections in people with HIV. *Aids* 2023; **37**(6): 877-82.

318. Castelli JM, Rearte A, Olszevicki S, et al. Effectiveness of mRNA-1273, BNT162b2, and BBIBP-CorV vaccines against infection and mortality in children in Argentina, during predominance of delta and omicron covid-19 variants: test negative, case-control study. *Bmj* 2022; **379**: e073070.

319. Casutt A, Papadimitriou-Olivgeris M, Ioakeim F, Aubert JD, Manuel O, Koutsokera A. Outcomes of SARS-CoV-2 infection among lung transplant recipients: A single center retrospective study. *Transpl Infect Dis* 2023; **25**(1): e14007.

320. Cegolon L, Ronchese F, Ricci F, Negro C, Larese-Filon F. SARS-CoV-2 Infection in Health Care Workers of Trieste (North-Eastern Italy), 1 October 2020-7 February 2022: Occupational Risk and the Impact of the Omicron Variant. *Viruses* 2022; **14**(8).

321. Cerqueira-Silva T, Shah SA, Robertson C, et al. Effectiveness of mRNA boosters after homologous primary series with BNT162b2 or ChAdOx1 against symptomatic infection and severe COVID-19 in Brazil and Scotland: A test-negative design case-control study. *PLoS Med* 2023; **20**(1): e1004156.

322. Chaki SP, Kahl-McDonagh MM, Neuman BW, Zuelke KA. Receptor-Binding-Motif-Targeted Sanger Sequencing: a Quick and Cost-Effective Strategy for Molecular Surveillance of SARS-CoV-2 Variants. *Microbiol Spectr* 2022; **10**(3): e0066522.

323. Chakraborty C, Bhattacharya M, Sharma AR, Dhama K, Lee SS. Continent-wide evolutionary trends of emerging SARS-CoV-2 variants: dynamic profiles from Alpha to Omicron. *Geroscience* 2022; **44**(5): 2371-92.

324. Chambers C, Samji H, Cooper CL, et al. Coronavirus disease 2019 vaccine effectiveness among a population-based cohort of people living with HIV. *Aids* 2022; **36**(15): F17-f26.

325. Chan JF, Oh YJ, Yuan S, et al. A molecularly engineered, broad-spectrum anti-coronavirus lectin inhibits SARS-CoV-2 and MERS-CoV infection in vivo. *Cell Rep Med* 2022; **3**(10): 100774.

326. Chang H, Zhang X, Su H, et al. Epidemiological characteristics of paediatric Omicron infection during the outbreak of SARS-CoV-2 infection during March-May in 2022 in Shanghai, China. *Epidemiol Infect* 2023; **151**: e81.

327. Chang ZW, Goh YS, Rouers A, et al. Third dose of BNT162b2 improves immune response in liver transplant recipients to ancestral strain but not Omicron BA.1 and XBB. *Front Immunol* 2023; **14**: 1206016.

328. Chassalevris T, Chaintoutis SC, Koureas M, et al. SARS-CoV-2 wastewater monitoring using a novel PCR-based method rapidly captured the Delta-to-Omicron ΒΑ.1 transition patterns in the absence of conventional surveillance evidence. *Sci Total Environ* 2022; **844**: 156932.

329. Chatterjee D, Tauzin A, Marchitto L, et al. SARS-CoV-2 Omicron Spike recognition by plasma from individuals receiving BNT162b2 mRNA vaccination with a 16-week interval between doses. *Cell Rep* 2022; **38**(9): 110429.

330. Chau NVV, Nguyet LA, Dung NT, et al. Kinetics of Neutralizing Antibodies against Omicron Variant in Vietnamese Healthcare Workers after Primary Immunization with ChAdOx1-S and Booster Immunization with BNT162b2. *Am J Trop Med Hyg* 2023; **108**(1): 137-44.

331. Chemaitelly H, Ayoub HH, Tang P, et al. Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting: a retrospective population-based cohort study. *Lancet Infect Dis* 2023; **23**(7): 816-27.

332. Chemaitelly H, Nagelkerke N, Ayoub HH, et al. Duration of immune protection of SARS-CoV-2 natural infection against reinfection. *J Travel Med* 2022; **29**(8).

333. Chen B, Zhao Y, Jin Z, He D, Li H. Twice evasions of Omicron variants explain the temporal patterns in six Asian and Oceanic countries. *BMC Infect Dis* 2023; **23**(1): 25.

334. Chen CP, Huang KA, Shih SR, et al. Anti-Spike Antibody Response to Natural Infection with SARS-CoV-2 and Its Activity against Emerging Variants. *Microbiol Spectr* 2022; **10**(4): e0074322.

335. Chen CS, Jian MJ, Chang CK, et al. Monitoring algorithm of hospitalized patients in a medical center with SARS-CoV-2 (Omicron variant) infection: clinical epidemiological surveillance and immunological assessment. *PeerJ* 2023; **11**: e14666.

336. Chen G, Lu H. Oral high-dose acetylcysteine: Effective against the Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)? *Drug Discov Ther* 2022; **16**(3): 139-41.

337. Chen P, Bergman P, Blennow O, et al. Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: a one-year follow-up of the prospective clinical trial COVAXID. *EBioMedicine* 2023; **94**: 104700.

338. Chen W, Zhang L, Li J, et al. The kinetics of IgG subclasses and contributions to neutralizing activity against SARS-CoV-2 wild-type strain and variants in healthy adults immunized with inactivated vaccine. *Immunology* 2022; **167**(2): 221-32.

339. Chen Y, Chen Z, Wang X, Xiong H, Shuang F, Liu X. Influencing factors of nucleic acid negative conversion in patients with mild and common COVID-19 induced by the Omicron variant of SARS-COV-2. *Zhejiang Da Xue Xue Bao Yi Xue Ban* 2022; **51**(6): 731-7.

340. Chen Y, Geng Y, Jiang J, Xiong G, Lei C. Smell and taste dysfunction in patients infected with the Omicron variant of severe acute respiratory syndrome coronavirus-2. *Acta Otolaryngol* 2023; **143**(6): 489-94.

341. Chen Y, Han Y, Yang J, Ma Y, Li J, Zhang R. Impact of SARS-CoV-2 Variants on the Analytical Sensitivity of rRT-PCR Assays. *J Clin Microbiol* 2022; **60**(4): e0237421.

342. Chen Y, Ma Y, Han Y, et al. Evaluation of Four Strategies for SARS-CoV-2 Detection: Characteristics and Prospects. *Microbiol Spectr* 2022; **10**(6): e0214322.

343. Chen Z, Wu C, Yuan Y, et al. CRISPR-Cas13a-powered electrochemical biosensor for the detection of the L452R mutation in clinical samples of SARS-CoV-2 variants. *J Nanobiotechnology* 2023; **21**(1): 141.

344. Cheng F, Xiang H, Gale RP, et al. SARS-CoV-2 Omicron BA.5.2-infection and COVID-19 in persons with chronic myeloid leukaemia. *J Cancer Res Clin Oncol* 2023; **149**(13): 11025-30.

345. Cheng HL, Lim SM, Jia H, et al. Rapid Evaluation of Vaccine Booster Effectiveness against SARS-CoV-2 Variants. *Microbiol Spectr* 2022; **10**(5): e0225722.

346. Cheng VC, Lung DC, Wong SC, et al. Outbreak investigation of airborne transmission of Omicron (B.1.1.529) - SARS-CoV-2 variant of concern in a restaurant: Implication for enhancement of indoor air dilution. *J Hazard Mater* 2022; **430**: 128504.

347. Cheng VCC, Ip JD, Chu AWH, et al. Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Omicron Subvariant BA.2 in a Single-Source Community Outbreak. *Clin Infect Dis* 2022; **75**(1): e44-e9.

348. Chernyshev M, Sakharkar M, Connor RI, et al. Vaccination of SARS-CoV-2-infected individuals expands a broad range of clonally diverse affinity-matured B cell lineages. *Nat Commun* 2023; **14**(1): 2249.

349. Chiew CJ, Premikha M, Chong CY, et al. Effectiveness of primary series and booster vaccination against SARS-CoV-2 infection and hospitalisation among adolescents aged 12-17 years in Singapore: a national cohort study. *Lancet Infect Dis* 2023; **23**(2): 177-82.

350. Chiu MC, Li C, Liu X, et al. Human Nasal Organoids Model SARS-CoV-2 Upper Respiratory Infection and Recapitulate the Differential Infectivity of Emerging Variants. *mBio* 2022; **13**(4): e0194422.

351. Chiu MC, Zhang S, Li C, et al. Apical-Out Human Airway Organoids Modeling SARS-CoV-2 Infection. *Viruses* 2023; **15**(5).

352. Choi G, Lim AY, Choi S, Park K, Lee SY, Kim JH. Viral shedding patterns of symptomatic SARS-CoV-2 infections by periods of variant predominance and vaccination status in Gyeonggi Province, Korea. *Epidemiol Health* 2023; **45**: e2023008.

353. Choi SH, Park JY, Kweon OJ, et al. Immune Responses After Vaccination With Primary 2-Dose ChAdOx1 Plus a Booster of BNT162b2 or Vaccination With Primary 2-Dose BNT162b2 Plus a Booster of BNT162b2 and the Occurrence of Omicron Breakthrough Infection. *J Korean Med Sci* 2023; **38**(20): e155.

354. Chong KC, Chan PK, Hung CT, et al. Changes in all-cause and cause-specific excess mortality before and after the Omicron outbreak of COVID-19 in Hong Kong. *J Glob Health* 2023; **13**: 06017.

355. Chua FJD, Kim SY, Hill E, et al. Co-incidence of BA.1 and BA.2 at the start of Singapore's Omicron wave revealed by Community and University Campus wastewater surveillance. *Sci Total Environ* 2023; **875**: 162611.

356. Chung HY, Jian MJ, Chang CK, et al. Accelerating pandemic response with the emergency Omicron RT-PCR test: A comprehensive solution for COVID-19 diagnosis and tracking. *J Med Virol* 2023; **95**(7): e28914.

357. Chung HY, Jian MJ, Chang CK, et al. Emergency SARS-CoV-2 Variants of Concern: Novel Multiplex Real-Time RT-PCR Assay for Rapid Detection and Surveillance. *Microbiol Spectr* 2022; **10**(1): e0251321.

358. Ciccimarra F, Luxi N, Bellitto C, et al. Exploring the Use of Monoclonal Antibodies and Antiviral Therapies for Early Treatment of COVID-19 Outpatients in a Real-World Setting: A Nationwide Study from England and Italy. *BioDrugs* 2023; **37**(5): 675-84.

359. Clark C, Schrecker J, Hardison M, Taitel MS. Validation of reduced S-gene target performance and failure for rapid surveillance of SARS-CoV-2 variants. *PLoS One* 2022; **17**(10): e0275150.

360. Cocherie T, Bastide M, Sakhi S, et al. Decreased Sensitivity of Rapid Antigen Test Is Associated with a Lower Viral Load of Omicron than Delta SARS-CoV-2 Variant. *Microbiol Spectr* 2022; **10**(5): e0192222.

361. Cohen MJ, Oster Y, Moses AE, Spitzer A, Benenson S. Association of Receiving a Fourth Dose of the BNT162b Vaccine With SARS-CoV-2 Infection Among Health Care Workers in Israel. *JAMA Netw Open* 2022; **5**(8): e2224657.

362. Colman E, Puspitarani GA, Enright J, Kao RR. Ascertainment rate of SARS-CoV-2 infections from healthcare and community testing in the UK. *J Theor Biol* 2023; **558**: 111333.

363. Cook CE, Patel NJ, Fu X, et al. Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines Against COVID-19 Infection Among Patients With Systemic Autoimmune Rheumatic Diseases on Immunomodulatory Medications. *J Rheumatol* 2023; **50**(5): 697-703.

364. Coombes NS, Bewley KR, Le Duff Y, et al. Assessment of the Biological Impact of SARS-CoV-2 Genetic Variation Using an Authentic Virus Neutralisation Assay with Convalescent Plasma, Vaccinee Sera, and Standard Reagents. *Viruses* 2023; **15**(3).

365. Corsi Decenti E, Salvatore MA, Mandolini D, Donati S. Vaccination against SARS-CoV-2 in pregnancy during the Omicron wave: the prospective cohort study of the Italian obstetric surveillance system. *Clin Microbiol Infect* 2023; **29**(6): 772-80.

366. Costiniuk CT, Singer J, Lee T, et al. Antibody neutralization capacity after coronavirus disease 2019 vaccination in people with HIV in Canada. *Aids* 2023; **37**(12): F25-f35.

367. Cui Q, Shi Z, Yimamaidi D, et al. Dynamic variations in COVID-19 with the SARS-CoV-2 Omicron variant in Kazakhstan and Pakistan. *Infect Dis Poverty* 2023; **12**(1): 18.

368. Curatola A, Ferretti S, Graglia B, et al. COVID-19 increased in Italian children in the autumn and winter 2021-2022 period when Omicron was the dominant variant. *Acta Paediatr* 2023; **112**(2): 290-5.

369. D'Abramo A, Vita S, Colavita F, et al. The first case of meningitis associated with SARS-CoV-2 BA.2 variant infection with persistent viremia. *Int J Infect Dis* 2022; **124**: 38-40.

370. da Silva MS, Gularte JS, Filippi M, et al. Genomic and epidemiologic surveillance of SARS-CoV-2 in Southern Brazil and identification of a new Omicron-L452R sublineage. *Virus Res* 2022; **321**: 198907.

371. Dai YC, Lin YC, Ching LL, et al. Identification of severe acute respiratory syndrome coronavirus 2 breakthrough infections by anti-nucleocapsid antibody among fully vaccinated non-healthcare workers during the transition from the delta to omicron wave. *Front Med (Lausanne)* 2022; **9**: 1019490.

372. Dalal S, Vishwakarma VP, Sisaudia V, Narwal P. Non-iterative learning machine for identifying CoViD19 using chest X-ray images. *Sci Rep* 2022; **12**(1): 11880.

373. Damin F, Galbiati S, Clementi N, et al. Dual-Domain Reporter Approach for Multiplex Identification of Major SARS-CoV-2 Variants of Concern in a Microarray-Based Assay. *Biosensors (Basel)* 2023; **13**(2).

374. Dang TTT, Anzurez A, Nakayama-Hosoya K, et al. Breadth and Durability of SARS-CoV-2-Specific T Cell Responses following Long-Term Recovery from COVID-19. *Microbiol Spectr* 2023; **11**(4): e0214323.

375. Daniell H, Nair SK, Guan H, et al. Debulking different Corona (SARS-CoV-2 delta, omicron, OC43) and Influenza (H1N1, H3N2) virus strains by plant viral trap proteins in chewing gums to decrease infection and transmission. *Biomaterials* 2022; **288**: 121671.

376. Dapporto F, Marchi S, Leonardi M, et al. Antibody Avidity and Neutralizing Response against SARS-CoV-2 Omicron Variant after Infection or Vaccination. *J Immunol Res* 2022; **2022**: 4813199.

377. Das R, Hyer RN, Burton P, Miller JM, Kuter BJ. Emerging heterologous mRNA-based booster strategies within the COVID-19 vaccine landscape. *Hum Vaccin Immunother* 2023; **19**(1): 2153532.

378. Dasdemir S, Uysal Yazici M, Gudeloglu E, Akkuzu E, Tezer H. Croup as a Previously Unrecognized Symptom of COVID-19 in Infants. *Pediatr Infect Dis J* 2022; **41**(8): e332.

379. Daviña-Nuñez C, Pérez-Castro S, Martínez-Lamas L, et al. Case report: BA.1 subvariant showing a BA.2-like pattern using a variant-specific PCR assay due to a single point mutation downstream the spike 69/70 deletion. *Virol J* 2022; **19**(1): 168.

380. De Cos O, Castillo V, Cantarero D. The Role of Functional Urban Areas in the Spread of COVID-19 Omicron (Northern Spain). *J Urban Health* 2023; **100**(2): 314-26.

381. de Michelena P, Torres I, Ferrando EC, et al. RNA loads of severe acute respiratory syndrome coronavirus 2 in patients with breakthrough coronavirus disease 2019 caused by the Delta and Omicron variants. *Clin Microbiol Infect* 2023; **29**(2): 256.e1-.e4.

382. Debes AK, Xiao S, Egbert ER, et al. Neutralizing SARS-CoV-2 Spike Antibodies against Omicron in Paired Samples after Two or Three Doses of mRNA Vaccine. *Microbiol Spectr* 2022; **10**(5): e0204622.

383. DeCuir J, Surie D, Zhu Y, et al. Effectiveness of Monovalent mRNA COVID-19 Vaccination in Preventing COVID-19-Associated Invasive Mechanical Ventilation and Death Among Immunocompetent Adults During the Omicron Variant Period - IVY Network, 19 U.S. States, February 1, 2022-January 31, 2023. *MMWR Morb Mortal Wkly Rep* 2023; **72**(17): 463-8.

384. Deng H, Lin H, Mai Y, Liu H, Chen W. Clinical features and predictive factors related to liver injury in SARS-CoV-2 Delta and Omicron variant-infected patients. *Eur J Gastroenterol Hepatol* 2022; **34**(9): 933-9.

385. Deo R, Choudhary MC, Moser C, et al. Symptom and Viral Rebound in Untreated SARS-CoV-2 Infection. *Ann Intern Med* 2023; **176**(3): 348-54.

386. DeSilva MB, Mitchell PK, Klein NP, et al. Protection of Two and Three mRNA Vaccine Doses Against Severe Outcomes Among Adults Hospitalized With COVID-19-VISION Network, August 2021 to March 2022. *J Infect Dis* 2023; **227**(8): 961-9.

387. Dewald F, Detmer S, Pirkl M, et al. Viral Load Dynamics in SARS-CoV-2 Omicron Breakthrough Infections. *J Infect Dis* 2022; **226**(10): 1721-5.

388. Ding D, Wen Y, Liao CM, et al. Self-Adjuvanting Protein Vaccine Conjugated with a Novel Synthetic TLR4 Agonist on Virus-Like Liposome Induces Potent Immunity against SARS-CoV-2. *J Med Chem* 2023; **66**(2): 1467-83.

389. Dolinová I, Prattingerová J, Kočí P, et al. Multi-branch cooperation on SARS-CoV-2 omicron capture: a case report. *Cas Lek Cesk* 2022; **161**(1): 24-7.

390. Doria G, Clemente C, Coelho E, et al. An isothermal lab-on-phone test for easy molecular diagnosis of SARS-CoV-2 near patients and in less than 1 hour. *Int J Infect Dis* 2022; **123**: 1-8.

391. Doron A, Piura Y, Vigiser I, et al. BNT162b2 mRNA COVID-19 vaccine three-dose safety and risk of COVID-19 in patients with myasthenia gravis during the alpha, delta, and omicron waves. *J Neurol* 2022; **269**(12): 6193-201.

392. Doucette EJ, Gray J, Fonseca K, et al. A longitudinal seroepidemiology study to evaluate antibody response to SARS-CoV-2 virus infection and vaccination in children in Calgary, Canada from July 2020 to April 2022: Alberta COVID-19 Childhood Cohort (AB3C) Study. *PLoS One* 2023; **18**(4): e0284046.

393. Du Z, Liu C, Wang L, et al. Shorter serial intervals and incubation periods in SARS-CoV-2 variants than the SARS-CoV-2 ancestral strain. *J Travel Med* 2022; **29**(6).

394. Duan W, Ding Q, Peng S, et al. Chinese university students showed less disordered eating during the COVID-19 campus lockdown. *Eat Weight Disord* 2023; **28**(1): 47.

395. Eales O, de Oliveira Martins L, Page AJ, et al. Dynamics of competing SARS-CoV-2 variants during the Omicron epidemic in England. *Nat Commun* 2022; **13**(1): 4375.

396. Eales O, Haw D, Wang H, et al. Dynamics of SARS-CoV-2 infection hospitalisation and infection fatality ratios over 23 months in England. *PLoS Biol* 2023; **21**(5): e3002118.

397. El-Boghdadly K, Cook TM, Goodacre T, et al. Timing of elective surgery and risk assessment after SARS-CoV-2 infection: an update: A multidisciplinary consensus statement on behalf of the Association of Anaesthetists, Centre for Perioperative Care, Federation of Surgical Specialty Associations, Royal College of Anaesthetists, Royal College of Surgeons of England. *Anaesthesia* 2022; **77**(5): 580-7.

398. Eldesouki RE, Uhteg K, Mostafa HH. The circulation of Non-SARS-CoV-2 respiratory viruses and coinfections with SARS-CoV-2 during the surge of the Omicron variant. *J Clin Virol* 2022; **153**: 105215.

399. Ellingson KD, Hollister J, Porter CJ, et al. Risk Factors for Reinfection with SARS-CoV-2 Omicron Variant among Previously Infected Frontline Workers. *Emerg Infect Dis* 2023; **29**(3): 599-604.

400. Elliott P, Eales O, Bodinier B, et al. Dynamics of a national Omicron SARS-CoV-2 epidemic during January 2022 in England. *Nat Commun* 2022; **13**(1): 4500.

401. Ellipilli S, Wang H, Lee WJ, Shu D, Guo P. Proof-of-concept for speedy development of rapid and simple at-home method for potential diagnosis of early COVID-19 mutant infections using nanogold and aptamer. *Nanomedicine* 2022; **45**: 102590.

402. Ergoren MC, Akan G, Volkan E, et al. The "vaccine" hubbub: Viral load comparisons of SARS-CoV-2 Delta and Omicron variants against different vaccine-booster vaccine combinations. *J Med Virol* 2023; **95**(1): e28309.

403. Ertesvåg NU, Iversen A, Blomberg B, et al. Post COVID-19 condition after delta infection and omicron reinfection in children and adolescents. *EBioMedicine* 2023; **92**: 104599.

404. Evans A, Qi C, Adebayo JO, et al. Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on preventing hospital admission among higher-risk patients with COVID-19 in Wales: A retrospective cohort study. *J Infect* 2023; **86**(4): 352-60.

405. Eyre DW, Futschik M, Tunkel S, et al. Performance of antigen lateral flow devices in the UK during the alpha, delta, and omicron waves of the SARS-CoV-2 pandemic: a diagnostic and observational study. *Lancet Infect Dis* 2023; **23**(8): 922-32.

406. Fabiani M, Margiotti K, Monaco F, et al. Dynamics of SARS-CoV-2-Specific B Cell Memory Responses in Infected and Vaccinated Individuals. *Viral Immunol* 2023; **36**(5): 343-50.

407. Fabiani M, Mateo-Urdiales A, Sacco C, et al. Relative effectiveness of a 2nd booster dose of COVID-19 mRNA vaccine up to four months post administration in individuals aged 80 years or more in Italy: A retrospective matched cohort study. *Vaccine* 2023; **41**(1): 76-84.

408. Fachrucha F, Sutoyo DK, Nurwidya F, et al. Severe acute respiratory syndrome coronavirus-2 antibody response after Moderna vaccine booster on healthcare providers. *J Infect Dev Ctries* 2023; **17**(5): 617-22.

409. Fan G, Jin Y, Wang Q, Yue Y. Assessing the comparability of cycle threshold values derived from five external quality assessment rounds for omicron nucleic acid testing. *Virol J* 2023; **20**(1): 119.

410. Fan N, Chen K, Zhu R, et al. Manganese-coordinated mRNA vaccines with enhanced mRNA expression and immunogenicity induce robust immune responses against SARS-CoV-2 variants. *Sci Adv* 2022; **8**(51): eabq3500.

411. Fayad N, Habib WA, El-Shesheny R, et al. Lebanese SARS-CoV-2 genomics: 24 months of the pandemic. *Virus Res* 2022; **317**: 198824.

412. Feng Z, Huo D, Cui S, et al. Epidemiological features, genomic characteristics, and origin tracing of the COVID-19 outbreaks in Beijing from January to September 2022. *J Med Virol* 2023; **95**(3): e28613.

413. Ferdinands JM, Rao S, Dixon BE, et al. Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022. *MMWR Morb Mortal Wkly Rep* 2022; **71**(7): 255-63.

414. Ferdinands JM, Rao S, Dixon BE, et al. Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study. *Bmj* 2022; **379**: e072141.

415. Ferreira VH, Hu Q, Kurtesi A, et al. Impact of Omicron BA.1 infection on BA.4/5 immunity in transplant recipients. *Am J Transplant* 2023; **23**(2): 278-83.

416. Fierro A, Romano S, Liccardo A. Vaccination and variants: Retrospective model for the evolution of Covid-19 in Italy. *PLoS One* 2022; **17**(7): e0265159.

417. Flacco ME, Soldato G, Acuti Martellucci C, et al. Risk of SARS-CoV-2 Reinfection 18 Months After Primary Infection: Population-Level Observational Study. *Front Public Health* 2022; **10**: 884121.

418. Flisiak R, Zarębska-Michaluk D, Rogalska M, et al. Real-world experience with molnupiravir during the period of SARS-CoV-2 Omicron variant dominance. *Pharmacol Rep* 2022; **74**(6): 1279-85.

419. Florentino PTV, Millington T, Cerqueira-Silva T, et al. Vaccine effectiveness of two-dose BNT162b2 against symptomatic and severe COVID-19 among adolescents in Brazil and Scotland over time: a test-negative case-control study. *Lancet Infect Dis* 2022; **22**(11): 1577-86.

420. Floyd R, Hunter S, Murphy N, Lindow SW, O'Connell MP. A retrospective cohort study of pregnancy outcomes during the pandemic period of the SARS-CoV-2 omicron variant: A single center's experience. *Int J Gynaecol Obstet* 2022; **159**(2): 605-6.

421. Focosi D. Molnupiravir: From Hope to Epic Fail? *Viruses* 2022; **14**(11).

422. Fowokan A, Samji H, Puyat JH, et al. Effectiveness of COVID-19 vaccines in people living with HIV in British Columbia and comparisons with a matched HIV-negative cohort: a test-negative design. *Int J Infect Dis* 2023; **127**: 162-70.

423. Franchini M, Focosi D, Mengoli C, et al. Neutralizing antibody levels against SARS-CoV-2 variants of concern Delta and Omicron in vaccine breakthrough-infected blood donors. *Transfusion* 2022; **62**(6): 1171-6.

424. Franchini M, Focosi D, Percivalle E, et al. Variant of Concern-Matched COVID-19 Convalescent Plasma Usage in Seronegative Hospitalized Patients. *Viruses* 2022; **14**(7).

425. Frutos AM, Kuan G, Lopez R, et al. Infection-Induced Immunity Is Associated With Protection Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Decreased Infectivity. *Clin Infect Dis* 2023; **76**(12): 2126-33.

426. Fryer HA, Hartley GE, Edwards ESJ, et al. COVID-19 Adenoviral Vector Vaccination Elicits a Robust Memory B Cell Response with the Capacity to Recognize Omicron BA.2 and BA.5 Variants. *J Clin Immunol* 2023; **43**(7): 1506-18.

427. Fuller CC, Cosgrove A, Shinde M, et al. Treatment and care received by children hospitalized with COVID-19 in a large hospital network in the United States, February 2020 to September 2021. *PLoS One* 2023; **18**(7): e0288284.

428. Furuse Y. Properties of the Omicron Variant of SARS-CoV-2 Affect Public Health Measure Effectiveness in the COVID-19 Epidemic. *Int J Environ Res Public Health* 2022; **19**(9).

429. Fuzzen M, Harper NBJ, Dhiyebi HA, et al. An improved method for determining frequency of multiple variants of SARS-CoV-2 in wastewater using qPCR assays. *Sci Total Environ* 2023; **881**: 163292.

430. Galani A, Markou A, Dimitrakopoulos L, et al. Delta SARS-CoV-2 variant is entirely substituted by the omicron variant during the fifth COVID-19 wave in Attica region. *Sci Total Environ* 2023; **856**(Pt 1): 159062.

431. Gallichotte EN, Nehring M, Stromberg S, et al. Impact of Prior Infection on SARS-CoV-2 Antibody Responses in Vaccinated Long-Term Care Facility Staff. *mSphere* 2022; **7**(4): e0016922.

432. Galmiche S, Cortier T, Charmet T, et al. SARS-CoV-2 incubation period across variants of concern, individual factors, and circumstances of infection in France: a case series analysis from the ComCor study. *Lancet Microbe* 2023; **4**(6): e409-e17.

433. Gao L, Li Y, He P, et al. Safety and immunogenicity of a protein subunit COVID-19 vaccine (ZF2001) in healthy children and adolescents aged 3-17 years in China: a randomised, double-blind, placebo-controlled, phase 1 trial and an open-label, non-randomised, non-inferiority, phase 2 trial. *Lancet Child Adolesc Health* 2023; **7**(4): 269-79.

434. Gao S, Shen M, Wang X, Wang J, Martcheva M, Rong L. A multi-strain model with asymptomatic transmission: Application to COVID-19 in the US. *J Theor Biol* 2023; **565**: 111468.

435. Gao X, Chan PK, Wong KC, et al. Characterization of METRNβ as a novel biomarker of Coronavirus disease 2019 severity and prognosis. *Front Immunol* 2023; **14**: 1111920.

436. Garziano M, Utyro O, Strizzi S, et al. Saliva and Plasma Neutralizing Activity Induced by the Administration of a Third bnt162b2 Vaccine Dose. *Int J Mol Sci* 2022; **23**(22).

437. Gatti G, Brandolini M, Mancini A, et al. Genomic and Temporal Analysis of Deletions Correlated to qRT-PCR Dropout in N Gene in Alpha, Delta and Omicron Variants. *Viruses* 2023; **15**(8).

438. Gazit S, Saciuk Y, Perez G, Peretz A, Pitzer VE, Patalon T. Short term, relative effectiveness of four doses versus three doses of BNT162b2 vaccine in people aged 60 years and older in Israel: retrospective, test negative, case-control study. *Bmj* 2022; **377**: e071113.

439. Geismar C, Nguyen V, Fragaszy E, et al. Bayesian reconstruction of household transmissions to infer the serial interval of COVID-19 by variants of concern: analysis from a prospective community cohort study (Virus Watch). *Lancet* 2022; **400 Suppl 1**: S40.

440. Geismar C, Nguyen V, Fragaszy E, et al. Symptom profiles of community cases infected by influenza, RSV, rhinovirus, seasonal coronavirus, and SARS-CoV-2 variants of concern. *Sci Rep* 2023; **13**(1): 12511.

441. Gershengorn HB, Patel S, Ferreira T, Das S, Parekh DJ, Shukla B. The clinical effectiveness of REGEN-COV in SARS-CoV-2 infection with Omicron versus Delta variants. *PLoS One* 2022; **17**(12): e0278770.

442. Ghasemi A, Khodashahi R, Aliakbarian M, et al. Efficacy of Sinopharm Vaccine Among Stem Cell Transplant Recipients During Two Peaks of Delta and Omicron variants of COVID-19. *Curr Drug Saf* 2023; **18**(4): 540-6.

443. Gilboa M, Gonen T, Barda N, et al. Factors Associated With Protection From SARS-CoV-2 Omicron Variant Infection and Disease Among Vaccinated Health Care Workers in Israel. *JAMA Netw Open* 2023; **6**(5): e2314757.

444. Gilboa M, Regev-Yochay G, Mandelboim M, et al. Durability of Immune Response After COVID-19 Booster Vaccination and Association With COVID-19 Omicron Infection. *JAMA Netw Open* 2022; **5**(9): e2231778.

445. Girardin FR, Tzankov A, Pantaleo G, Livio F, Greub G. Multifocal lymphadenopathies with polyclonal reactions primed after EBV infection in a mRNA-1273 vaccine recipient. *Swiss Med Wkly* 2022; **152**: w30188.

446. Gladkikh A, Dedkov V, Sharova A, et al. Epidemiological Features of COVID-19 in Northwest Russia in 2021. *Viruses* 2022; **14**(5).

447. Glocker MO, Opuni KFM, Thiesen HJ. From Free Binding Energy Calculations of SARS-CoV-2-Receptor Interactions to Cellular Immune Responses. *Medicina (Kaunas)* 2022; **58**(2).

448. Goel AR, Chiang SS, Ibrahim O, Yalcindag A. Multisystem Inflammatory Syndrome in an Adolescent Following SARS-CoV-2 Exposure Despite Three Doses of a COVID-19 Vaccine. *R I Med J (2013)* 2022; **105**(5): 41-5.

449. Goiriz L, Ruiz R, Garibo IOÒ, Conejero JA, Rodrigo G. A variant-dependent molecular clock with anomalous diffusion models SARS-CoV-2 evolution in humans. *Proc Natl Acad Sci U S A* 2023; **120**(30): e2303578120.

450. Gonçalves-Brito AS, Magaldi M, Farias BO, et al. Environmental genomic surveillance of SARS-CoV-2 in wastewater in Rio de Janeiro, Brazil. *J Water Health* 2023; **21**(5): 653-62.

451. Gosdin L, Chang D, Olsen EO, et al. SARS-CoV-2 During Omicron Variant Predominance Among Infants Born to People With SARS-CoV-2. *Pediatrics* 2023; **151**(5).

452. Goswami C, Sheldon M, Bixby C, et al. Identification of SARS-CoV-2 variants using viral sequencing for the Centers for Disease Control and Prevention genomic surveillance program. *BMC Infect Dis* 2022; **22**(1): 404.

453. Grabowski F, Kochańczyk M, Lipniacki T. The Spread of SARS-CoV-2 Variant Omicron with a Doubling Time of 2.0-3.3 Days Can Be Explained by Immune Evasion. *Viruses* 2022; **14**(2).

454. Granerud BK, Ueland T, Lind A, et al. Omicron Variant Generates a Higher and More Sustained Viral Load in Nasopharynx and Saliva Than the Delta Variant of SARS-CoV-2. *Viruses* 2022; **14**(11).

455. Grebe E, Yu EA, Bravo MD, et al. Coronavirus Disease 2019 Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection in the United States Before the Delta- and Omicron-Associated Surges: A Retrospective Cohort Study of Repeat Blood Donors. *J Infect Dis* 2022; **226**(9): 1556-61.

456. Green A, Curtis H, Hulme W, et al. Describing the population experiencing COVID-19 vaccine breakthrough following second vaccination in England: a cohort study from OpenSAFELY. *BMC Med* 2022; **20**(1): 243.

457. Green A, Jones H, Nero A, et al. A case of hyperhemolysis syndrome in sickle cell disease and concomitant COVID-19. *Transfus Apher Sci* 2023; **62**(4): 103712.

458. Greene SK, Levin-Rector A, Kyaw NTT, et al. Comparative hospitalization risk for SARS-CoV-2 Omicron and Delta variant infections, by variant predominance periods and patient-level sequencing results, New York City, August 2021-January 2022. *Influenza Other Respir Viruses* 2023; **17**(1): e13062.

459. Grenfell RFQ, Almeida NBF, Filgueiras PS, et al. Immunogenicity, Effectiveness, and Safety of Inactivated Virus (CoronaVac) Vaccine in a Two-Dose Primary Protocol and BNT162b2 Heterologous Booster in Brazil (Immunita-001): A One Year Period Follow Up Phase 4 Study. *Front Immunol* 2022; **13**: 918896.

460. Grenfell RFQ, Oyeyemi OT. Access to COVID-19 vaccines and testing in Africa: the importance of COVAX - Nigeria as a case study. *Pathog Glob Health* 2023; **117**(2): 152-66.

461. Grewal R, Nguyen L, Buchan SA, Wilson SE, Costa AP, Kwong JC. Effectiveness and Duration of Protection of a Fourth Dose of Coronavirus Disease 2019 Messenger RNA Vaccine Among Long-term Care Residents in Ontario, Canada. *J Infect Dis* 2023; **227**(8): 977-80.

462. Guedes AR, Oliveira MS, Tavares BM, et al. Reinfection rate in a cohort of healthcare workers over 2 years of the COVID-19 pandemic. *Sci Rep* 2023; **13**(1): 712.

463. Guernsey D, 3rd, Kostin S, Silver M, Vazquez H, Zerzan J. The evolving relationship between COVID-19 and serious bacterial infection evaluation in febrile neonates. *Acta Paediatr* 2023; **112**(7): 1398-403.

464. Guevara R, Prado-Vivar B, Márquez S, et al. Occurrence of SARS-CoV-2 reinfections at regular intervals in Ecuador. *Front Cell Infect Microbiol* 2022; **12**: 951383.

465. Gui H, Zhang Z, Chen B, et al. Development and validation of a nomogram to predict failure of 14-day negative nucleic acid conversion in adults with non-severe COVID-19 during the Omicron surge: a retrospective multicenter study. *Infect Dis Poverty* 2023; **12**(1): 7.

466. Guo Y, Li B, Duan T, et al. A panel regression analysis for the COVID-19 epidemic in the United States. *PLoS One* 2022; **17**(8): e0273344.

467. Guo Y, Wu S, Ye W, et al. Impact of public health and social measures on contact dynamics during a SARS-CoV-2 Omicron variant outbreak in Quanzhou, China, March to April 2022. *Int J Infect Dis* 2023; **131**: 46-9.

468. Gupta S, Kumar A, Gupta N, Bharti DR, Aggarwal N, Ravi V. A two-step process for in silico screening to assess the performance of qRTPCR kits against variant strains of SARS-CoV-2. *BMC Genomics* 2022; **23**(1): 755.

469. Gürer Giray B, Güven Açık G. SARS-CoV-2 and mutation RT-qPCR test positivity correlation with ABO and Rh blood types. *J Med Virol* 2022; **94**(10): 4776-9.

470. Hahn G, Lee S, Prokopenko D, et al. Unsupervised outlier detection applied to SARS-CoV-2 nucleotide sequences can identify sequences of common variants and other variants of interest. *BMC Bioinformatics* 2022; **23**(1): 547.

471. Hajizadeh F, Khanizadeh S, Khodadadi H, et al. SARS-COV-2 RBD (Receptor binding domain) mutations and variants (A sectional-analytical study). *Microb Pathog* 2022; **168**: 105595.

472. Halasa NB, Olson SM, Staat MA, et al. Maternal Vaccination and Risk of Hospitalization for Covid-19 among Infants. *N Engl J Med* 2022; **387**(2): 109-19.

473. Hansen C, Perofsky AC, Burstein R, et al. Trends in Risk Factors and Symptoms Associated With SARS-CoV-2 and Rhinovirus Test Positivity in King County, Washington, June 2020 to July 2022. *JAMA Netw Open* 2022; **5**(12): e2245861.

474. Hao Z, Zhang W. Anxiety among College Students Who Self-Isolated During the Omicron Variant of SARS-CoV-2 in China. *Eval Health Prof* 2023; **46**(1): 105-9.

475. Hardick J, Gallagher N, Sachithanandham J, et al. Evaluation of Four Point of Care (POC) Antigen Assays for the Detection of the SARS-CoV-2 Variant Omicron. *Microbiol Spectr* 2022; **10**(3): e0102522.

476. Harrigan SP, Wilton J, Chong M, et al. Clinical Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant Relative to Delta in British Columbia, Canada: A Retrospective Analysis of Whole-Genome Sequenced Cases. *Clin Infect Dis* 2023; **76**(3): e18-e25.

477. Hart WS, Miller E, Andrews NJ, et al. Generation time of the alpha and delta SARS-CoV-2 variants: an epidemiological analysis. *Lancet Infect Dis* 2022; **22**(5): 603-10.

478. Haschka T, Vergu E, Roche B, Poletto C, Opatowski L. Retrospective analysis of SARS-CoV-2 omicron invasion over delta in French regions in 2021-22: a status-based multi-variant model. *BMC Infect Dis* 2022; **22**(1): 815.

479. Hastert FD, Henss L, von Rhein C, et al. Longitudinal Analysis of Coronavirus-Neutralizing Activity in COVID-19 Patients. *Viruses* 2022; **14**(5).

480. Havers FP, Patel K, Whitaker M, et al. Laboratory-Confirmed COVID-19-Associated Hospitalizations Among Adults During SARS-CoV-2 Omicron BA.2 Variant Predominance - COVID-19-Associated Hospitalization Surveillance Network, 14 States, June 20, 2021-May 31, 2022. *MMWR Morb Mortal Wkly Rep* 2022; **71**(34): 1085-91.

481. Hawkins LPA, Pallett SJC, Mazzella A, et al. Transmission dynamics and associated mortality of nosocomial COVID-19 throughout 2021: a retrospective study at a large teaching hospital in London. *J Hosp Infect* 2023; **133**: 62-9.

482. Hayashi K, Nishiura H. Time-dependent risk of COVID-19 death with overwhelmed health-care capacity in Japan, 2020-2022. *BMC Infect Dis* 2022; **22**(1): 933.

483. He H, Chen G, Chen CY. NHGNN-DTA: a node-adaptive hybrid graph neural network for interpretable drug-target binding affinity prediction. *Bioinformatics* 2023; **39**(6).

484. He Q, Dou X, Liu Y, et al. Characteristics and outcomes of COVID-19 in patients with plasma cell dyscrasias during the first Omicron wave in Beijing since December 2022: a retrospective study at a National Clinical Research Center for Hematologic Disease. *Ann Hematol* 2023; **102**(10): 2857-64.

485. Heinen N, Marheinecke CS, Bessen C, et al. In-depth analysis of T cell immunity and antibody responses in heterologous prime-boost-boost vaccine regimens against SARS-CoV-2 and Omicron variant. *Front Immunol* 2022; **13**: 1062210.

486. Hippisley-Cox J, Khunti K, Sheikh A, Nguyen-Van-Tam JS, Coupland CAC. Risk prediction of covid-19 related death or hospital admission in adults testing positive for SARS-CoV-2 infection during the omicron wave in England (QCOVID4): cohort study. *Bmj* 2023; **381**: e072976.

487. Hirose R, Itoh Y, Ikegaya H, et al. Differences in environmental stability among SARS-CoV-2 variants of concern: both omicron BA.1 and BA.2 have higher stability. *Clin Microbiol Infect* 2022; **28**(11): 1486-91.

488. Hon KL, Leung KKY. Elimination, Containment, and Mitigation of COVID-19: A Personal Story about International Travels. *Curr Pediatr Rev* 2023; **19**(3): 218-22.

489. Honda-Okubo Y, Antipov A, Andre G, Barati S, Kafi H, Petrovsky N. Ability of SpikoGen®, an Advax-CpG adjuvanted recombinant spike protein vaccine, to induce cross-neutralising antibodies against SARS-CoV-2 variants. *Immunology* 2023; **170**(2): 193-201.

490. Hori M, Yasuda K, Takahashi H, et al. The Impact of Liver Chemistries on Respiratory Failure among Hemodialysis Patients with COVID-19 during the Omicron Wave. *Intern Med* 2023; **62**(18): 2617-25.

491. Horikoshi Y, Shibata M, Funakoshi H, Baba S, Miyama S. Post coronavirus disease 2019 condition in children at a children's hospital in Japan. *Pediatr Int* 2023; **65**(1): e15458.

492. Hosseinian S, de Assis R, Khalil G, et al. Analysis and comparison of SARS-CoV-2 variant antibodies and neutralizing activity for 6 months after a booster mRNA vaccine in a healthcare worker population. *Front Immunol* 2023; **14**: 1166261.

493. Hu C, Liu YK, Sun QD, et al. Clinical characteristics and risk factors for a prolonged length of stay of patients with asymptomatic and mild COVID-19 during the wave of Omicron from Shanghai, China. *BMC Infect Dis* 2022; **22**(1): 947.

494. Hu S, Xiong C, Zhao Y, Yuan X, Wang X. Vaccination, human mobility, and COVID-19 health outcomes: Empirical comparison before and during the outbreak of SARS-Cov-2 B.1.1.529 (Omicron) variant. *Vaccine* 2023; **41**(35): 5097-112.

495. Hu X, Mu Y, Deng R, Yi G, Yao L, Zhang J. Genome characterization based on the Spike-614 and NS8-84 loci of SARS-CoV-2 reveals two major possible onsets of the COVID-19 pandemic. *PLoS One* 2023; **18**(6): e0279221.

496. Huiberts AJ, de Gier B, Hoeve CE, et al. Vaccine effectiveness of primary and booster COVID-19 vaccinations against SARS-CoV-2 infection in the Netherlands from July 12, 2021 to June 6, 2022: A prospective cohort study. *Int J Infect Dis* 2023; **133**: 36-42.

497. Hurford A, Martignoni MM, Loredo-Osti JC, et al. Pandemic modelling for regions implementing an elimination strategy. *J Theor Biol* 2023; **561**: 111378.

498. Hwang S, Baek SH, Park D. Interaction Analysis of the Spike Protein of Delta and Omicron Variants of SARS-CoV-2 with hACE2 and Eight Monoclonal Antibodies Using the Fragment Molecular Orbital Method. *J Chem Inf Model* 2022; **62**(7): 1771-82.

499. Iijima H, Kubota M, Ogimi C. Change in Seizure Incidence in Febrile Children With COVID-19 in the Era of Omicron Variant of Concern. *J Pediatric Infect Dis Soc* 2022; **11**(11): 514-7.

500. Iijima T, Sakai J, Kanamori D, et al. A New Method to Detect Variants of SARS-CoV-2 Using Reverse Transcription Loop-Mediated Isothermal Amplification Combined with a Bioluminescent Assay in Real Time (RT-LAMP-BART). *Int J Mol Sci* 2023; **24**(13).

501. Iio K, Hagiwara Y, Saito O, Ishida Y, Horikoshi Y. Seizure in children with severe acute respiratory syndrome coronavirus 2 Omicron variant infection. *Pediatr Int* 2022; **64**(1): e15255.

502. Innes GK, Schmitz BW, Brierley PE, et al. Wastewater-Based Epidemiology Mitigates COVID-19 Outbreaks at a Food Processing Facility near the Mexico-U.S. Border-November 2020-March 2022. *Viruses* 2022; **14**(12).

503. Ionescu IG, Skowronski DM, Sauvageau C, et al. BNT162b2 Effectiveness Against Delta and Omicron Variants of Severe Acute Respiratory Syndrome Coronavirus 2 in Adolescents Aged 12-17 Years, by Dosing Interval and Duration. *J Infect Dis* 2023; **227**(9): 1073-83.

504. Ishihara T, Iida O, Takahara M, et al. Clinical course of patients with chronic limb-threatening ischemia developing COVID-19. *J Cardiol* 2022; **80**(6): 545-8.

505. Ito K, Piantham C, Nishiura H. Estimating relative generation times and reproduction numbers of Omicron BA.1 and BA.2 with respect to Delta variant in Denmark. *Math Biosci Eng* 2022; **19**(9): 9005-17.

506. Iwamura N, Tsutsumi K. SARS-CoV-2 airborne infection probability estimated by using indoor carbon dioxide. *Environ Sci Pollut Res Int* 2023; **30**(32): 79227-40.

507. Jacob R, Liu K, Marinelli T. Successful liver transplantation for hepatitis B-related acute liver failure in a patient with active COVID-19. *Transpl Infect Dis* 2022; **24**(4): e13889.

508. Jacot D, von Rotz U, Pellaton C, et al. SARS-CoV-2 neutralizing antibody response in vaccinated and non-vaccinated hospital healthcare workers with or without history of infection. *Microbes Infect* 2023; **25**(1-2): 105077.

509. Jain V, Serisier A, Lorgelly P. The Real-World Impact of Vaccination on COVID-19 Cases During Europe's Fourth Wave. *Int J Public Health* 2022; **67**: 1604793.

510. Jamaati H, Karimi S, Ghorbani F, et al. Effectiveness of different vaccine platforms in reducing mortality and length of ICU stay in severe and critical cases of COVID-19 in the Omicron variant era: A national cohort study in Iran. *J Med Virol* 2023; **95**(3): e28607.

511. Jeewandara C, Aberathna IS, Dayarathna S, et al. Comparison of the kinetics and magnitude of antibody responses to different SARS-CoV-2 proteins in Sinopharm/BBIBP-CorV vaccinees following the BNT162b2 booster or natural infection. *PLoS One* 2022; **17**(10): e0274845.

512. Jelic M, Silveira L, Lang S, et al. Changing Characteristics of Children With COVID-19 in Colorado Admitted During Different Variant Periods. *Pediatr Infect Dis J* 2023; **42**(8): 679-84.

513. Jessen R, Nielsen L, Larsen NB, et al. A RT-qPCR system using a degenerate probe for specific identification and differentiation of SARS-CoV-2 Omicron (B.1.1.529) variants of concern. *PLoS One* 2022; **17**(10): e0274889.

514. Jo SJ, Kim J, Kim S, et al. Simple Saliva Sample Collection for the Detection of SARS-CoV-2 Variants Compared With Nasopharyngeal Swab Sample. *Arch Pathol Lab Med* 2022; **146**(12): 1435-40.

515. Johnson AG, Linde L, Ali AR, et al. COVID-19 Incidence and Mortality Among Unvaccinated and Vaccinated Persons Aged ≥12 Years by Receipt of Bivalent Booster Doses and Time Since Vaccination - 24 U.S. Jurisdictions, October 3, 2021-December 24, 2022. *MMWR Morb Mortal Wkly Rep* 2023; **72**(6): 145-52.

516. Jones AC, Meredith GR, Leong D, et al. Pandemic Response Officers: Integration Between Medical, Public Health, and Higher Education Systems to Expedite Prevention and Response. *J Public Health Manag Pract* 2023; **29**(4): 556-62.

517. Jorgensen SCJ, Hernandez A, Fell DB, et al. Maternal mRNA covid-19 vaccination during pregnancy and delta or omicron infection or hospital admission in infants: test negative design study. *Bmj* 2023; **380**: e074035.

518. Jørgensen TS, Pedersen MS, Blin K, et al. SpikeSeq: A rapid, cost efficient and simple method to identify SARS-CoV-2 variants of concern by Sanger sequencing part of the spike protein gene. *J Virol Methods* 2023; **312**: 114648.

519. Joung J, Yang H, Choi YJ, Lee J, Ko Y. The Impact of Omicron Wave on Pediatric Febrile Seizure. *J Korean Med Sci* 2023; **38**(3): e18.

520. Joung Y, Kim K, Lee S, et al. Rapid and Accurate On-Site Immunodiagnostics of Highly Contagious Severe Acute Respiratory Syndrome Coronavirus 2 Using Portable Surface-Enhanced Raman Scattering-Lateral Flow Assay Reader. *ACS Sens* 2022; **7**(11): 3470-80.

521. Jung J, Kang SW, Lee S, et al. Risk of transmission of COVID-19 from healthcare workers returning to work after a 5-day isolation, and kinetics of shedding of viable SARS-CoV-2 variant B.1.1.529 (Omicron). *J Hosp Infect* 2023; **131**: 228-33.

522. Kajiya T, Sawayama H, Arima E, et al. Novel RT-PCR Using Sugar Chain-Immobilized Gold-Nanoparticles Correlates Patients' Symptoms: The Follow-Up Study of COVID-19 Hospitalized Patients. *Viruses* 2022; **14**(11).

523. Kaku CI, Starr TN, Zhou P, et al. Evolution of antibody immunity following Omicron BA.1 breakthrough infection. *Nat Commun* 2023; **14**(1): 2751.

524. Kalu IC, Zimmerman KO, Goldman JL, et al. SARS-CoV-2 Screening Testing Programs for Safe In-person Learning in K-12 Schools. *J Pediatric Infect Dis Soc* 2023; **12**(2): 64-72.

525. Kang W, Yang P, Dang B, et al. Dynamics of disease characteristics and viral RNA decay in patients with asymptomatic and mild infections during the Omicron wave in Shanghai, China: A retrospective cohort study. *Int J Infect Dis* 2023; **130**: 60-70.

526. Kantauskaite M, Müller L, Hillebrandt J, et al. Immune response to third SARS-CoV-2 vaccination in seronegative kidney transplant recipients: Possible improvement by mycophenolate mofetil reduction. *Clin Transplant* 2022; **36**(11): e14790.

527. Karako K, Song P, Chen Y, Karako T. Trends in managing COVID-19 from an emerging infectious disease to a common respiratory infectious disease: What are the subsequent impacts on and new challenges for healthcare systems? *Biosci Trends* 2022; **16**(6): 381-5.

528. Kato S, Yoshikura N, Kimura A, Shimohata T. Possible Autoimmune Encephalitis Associated with the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant Successfully Treated with Steroids. *Intern Med* 2022; **61**(24): 3739-41.

529. Katsuta T, Aizawa Y, Shoji K, et al. Acute and Postacute Clinical Characteristics of Coronavirus Disease 2019 in Children in Japan. *Pediatr Infect Dis J* 2023; **42**(3): 240-6.

530. Keeling MJ. Patterns of reported infection and reinfection of SARS-CoV-2 in England. *J Theor Biol* 2023; **556**: 111299.

531. Kelly JD, Leonard S, Hoggatt KJ, et al. Incidence of Severe COVID-19 Illness Following Vaccination and Booster With BNT162b2, mRNA-1273, and Ad26.COV2.S Vaccines. *Jama* 2022; **328**(14): 1427-37.

532. Kerr S, Vasileiou E, Robertson C, Sheikh A. COVID-19 vaccine effectiveness against symptomatic SARS-CoV-2 infection and severe COVID-19 outcomes from Delta AY.4.2: Cohort and test-negative study of 5.4 million individuals in Scotland. *J Glob Health* 2022; **12**: 05025.

533. Khajotia R. Omicron: the highly mutational COVID-19 variant with immune escape. *Pan Afr Med J* 2022; **41**: 84.

534. Khan A, Heng W, Imran K, et al. Discovery of Isojacareubin as a covalent inhibitor of SARS-CoV-2 main protease using structural and experimental approaches. *J Med Virol* 2023; **95**(2): e28542.

535. Khasawneh AI, Himsawi NM, Abu-Raideh JA, et al. Prevalence of SARS-COV-2 and other respiratory pathogens among a Jordanian subpopulation during Delta-to-Omicron transition: Winter 2021/2022. *PLoS One* 2023; **18**(3): e0283804.

536. Khatri R, Siddqui G, Sadhu S, et al. Intrinsic D614G and P681R/H mutations in SARS-CoV-2 VoCs Alpha, Delta, Omicron and viruses with D614G plus key signature mutations in spike protein alters fusogenicity and infectivity. *Med Microbiol Immunol* 2023; **212**(1): 103-22.

537. Khoo SH, FitzGerald R, Saunders G, et al. Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial. *Lancet Infect Dis* 2023; **23**(2): 183-95.

538. Khoury L, Pillar G, Shehadeh S. COVID-19 in neonates and infants younger than 6 months - a mild viral illness. *Eur J Pediatr* 2023; **182**(7): 3287-91.

539. Kiani SJ, Ramshini M, Bokharaei-Salim F, et al. High resolution melting curve analysis for rapid detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants. *Acta Virol* 2023; **67**(1): 91-8.

540. Kim H, Kim HS, Kim HM, et al. Impact of vaccination and the omicron variant on COVID-19 severity in pregnant women. *Am J Infect Control* 2023; **51**(3): 351-3.

541. Kim JA, Bang HI, Shin JW, et al. Immunogenicity of Third-dose BNT162b2 mRNA Vaccine Following Two Doses of ChAdOx1 in Health Care Workers: A Prospective Longitudinal Study. *Ann Lab Med* 2022; **42**(6): 688-92.

542. Kim WJ, Choi SH, Park JY, Song JS, Chung JW, Choi ST. SARS-CoV-2 Omicron escapes mRNA vaccine booster-induced antibody neutralisation in patients with autoimmune rheumatic diseases: an observational cohort study. *Ann Rheum Dis* 2022; **81**(11): 1585-93.

543. Kirby RP, Maimaran M, Palamountain KM. Is there a "price that's right" for at-home COVID tests? *PLoS One* 2023; **18**(3): e0282043.

544. Kirca F, Aydoğan S, Gözalan A, et al. Comparison of clinical characteristics of wild-type SARS-CoV-2 and Omicron. *Rev Assoc Med Bras (1992)* 2022; **68**(10): 1476-80.

545. Kiss Z, Wittmann I, Polivka L, et al. Nationwide Effectiveness of First and Second SARS-CoV2 Booster Vaccines During the Delta and Omicron Pandemic Waves in Hungary (HUN-VE 2 Study). *Front Immunol* 2022; **13**: 905585.

546. Kitonsa J, Kamacooko O, Ruzagira E, et al. A phase I COVID-19 vaccine trial among SARS-CoV-2 seronegative and seropositive individuals in Uganda utilizing a self-amplifying RNA vaccine platform: Screening and enrollment experiences. *Hum Vaccin Immunother* 2023; **19**(2): 2240690.

547. Klén R, Purohit D, Gómez-Huelgas R, et al. Development and evaluation of a machine learning-based in-hospital COVID-19 disease outcome predictor (CODOP): A multicontinental retrospective study. *Elife* 2022; **11**.

548. Klineova S, Farber RS, DeAngelis T, et al. Vaccine-breakthrough SARS-CoV-2 infections in people with multiple sclerosis and related conditions: An observational study by the New York COVID-19 Neuro-Immunology Consortium (NYCNIC-2). *Mult Scler* 2023; **29**(8): 990-1000.

549. Klink GV, Danilenko D, Komissarov AB, et al. An Early SARS-CoV-2 Omicron Outbreak in a Dormitory in Saint Petersburg, Russia. *Viruses* 2023; **15**(7).

550. Ko K, Takahashi K, Nagashima S, et al. Exercising the Sanger Sequencing Strategy for Variants Screening and Full-Length Genome of SARS-CoV-2 Virus during Alpha, Delta, and Omicron Outbreaks in Hiroshima. *Viruses* 2022; **14**(4).

551. Kodchakorn K, Kongtawelert P. Molecular dynamics study on the strengthening behavior of Delta and Omicron SARS-CoV-2 spike RBD improved receptor-binding affinity. *PLoS One* 2022; **17**(11): e0277745.

552. Kohmer N, Stein S, Schenk B, et al. Heterologous prime-boost immunization with ChAdOx1-S and BNT162b2: reactogenicity and immunogenicity in a prospective cohort study. *Int J Infect Dis* 2023; **128**: 166-75.

553. Kong W, Zhong Q, Chen M, et al. Ad5-nCoV booster and Omicron variant breakthrough infection following two doses of inactivated vaccine elicit comparable antibody levels against Omicron variants. *J Med Virol* 2023; **95**(1): e28163.

554. Kostaki EG, Mossialos E, Tseti I, Sfikakis PP, Paraskevis D. Mapping the Early Dispersal Patterns of SARS-CoV-2 Omicron BA.4 and BA.5 Subvariants in the Absence of Travel Restrictions and Testing at the Borders in Europe. *Viruses* 2022; **15**(1).

555. Kotsiou OS, Vavougios GD, Papagiannis D, et al. Lessons We Have Learned Regarding Seroprevalence in High and Low SARS-CoV-2 Contexts in Greece before the Omicron Pandemic Wave. *Int J Environ Res Public Health* 2022; **19**(10).

556. Kovacs T, Kurtan K, Varga Z, Nagy P, Panyi G, Zakany F. Veklury® (remdesivir) formulations inhibit initial membrane-coupled events of SARS-CoV-2 infection due to their sulfobutylether-β-cyclodextrin content. *Br J Pharmacol* 2023; **180**(16): 2064-84.

557. Koyama T, Miyakawa K, Tokumasu R, S SJ, Kudo M, Ryo A. Evasion of vaccine-induced humoral immunity by emerging sub-variants of SARS-CoV-2. *Future Microbiol* 2022; **17**: 417-24.

558. Krutikov M, Stirrup O, Nacer-Laidi H, et al. Outcomes of SARS-CoV-2 omicron infection in residents of long-term care facilities in England (VIVALDI): a prospective, cohort study. *Lancet Healthy Longev* 2022; **3**(5): e347-e55.

559. Kumar N, Kaushik R, Singh A, et al. Bayesian Molecular Dating Analyses Combined with Mutational Profiling Suggest an Independent Origin and Evolution of SARS-CoV-2 Omicron BA.1 and BA.2 Sub-Lineages. *Viruses* 2022; **14**(12).

560. Kumar R, Gupta M, Agarwal A, Mukherjee A, Islam SMN. Epidemic efficacy of Covid-19 vaccination against Omicron: An innovative approach using enhanced residual recurrent neural network. *PLoS One* 2023; **18**(3): e0280026.

561. Kumar S, Choudhary S, Thakur S, Kumar A, Kumar S. Surveillance of omicron variant in Kangra District of Himachal Pradesh, India during the 3rd disease wave of COVID-19. *J Infect Dev Ctries* 2023; **17**(4): 448-53.

562. Kumar S, King MD. Numerical investigation on indoor environment decontamination after sneezing. *Environ Res* 2022; **213**: 113665.

563. Kurosaki S, Otani A, Senoo S, Hataya H, Horikoshi Y. A child with the Omicron variant coronavirus disease 2019 pneumonia complicated with arrhythmia. *Pediatr Int* 2022; **64**(1): e15299.

564. Kurpas MK, Jaksik R, Kuś P, Kimmel M. Genomic Analysis of SARS-CoV-2 Alpha, Beta and Delta Variants of Concern Uncovers Signatures of Neutral and Non-Neutral Evolution. *Viruses* 2022; **14**(11).

565. La Rosa G, Brandtner D, Bonanno Ferraro G, et al. Wastewater surveillance of SARS-CoV-2 variants in October-November 2022 in Italy: detection of XBB.1, BA.2.75 and rapid spread of the BQ.1 lineage. *Sci Total Environ* 2023; **873**: 162339.

566. La Rosa G, Iaconelli M, Veneri C, et al. The rapid spread of SARS-COV-2 Omicron variant in Italy reflected early through wastewater surveillance. *Sci Total Environ* 2022; **837**: 155767.

567. Laake I, Skodvin SN, Blix K, et al. Effectiveness of mRNA Booster Vaccination Against Mild, Moderate, and Severe COVID-19 Caused by the Omicron Variant in a Large, Population-Based, Norwegian Cohort. *J Infect Dis* 2022; **226**(11): 1924-33.

568. Lai A, Bergna A, Della Ventura C, et al. Epidemiological and Clinical Features of SARS-CoV-2 Variants Circulating between April-December 2021 in Italy. *Viruses* 2022; **14**(11).

569. Lai E, Kennedy EB, Lozach J, et al. A Method for Variant Agnostic Detection of SARS-CoV-2, Rapid Monitoring of Circulating Variants, and Early Detection of Emergent Variants Such as Omicron. *J Clin Microbiol* 2022; **60**(7): e0034222.

570. Laird-Gion J, Dionne A, Gauvreau K, et al. MIS-C across three SARS-CoV-2 variants: Changes in COVID-19 testing and clinical characteristics in a cohort of U.S. children. *Eur J Pediatr* 2023; **182**(6): 2865-72.

571. Lamothe G, Carbonneau J, Joly Beauparlant C, et al. Rapid and Technically Simple Detection of SARS-CoV-2 Variants Using CRISPR Cas12 and Cas13. *Crispr j* 2023; **6**(4): 369-85.

572. Lande J, Pillay A, Chandra R. Deep learning for COVID-19 topic modelling via Twitter: Alpha, Delta and Omicron. *PLoS One* 2023; **18**(8): e0288681.

573. Langlete P, Tesli M, Veneti L, Starrfelt J, Elstrøm P, Meijerink H. Estimated vaccine effectiveness against SARS-CoV-2 Delta and Omicron infections among health care workers and the general adult population in Norway, August 2021 - January 2022. *Vaccine* 2023; **41**(26): 3923-9.

574. Lapointe HR, Mwimanzi F, Cheung PK, et al. Antibody response durability following three-dose coronavirus disease 2019 vaccination in people with HIV receiving suppressive antiretroviral therapy. *Aids* 2023; **37**(5): 709-21.

575. Lasagna A, Cassaniti I, Arena F, et al. Persistence of Immune Response Elicited by Three Doses of mRNA Vaccine against SARS-CoV-2 in a Cohort of Patients with Solid Tumors: A One-Year Follow-Up. *Int J Mol Sci* 2023; **24**(7).

576. Lauring AS, Tenforde MW, Chappell JD, et al. Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study. *Bmj* 2022; **376**: e069761.

577. Lavender B, Hooker C, Frampton C, et al. Robust immunogenicity of a third BNT162b2 vaccination against SARS-CoV-2 Omicron variant in a naïve New Zealand cohort. *Vaccine* 2023; **41**(38): 5535-44.

578. Le Gleut R, Plank M, Pütz P, et al. The representative COVID-19 cohort Munich (KoCo19): from the beginning of the pandemic to the Delta virus variant. *BMC Infect Dis* 2023; **23**(1): 466.

579. Lee DW, Kim JM, Park AK, et al. Genomic epidemiology of SARS- CoV-2 Omicron variants in the Republic of Korea. *Sci Rep* 2022; **12**(1): 22414.

580. Lee Y, Kim YS, Lee DI, et al. Comparison of the Diagnostic Performance of Deep Learning Algorithms for Reducing the Time Required for COVID-19 RT-PCR Testing. *Viruses* 2023; **15**(2).

581. Lee YY, Kim YO. Afebrile benign convulsions with or without a reversible splenial lesion in two pediatric patients with COVID-19. *BMC Pediatr* 2023; **23**(1): 198.

582. Lefferts B, Blake I, Bruden D, et al. Antigen Test Positivity After COVID-19 Isolation - Yukon-Kuskokwim Delta Region, Alaska, January-February 2022. *MMWR Morb Mortal Wkly Rep* 2022; **71**(8): 293-8.

583. Leiner J, Pellissier V, Hohenstein S, et al. Characteristics and outcomes of COVID-19 patients during B.1.1.529 (Omicron) dominance compared to B.1.617.2 (Delta) in 89 German hospitals. *BMC Infect Dis* 2022; **22**(1): 802.

584. León TM, Dorabawila V, Nelson L, et al. COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis - California and New York, May-November 2021. *MMWR Morb Mortal Wkly Rep* 2022; **71**(4): 125-31.

585. León UA, Pérez AGC, Avila-Vales E. Modeling the SARS-CoV-2 Omicron variant dynamics in the United States with booster dose vaccination and waning immunity. *Math Biosci Eng* 2023; **20**(6): 10909-53.

586. Leung K, Lau EHY, Wong CKH, Leung GM, Wu JT. Estimating the transmission dynamics of SARS-CoV-2 Omicron BF.7 in Beijing after adjustment of the zero-COVID policy in November-December 2022. *Nat Med* 2023; **29**(3): 579-82.

587. Levitt JE, Hedlin H, Duong S, et al. Evaluation of Acebilustat, a Selective Inhibitor of Leukotriene B4 Biosynthesis, for Treatment of Outpatients With Mild-Moderate Coronavirus Disease 2019: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial. *Clin Infect Dis* 2023; **77**(2): 186-93.

588. Levy N, Koppel JH, Kaplan O, et al. Severity and Incidence of Multisystem Inflammatory Syndrome in Children During 3 SARS-CoV-2 Pandemic Waves in Israel. *Jama* 2022; **327**(24): 2452-4.

589. Lewnard JA, Hong VX, Patel MM, Kahn R, Lipsitch M, Tartof SY. Clinical outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant infection in Southern California. *Nat Med* 2022; **28**(9): 1933-43.

590. Li B, Guo J, Hu W, Chen Y. Binding affinity improvement analysis of multiple-mutant Omicron on 2019-nCov to human ACE2 by in silico predictions. *J Mol Model* 2023; **29**(5): 155.

591. Li C, Wang K, Wu L, Song B, Tan J, Su H. Prehospital physiological parameters related illness severity scores can accurately discriminate the severe/critical state in adult patients with COVID-19. *Ann Med* 2023; **55**(2): 2239829.

592. Li G, Zhang W, Jia D, Rong J, Yu Z, Wu D. Epidemic of the SARS-CoV-2 Omicron variant in Shanghai, China in 2022: Transient and persistent effects on Out-of-hospital cardiac arrests. *Resuscitation* 2023; **186**: 109722.

593. Li J, Gao Z, Chen J, et al. Development of a panel of three multiplex allele-specific qRT-PCR assays for quick differentiation of recombinant variants and Omicron subvariants of SARS-CoV-2. *Front Cell Infect Microbiol* 2022; **12**: 953027.

594. Li J, Wu YN, Zhang S, Kang XP, Jiang T. Deep learning based on biologically interpretable genome representation predicts two types of human adaptation of SARS-CoV-2 variants. *Brief Bioinform* 2022; **23**(3).

595. Li K, Shi J, Liu X, et al. Early warning signals for Omicron outbreaks in China: A retrospective study. *J Med Virol* 2023; **95**(1): e28341.

596. Li M, Peng H, Duan G, et al. Older age and depressive state are risk factors for re-positivity with SARS-CoV-2 Omicron variant. *Front Public Health* 2022; **10**: 1014470.

597. Li R, Jin C, Zhang L, et al. Clinical characteristics and risk factors analysis of viral shedding time in mildly symptomatic and asymptomatic patients with SARS-CoV-2 Omicron variant infection in Shanghai. *Front Public Health* 2022; **10**: 1073387.

598. Li S, Duan X, Jiang N, et al. Vaccination increased host antiviral gene expression and reduced COVID-19 severity during the Omicron variant outbreak in Fuyang City, China. *Int Immunopharmacol* 2023; **120**: 110333.

599. Li T, Xu J, Gao Y, Wang X, Xu Y. Exploring the clinical application value of peripheral blood T lymphocyte subset in patients with asymptomatic omicron infection. *Eur J Med Res* 2023; **28**(1): 223.

600. Linas BP, Xiao J, Dalgic OO, et al. Projecting COVID-19 Mortality as States Relax Nonpharmacologic Interventions. *JAMA Health Forum* 2022; **3**(4): e220760.

601. Lindahl H, Klingström J, Da Silva Rodrigues R, et al. Neutralizing SARS-CoV-2 Antibodies in Commercial Immunoglobulin Products Give Patients with X-Linked Agammaglobulinemia Limited Passive Immunity to the Omicron Variant. *J Clin Immunol* 2022; **42**(6): 1130-6.

602. Link-Gelles R, Levy ME, Natarajan K, et al. Estimation of COVID-19 mRNA Vaccine Effectiveness and COVID-19 Illness and Severity by Vaccination Status During Omicron BA.4 and BA.5 Sublineage Periods. *JAMA Netw Open* 2023; **6**(3): e232598.

603. Lippiello E, Petrillo G, Baccari S, de Arcangelis L. Estimating generation time of SARS-CoV-2 variants in Italy from the daily incidence rate. *Sci Rep* 2023; **13**(1): 11543.

604. Liu B, Gidding H, Stepien S, Cretikos M, Macartney K. Relative effectiveness of COVID-19 vaccination with 3 compared to 2 doses against SARS-CoV-2 B.1.1.529 (Omicron) among an Australian population with low prior rates of SARS-CoV-2 infection. *Vaccine* 2022; **40**(43): 6288-94.

605. Liu B, Stepien S, Pye V, et al. High Attack Rate of Severe Acute Respiratory Syndrome Coronavirus 2 B.1.1.529 Among 2-Dose Vaccinated Populations in 2 Indoor Entertainment Setting Outbreaks. *J Infect Dis* 2022; **226**(11): 1882-6.

606. Liu C, Lu J, Li P, et al. A comparative study on epidemiological characteristics, transmissibility, and pathogenicity of three COVID-19 outbreaks caused by different variants. *Int J Infect Dis* 2023; **134**: 78-87.

607. Liu KJ, Zelazowska MA, McBride KM. The Longitudinal Analysis of Convergent Antibody VDJ Regions in SARS-CoV-2-Positive Patients Using RNA-Seq. *Viruses* 2023; **15**(6).

608. Liu L, Xie S, Li C, Su L, Zhu C. Effect of nasal irrigation in adults infected with Omicron variant of COVID-19: A quasi-experimental study. *Front Public Health* 2022; **10**: 1046112.

609. Liu TH, Huang PY, Wu JY, et al. Clinical effectiveness of nirmatrelvir plus ritonavir in patients with COVID-19 and substance use disorders based on real-world data. *J Med Virol* 2023; **95**(5): e28801.

610. Liu X, Munro APS, Wright A, et al. Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial. *J Infect* 2023; **87**(1): 18-26.

611. Liu Y, Yu Y, Zhao Y, He D. Reduction in the infection fatality rate of Omicron variant compared with previous variants in South Africa. *Int J Infect Dis* 2022; **120**: 146-9.

612. Liu Z, Le K, Zhou X, et al. Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study. *Lancet Gastroenterol Hepatol* 2023; **8**(2): 145-56.

613. Loc HN, Hoan VM, Vuong NL, et al. Traditional Vietnamese medicine Kovir capsule for non-severe COVID-19 patients: A phase III double-blind randomized controlled trial. *Phytother Res* 2023; **37**(6): 2395-404.

614. Lopez P, Bravo L, Buntinx E, et al. Safety and immunogenicity of SCB-2019, an adjuvanted, recombinant SARS-CoV-2 trimeric S-protein subunit COVID-19 vaccine in healthy 12-17 year-old adolescents. *Hum Vaccin Immunother* 2023; **19**(1): 2206359.

615. López-Güell K, Prats-Uribe A, Català M, Prats C, Hein J, Prieto-Alhambra D. The impact of COVID-19 certification mandates on the number of cases of and hospitalizations with COVID-19 in the UK: A difference-in-differences analysis. *Front Public Health* 2023; **11**: 1019223.

616. Lozano-Rodríguez R, Avendaño-Ortíz J, Terrón V, et al. mRNA-1273 boost after BNT162b2 vaccination generates comparable SARS-CoV-2-specific functional responses in naïve and COVID-19-recovered individuals. *Front Immunol* 2023; **14**: 1136029.

617. Ludvigsson JF. Convulsions in children with COVID-19 during the Omicron wave. *Acta Paediatr* 2022; **111**(5): 1023-6.

618. Luna-Muschi A, Noguera SV, Borges IC, et al. Characterization of Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant Shedding and Predictors of Viral Culture Positivity on Vaccinated Healthcare Workers With Mild Coronavirus Disease 2019. *J Infect Dis* 2022; **226**(10): 1726-30.

619. Lundberg AL, Lorenzo-Redondo R, Hultquist JF, et al. Overlapping Delta and Omicron Outbreaks During the COVID-19 Pandemic: Dynamic Panel Data Estimates. *JMIR Public Health Surveill* 2022; **8**(6): e37377.

620. Lundberg AL, Lorenzo-Redondo R, Ozer EA, et al. Has Omicron Changed the Evolution of the Pandemic? *JMIR Public Health Surveill* 2022; **8**(1): e35763.

621. Ma H, Zong HF, Liu JJ, et al. Long-term passaging of pseudo-typed SARS-CoV-2 reveals the breadth of monoclonal and bispecific antibody cocktails. *Acta Pharmacol Sin* 2023; **44**(7): 1455-63.

622. Ma S, Ren Q, Jiang L, et al. A triple-aptamer tetrahedral DNA nanostructures based carbon-nanotube-array transistor biosensor for rapid virus detection. *Talanta* 2024; **266**(Pt 1): 124973.

623. Ma W, Fu H, Jian F, Cao Y, Li M. Immune evasion and ACE2 binding affinity contribute to SARS-CoV-2 evolution. *Nat Ecol Evol* 2023; **7**(9): 1457-66.

624. Ma W, Yang J, Fu H, et al. Genomic Perspectives on the Emerging SARS-CoV-2 Omicron Variant. *Genomics Proteomics Bioinformatics* 2022; **20**(1): 60-9.

625. Ma Y, Xu S, Luo Y, et al. Epidemiological characteristics and transmission dynamics of the COVID-19 outbreak in Hohhot, China: a time-varying SQEIAHR model analysis. *Front Public Health* 2023; **11**: 1175869.

626. Mack CD, Wasserman EB, Killerby ME, et al. Results from a Test-to-Release from Isolation Strategy Among Fully Vaccinated National Football League Players and Staff Members with COVID-19 - United States, December 14-19, 2021. *MMWR Morb Mortal Wkly Rep* 2022; **71**(8): 299-305.

627. Macori G, Russell T, Barry G, et al. Inactivation and Recovery of High Quality RNA From Positive SARS-CoV-2 Rapid Antigen Tests Suitable for Whole Virus Genome Sequencing. *Front Public Health* 2022; **10**: 863862.

628. Madelon N, Heikkilä N, Sabater Royo I, et al. Omicron-Specific Cytotoxic T-Cell Responses After a Third Dose of mRNA COVID-19 Vaccine Among Patients With Multiple Sclerosis Treated With Ocrelizumab. *JAMA Neurol* 2022; **79**(4): 399-404.

629. Maeda H, Saito N, Igarashi A, et al. Effectiveness of mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections during the SARS-CoV-2 Omicron BA.1 and BA.2 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS). *Expert Rev Vaccines* 2023; **22**(1): 288-98.

631. Magawa S, Nii M, Maki S, et al. Comparative study of the usefulness of risk score assessment in the early stages of COVID-19 affected pregnancies: Omicron variant versus previous variants. *J Obstet Gynaecol Res* 2022; **48**(11): 2721-9.

632. Magnus MC, Håberg SE, Carlsen E, Kwong JC, Buchan SA, Fell DB. Pregnancy Status at the Time of Coronavirus Disease 2019 Vaccination and Incidence of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. *Clin Infect Dis* 2023; **76**(1): 57-65.

634. Mahajan NN, Kesarwani S, Salunke C, et al. Clinical presentation, pregnancy complications, and outcomes of pregnant women with COVID-19 during the Omicron-dominant third wave in Mumbai, India. *Int J Gynaecol Obstet* 2022; **159**(3): 968-73.

635. Maher MC, Bartha I, Weaver S, et al. Predicting the mutational drivers of future SARS-CoV-2 variants of concern. *Sci Transl Med* 2022; **14**(633): eabk3445.

636. Maiti S, Banerjee A, Santra D, Kanwar M. Immunoinformatic paradigm predicts macrophage and T-cells epitope responses against globally conserved spike fragments of SARS CoV-2 for universal vaccination. *Int Immunopharmacol* 2022; **108**: 108847.

637. Malaga JL, Pajuelo MJ, Okamoto M, et al. Rapid Detection of SARS-CoV-2 RNA Using Reverse Transcription Recombinase Polymerase Amplification (RT-RPA) with Lateral Flow for N-Protein Gene and Variant-Specific Deletion-Insertion Mutation in S-Protein Gene. *Viruses* 2023; **15**(6).

638. Mallapaty S. Omicron-variant border bans ignore the evidence, say scientists. *Nature* 2021; **600**(7888): 199.

639. Mambelli E, Gasperoni L, Maldini L, Biagetti C, Rigotti A. Sotrovimab in SARS-COV-2 chronic hemodialysis patients in the Omicron era. Is intradialytic administration feasible? Report of 4 cases. *J Nephrol* 2023; **36**(3): 669-72.

640. Manathunga SS, Abeyagunawardena IA, Dharmaratne SD. A comparison of transmissibility of SARS-CoV-2 variants of concern. *Virol J* 2023; **20**(1): 59.

641. Manciulli T, Spinicci M, Rossetti B, et al. Safety and Efficacy of Outpatient Treatments for COVID-19: Real-Life Data from a Regionwide Cohort of High-Risk Patients in Tuscany, Italy (the FEDERATE Cohort). *Viruses* 2023; **15**(2).

642. Mannsverk S, Bergholm J, Palanisamy N, et al. SARS-CoV-2 variants of concern and spike protein mutational dynamics in a Swedish cohort during 2021, studied by Nanopore sequencing. *Virol J* 2022; **19**(1): 164.

643. Mannucci PM, Galbussera AA, D'Avanzo B, et al. Two years of SARS-CoV-2 pandemic and COVID-19 in Lombardy, Italy. *Intern Emerg Med* 2023; **18**(5): 1445-51.

644. Mariani F, Morello R, Traini DO, et al. Risk Factors for Persistent Anosmia and Dysgeusia in Children with SARS-CoV-2 Infection: A Retrospective Study. *Children (Basel)* 2023; **10**(3).

645. Maringer Y, Nelde A, Schroeder SM, et al. Durable spike-specific T cell responses after different COVID-19 vaccination regimens are not further enhanced by booster vaccination. *Sci Immunol* 2022; **7**(78): eadd3899.

646. Marking U, Havervall S, Norin NG, et al. Correlates of protection and viral load trajectories in omicron breakthrough infections in triple vaccinated healthcare workers. *Nat Commun* 2023; **14**(1): 1577.

647. Martin-Blondel G, Marcelin AG, Soulié C, et al. Time to negative PCR conversion amongst high-risk patients with mild-to-moderate Omicron BA.1 and BA.2 COVID-19 treated with sotrovimab or nirmatrelvir. *Clin Microbiol Infect* 2023; **29**(4): 543.e5-.e9.

648. Martínez-Murcia A, Garcia-Sirera A, Navarro A, Pérez L. SARS-CoV-2 Variants Identification; A Fast and Affordable Strategy Based on Partial S-Gene Targeted PCR Sequencing. *Viruses* 2022; **14**(11).

649. Martins-Filho PR, de Souza Araújo AA, Quintans-Júnior LJ, et al. Dynamics of hospitalizations and in-hospital deaths from COVID-19 in northeast Brazil: a retrospective analysis based on the circulation of SARS-CoV-2 variants and vaccination coverage. *Epidemiol Health* 2022; **44**: e2022036.

650. Marziano V, Guzzetta G, Menegale F, et al. Estimating SARS-CoV-2 infections and associated changes in COVID-19 severity and fatality. *Influenza Other Respir Viruses* 2023; **17**(8): e13181.

651. Maslo C, Friedland R, Toubkin M, Laubscher A, Akaloo T, Kama B. Characteristics and Outcomes of Hospitalized Patients in South Africa During the COVID-19 Omicron Wave Compared With Previous Waves. *Jama* 2022; **327**(6): 583-4.

652. Mastrorosa I, Cozzi-Lepri A, Colavita F, et al. SARS-CoV-2 nasopharyngeal viral load in individuals infected with BA.2, compared to Alpha, Gamma, Delta and BA.1 variants: A single-center comparative analysis. *J Clin Virol* 2022; **157**: 105299.

653. Matsumura Y, Yamamoto M, Shinohara K, et al. High mortality and morbidity among vaccinated residents infected with the SARS-CoV-2 Omicron variant during an outbreak in a nursing home in Kyoto City, Japan. *Am J Infect Control* 2023; **51**(7): 800-6.

654. Mattiuzzi C, Henry BM, Lippi G. Regional Association between Mean Air Temperature and Case Numbers of Multiple SARS-CoV-2 Lineages throughout the Pandemic. *Viruses* 2022; **14**(9).

655. Mattiuzzi C, Henry BM, Lippi G. Correlation between relative age-standardized mortality rates and COVID-19 mortality over time in Italy. *Acta Biomed* 2023; **94**(2): e2023056.

656. Mautner L, Hoyos M, Dangel A, Berger C, Ehrhardt A, Baiker A. Replication kinetics and infectivity of SARS-CoV-2 variants of concern in common cell culture models. *Virol J* 2022; **19**(1): 76.

657. Mayer C, Woo MS, Brehm TT, et al. History of cerebrovascular disease but not dementia increases the risk for secondary vascular events during SARS-CoV-2 infection with presumed Omicron variant: a retrospective observational study. *Eur J Neurol* 2023; **30**(8): 2297-304.

658. Mazzotta V, Cozzi Lepri A, Colavita F, et al. Viral load decrease in SARS-CoV-2 BA.1 and BA.2 Omicron sublineages infection after treatment with monoclonal antibodies and direct antiviral agents. *J Med Virol* 2023; **95**(1): e28186.

659. McCarthy MW. Original antigen sin and COVID-19: implications for seasonal vaccination. *Expert Opin Biol Ther* 2022; **22**(11): 1353-8.

660. Mediavilla JR, Lozy T, Lee A, et al. Molecular and Clinical Epidemiology of SARS-CoV-2 Infection among Vaccinated and Unvaccinated Individuals in a Large Healthcare Organization from New Jersey. *Viruses* 2023; **15**(8).

661. Mefsin YM, Chen D, Bond HS, et al. Epidemiology of Infections with SARS-CoV-2 Omicron BA.2 Variant, Hong Kong, January-March 2022. *Emerg Infect Dis* 2022; **28**(9): 1856-8.

662. Mehta P, Ravi V, Devi P, et al. Mutational dynamics across VOCs in International travellers and Community transmission underscores importance of Spike-ACE2 interaction. *Microbiol Res* 2022; **262**: 127099.

663. Mehta S, Singh Gambhir R, Singh B, Goel R, Singh Ghuman K, Aggarwal A. Covid-19 update: Omicron variant - a new emerging threat. *Rocz Panstw Zakl Hig* 2022; **73**(1): 13-6.

664. Mella-Torres A, Escobar A, Barrera-Avalos C, et al. Epidemiological characteristics of Omicron and Delta SARS-CoV-2 variant infection in Santiago, Chile. *Front Public Health* 2022; **10**: 984433.

665. Menges D, Zens KD, Ballouz T, et al. Heterogenous humoral and cellular immune responses with distinct trajectories post-SARS-CoV-2 infection in a population-based cohort. *Nat Commun* 2022; **13**(1): 4855.

666. Merid Y, Tekleselasie W, Tesfaye E, et al. SARS-CoV-2 Infection-and mRNA Vaccine-induced Humoral Immunity among Schoolchildren in Hawassa, Ethiopia. *Front Immunol* 2023; **14**: 1163688.

667. Mermin-Bunnell K, Ahn WK. It's Time to be disgusting about COVID-19: Effect of disgust priming on COVID-19 public health compliance among liberals and conservatives. *PLoS One* 2022; **17**(5): e0267735.

668. Mikulska M, Testi D, Russo C, et al. Outcome of early treatment of SARS-CoV-2 infection in patients with haematological disorders. *Br J Haematol* 2023; **201**(4): 628-39.

669. Miller AD, Yousaf AR, Bornstein E, et al. Multisystem Inflammatory Syndrome in Children During Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Delta and Omicron Variant Circulation-United States, July 2021-January 2022. *Clin Infect Dis* 2022; **75**(Suppl 2): S303-s7.

670. Mingyu L, Shelan L, Liebo Z, et al. Analysis of a super-transmission of SARS-CoV-2 omicron variant BA.5.2 in the outdoor night market. *Front Public Health* 2023; **11**: 1153303.

671. Miraz MMH, Ullah MA, Nayem AA, et al. Nigelladine A among Selected Compounds from Nigella sativa Exhibits Propitious Interaction with Omicron Variant of SARS-CoV-2: An In Silico Study. *Int J Clin Pract* 2023; **2023**: 9917306.

672. Mohapatra RK, Tiwari R, Sarangi AK, et al. Twin combination of Omicron and Delta variants triggering a tsunami wave of ever high surges in COVID-19 cases: A challenging global threat with a special focus on the Indian subcontinent. *J Med Virol* 2022; **94**(5): 1761-5.

673. Monaco MGL, Spiteri G, Caliskan G, et al. SARS-CoV-2 and Its Variants in Thrice-Infected Health Workers: A Case Series from an Italian University Hospital. *Viruses* 2022; **14**(11).

674. Mondi A, Mastrorosa I, Piselli P, et al. Evolution of SARS-CoV-2 variants of concern over a period of Delta and Omicron cocirculation, among patients hospitalized for COVID-19 in an Italian reference hospital: Impact on clinical outcomes. *J Med Virol* 2023; **95**(6): e28831.

675. Monge S, Rojas-Benedicto A, Olmedo C, et al. Effectiveness of a Second Dose of an mRNA Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Omicron Infection in Individuals Previously Infected by Other Variants. *Clin Infect Dis* 2023; **76**(3): e367-e74.

676. Monge S, Rojas-Benedicto A, Olmedo C, et al. Effectiveness of mRNA vaccine boosters against infection with the SARS-CoV-2 omicron (B.1.1.529) variant in Spain: a nationwide cohort study. *Lancet Infect Dis* 2022; **22**(9): 1313-20.

677. Montes-González JA, Zaragoza-Jiménez CA, Antonio-Villa NE, et al. Protection of hybrid immunity against SARS-CoV-2 reinfection and severe COVID-19 during periods of Omicron variant predominance in Mexico. *Front Public Health* 2023; **11**: 1146059.

678. Moragas M, Golemba MD, Fernández MF, et al. COVID-19 in immunocompromised children: comparison of SARS-CoV-2 viral load dynamics between the first and third waves. *Braz J Microbiol* 2023; **54**(3): 1859-64.

679. Morinaga Y, Yamada H, Yoshida Y, Kawasuji H, Yamamoto Y. Analytical sensitivity of six lateral flow antigen test kits for variant strains of SARS-CoV-2. *J Infect Chemother* 2023; **29**(2): 131-5.

680. Moriwaki K, Fujimoto N, Murakami H, et al. Different Types of Myocardial Injury due to the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Omicron Variant. *Int Heart J* 2023; **64**(1): 85-9.

681. Morris CP, Eldesouki RE, Fall A, et al. SARS-CoV-2 reinfections during the Delta and Omicron waves. *JCI Insight* 2022; **7**(20).

682. Morris CP, Eldesouki RE, Sachithanandham J, et al. Omicron Subvariants: Clinical, Laboratory, and Cell Culture Characterization. *Clin Infect Dis* 2023; **76**(7): 1276-84.

683. Mues KE, Kirk B, Patel DA, et al. Real-world comparative effectiveness of mRNA-1273 and BNT162b2 vaccines among immunocompromised adults identified in administrative claims data in the United States. *Vaccine* 2022; **40**(47): 6730-9.

684. Mukae H, Yotsuyanagi H, Ohmagari N, et al. Efficacy and Safety of Ensitrelvir in Patients With Mild-to-Moderate Coronavirus Disease 2019: The Phase 2b Part of a Randomized, Placebo-Controlled, Phase 2/3 Study. *Clin Infect Dis* 2023; **76**(8): 1403-11.

685. Munoz FM, Posavad CM, Richardson BA, et al. COVID-19 booster vaccination during pregnancy enhances maternal binding and neutralizing antibody responses and transplacental antibody transfer to the newborn. *Vaccine* 2023; **41**(36): 5296-303.

686. Mwimanzi F, Lapointe HR, Cheung PK, et al. Older Adults Mount Less Durable Humoral Responses to Two Doses of COVID-19 mRNA Vaccine but Strong Initial Responses to a Third Dose. *J Infect Dis* 2022; **226**(6): 983-94.

687. Nab L, Parker EPK, Andrews CD, et al. Changes in COVID-19-related mortality across key demographic and clinical subgroups in England from 2020 to 2022: a retrospective cohort study using the OpenSAFELY platform. *Lancet Public Health* 2023; **8**(5): e364-e77.

688. Nadeem MU, Kulich SJ, Bokhari IH. The assessment and validation of the depression, anxiety, and stress scale (DASS-21) among frontline doctors in Pakistan during fifth wave of COVID-19. *Front Public Health* 2023; **11**: 1192733.

689. Natarajan K, Prasad N, Dascomb K, et al. Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults - VISION Network, 10 States, December 2021-March 2022. *MMWR Morb Mortal Wkly Rep* 2022; **71**(13): 495-502.

690. Nelson DJ, Shilts MH, Pakala SB, Das SR, Schmitz JE, Haselton FR. Ligation-based assay for variant typing without sequencing: Application to SARS-CoV-2 variants of concern. *Influenza Other Respir Viruses* 2023; **17**(1): e13083.

691. Nersisyan SA, Shkurnikov MY, Zhiyanov AP, Novosad VO, Tonevitsky AG. Differences in Presentation of SARS-CoV-2 Omicron Strain Variant BA.1-BA.5 Peptides by HLA Molecules. *Dokl Biochem Biophys* 2022; **507**(1): 298-301.

692. Newman J, Thakur N, Peacock TP, et al. Neutralizing antibody activity against 21 SARS-CoV-2 variants in older adults vaccinated with BNT162b2. *Nat Microbiol* 2022; **7**(8): 1180-8.

693. Ng SC, Chu AWH, Chan WM, et al. Re-examine the transfusion transmitted risk of SARS-CoV-2 virus during a major COVID-19 outbreak in 2022. *Transfus Med* 2023; **33**(4): 315-9.

694. Nguyen LT, Macaluso NC, Pizzano BLM, et al. A thermostable Cas12b from Brevibacillus leverages one-pot discrimination of SARS-CoV-2 variants of concern. *EBioMedicine* 2022; **77**: 103926.

695. Nguyen NN, Houhamdi L, Delorme L, Colson P, Gautret P. Reinfections with Different SARS-CoV-2 Omicron Subvariants, France. *Emerg Infect Dis* 2022; **28**(11): 2341-3.

696. Nguyen VG, Yavlinsky A, Beale S, et al. Comparative effectiveness of different primary vaccination courses on mRNA-based booster vaccines against SARs-COV-2 infections: a time-varying cohort analysis using trial emulation in the Virus Watch community cohort. *Int J Epidemiol* 2023; **52**(2): 342-54.

697. Nicora G, Salemi M, Marini S, Bellazzi R. Predicting emerging SARS-CoV-2 variants of concern through a One Class dynamic anomaly detection algorithm. *BMJ Health Care Inform* 2022; **29**(1).

698. Nicot F, Trémeaux P, Latour J, et al. Whole-genome single molecule real-time sequencing of SARS-CoV-2 Omicron. *J Med Virol* 2023; **95**(2): e28564.

699. Niemann CU, da Cunha-Bang C, Helleberg M, Ostrowski SR, Brieghel C. Patients with CLL have a lower risk of death from COVID-19 in the Omicron era. *Blood* 2022; **140**(5): 445-50.

700. Nincevic J, Jurcev-Savicevic A, Versic S, et al. How Different Predominant SARS-CoV-2 Variants of Concern Affected Clinical Patterns and Performances of Infected Professional Players during Two Soccer Seasons: An Observational Study from Split, Croatia. *Int J Environ Res Public Health* 2023; **20**(3).

701. Nishiyama Y, Wasano K. Endoscopic findings of laryngitis caused by SARS-CoV-2/Omicron variant infection. *Infection* 2023; **51**(1): 283-4.

702. Niu Y, Luo L, Yang S, et al. Comparison of epidemiological characteristics and transmissibility of different strains of COVID-19 based on the incidence data of all local outbreaks in China as of March 1, 2022. *Front Public Health* 2022; **10**: 949594.

703. Niveditha D, Khan S, Khilari A, et al. A tale of two waves: Delineating diverse genomic and transmission landscapes driving the COVID-19 pandemic in Pune, India. *J Infect Public Health* 2023; **16**(8): 1290-300.

704. Nocini R, Henry BM, Mattiuzzi C, Lippi G. Evolution of throat symptoms during the COVID-19 pandemic in the US. *Diagnosis (Berl)* 2022; **9**(4): 485-90.

705. Nogimori T, Suzuki K, Masuta Y, et al. Functional changes in cytotoxic CD8+ T-cell cross-reactivity against the SARS-CoV-2 Omicron variant after mRNA vaccination. *Front Immunol* 2022; **13**: 1081047.

706. Nunez-Castilla J, Stebliankin V, Baral P, et al. Potential Autoimmunity Resulting from Molecular Mimicry between SARS-CoV-2 Spike and Human Proteins. *Viruses* 2022; **14**(7).

707. Nyinawingeri A, Staff M. Identifying a more severe emergent COVID-19 variant using Emergency Departments' routinely collected clinical measures. *Commun Dis Intell (2018)* 2023; **47**.

708. Obeid D, Al-Qahtani A, Almaghrabi R, et al. Analysis of SARS-CoV-2 genomic surveillance data during the Delta and Omicron waves at a Saudi tertiary referral hospital. *J Infect Public Health* 2023; **16**(2): 171-81.

709. Odak I, Schultze-Florey CR, Hammerschmidt SI, et al. Longitudinal Tracking of Immune Responses in COVID-19 Convalescents Reveals Absence of Neutralization Activity Against Omicron and Staggered Impairment to Other SARS-CoV-2 Variants of Concern. *Front Immunol* 2022; **13**: 863039.

710. Ogawa F, Oi Y, Honzawa H, et al. Severity predictors of COVID-19 in SARS-CoV-2 variant, delta and omicron period; single center study. *PLoS One* 2022; **17**(10): e0273134.

711. Ogrič M, Žigon P, Podovšovnik E, et al. Differences in SARS-CoV-2-Specific Antibody Responses After the First, Second, and Third Doses of BNT162b2 in Naïve and Previously Infected Individuals: A 1-Year Observational Study in Healthcare Professionals. *Front Immunol* 2022; **13**: 876533.

712. Oh SM, Ham SY, Suh HJ, Lee E, Park SW. Clinical Characteristics of COVID-19: Use of Steroids in Mostly Unvaccinated COVID-19 Patients Before the Omicron Variant. *J Korean Med Sci* 2022; **37**(29): e228.

713. Oltolini C, Acerbis A, Orofino G, et al. Case Report: Favorable outcome of allogeneic hematopoietic stem cell transplantation in SARSCoV2 positive recipient, risk-benefit balance between infection and leukemia. *Front Immunol* 2023; **14**: 1184956.

714. Ong SWX, Tham SM, Koh LP, et al. External validation of the PRIORITY model in predicting COVID-19 critical illness in vaccinated and unvaccinated patients. *Clin Microbiol Infect* 2022; **28**(6): 884.e1-.e3.

715. Ordaya EE, Vergidis P, Razonable RR, Yao JD, Beam E. Genotypic and predicted phenotypic analysis of SARS-COV-2 Omicron subvariants in immunocompromised patients with COVID-19 following tixagevimab-cilgavimab prophylaxis. *J Clin Virol* 2023; **160**: 105382.

716. Orf GS, Pérez LJ, Ciuoderis K, et al. The Principles of SARS-CoV-2 Intervariant Competition Are Exemplified in the Pre-Omicron Era of the Colombian Epidemic. *Microbiol Spectr* 2023; **11**(3): e0534622.

717. Ou S, Huang Z, Lan M, et al. The duration and breadth of antibody responses to 3-dose of inactivated COVID-19 vaccinations in healthy blood donors: An observational study. *Front Immunol* 2022; **13**: 1027924.

718. Overheu O, Lendowski S, Quast DR, et al. Longitudinal data on humoral response and neutralizing antibodies against SARS-CoV-2 Omicron BA.1 and subvariants BA.4/5 and BQ.1.1 after COVID-19 vaccination in cancer patients. *J Cancer Res Clin Oncol* 2023; **149**(12): 10633-44.

719. Özbay Kurt FG, Lepper A, Gerhards C, et al. Booster dose of mRNA vaccine augments waning T cell and antibody responses against SARS-CoV-2. *Front Immunol* 2022; **13**: 1012526.

720. Özüdoğru O, Bahçe YG, Acer Ö. SARS CoV-2 reinfection rate is higher in the Omicron variant than in the Alpha and Delta variants. *Ir J Med Sci* 2023; **192**(2): 751-6.

721. Pabbaraju K, Zelyas N, Wong A, et al. Evolving strategy for an evolving virus: Development of real-time PCR assays for detecting all SARS-CoV-2 variants of concern. *J Virol Methods* 2022; **307**: 114553.

722. Pacchiarini N, Sawyer C, Williams C, et al. Epidemiological analysis of the first 1000 cases of SARS-CoV-2 lineage BA.1 (B.1.1.529, Omicron) compared with co-circulating Delta in Wales, UK. *Influenza Other Respir Viruses* 2022; **16**(6): 986-93.

723. Pagano L, Salmanton-García J, Marchesi F, et al. Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey. *Blood* 2022; **140**(26): 2773-87.

724. Palladino R, Mercogliano M, Fiorilla C, et al. Association between COVID-19 and Sick Leave for Healthcare Workers in a Large Academic Hospital in Southern Italy: An Observational Study. *Int J Environ Res Public Health* 2022; **19**(15).

725. Palomino-Cabrera R, Tejerina F, Molero-Salinas A, et al. Frequent Emergence of Resistance Mutations Following Complex Intra-Host Genomic Dynamics in SARS-CoV-2 Patients Receiving Sotrovimab. *Antimicrob Agents Chemother* 2023; **67**(7): e0026623.

726. Papadimitriou-Olivgeris M, Cipriano A, Guggisberg N, et al. Outcome of COVID-19 in Kidney Transplant Recipients Through the SARS-CoV-2 Variants Eras: Role of Anti-SARS-CoV-2 Monoclonal Antibodies. *Transpl Int* 2022; **35**: 10721.

727. Park SW, Sun K, Abbott S, et al. Inferring the differences in incubation-period and generation-interval distributions of the Delta and Omicron variants of SARS-CoV-2. *Proc Natl Acad Sci U S A* 2023; **120**(22): e2221887120.

728. Patriquin G, LeBlanc JJ, Gillis HA, McCracken GR, Pettipas JJ, Hatchette TF. Combined oropharyngeal/nares and nasopharyngeal swab sampling remain effective for molecular detection of SARS-CoV-2 Omicron variant. *J Med Microbiol* 2022; **71**(6).

729. Paz M, Aldunate F, Arce R, Ferreiro I, Cristina J. An evolutionary insight into Severe Acute Respiratory Syndrome Coronavirus 2 Omicron variant of concern. *Virus Res* 2022; **314**: 198753.

730. Pei L, Chen Y, Zheng X, et al. Comorbidities prolonged viral shedding of patients infected with SARS-CoV-2 omicron variant in Shanghai: A multi-center, retrospective, observational study. *J Infect Public Health* 2023; **16**(2): 182-9.

731. Peña Rodríguez M, Hernández Bello J, Vega Magaña N, et al. Prevalence of symptoms, comorbidities, and reinfections in individuals infected with Wild-Type SARS-CoV-2, Delta, or Omicron variants: a comparative study in western Mexico. *Front Public Health* 2023; **11**: 1149795.

732. Peñas-Utrilla D, Pérez-Lago L, Molero-Salinas A, et al. Systematic genomic analysis of SARS-CoV-2 co-infections throughout the pandemic and segregation of the strains involved. *Genome Med* 2023; **15**(1): 57.

733. Peñas-Utrilla D, Sanz A, Catalán P, et al. A mutation responsible for impaired detection by the Xpert SARS-CoV-2 assay independently emerged in different lineages during the SARS-CoV-2 pandemic. *BMC Microbiol* 2023; **23**(1): 190.

734. Peng Y, Chen SY, Wang ZN, et al. Dicoumarol is an effective post-exposure prophylactic for SARS-CoV-2 Omicron infection in human airway epithelium. *Signal Transduct Target Ther* 2023; **8**(1): 242.

735. Perez-Guzman PN, Knock E, Imai N, et al. Epidemiological drivers of transmissibility and severity of SARS-CoV-2 in England. *Nat Commun* 2023; **14**(1): 4279.

736. Perez-Saez J, Zaballa ME, Lamour J, et al. Long term anti-SARS-CoV-2 antibody kinetics and correlate of protection against Omicron BA.1/BA.2 infection. *Nat Commun* 2023; **14**(1): 3032.

737. Petersen MS, S ÍK, Eliasen EH, et al. Clinical characteristics of the Omicron variant - results from a Nationwide Symptoms Survey in the Faroe Islands. *Int J Infect Dis* 2022; **122**: 636-43.

738. Petrakis V, Rafailidis P, Trypsianis G, Papazoglou D, Panagopoulos P. The Antiviral Effect of Nirmatrelvir/Ritonavir during COVID-19 Pandemic Real-World Data. *Viruses* 2023; **15**(4).

739. Petrie JG, King JP, McClure DL, et al. Effectiveness of first and second COVID-19 mRNA vaccine monovalent booster doses during a period of circulation of Omicron variant sublineages: December 2021-July 2022. *Influenza Other Respir Viruses* 2023; **17**(3): e13104.

740. Petros BA, Turcinovic J, Welch NL, et al. Early Introduction and Rise of the Omicron Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variant in Highly Vaccinated University Populations. *Clin Infect Dis* 2023; **76**(3): e400-e8.

741. Pham D, Maddocks S, Dwyer DE, Sintchenko V, Kok J, Rockett RJ. Development and Validation of an In-House Real-Time Reverse-Transcriptase Polymerase Chain Reaction Assay for SARS-CoV-2 Omicron Lineage Subtyping between BA.1 and BA.2. *Viruses* 2022; **14**(8).

742. Picard G, Fournier L, Maisa A, et al. Emergence, spread and characterisation of the SARS-CoV-2 variant B.1.640 circulating in France, October 2021 to February 2022. *Euro Surveill* 2023; **28**(22).

743. Piché-Renaud PP, Swayze S, Buchan SA, et al. COVID-19 Vaccine Effectiveness Against Omicron Infection and Hospitalization. *Pediatrics* 2023; **151**(4).

744. Piersiala K, Kakabas L, Bruckova A, Starkhammar M, Cardell LO. Acute odynophagia: A new symptom of COVID-19 during the SARS-CoV-2 Omicron variant wave in Sweden. *J Intern Med* 2022; **292**(1): 154-61.

745. Pilapil JD, Notarte KI, Yeung KL. The dominance of co-circulating SARS-CoV-2 variants in wastewater. *Int J Hyg Environ Health* 2023; **253**: 114224.

746. Pinto Pereira SM, Mensah A, Nugawela MD, et al. Long COVID in Children and Young after Infection or Reinfection with the Omicron Variant: A Prospective Observational Study. *J Pediatr* 2023; **259**: 113463.

747. Pople D, Monk EJM, Evans S, et al. Burden of SARS-CoV-2 infection in healthcare workers during second wave in England and impact of vaccines: prospective multicentre cohort study (SIREN) and mathematical model. *Bmj* 2022; **378**: e070379.

748. Portmann L, de Kraker MEA, Fröhlich G, et al. Hospital Outcomes of Community-Acquired SARS-CoV-2 Omicron Variant Infection Compared With Influenza Infection in Switzerland. *JAMA Netw Open* 2023; **6**(2): e2255599.

749. Price AM, Olson SM, Newhams MM, et al. BNT162b2 Protection against the Omicron Variant in Children and Adolescents. *N Engl J Med* 2022; **386**(20): 1899-909.

750. Prince T, Dong X, Penrice-Randal R, et al. Analysis of SARS-CoV-2 in Nasopharyngeal Samples from Patients with COVID-19 Illustrates Population Variation and Diverse Phenotypes, Placing the Growth Properties of Variants of Concern in Context with Other Lineages. *mSphere* 2022; **7**(3): e0091321.

751. Pu Y, Zhang W, Xu X, et al. A retrospective study investigating the anxiety and depression level of novel coronavirus Omicron patients in 2022. *Medicine (Baltimore)* 2022; **101**(51): e32438.

752. Puenpa J, Rattanakomol P, Saengdao N, et al. Molecular characterisation and tracking of severe acute respiratory syndrome coronavirus 2 in Thailand, 2020-2022. *Arch Virol* 2023; **168**(1): 26.

753. Purvis RS, Vincenzo JL, Spear M, et al. Factors Associated With Marshallese and Hispanic Adults' Willingness to Receive a COVID-19 Booster Dose. *J Prim Care Community Health* 2023; **14**: 21501319231171440.

754. Puyskens A, Michel J, Stoliaroff-Pepin A, et al. Direct comparison of clinical diagnostic sensitivity of saliva from buccal swabs versus combined oro-/nasopharyngeal swabs in the detection of SARS-CoV-2 B.1.1.529 Omicron. *J Clin Virol* 2023; **165**: 105496.

755. Qi R, Wang G, Wang X, et al. A full genome tiling array enhanced the inspection and quarantine of SARS-CoV-2. *Virol J* 2023; **20**(1): 42.

756. Qu Y, Lee CY, Lam KF. A novel method to monitor COVID-19 fatality rate in real-time, a key metric to guide public health policy. *Sci Rep* 2022; **12**(1): 18277.

757. Quee FA, Hogema BM, Slot E, et al. Booster vaccinations and Omicron: the effects on SARS-CoV-2 antibodies in Dutch blood donors. *BMC Infect Dis* 2023; **23**(1): 464.

758. Rabil MJ, Tunc S, Bish DR, Bish EK. Effective screening strategies for safe opening of universities under Omicron and Delta variants of COVID-19. *Sci Rep* 2022; **12**(1): 21309.

760. Rahmani S, Rezaei N. SARS-CoV-2 Omicron variant: Why global communities should take it seriously? *Immun Inflamm Dis* 2022; **10**(5): e618.

761. Rao S, Jing N, Liu X, et al. Clinical Subphenotypes of Multisystem Inflammatory Syndrome in Children: An EHR-based cohort study from the RECOVER program. *medRxiv* 2022.

762. Ray SK, Mukherjee S. A New Year, Newfangled COVID-19 Variant B.1.640.2 (IHU): What We Know So Far? *Infect Disord Drug Targets* 2023; **23**(2): e310822208284.

763. Rector A, Bloemen M, Thijssen M, et al. Monitoring of SARS-CoV-2 concentration and circulation of variants of concern in wastewater of Leuven, Belgium. *J Med Virol* 2023; **95**(2): e28587.

764. Redd AD, Nardin A, Kared H, et al. Minimal Crossover between Mutations Associated with Omicron Variant of SARS-CoV-2 and CD8(+) T-Cell Epitopes Identified in COVID-19 Convalescent Individuals. *mBio* 2022; **13**(2): e0361721.

765. Reichert E, Schaeffer B, Gantt S, et al. Methods for early characterisation of the severity and dynamics of SARS-CoV-2 variants: a population-based time series analysis in South Africa. *Lancet Microbe* 2022; **3**(10): e753-e61.

766. Ren J, Liu M, Liu Y, Liu J. Optimal resource allocation with spatiotemporal transmission discovery for effective disease control. *Infect Dis Poverty* 2022; **11**(1): 34.

767. Ren Z, Nishimura M, Tjan LH, et al. Large-scale serosurveillance of COVID-19 in Japan: Acquisition of neutralizing antibodies for Delta but not for Omicron and requirement of booster vaccination to overcome the Omicron's outbreak. *PLoS One* 2022; **17**(4): e0266270.

768. Rochman ND, Faure G, Wolf YI, Freddolino PL, Zhang F, Koonin EV. Epistasis at the SARS-CoV-2 Receptor-Binding Domain Interface and the Propitiously Boring Implications for Vaccine Escape. *mBio* 2022; **13**(2): e0013522.

769. Rockett RJ, Draper J, Gall M, et al. Co-infection with SARS-CoV-2 Omicron and Delta variants revealed by genomic surveillance. *Nat Commun* 2022; **13**(1): 2745.

770. Rodriguez PE, Silva AP, Miglietta EA, et al. Humoral response and neutralising capacity at 6 months post-vaccination against COVID-19 among institutionalised older adults in Argentina. *Front Immunol* 2022; **13**: 992370.

771. Rodríguez-Grande C, Estévez A, Palomino-Cabrera R, et al. Early SARS-CoV-2 Reinfections Involving the Same or Different Genomic Lineages, Spain. *Emerg Infect Dis* 2023; **29**(6): 1154-61.

772. Rosa RG, Falavigna M, Manfio JL, et al. BNT162b2 mRNA COVID-19 against symptomatic Omicron infection following a mass vaccination campaign in southern Brazil: A prospective test-negative design study. *Vaccine* 2023; **41**(37): 5461-8.

773. Rostad CA, Chen X, Sun HY, et al. Functional Antibody Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Variants in Children With Coronavirus Disease 2019, Multisystem Inflammatory Syndrome in Children, and After Two Doses of BNT162b2 Vaccination. *J Infect Dis* 2022; **226**(7): 1237-42.

774. Ruan D, Ye ZW, Yuan S, et al. Human early syncytiotrophoblasts are highly susceptible to SARS-CoV-2 infection. *Cell Rep Med* 2022; **3**(12): 100849.

775. Rubin R. How Immune-Evasive Omicron Offspring and a Lack of Mitigation Measures Could Shape a COVID-19 Winter Wave. *Jama* 2022; **328**(21): 2092-5.

776. Rui J, Zheng JX, Chen J, et al. Optimal control strategies of SARS-CoV-2 Omicron supported by invasive and dynamic models. *Infect Dis Poverty* 2022; **11**(1): 115.

777. Ruis C, Peacock TP, Polo LM, et al. A lung-specific mutational signature enables inference of viral and bacterial respiratory niche. *Microb Genom* 2023; **9**(5).

778. Russ MJ, Sombrotto LB, Brody BD. Inpatient psychiatry response to the SARS-CoV-2 Omicron variant surge. *Psychiatry Res* 2022; **316**: 114746.

779. Russo AG, Murtas R, Tunesi S, Decarli A, Bergamaschi W. Boosters and time from the last anti-COVID-19 vaccine dose: lead public health choices by real-time epidemiological assessment. *Epidemiol Prev* 2022; **46**(1-2): 34-46.

780. Rzymski P, Kasianchuk N, Sikora D, Poniedziałek B. COVID-19 vaccinations and rates of infections, hospitalizations, ICU admissions, and deaths in Europe during SARS-CoV-2 Omicron wave in the first quarter of 2022. *J Med Virol* 2023; **95**(1): e28131.

781. Sahin A, Karadag-Oncel E, Buyuksen O, et al. The diversity in the clinical features of children hospitalized with COVID-19 during the nonvariant, Alpha (B.1.1.7), Delta (B.1.617.2), and Omicron (B.1.1.529) variant periods of SARS CoV-2: Caution for neurological symptoms in Omicron variant. *J Med Virol* 2023; **95**(3): e28628.

782. Salvesen K, Ter Haar G, Miloro P, et al. ISUOG Safety Committee updated recommendation on use of respirators by practitioners undertaking obstetric and gynecological ultrasound in context of SARS-CoV-2 Omicron variant of concern. *Ultrasound Obstet Gynecol* 2022; **59**(3): 411.

783. Sangsanont J, Rattanakul S, Makkaew P, et al. Wastewater monitoring in tourist cities as potential sentinel sites for near real-time dynamics of imported SARS-CoV-2 variants. *Sci Total Environ* 2023; **860**: 160317.

784. Sanz-Leon P, Hamilton LHW, Raison SJ, et al. Modelling herd immunity requirements in Queensland: impact of vaccination effectiveness, hesitancy and variants of SARS-CoV-2. *Philos Trans A Math Phys Eng Sci* 2022; **380**(2233): 20210311.

785. Schill R, Nelson KL, Harris-Lovett S, Kantor RS. The dynamic relationship between COVID-19 cases and SARS-CoV-2 wastewater concentrations across time and space: Considerations for model training data sets. *Sci Total Environ* 2023; **871**: 162069.

786. Schrag SJ, Verani JR, Dixon BE, et al. Estimation of COVID-19 mRNA Vaccine Effectiveness Against Medically Attended COVID-19 in Pregnancy During Periods of Delta and Omicron Variant Predominance in the United States. *JAMA Netw Open* 2022; **5**(9): e2233273.

787. Schuller M, Ginthör NE, Paller A, et al. Reduced COVID-19 morbidity and mortality in hemodialysis patients across the various Omicron sublineages-A retrospective analysis. *Front Public Health* 2023; **11**: 1218188.

788. Schultz BM, Melo-González F, Duarte LF, et al. A Booster Dose of CoronaVac Increases Neutralizing Antibodies and T Cells that Recognize Delta and Omicron Variants of Concern. *mBio* 2022; **13**(4): e0142322.

789. Schumann VF, de Castro Cuadrat RR, Wyler E, et al. SARS-CoV-2 infection dynamics revealed by wastewater sequencing analysis and deconvolution. *Sci Total Environ* 2022; **853**: 158931.

790. Schumm L, Blankenburg J, Kahre E, et al. Lower SARS-CoV-2 household transmission in children and adolescents compared to adults. *Sci Rep* 2022; **12**(1): 22453.

791. Schwab C, Domke LM, Rose F, Hausser I, Schirmacher P, Longerich T. Cell tropism and viral clearance during SARS-CoV-2 lung infection. *Pathol Res Pract* 2022; **236**: 154000.

792. Scribner C, Patel KI, Tunik M. Pediatric Croup Due to Omicron Infection Is More Severe Than Non-COVID Croup. *Pediatr Emerg Care* 2023; **39**(9): 651-3.

793. Scutari R, Fox V, De Ioris MA, et al. A case of SARS-CoV-2 Omicron reinfection resulting in a significant immunity boost in a paediatric patient affected by B-cell acute lymphoblastic leukemia. *BMC Infect Dis* 2023; **23**(1): 133.

794. Seaman MS, Siedner MJ, Boucau J, et al. Vaccine breakthrough infection leads to distinct profiles of neutralizing antibody responses by SARS-CoV-2 variant. *JCI Insight* 2022; **7**(19).

795. Seaton CL, Cohen A, Henninger EM, et al. Coronavirus Disease 2019 (COVID-19) Perinatal Outcomes Across the Pandemic at an Academic Medical Center in New York City. *Obstet Gynecol* 2023; **141**(1): 144-51.

796. Seki Y, Yoshihara Y, Nojima K, et al. Safety and immunogenicity of the Pfizer/BioNTech SARS-CoV-2 mRNA third booster vaccine dose against the BA.1 and BA.2 Omicron variants. *Med* 2022; **3**(6): 406-21.e4.

797. Selvavinayagam ST, Yong YK, Joseph N, et al. Low SARS-CoV-2 viral load among vaccinated individuals infected with Delta B.1.617.2 and Omicron BA.1.1.529 but not with Omicron BA.1.1 and BA.2 variants. *Front Public Health* 2022; **10**: 1018399.

798. Sendi P, Widmer N, Branca M, et al. Do quantitative levels of antispike-IgG antibodies aid in predicting protection from SARS-CoV-2 infection? Results from a longitudinal study in a police cohort. *J Med Virol* 2023; **95**(7): e28904.

799. Sgorlon G, Roca TP, Passos-Silva AM, et al. The emergence of Omicron VOC and its rapid spread and persistence in the Western Amazon. *PLoS One* 2023; **18**(8): e0285742.

800. Shanes ED, Miller ES, Otero S, et al. Placental Pathology After SARS-CoV-2 Infection in the Pre-Variant of Concern, Alpha / Gamma, Delta, or Omicron Eras. *Int J Surg Pathol* 2023; **31**(4): 387-97.

801. Shao F, Li B, Shang JJ, Liu WB, Wang HB, Liu QQ. Characterization of mild or asymptomatic patient admitted with Omicron variant of COVID-19 infection in Tibetan mobile cabin hospital China, August-October 2022. *Front Public Health* 2023; **11**: 1174944.

802. Shen N, Wu YF, Chen YW, et al. Clinical characteristics of pediatric cases infected with the SARS-CoV-2 Omicron variant in a tertiary children's medical center in Shanghai, China. *World J Pediatr* 2023; **19**(1): 87-95.

803. Shen X, Wang P, Shen J, et al. Neurological Manifestations of hospitalized patients with mild to moderate infection with SARS-CoV-2 Omicron variant in Shanghai, China. *J Infect Public Health* 2023; **16**(2): 155-62.

804. Shin DH, Jang H, Lee S, Choi BS, Kim D, Oh HS. Trends in Confirmed COVID-19 Cases in the Korean Military Before and After the Emergence of the Omicron Variant. *J Korean Med Sci* 2022; **37**(34): e260.

805. Shingleton J, Dyke S, Herrick A, Finnie T. Understanding the immunological landscape of England during SARS-CoV2 Omicron variant wave. *PLoS One* 2022; **17**(10): e0264870.

806. Shiraz R, Tripathi S. Enhanced recombination among Omicron subvariants of SARS-CoV-2 contributes to viral immune escape. *J Med Virol* 2023; **95**(2): e28519.

807. Shitaoka K, Higashiura A, Kawano Y, et al. Structural basis of spike RBM-specific human antibodies counteracting broad SARS-CoV-2 variants. *Commun Biol* 2023; **6**(1): 395.

808. Shoji K, Tsuzuki S, Akiyama T, et al. Comparison of clinical characteristics of COVID-19 in pregnant women between the Delta and Omicron variants of concern predominant periods. *J Infect Chemother* 2023; **29**(1): 33-8.

809. Shrestha NK, Shrestha P, Burke PC, Nowacki AS, Terpeluk P, Gordon SM. Coronavirus Disease 2019 Vaccine Boosting in Previously Infected or Vaccinated Individuals. *Clin Infect Dis* 2022; **75**(12): 2169-77.

810. Silva LM, Riani LR, Leite JB, et al. The Influence of the Omicron Variant on RNA Extraction and RT-qPCR Detection of SARS-CoV-2 in a Laboratory in Brazil. *Viruses* 2023; **15**(8).

811. Simayi A, Li C, Chen C, et al. Kinetics of SARS-CoV-2 neutralizing antibodies in Omicron breakthrough cases with inactivated vaccination: Role in inferring the history and duration of infection. *Front Immunol* 2023; **14**: 1083523.

812. Simon G, Favresse J, Gillot C, et al. Kinetics and ability of binding antibody and surrogate virus neutralization tests to predict neutralizing antibodies against the SARS-CoV-2 Omicron variant following BNT162b2 booster administration. *Clin Chem Lab Med* 2023; **61**(10): 1875-85.

813. Singh P, Negi SS, Bhargava A, Kolla VP, Arora RD. A Preliminary Genomic Analysis of the Omicron Variants of SARS-CoV-2 in Central India During the third wave of the COVID-19 Pandemic. *Arch Med Res* 2022; **53**(6): 574-84.

814. Slavov SN, de La-Roque DGL, da Costa PNM, et al. Dynamics of SARS-CoV-2 Variants of Concern in Vaccination Model City in the State of Sao Paulo, Brazil. *Viruses* 2022; **14**(10).

815. Smith LE, Potts HW, Amlôt R, Fear NT, Michie S, Rubin GJ. How has the emergence of the Omicron SARS-CoV-2 variant of concern influenced worry, perceived risk and behaviour in the UK? A series of cross-sectional surveys. *BMJ Open* 2022; **12**(8): e061203.

816. Socan M, Prosenc K, Mrzel M. Seroprevalence of Anti-SARS-CoV-2 Antibodies Following the Omicron BA.1 Wave. *Int J Environ Res Public Health* 2023; **20**(4).

817. Sokhansanj BA, Rosen GL. Predicting COVID-19 disease severity from SARS-CoV-2 spike protein sequence by mixed effects machine learning. *Comput Biol Med* 2022; **149**: 105969.

818. Solera JT, Árbol BG, Alshahrani A, et al. Impact of Vaccination and Early Monoclonal Antibody Therapy on Coronavirus Disease 2019 Outcomes in Organ Transplant Recipients During the Omicron Wave. *Clin Infect Dis* 2022; **75**(12): 2193-200.

819. Somersan-Karakaya S, Mylonakis E, Menon VP, et al. Casirivimab and Imdevimab for the Treatment of Hospitalized Patients With COVID-19. *J Infect Dis* 2022; **227**(1): 23-34.

820. Song J, Jing Q, Zhu E, et al. Alterations in smell or taste in individuals infected with SARS-CoV-2 during periods of Omicron variant dominance. *Int J Infect Dis* 2023; **128**: 278-84.

821. Song M, Wong MC, Li L, et al. Rapid point-of-care detection of SARS-CoV-2 RNA with smartphone-based upconversion luminescence diagnostics. *Biosens Bioelectron* 2023; **222**: 114987.

822. Søraas A, Grødeland G, Granerud BK, et al. Breakthrough infections with the omicron and delta variants of SARS-CoV-2 result in similar re-activation of vaccine-induced immunity. *Front Immunol* 2022; **13**: 964525.

823. Sorg AL, Schönfeld V, Siedler A, et al. SARS-CoV-2 variants and the risk of pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 among children in Germany. *Infection* 2023; **51**(3): 729-35.

824. Spicer KB, Glick C, Thoroughman DA. Adolescent COVID-19 Cases During the SARS-CoV-2 Delta and Omicron Variant Surges in Kentucky: Association With Vaccination and Prior Infection. *J Adolesc Health* 2023; **73**(3): 536-42.

825. Sprengholz P, Bruckmann R, Wiedermann M, Brockmann D, Betsch C. From delta to omicron: The role of individual factors and social context in self-reported compliance with pandemic regulations and recommendations. *Soc Sci Med* 2023; **317**: 115633.

826. Stanhope BJ, Peterson B, Knight B, et al. Development, testing and validation of a SARS-CoV-2 multiplex panel for detection of the five major variants of concern on a portable PCR platform. *Front Public Health* 2022; **10**: 1042647.

827. Stati G, Amerio P, Nubile M, Sancilio S, Rossi F, Di Pietro R. Concern about the Effectiveness of mRNA Vaccination Technology and Its Long-Term Safety: Potential Interference on miRNA Machinery. *Int J Mol Sci* 2023; **24**(2).

828. Stefanelli P, Trentini F, Petrone D, et al. Tracking the progressive spread of the SARS-CoV-2 Omicron variant in Italy, December 2021 to January 2022. *Euro Surveill* 2022; **27**(45).

829. Sternberg MR, Johnson A, King J, et al. Application of a life table approach to assess duration of BNT162b2 vaccine-derived immunity by age using COVID-19 case surveillance data during the Omicron variant period. *PLoS One* 2023; **18**(9): e0291678.

830. Stirrup O, Shrotri M, Adams NL, et al. Effectiveness of successive booster vaccine doses against SARS-CoV-2 related mortality in residents of long-term care facilities in the VIVALDI study. *Age Ageing* 2023; **52**(8).

831. Subramoney K, Mtileni N, Bharuthram A, et al. Identification of SARS-CoV-2 Omicron variant using spike gene target failure and genotyping assays, Gauteng, South Africa, 2021. *J Med Virol* 2022; **94**(8): 3676-84.

832. Suddhapas K, Choi MH, Shortreed MR, Timperman A. Evaluation of Variant-Specific Peptides for Detection of SARS-CoV-2 Variants of Concern. *J Proteome Res* 2022; **21**(10): 2443-52.

833. Sun H, Xu J, Zhang G, et al. Developing Pseudovirus-Based Neutralization Assay against Omicron-Included SARS-CoV-2 Variants. *Viruses* 2022; **14**(6).

834. Suntronwong N, Vichaiwattana P, Klinfueng S, et al. SARS-CoV-2 infection- induced seroprevalence among children and associated risk factors during the pre- and omicron-dominant wave, from January 2021 through December 2022, Thailand: A longitudinal study. *PLoS One* 2023; **18**(4): e0279147.

835. Surie D, Bonnell L, Adams K, et al. Effectiveness of Monovalent mRNA Vaccines Against COVID-19-Associated Hospitalization Among Immunocompetent Adults During BA.1/BA.2 and BA.4/BA.5 Predominant Periods of SARS-CoV-2 Omicron Variant in the United States - IVY Network, 18 States, December 26, 2021-August 31, 2022. *MMWR Morb Mortal Wkly Rep* 2022; **71**(42): 1327-34.

836. Surie D, DeCuir J, Zhu Y, et al. Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Hospitalization Among Immunocompetent Adults Aged ≥65 Years - IVY Network, 18 States, September 8-November 30, 2022. *MMWR Morb Mortal Wkly Rep* 2022; **71**(5152): 1625-30.

837. Sutandhio S, Furukawa K, Kurahashi Y, et al. Fourth mRNA vaccination increases cross-neutralizing antibody titers against SARS-CoV-2 variants, including BQ.1.1 and XBB, in a very elderly population. *J Infect Public Health* 2023; **16**(7): 1064-72.

838. Suzuki H, Akashi Y, Kato D, et al. Analytical performance of the rapid qualitative antigen kit for the detection of SARS-CoV-2 during widespread circulation of the Omicron variant. *J Infect Chemother* 2023; **29**(3): 257-62.

839. Tabatabai M, Juarez PD, Matthews-Juarez P, et al. An Analysis of COVID-19 Mortality During the Dominancy of Alpha, Delta, and Omicron in the USA. *J Prim Care Community Health* 2023; **14**: 21501319231170164.

840. Tagliamento M, Gennari A, Lambertini M, et al. Pandemic Phase-Adjusted Analysis of COVID-19 Outcomes Reveals Reduced Intrinsic Vulnerability and Substantial Vaccine Protection From Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Breast Cancer. *J Clin Oncol* 2023; **41**(15): 2800-14.

841. Tahsin A, Ahmed R, Bhattacharjee P, et al. Most frequently harboured missense variants of hACE2 across different populations exhibit varying patterns of binding interaction with spike glycoproteins of emerging SARS-CoV-2 of different lineages. *Comput Biol Med* 2022; **148**: 105903.

842. Takahashi Y, Tanaka H, Koga Y, et al. Change over Time in the Risk of Death among Japanese COVID-19 Cases Caused by the Omicron Variant Depending on Prevalence of Sublineages. *Int J Environ Res Public Health* 2023; **20**(4).

843. Tamandjou C, Auvigne V, Schaeffer J, Vaux S, Parent du Châtelet I. Effectiveness of second booster compared to first booster and protection conferred by previous SARS-CoV-2 infection against symptomatic Omicron BA.2 and BA.4/5 in France. *Vaccine* 2023; **41**(17): 2754-60.

844. Tamandjou Tchuem CR, Auvigne V, Vaux S, et al. Vaccine effectiveness and duration of protection of COVID-19 mRNA vaccines against Delta and Omicron BA.1 symptomatic and severe COVID-19 outcomes in adults aged 50 years and over in France. *Vaccine* 2023; **41**(13): 2280-8.

845. Tan CY, Chiew CJ, Pang D, et al. Vaccine effectiveness against Delta, Omicron BA.1, and BA.2 in a highly vaccinated Asian setting: a test-negative design study. *Clin Microbiol Infect* 2023; **29**(1): 101-6.

846. Tan CY, Chiew CJ, Pang D, et al. Protective immunity of SARS-CoV-2 infection and vaccines against medically attended symptomatic omicron BA.4, BA.5, and XBB reinfections in Singapore: a national cohort study. *Lancet Infect Dis* 2023; **23**(7): 799-805.

847. Tan KS, Ang AXY, Tay DJW, et al. Detection of hospital environmental contamination during SARS-CoV-2 Omicron predominance using a highly sensitive air sampling device. *Front Public Health* 2022; **10**: 1067575.

848. Tang CY, Boftsi M, Staudt L, et al. SARS-CoV-2 and influenza co-infection: A cross-sectional study in central Missouri during the 2021-2022 influenza season. *Virology* 2022; **576**: 105-10.

849. Tang J, Novak T, Hecker J, et al. Cross-reactive immunity against the SARS-CoV-2 Omicron variant is low in pediatric patients with prior COVID-19 or MIS-C. *Nat Commun* 2022; **13**(1): 2979.

850. Tangwangvivat R, Wacharapluesadee S, Pinyopornpanish P, et al. SARS-CoV-2 Variants Detection Strategies in Wastewater Samples Collected in the Bangkok Metropolitan Region. *Viruses* 2023; **15**(4).

851. Tao Y, Ma M, Hu F, et al. A longitudinal study of humoral immune responses induced by a 3-dose inactivated COVID-19 vaccine in an observational, prospective cohort. *BMC Immunol* 2022; **23**(1): 57.

852. Tartof SY, Frankland TB, Slezak JM, et al. Effectiveness Associated With BNT162b2 Vaccine Against Emergency Department and Urgent Care Encounters for Delta and Omicron SARS-CoV-2 Infection Among Adolescents Aged 12 to 17 Years. *JAMA Netw Open* 2022; **5**(8): e2225162.

853. Tartof SY, Slezak JM, Puzniak L, et al. Effectiveness and durability of BNT162b2 vaccine against hospital and emergency department admissions due to SARS-CoV-2 omicron sub-lineages BA.1 and BA.2 in a large health system in the USA: a test-negative, case-control study. *Lancet Respir Med* 2023; **11**(2): 176-87.

854. Tassetto M, Garcia-Knight M, Anglin K, et al. Detection of Higher Cycle Threshold Values in Culturable SARS-CoV-2 Omicron BA.1 Sublineage Compared with Pre-Omicron Variant Specimens - San Francisco Bay Area, California, July 2021-March 2022. *MMWR Morb Mortal Wkly Rep* 2022; **71**(36): 1151-4.

855. Tenforde MW, Self WH, Zhu Y, et al. Protection of Messenger RNA Vaccines Against Hospitalized Coronavirus Disease 2019 in Adults Over the First Year Following Authorization in the United States. *Clin Infect Dis* 2023; **76**(3): e460-e8.

856. Tenforde MW, Weber ZA, Natarajan K, et al. Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults - VISION Network, Nine States, September-November 2022. *MMWR Morb Mortal Wkly Rep* 2022; **71**(5152): 1616-24.

858. Tetsuhara K, Akamine S, Matsubara Y, et al. Severe encephalopathy associated with SARS-CoV-2 Omicron BA.1 variant infection in a neonate. *Brain Dev* 2022; **44**(10): 743-7.

859. Teyssou E, Marot S, Cocherie T, et al. Prolonged replication of BA.1 and BA.2 Omicron lineages compared to Delta variant in nasopharyngeal samples from COVID-19 patients. *Infect Dis Now* 2023; **53**(1): 104629.

860. Thakkar A, Pradhan K, Duva B, et al. Study of efficacy and longevity of immune response to third and fourth doses of COVID-19 vaccines in patients with cancer: A single arm clinical trial. *Elife* 2023; **12**.

861. Theaux C, Martin Y, Montoto Piazza L, et al. Persistence of SARS-CoV-2 RNA shedding and infectivity in immunized population: Prospective study along different epidemiological periods in Argentina. *PLoS One* 2023; **18**(5): e0285704.

862. Thi Hong Nguyen N, Ou TY, Huy LD, et al. A global analysis of COVID-19 infection fatality rate and its associated factors during the Delta and Omicron variant periods: an ecological study. *Front Public Health* 2023; **11**: 1145138.

863. Thompson EA, Ngecu W, Stoddart L, et al. Heterologous versus homologous boosting elicits qualitatively distinct, BA.5-cross-reactive T cells in transplant recipients. *JCI Insight* 2023; **8**(10).

864. Thompson MG, Natarajan K, Irving SA, et al. Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022. *MMWR Morb Mortal Wkly Rep* 2022; **71**(4): 139-45.

865. Thompson MG, Yoon SK, Naleway AL, et al. Association of mRNA Vaccination With Clinical and Virologic Features of COVID-19 Among US Essential and Frontline Workers. *Jama* 2022; **328**(15): 1523-33.

866. Thongsing A, Eizadkhah D, Fields C, Ballaban-Gil K. Provoked seizures and status epilepticus in a pediatric population with COVID-19 disease. *Epilepsia* 2022; **63**(8): e86-e91.

867. Tjaden AH, Gibbs M, Runyon M, Weintraub WS, Taylor YJ, Edelstein SL. Association between self-reported masking behavior and SARS-CoV-2 infection wanes from Pre-Delta to Omicron-predominant periods - North Carolina COVID-19 Community Research Partnership (NC-CCRP). *Am J Infect Control* 2023; **51**(3): 261-7.

868. Tobin RJ, Wood JG, Jayasundara D, et al. Real-time analysis of hospital length of stay in a mixed SARS-CoV-2 Omicron and Delta epidemic in New South Wales, Australia. *BMC Infect Dis* 2023; **23**(1): 28.

869. Tolbert WD, Chen Y, Sun L, et al. The molecular basis of the neutralization breadth of the RBD-specific antibody CoV11. *Front Immunol* 2023; **14**: 1178355.

870. Tomaszewski T, Ali MA, Caetano-Anollés K, Caetano-Anollés G. Seasonal effects decouple SARS-CoV-2 haplotypes worldwide. *F1000Res* 2023; **12**: 267.

871. Tomioka K, Uno K, Yamada M. Association between vaccination status and severe health consequences among community-dwelling COVID-19 patients during Omicron BA.1/BA.2 and BA.5-predominant periods in Japan. *Environ Health Prev Med* 2023; **28**: 35.

872. Tomiyama T, Suzuki R, Harada N, et al. A third dose of the BNT162b2 mRNA vaccine sufficiently improves the neutralizing activity against SARS-CoV-2 variants in liver transplant recipients. *Front Cell Infect Microbiol* 2023; **13**: 1197349.

873. Tong C, Shi W, Zhang A, Shi Z. Tracking and controlling the spatiotemporal spread of SARS-CoV-2 Omicron variant in South Africa. *Travel Med Infect Dis* 2022; **46**: 102252.

875. Trémeaux P, Latour J, Ranger N, et al. SARS-CoV-2 Co-Infections and Recombinations Identified by Long-Read Single-Molecule Real-Time Sequencing. *Microbiol Spectr* 2023; **11**(4): e0049323.

876. Trigo-Tasende N, Vallejo JA, Rumbo-Feal S, et al. Wastewater early warning system for SARS-CoV-2 outbreaks and variants in a Coruña, Spain. *Environ Sci Pollut Res Int* 2023; **30**(32): 79315-34.

877. Tsang NNY, So HC, Cowling BJ, Leung GM, Ip DKM. Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study. *Lancet Infect Dis* 2023; **23**(4): 421-34.

878. Tsao J, Kussman A, Segovia NA, Abrams GD, Boehm AB, Hwang CE. Prevalence of Positive Rapid Antigen Tests After 7-Day Isolation Following SARS-CoV-2 Infection in College Athletes During Omicron Variant Predominance. *JAMA Netw Open* 2022; **5**(10): e2237149.

879. Tso WW, Kwan MY, Kwok JS, et al. Clinical characteristics of unvaccinated or incompletely vaccinated children with neurological manifestations due to SARS-CoV-2 Omicron infection. *J Med Virol* 2023; **95**(7): e28895.

880. Tso WWY, Kwan MYW, Wang YL, et al. Severity of SARS-CoV-2 Omicron BA.2 infection in unvaccinated hospitalized children: comparison to influenza and parainfluenza infections. *Emerg Microbes Infect* 2022; **11**(1): 1742-50.

881. Tsuzuki S, Akiyama T, Matsunaga N, Ohmagari N. Association between physical activity status and severity of COVID-19 in older adults. *Epidemiol Infect* 2022; **150**: e189.

882. Tu H, Wang X, Tang S. Exploring COVID-19 transmission patterns and key factors during epidemics caused by three major strains in Asia. *J Theor Biol* 2023; **557**: 111336.

883. Tuan JJ, Sharma M, Kayani J, et al. Outcomes of pregnant women exposed to Sotrovimab for the treatment of COVID-19 in the BA.1 Omicron predominant era (PRESTO). *BMC Infect Dis* 2023; **23**(1): 258.

884. Tupper P, Pai S, Colijn C. COVID-19 cluster size and transmission rates in schools from crowdsourced case reports. *Elife* 2022; **11**.

885. Tut G, Lancaster T, Krutikov M, et al. Strong peak immunogenicity but rapid antibody waning following third vaccine dose in older residents of care homes. *Nat Aging* 2023; **3**(1): 93-104.

886. Umunnakwe CN, Makatini ZN, Maphanga M, et al. Evaluation of a commercial SARS-CoV-2 multiplex PCR genotyping assay for variant identification in resource-scarce settings. *PLoS One* 2022; **17**(6): e0269071.

887. Ung TTH, Hoang PVM, Nguyen SV, et al. Occurrence of the Omicron variant of SARS-CoV-2 in northern Viet Nam in early 2022. *Western Pac Surveill Response J* 2022; **13**(3): 1-5.

888. Uršič T, Kogoj R, Šikonja J, et al. Performance of nasopharyngeal swab and saliva in detecting Delta and Omicron SARS-CoV-2 variants. *J Med Virol* 2022; **94**(10): 4704-11.

889. Vaira LA, Lechien JR, Salzano G, et al. SARS-CoV-2 Effects on Psychophysical Olfactory Scores: Prospective Study With Evaluation Before and 60-Days After Infection. *Otolaryngol Head Neck Surg* 2023; **168**(5): 1249-52.

890. Van Goethem N, Chung PYJ, Meurisse M, et al. Clinical Severity of SARS-CoV-2 Omicron Variant Compared with Delta among Hospitalized COVID-19 Patients in Belgium during Autumn and Winter Season 2021-2022. *Viruses* 2022; **14**(6).

891. Van Heirstraeten L, Ekinci E, Smet M, et al. Detection of SARS-CoV-2 in young children attending day-care centres in Belgium, May 2020 to February 2022. *Euro Surveill* 2022; **27**(21).

892. van Kempen ZLE, Stalman EW, Steenhuis M, et al. SARS-CoV-2 omicron breakthrough infections in patients with multiple sclerosis. *J Neurol Neurosurg Psychiatry* 2023; **94**(4): 280-3.

893. Vanhulle E, Doijen J, Stroobants J, et al. Cellular electrical impedance to profile SARS-CoV-2 fusion inhibitors and to assess the fusogenic potential of spike mutants. *Antiviral Res* 2023; **213**: 105587.

894. Vanoni S, Matulevicius A, Avdiu B, et al. SARS-CoV-2 variants of concern surveillance including Omicron using RT-PCR-based genotyping offers comparable performance to whole genome sequencing. *Front Cell Infect Microbiol* 2022; **12**: 960065.

895. Vattiatio G, Lustig A, Maclaren OJ, Plank MJ. Modelling the dynamics of infection, waning of immunity and re-infection with the Omicron variant of SARS-CoV-2 in Aotearoa New Zealand. *Epidemics* 2022; **41**: 100657.

896. Verkhivker G, Agajanian S, Kassab R, Krishnan K. Computer Simulations and Network-Based Profiling of Binding and Allosteric Interactions of SARS-CoV-2 Spike Variant Complexes and the Host Receptor: Dissecting the Mechanistic Effects of the Delta and Omicron Mutations. *Int J Mol Sci* 2022; **23**(8).

897. Vicentini M, Venturelli F, Mancuso P, et al. Risk of SARS-CoV-2 reinfection by vaccination status, predominant variant and time from prior infection: a cohort study, Reggio Emilia province, Italy, February 2020 to February 2022. *Euro Surveill* 2023; **28**(13).

898. Viloria Winnett A, Akana R, Shelby N, et al. Daily SARS-CoV-2 Nasal Antigen Tests Miss Infected and Presumably Infectious People Due to Viral Load Differences among Specimen Types. *Microbiol Spectr* 2023; **11**(4): e0129523.

899. Vo V, Tillett RL, Papp K, et al. Detection of the Omicron BA.1 Variant of SARS-CoV-2 in Wastewater From a Las Vegas Tourist Area. *JAMA Netw Open* 2023; **6**(2): e230550.

900. von Bülow S, Sikora M, Blanc FEC, Covino R, Hummer G. Antibody accessibility determines location of spike surface mutations in SARS-CoV-2 variants. *PLoS Comput Biol* 2023; **19**(1): e1010822.

901. Voutouri C, Hardin CC, Naranbhai V, et al. Mechanistic model for booster doses effectiveness in healthy, cancer, and immunosuppressed patients infected with SARS-CoV-2. *Proc Natl Acad Sci U S A* 2023; **120**(3): e2211132120.

902. Wan EYF, Mok AHY, Yan VKC, et al. Effectiveness of BNT162b2 and CoronaVac vaccinations against SARS-CoV-2 omicron infection in people aged 60 years or above: a case-control study. *J Travel Med* 2022; **29**(8).

903. Wang B, Chen L, Sui H, et al. The Environmental Stability of SARS-CoV-2 Variants Omicron BA.1 and BA.5 on the Surfaces of Widely Used Transport Packaging Materials. *Microbiol Spectr* 2023; **11**(3): e0488122.

904. Wang CY, Peng WJ, Kuo BS, et al. Toward a pan-SARS-CoV-2 vaccine targeting conserved epitopes on spike and non-spike proteins for potent, broad and durable immune responses. *PLoS Pathog* 2023; **19**(4): e1010870.

905. Wang H, Chen R, Guo J, Shui L, Xiong J, Chen Y. Pneumonia in newly diagnosed patients infected with the Omicron variant: a population-based study of Chinese patients in Chongqing. *BMJ Open Respir Res* 2023; **10**(1).

906. Wang H, Li T, Gao H, et al. Lessons drawn from Shanghai for controlling highly transmissible SARS-CoV-2 variants: insights from a modelling study. *BMC Infect Dis* 2023; **23**(1): 331.

907. Wang H, Sun K, Wang Y. Exploring the Chinese Public's Perception of Omicron Variants on Social Media: LDA-Based Topic Modeling and Sentiment Analysis. *Int J Environ Res Public Health* 2022; **19**(14).

908. Wang H, Wright T, Everhart K, Oyeniran SJ, Mejias A, Leber AL. SARS-CoV-2 Reinfection With Different SARS-CoV-2 Variants in Children, Ohio, United States. *J Pediatric Infect Dis Soc* 2023; **12**(4): 198-204.

909. Wang H, Yang Q, Li F, et al. The Risk Factors and Outcomes for Radiological Abnormalities in Early Convalescence of COVID-19 Patients Caused by the SARS-CoV-2 Omicron Variant: A Retrospective, Multicenter Follow-up Study. *J Korean Med Sci* 2023; **38**(8): e55.

910. Wang J, Chan YC, Niu R, Wong EWM, van Wyk MA. Modeling the Impact of Vaccination on COVID-19 and Its Delta and Omicron Variants. *Viruses* 2022; **14**(7).

911. Wang K, Guo Z, Zeng T, et al. Transmission Characteristics and Inactivated Vaccine Effectiveness Against Transmission of SARS-CoV-2 Omicron BA.5 Variants in Urumqi, China. *JAMA Netw Open* 2023; **6**(3): e235755.

912. Wang T, Wang C, Myshkevych Y, Mantilla-Calderon D, Talley E, Hong PY. SARS-CoV-2 wastewater-based epidemiology in an enclosed compound: A 2.5-year survey to identify factors contributing to local community dissemination. *Sci Total Environ* 2023; **875**: 162466.

913. Wang TY, Wahed AS, Morris A, et al. Effect of Thromboprophylaxis on Clinical Outcomes After COVID-19 Hospitalization. *Ann Intern Med* 2023; **176**(4): 515-23.

914. Wang X, Zein J, Ji X, Lin DY. Impact of Vaccination, Prior Infection, and Therapy on Omicron Infection and Mortality. *J Infect Dis* 2023; **227**(8): 970-6.

915. Wang Y, Zhao D, Chen X, Liu X, Xiao W, Feng L. The effect of nirmatrelvir-ritonavir on viral clearance and length of hospital stay in patients infected with SARS-CoV-2 omicron variants. *Influenza Other Respir Viruses* 2023; **17**(2): e13095.

916. Wang Z, Liu B, Luan J, Lu S, Zhang Z, Ba J. Real-time risk ranking of emerging epidemics based on optimized moving average prediction limit-taking the COVID-19 pandemic as an example. *BMC Public Health* 2023; **23**(1): 1039.

917. Ward IL, Bermingham C, Ayoubkhani D, et al. Risk of covid-19 related deaths for SARS-CoV-2 omicron (B.1.1.529) compared with delta (B.1.617.2): retrospective cohort study. *Bmj* 2022; **378**: e070695.

918. Ward T, Glaser A, Overton CE, Carpenter B, Gent N, Seale AC. Replacement dynamics and the pathogenesis of the Alpha, Delta and Omicron variants of SARS-CoV-2. *Epidemiol Infect* 2022; **151**: e32.

919. Wassenaar TM, Wanchai V, Buzard G, Ussery DW. The first three waves of the Covid-19 pandemic hint at a limited genetic repertoire for SARS-CoV-2. *FEMS Microbiol Rev* 2022; **46**(3).

920. Wei Y, Jia KM, Zhao S, et al. Estimation of Vaccine Effectiveness of CoronaVac and BNT162b2 Against Severe Outcomes Over Time Among Patients With SARS-CoV-2 Omicron. *JAMA Netw Open* 2023; **6**(2): e2254777.

921. Werbel WA, Weld ED, Advani SD, Patel PK, Sundaram ME, Phadke VK. Your Outpatient has Coronavirus Disease 2019: What Are the Treatment Options in the Current Severe Acute Respiratory Syndrome Coronavirus 2 Variant Climate? *Clin Infect Dis* 2023; **77**(1): 32-7.

922. Whitaker M, Elliott J, Bodinier B, et al. Variant-specific symptoms of COVID-19 in a study of 1,542,510 adults in England. *Nat Commun* 2022; **13**(1): 6856.

923. Wilhelm A, Agrawal S, Schoth J, et al. Early Detection of SARS-CoV-2 Omicron BA.4 and BA.5 in German Wastewater. *Viruses* 2022; **14**(9).

924. Wilhelm A, Schoth J, Meinert-Berning C, et al. Wastewater surveillance allows early detection of SARS-CoV-2 omicron in North Rhine-Westphalia, Germany. *Sci Total Environ* 2022; **846**: 157375.

925. Willyard C. What the Omicron wave is revealing about human immunity. *Nature* 2022; **602**(7895): 22-5.

926. Wnuk K, Sudol J, Spilman P, Soon-Shiong P. Peptidome Surveillance Across Evolving SARS-CoV-2 Lineages Reveals HLA Binding Conservation in Nucleocapsid Among Variants With Most Potential for T-Cell Epitope Loss in Spike. *Front Immunol* 2022; **13**: 918928.

927. Wong AM, Lin JJ, Hsia SH, Lin KL. MRI of fatal course of acute hemorrhagic leukoencephalitis in a child with SARS-CoV-2 omicron BA 2.0 infection. *Neuroradiology* 2023; **65**(7): 1179-81.

928. Wong CKH, Au ICH, Lau KTK, Lau EHY, Cowling BJ, Leung GM. Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study. *Lancet Infect Dis* 2022; **22**(12): 1681-93.

929. Woo MS, Mayer C, Brehm TT, et al. Absence of self-reported neuropsychiatric and somatic symptoms after Omicron variant SARS-CoV-2 breakthrough infections. *Brain Commun* 2023; **5**(2): fcad092.

930. Woopen C, Konofalska U, Akgün K, Ziemssen T. Case report: Variant-specific pre-exposure prophylaxis of SARS-CoV-2 infection in multiple sclerosis patients lacking vaccination responses. *Front Immunol* 2022; **13**: 897748.

931. Wrenn JO, Pakala SB, Vestal G, et al. COVID-19 severity from Omicron and Delta SARS-CoV-2 variants. *Influenza Other Respir Viruses* 2022; **16**(5): 832-6.

932. Wu J, Shi X, Tao B, Zhan Y, Lu X, Wang J. Inactivated COVID-19 vaccine booster dose shortened the viral shedding time of patients infected with the Omicron variant BA.2. *Int J Infect Dis* 2023; **131**: 26-31.

933. Wu J, Wei Y, Shen F, et al. Vaccination Is Associated With Shorter Time to Target Cycle Threshold Value in Patients With SARS-CoV-2 Omicron Variant. *Front Cell Infect Microbiol* 2022; **12**: 943407.

934. Wu JD, Li JX, Liu J, et al. Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b trial. *Lancet Infect Dis* 2023; **23**(9): 1020-30.

935. Wu X, Shan KJ, Zan F, Tang X, Qian Z, Lu J. Optimization and Deoptimization of Codons in SARS-CoV-2 and Related Implications for Vaccine Development. *Adv Sci (Weinh)* 2023; **10**(23): e2205445.

936. Xie J, Feng Y, Newby D, et al. Genetic risk, adherence to healthy lifestyle and acute cardiovascular and thromboembolic complications following SARS-COV-2 infection. *Nat Commun* 2023; **14**(1): 4659.

937. Xie R, Edwards KM, Adam DC, et al. Resurgence of Omicron BA.2 in SARS-CoV-2 infection-naive Hong Kong. *Nat Commun* 2023; **14**(1): 2422.

938. Xin H, Wang Z, Feng S, et al. Transmission dynamics of SARS-CoV-2 Omicron variant infections in Hangzhou, Zhejiang, China, January-February 2022. *Int J Infect Dis* 2023; **126**: 132-5.

939. Xu X, Deng Y, Ding J, et al. Real-time allelic assays of SARS-CoV-2 variants to enhance sewage surveillance. *Water Res* 2022; **220**: 118686.

940. Xu X, Wu H, Jin G, et al. Efficacy of Lianhua Qingwen for children with SARS-CoV-2 Omicron infection: A propensity score-matched retrospective cohort study. *Phytomedicine* 2023; **111**: 154665.

941. Xu X, Zhou S, Chen C, et al. Efficacy and safety of Reyanning mixture in patients infected with SARS-CoV-2 Omicron variant: A prospective, open-label, randomized controlled trial. *Phytomedicine* 2023; **108**: 154514.

942. Xue L, Jing S, Zhang K, Milne R, Wang H. Infectivity versus fatality of SARS-CoV-2 mutations and influenza. *Int J Infect Dis* 2022; **121**: 195-202.

943. Yadav SK, Kumar V, Akhter Y. Modeling Global COVID-19 Dissemination Data After the Emergence of Omicron Variant Using Multipronged Approaches. *Curr Microbiol* 2022; **79**(9): 286.

944. Yamaguchi T, Makino Y, Mabuchi Y, et al. Severity of SARS-CoV-2 infection in pregnant women and their neonates during the Omicron period compared to the pre-Omicron period: A retrospective cohort study. *J Obstet Gynaecol Res* 2023; **49**(5): 1348-54.

945. Yan T, Xu Y, Zheng R, et al. Accessible and Adaptable Multiplexed Real-Time PCR Approaches to Identify SARS-CoV-2 Variants of Concern. *Microbiol Spectr* 2022; **10**(5): e0322222.

946. Yan VKC, Wan EYF, Ye X, et al. Effectiveness of BNT162b2 and CoronaVac vaccinations against mortality and severe complications after SARS-CoV-2 Omicron BA.2 infection: a case-control study. *Emerg Microbes Infect* 2022; **11**(1): 2304-14.

947. Yang H, Chai X, Gong Y, et al. Severe hemolytic exacerbations of Chinese PNH patients infected SARS-CoV-2 Omicron. *Immun Inflamm Dis* 2023; **11**(8): e966.

948. Yang L, Dong W, Shen X, et al. Effect Analysis of Different Environmental Disinfection Methods on Reducing Contamination of Surfaces by the Omicron BA.2.2 Variant of SARS-CoV-2 and the Characteristics of Fomite Contamination in the Fever Clinic in the Out-Broken of Shanghai. *Food Environ Virol* 2023; **15**(2): 107-15.

949. Yang L, Zhong J, Wang W, et al. Clinical features of Omicron variant infection in 445 patients with coronavirus 19 disease. *Ann Saudi Med* 2023; **43**(3): 161-5.

950. Yang W, Liu R, Yan J, et al. Ultra-sensitive and specific detection of pathogenic nucleic acids using composite-excited hyperfine plasma spectroscopy combs sensitized by Au nanoarrays functionalized with 2D Ta(2)C-MXene. *Biosens Bioelectron* 2023; **235**: 115358.

951. Yang Y, Shi L, Jin X, Tong S. Effects of short-term quarantine on growth and development of children aged 1-36 months during the Omicron outbreak. *Eur J Pediatr* 2023; **182**(3): 1351-9.

952. Yang YY, Tseng YJ. The evolution of the spike protein and hACE2 interface of SARS-CoV-2 omicron variants determined by hydrogen bond formation. *Brief Funct Genomics* 2023; **22**(3): 291-301.

953. Yaniv K, Ozer E, Shagan M, Paitan Y, Granek R, Kushmaro A. Managing an evolving pandemic: Cryptic circulation of the Delta variant during the Omicron rise. *Sci Total Environ* 2022; **836**: 155599.

954. Yeo T, Siew RWE, Gulam MY, et al. COVID-19 infection after SARS-CoV-2 mRNA vaccination in Multiple Sclerosis, AQP4-antibody NMOSD and MOGAD patients during the Omicron subvariant BA.1/2 wave in Singapore. *J Neurol* 2023; **270**(6): 2817-25.

955. Yildirim Arslan S, Avcu G, Sahbudak Bal Z, Arslan A, Ozkinay FF, Kurugol Z. Evaluation of post-COVID symptoms of the SARS-CoV-2 Delta and Omicron variants in children: a prospective study. *Eur J Pediatr* 2023.

956. Yin Y, Lin J, Yuan S, et al. Vaccination status for mild and asymptomatic infections with SARS-CoV-2 Omicron BA.2 variant in Shanghai. *J Med Virol* 2023; **95**(5): e28767.

957. Ying-Hao P, Yuan-Yuan G, Hai-Dong Z, et al. Clinical characteristics and analysis of risk factors for disease progression of patients with SARS-CoV-2 Omicron variant infection: A retrospective study of 25207 cases in a Fangcang hospital. *Front Cell Infect Microbiol* 2022; **12**: 1009894.

958. Yoo J, Kim Y, Cha YM, et al. Heterologous vaccination (ChAdOx1 and BNT162b2) induces a better immune response against the omicron variant than homologous vaccination. *J Infect Public Health* 2023; **16**(10): 1537-43.

959. Yu P, Liu Z, Zhu Z, et al. Omicron variants breakthrough infection elicited higher specific memory immunity than third dose booster in healthy vaccinees. *Virol Sin* 2023; **38**(2): 233-43.

960. Yu Y, Yu Y, Zhao S, He D. A simple model to estimate the transmissibility of the Beta, Delta, and Omicron variants of SARS-COV-2 in South Africa. *Math Biosci Eng* 2022; **19**(10): 10361-73.

961. Zani A, Messali S, Caccuri F. Virucidal efficacy of a novel silver-based disinfectant against SARS-CoV-2 Omicron BA.5. *New Microbiol* 2023; **46**(1): 60-4.

962. Zárate S, Taboada B, Rosales-Rivera M, et al. Omicron-BA.1 Dispersion Rates in Mexico Varied According to the Regional Epidemic Patterns and the Diversity of Local Delta Subvariants. *Viruses* 2023; **15**(1).

963. Zeitler K, Piccicacco N, O'Neal M, et al. Evaluation of severe acute respiratory syndrome coronavirus 2 monoclonal antibodies in high-risk solid organ transplant recipients across three major coronavirus disease 2019 variant waves. *Transpl Infect Dis* 2023; **25**(4): e14095.

964. Zens KD, Llanas-Cornejo D, Menges D, et al. Longitudinal humoral and cell-mediated immune responses in a population-based cohort in Zurich, Switzerland between March and June 2022 - evidence for protection against Omicron SARS-CoV-2 infection by neutralizing antibodies and spike-specific T-cell responses. *Int J Infect Dis* 2023; **133**: 18-26.

965. Zerbo O, Ray GT, Fireman B, et al. Maternal SARS-CoV-2 vaccination and infant protection against SARS-CoV-2 during the first six months of life. *Nat Commun* 2023; **14**(1): 894.

966. Zhang H, Hua Q, Nani Xu N, et al. Evaluation of antibody kinetics and durability in healthy individuals vaccinated with inactivated COVID-19 vaccine (CoronaVac): A cross-sectional and cohort study in Zhejiang, China. *Elife* 2023; **12**.

967. Zhang J, Liu L, Zhang G, Li M, Ma B, Yang W. Treating patients infected with the SARS-CoV-2 Omicron variant with a traditional Chinese medicine, Shufeng Jiedu capsule. *Biosci Trends* 2022; **16**(3): 238-41.

968. Zhang J, Zhao D, Hu J, Huang X, Gu Q, Tao Z. Hepatic dysfunctions in COVID-19 patients infected by the omicron variant of SARS-CoV-2. *Front Public Health* 2022; **10**: 1049006.

969. Zhang L, Xie S, Lyu F, et al. Predictive value of immunoglobulin G, activated partial thromboplastin time, platelet, and indirect bilirubin for delayed viral clearance in patients infected with the Omicron variant. *PeerJ* 2023; **11**: e15443.

970. Zhang L, Zhang S, Han J, Yi Y, Zhou H, Li J. Paxlovid administration in elderly patient with COVID-19 caused by Omicron BA.2.0: A case report. *Medicine (Baltimore)* 2022; **101**(45): e31361.

971. Zhang S, Dong C, Zhen Q, et al. Unveiling a New Perspective on Distinguishing Omicron Breakthrough Cases and Postimmune COVID-19-Naive Individuals: Insights from Antibody Profiles. *Microbiol Spectr* 2023; **11**(4): e0180823.

972. Zhang W, Zhou S, Wang G, et al. Clinical predictors and RT-PCR profile of prolonged viral shedding in patients with SARS-CoV-2 Omicron variant in Shanghai: A retrospective observational study. *Front Public Health* 2022; **10**: 1015811.

973. Zhang Y, Liu J, Yang F, et al. COVID-19-related secretory otitis media in the omicron era: a case series. *Eur Arch Otorhinolaryngol* 2023; **280**(10): 4697-700.

974. Zhang Y, Qu JW, Zheng MN, et al. Neutralizing Antibody Responses against Five SARS-CoV-2 Variants and T Lymphocyte Change after Vaccine Breakthrough Infections from the SARS-CoV-2 Omicron BA.1 Variant in Tianjin, China: A Prospective Study. *Biomed Environ Sci* 2023; **36**(7): 614-24.

975. Zhang Z, Zhang H, Zhang Y, et al. Oridonin inhibits SARS-CoV-2 replication by targeting viral proteinase and polymerase. *Virol Sin* 2023; **38**(3): 470-9.

976. Zhao H, Han K, Gao C, et al. VOC-alarm: mutation-based prediction of SARS-CoV-2 variants of concern. *Bioinformatics* 2022; **38**(14): 3549-56.

977. Zhao H, Ye W, Yu X, Shi Y, Sheng J. Omicron COVID-19 variant outcomes and vaccination in non-severe and non-critical patients at admission. *Front Public Health* 2022; **10**: 974986.

978. Zhao L, Geng Q, Corchis-Scott R, McKay RM, Norton J, Xagoraraki I. Targeting a free viral fraction enhances the early alert potential of wastewater surveillance for SARS-CoV-2: a methods comparison spanning the transition between delta and omicron variants in a large urban center. *Front Public Health* 2023; **11**: 1140441.

979. Zhao L, Zou Y, Li Y, et al. Five-week warning of COVID-19 peaks prior to the Omicron surge in Detroit, Michigan using wastewater surveillance. *Sci Total Environ* 2022; **844**: 157040.

980. Zhao LP, Lybrand TP, Gilbert P, et al. Application of Statistical Learning to Identify Omicron Mutations in SARS-CoV-2 Viral Genome Sequence Data From Populations in Africa and the United States. *JAMA Netw Open* 2022; **5**(9): e2230293.

981. Zhao S, Guo Z, Sun S, et al. Effectiveness of BNT162b2 and Sinovac vaccines against the transmission of SARS-CoV-2 during Omicron-predominance in Hong Kong: A retrospective cohort study of COVID-19 cases. *J Clin Virol* 2023; **166**: 105547.

982. Zhao Y, Zhang H, Zhao Z, et al. Efficacy and safety of Oral LL-37 against the Omicron BA.5.1.3 variant of SARS-COV-2: A randomized trial. *J Med Virol* 2023; **95**(8): e29035.

983. Zheng B, Green ACA, Tazare J, et al. Comparative effectiveness of sotrovimab and molnupiravir for prevention of severe covid-19 outcomes in patients in the community: observational cohort study with the OpenSAFELY platform. *Bmj* 2022; **379**: e071932.

984. Zheng JX, Lv S, Tian LG, et al. The rapid and efficient strategy for SARS-CoV-2 Omicron transmission control: analysis of outbreaks at the city level. *Infect Dis Poverty* 2022; **11**(1): 114.

985. Zheng SY, Zhang YP, Liu YX, et al. Tracking of Mutational Signature of SARS-CoV-2 Omicron on Distinct Continents and Little Difference was Found. *Viruses* 2023; **15**(2).

986. Zheng XQ, Xu QY, Xie L, et al. Response and duration of serum anti-SARS-CoV-2 antibodies induced by the third dose of an inactivated vaccine: A prospective longitudinal cohort study at 21 serial time points over 641 days. *J Med Virol* 2023; **95**(4): e28703.

987. Zheng Y, Pan J, Jin M, et al. Efficacy of the neutralizing antibodies after the booster dose on SARS-CoV-2 Omicron variant and a two-year longitudinal antibody study on Wild Type convalescents. *Int Immunopharmacol* 2023; **119**: 110151.

988. Zhong W, Wu Y, Yue W, et al. Distinguishing COVID-19 from seasonal influenza in patients under age 65 years-a retrospective observational cohort study comparing the 2009 influenza A (H1N1) and 2022 SARS-CoV-2 pandemics. *Front Cell Infect Microbiol* 2023; **13**: 1179552.

989. Zhong W, Yang X, Jiang X, et al. Factors associated with prolonged viral shedding in older patients infected with Omicron BA.2.2. *Front Public Health* 2022; **10**: 1087800.

990. Zhou X, Huang X, Sun T, et al. Chronological changes of viral shedding in adult inpatients with Omicron infection in Shanghai, China. *Front Immunol* 2023; **14**: 1090498.

991. Zhou Y, Chen Z, He Y, et al. Humoral immune responses to inactivated COVID-19 vaccine up to 1 year in children with chronic hepatitis B infection. *Front Cell Infect Microbiol* 2023; **13**: 1201101.

992. Zhu R, Canena D, Sikora M, et al. Force-tuned avidity of spike variant-ACE2 interactions viewed on the single-molecule level. *Nat Commun* 2022; **13**(1): 7926.

993. Zhu Y, Yang X, Xun J, et al. Neutralization of five SARS-CoV-2 variants of concern by convalescent and BBIBP-CorV vaccinee serum. *Virol Sin* 2022; **37**(6): 831-41.

994. Zupin L, Moltrasio C, Tricarico PM, et al. Paraviral cutaneous manifestations associated to SARS-CoV-2 Omicron variant. *Infect Dis (Lond)* 2023; **55**(3): 181-8.

995. The health impact of long COVID during the 2021-2022 Omicron wave in Australia: a quantitative burden of disease study. *Int J Epidemiol* 2023; **52**(3): 967.

996. Abdel-Aty Y, Sulica L. Increased Incidence of Ulcerative Laryngitis During Spring 2022 Omicron-Variant Wave of COVID19. *J Voice* 2023.

997. Abu Shqara R, Frank Wolf M, Mikhail Mustafa S, et al. Maternal and Cord Anti-SARS-CoV-2-Spike IgG following COVID-19 Vaccination versus Infection during Pregnancy: A Prospective Study, Israel October 2021-March 2022. *Am J Perinatol* 2023.

998. Acuti Martellucci C, Flacco ME, Soldato G, et al. Effectiveness of COVID-19 Vaccines in the General Population of an Italian Region before and during the Omicron Wave. *Vaccines (Basel)* 2022; **10**(5).

999. Adiguzel Y, Shoenfeld Y. Shared 6mer Peptides of Human and Omicron (21K and 21L) at SARS-CoV-2 Mutation Sites. *Antibodies (Basel)* 2022; **11**(4).

1000. Aganovic A, Cao G, Kurnitski J, Wargocki P. New dose-response model and SARS-CoV-2 quanta emission rates for calculating the long-range airborne infection risk. *Build Environ* 2023; **228**: 109924.

1001. Ahmed El-Arabey A, Abdalla M, Rashad Abd-Allah A, Marenga HS, Modafer Y, Aloufi AS. Molecular dynamic and bioinformatic studies of metformin-induced ACE2 phosphorylation in the presence of different SARS-CoV-2 S protein mutations. *Saudi J Biol Sci* 2023; **30**(7): 103699.

1002. Ahmed MIM, Plank M, Castelletti N, et al. Impact of Omicron Variant Infection on Assessment of Spike-Specific Immune Responses Using the EUROIMMUN Quan-T-Cell SARS-CoV-2 Assay and Roche Elecsys Anti-SARS-CoV-2-S. *Diagnostics (Basel)* 2023; **13**(6).

1003. Ahn JY, Ko JH, Peck KR, et al. Immune Response Kinetics Following a Third Heterologous BNT162b2 Booster Dose After Primary 2-Dose ChAdOx1 Vaccination in Relation to Omicron Breakthrough Infection: A Prospective Nationwide Cohort Study in South Korea. *Open Forum Infect Dis* 2023; **10**(7): ofad363.

1004. Ai H, Wang Q, Liu W. A mathematical prediction model of infectious diseases considering vaccine and temperature, and its prediction in Hong Kong. *Heliyon* 2022; **8**(12): e12469.

1005. Ai L, Li Y, Zhou L, et al. Lyophilized mRNA-lipid nanoparticle vaccines with long-term stability and high antigenicity against SARS-CoV-2. *Cell Discov* 2023; **9**(1): 9.

1006. Ait Mahiout L, Bessonov N, Kazmierczak B, Volpert V. Mathematical modeling of respiratory viral infection and applications to SARS-CoV-2 progression. *Math Methods Appl Sci* 2022.

1007. Akavian I, Nitzan I, Talmy T, Nitecki M, Gendler S, Besor O. SARS-CoV-2 Omicron Variant: Clinical Presentation and Occupational Implications in Young and Healthy IDF Soldiers. *Mil Med* 2022.

1008. Al Janabi T, Pino M. To Boost or Not to Boost: Acceptability of a COVID-19 Booster Dose among Osteopathic Medical Students: A Cross-Sectional Study from a Medical School in New York. *Epidemiologia (Basel)* 2022; **3**(2): 218-28.

1009. Alam SS, Masukujjaman M, Al-Shaikh ME, Ali MH, Makhbul ZKM, Othman AS. Desire to stay shorter time at the shopping mall: insight from protection motivation (PMT), behavioral inhibition system (BIS), reactance, and expectancy theories. *Curr Psychol* 2022: 1-20.

1010. Albani VVL, Albani RAS, Massad E, Zubelli JP. Nowcasting and forecasting COVID-19 waves: the recursive and stochastic nature of transmission. *R Soc Open Sci* 2022; **9**(8): 220489.

1011. Albuainain A, Alkharashi M. Preoperative universal screening of coronavirus disease 2019 during Omicron outbreak in patients undergoing ophthalmic surgeries: Experience from a tertiary eye care center in Saudi Arabia. *Saudi J Ophthalmol* 2023; **37**(2): 131-6.

1012. Aleem A, Akbar Samad AB, Vaqar S. Emerging Variants of SARS-CoV-2 and Novel Therapeutics Against Coronavirus (COVID-19). StatPearls. Treasure Island (FL): StatPearls Publishing

Copyright © 2023, StatPearls Publishing LLC.; 2023.

1013. Alejo JL, Kim JD, Chiang TPY, et al. Patient-reported outcomes after Tixagevimab and Cilgavimab pre-exposure prophylaxis among solid organ transplant recipients: Safety, effectiveness, and perceptions of risk. *Clin Transplant* 2023; **37**(4): e14913.

1014. Ali E, Hatim A, Yassin M. SARS-CoV-2 omicron variant may present with severe sickle cell painful crisis: A report of two cases. *Clin Case Rep* 2022; **10**(6): e05934.

1015. Alkhatib M, Bellocchi MC, Marchegiani G, et al. First Case of a COVID-19 Patient Infected by Delta AY.4 with a Rare Deletion Leading to a N Gene Target Failure by a Specific Real Time PCR Assay: Novel Omicron VOC Might Be Doing Similar Scenario? *Microorganisms* 2022; **10**(2).

1016. Almalki SSR, Izhari MA, Alyahyawi HE, et al. Mutational Analysis of Circulating Omicron SARS-CoV-2 Lineages in the Al-Baha Region of Saudi Arabia. *J Multidiscip Healthc* 2023; **16**: 2117-36.

1017. Amanatidou E, Gkiouliava A, Pella E, et al. Breakthrough infections after COVID-19 vaccination: Insights, perspectives and challenges. *Metabol Open* 2022; **14**: 100180.

1018. Anibal JT, Landa AJ, Nguyen HT, et al. Digital Omicron detection using unscripted voice samples from social media. *medRxiv* 2022.

1019. Anichini G, Terrosi C, Gandolfo C, et al. Omicron Infection Evokes Cross-Protection against SARS-CoV-2 Variants in Vaccinees. *Vaccines (Basel)* 2022; **10**(5).

1021. Aoki A, Adachi H, Mori Y, et al. Rapid Identification of SARS-CoV-2 Omicron BA.5 Spike Mutation F486V in Clinical Specimens Using a High-Resolution Melting-Based Assay. *Viruses* 2022; **14**(11).

1022. Are EB, Song Y, Stockdale JE, Tupper P, Colijn C. COVID-19 endgame: From pandemic to endemic? Vaccination, reopening and evolution in low- and high-vaccinated populations. *J Theor Biol* 2023; **559**: 111368.

1023. Ariagno S, Ragoonanan D, Khazal S, et al. Prior COVID-19 infection may increase risk for developing endothelial dysfunction following hematopoietic cell transplantation. *Front Oncol* 2022; **12**: 1000215.

1024. Arshad M, Saeed M, Rahman AU, et al. The Assessment of Medication Effects in Omicron Patients through MADM Approach Based on Distance Measures of Interval-Valued Fuzzy Hypersoft Set. *Bioengineering (Basel)* 2022; **9**(11).

1025. Assawakosri S, Kanokudom S, Suntronwong N, et al. Neutralizing Activities Against the Omicron Variant After a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination. *J Infect Dis* 2022; **226**(8): 1372-81.

1026. Atanasov V, Barreto N, Whittle J, et al. Understanding COVID-19 Vaccine Effectiveness against Death Using a Novel Measure: COVID Excess Mortality Percentage. *Vaccines (Basel)* 2023; **11**(2).

1027. Atanasov V, Barreto N, Whittle J, et al. Selection Effects and COVID-19 Mortality Risk after Pfizer vs. Moderna Vaccination: Evidence from Linked Mortality and Vaccination Records. *Vaccines (Basel)* 2023; **11**(5).

1028. Avigan ZM, Paredes R, Boussi LS, et al. Updated COVID-19 clearance time among patients with cancer in the Delta and Omicron waves. *Cancer Med* 2023; **12**(16): 16869-75.

1029. Baek YJ, Lee YJ, Park SR, et al. Immunogenicity and Safety of Vaccines against Coronavirus Disease in Actively Treated Patients with Solid Tumors: A Prospective Cohort Study. *Cancer Res Treat* 2023; **55**(3): 746-57.

1030. Bahl A, Mielke N, Johnson S, Desai A, Qu L. Severe COVID-19 outcomes in pediatrics: An observational cohort analysis comparing Alpha, Delta, and Omicron variants. *Lancet Reg Health Am* 2023; **18**: 100405.

1031. Bai Y, Xu M, Liu C, et al. Travel-related Importation and Exportation Risks of SARS-CoV-2 Omicron Variant in 367 Prefectures (Cities) - China, 2022. *China CDC Wkly* 2022; **4**(40): 885-9.

1032. Bajema KL, Berry K, Streja E, et al. Effectiveness of COVID-19 treatment with nirmatrelvir-ritonavir or molnupiravir among U.S. Veterans: target trial emulation studies with one-month and six-month outcomes. *medRxiv* 2022.

1033. Banerjee I, Robinson J, Banerjee I, Sathian B. Omicron: The pandemic propagator and lockdown instigator - what can be learnt from South Africa and such discoveries in future. *Nepal J Epidemiol* 2021; **11**(4): 1126-9.

1034. Bao S, Lu G, Kang Y, et al. A diagnostic model for serious COVID-19 infection among older adults in Shanghai during the Omicron wave. *Front Med (Lausanne)* 2022; **9**: 1018516.

1035. Barozi V, Edkins AL, Tastan Bishop Ö. Evolutionary progression of collective mutations in Omicron sub-lineages towards efficient RBD-hACE2: Allosteric communications between and within viral and human proteins. *Comput Struct Biotechnol J* 2022; **20**: 4562-78.

1036. Bartoletti M, Azap O, Barac A, et al. European society of clinical microbiology and infectious diseases guidelines for coronavirus disease 2019: an update on treatment of patients with mild/moderate disease. *Clin Microbiol Infect* 2022; **28**(12): 1578-90.

1037. Bartsch YC, St Denis KJ, Kaplonek P, et al. Comprehensive antibody profiling of mRNA vaccination in children. *bioRxiv* 2022.

1038. Bates TA, Leier HC, McBride SK, et al. The time between vaccination and infection impacts immunity against SARS-CoV-2 variants. *medRxiv* 2023.

1039. Bates TA, Lu P, Kang YJ, et al. BNT162b2-induced neutralizing and non-neutralizing antibody functions against SARS-CoV-2 diminish with age. *Cell Rep* 2022; **41**(4): 111544.

1040. Batista-Roche JL, Gómez-Gil B, Lund G, Berlanga-Robles CA, García-Gasca A. Global m6A RNA Methylation in SARS-CoV-2 Positive Nasopharyngeal Samples in a Mexican Population: A First Approximation Study. *Epigenomes* 2022; **6**(3).

1041. Bayani F, Safaei Hashkavaei N, Karamian MR, Uskoković V, Sefidbakht Y. In silico design of a multi-epitope vaccine against the spike and the nucleocapsid proteins of the Omicron variant of SARS-CoV-2. *J Biomol Struct Dyn* 2023: 1-15.

1042. Bayani F, Safaei Hashkavaei N, Uversky VN, Mozaffari-Jovin S, Sefidbakht Y. Insights into the structural peculiarities of the N-terminal and receptor binding domains of the spike protein from the SARS-CoV-2 Omicron variant. *Comput Biol Med* 2022; **147**: 105735.

1043. Beavis AC, Li Z, Briggs K, et al. Efficacy of Parainfluenza Virus 5 (PIV5)-vectored Intranasal COVID-19 Vaccine as a Single Dose Vaccine and as a Booster against SARS-CoV-2 Variants. *bioRxiv* 2022.

1044. Belasen AR, Belasen AT, Bass M. Tracking the Uneven Outcomes of COVID-19 on Racial and Ethnic Groups: Implications for Health Policy. *J Racial Ethn Health Disparities* 2023.

1045. Belik M, Jalkanen P, Lundberg R, et al. Comparative analysis of COVID-19 vaccine responses and third booster dose-induced neutralizing antibodies against Delta and Omicron variants. *Nat Commun* 2022; **13**(1): 2476.

1047. Berry C, Pavot V, Anosova NG, et al. Beta-containing bivalent SARS-CoV-2 protein vaccine elicits durable broad neutralization in macaques and protection in hamsters. *Commun Med (Lond)* 2023; **3**(1): 75.

1048. Bestvina CM, Whisenant JG, Torri V, et al. Coronavirus Disease 2019 Outcomes, Patient Vaccination Status, and Cancer-Related Delays During the Omicron Wave: A Brief Report From the TERAVOLT Analysis. *JTO Clin Res Rep* 2022; **3**(8): 100335.

1049. Bhowmik R, Pardasani M, Mahajan S, et al. Persistent olfactory learning deficits during and post-COVID-19 infection. *Curr Res Neurobiol* 2023; **4**: 100081.

1050. Bi X, Zhang Y, Pan J, et al. Differences Between Omicron Infections and Fever Outpatients: Comparison of Clinical Manifestations and Initial Routine Hematology Indicators. *Infect Drug Resist* 2022; **15**: 5111-20.

1051. Bieber A, Brikman S, Novack L, et al. Fourth Dose of BNT162b2 Vaccine for Patients with Autoimmune Rheumatic Diseases in a Nationwide Setting. *Rheumatology (Oxford)* 2023.

1052. Bignon E, Marazzi M, Grandemange S, Monari A. Autophagy and evasion of the immune system by SARS-CoV-2. Structural features of the non-structural protein 6 from wild type and Omicron viral strains interacting with a model lipid bilayer. *Chem Sci* 2022; **13**(20): 6098-105.

1053. Binayke A, Zaheer A, Dandotiya J, et al. Proinflammatory Innate Cytokines and Distinct Metabolomic Signatures Shape the T Cell Response in Active COVID-19. *Vaccines (Basel)* 2022; **10**(10).

1054. Bingham J, Tempia S, Moultrie H, et al. Estimating the time-varying reproduction number for COVID-19 in South Africa during the first four waves using multiple measures of incidence for public and private sectors across four waves. *medRxiv* 2022.

1056. Bloom JD, Beichman AC, Neher RA, Harris K. Evolution of the SARS-CoV-2 mutational spectrum. *bioRxiv* 2022.

1057. Boehm AB, Hughes B, Duong D, et al. Wastewater concentrations of human influenza, metapneumovirus, parainfluenza, respiratory syncytial virus, rhinovirus, and seasonal coronavirus nucleic-acids during the COVID-19 pandemic: a surveillance study. *Lancet Microbe* 2023; **4**(5): e340-e8.

1058. Boehm AB, Hughes B, Wolfe MK, White BJ, Duong D, Chan-Herur V. Regional Replacement of SARS-CoV-2 Variant Omicron BA.1 with BA.2 as Observed through Wastewater Surveillance. *Environ Sci Technol Lett* 2022; **9**(6): 575-80.

1059. Boler M, Anderson M, Rodgers M, et al. Detection of SARS-CoV-2 antibodies after confirmed Omicron BA.1 and presumed BA.4/5 infections using Abbott ARCHITECT and Panbio assays. *IJID Reg* 2023; **7**: 277-80.

1060. Boucau J, Marino C, Regan J, et al. Duration of viable virus shedding in SARS-CoV-2 omicron variant infection. *medRxiv* 2022.

1061. Bouton TC, Atarere J, Turcinovic J, et al. Viral dynamics of Omicron and Delta SARS-CoV-2 variants with implications for timing of release from isolation: a longitudinal cohort study. *medRxiv* 2022.

1062. Božič A, Podgornik R. Evolutionary changes in the number of dissociable amino acids on spike proteins and nucleoproteins of SARS-CoV-2 variants. *Virus Evol* 2023; **9**(2): vead040.

1063. Branche A, Rouphael N, Diemert D, et al. Bivalent and Monovalent SARS-CoV-2 Variant Vaccine Boosters Improve coverage of the known Antigenic Landscape: Results of the COVID-19 Variant Immunologic Landscape (COVAIL) Trial. *Res Sq* 2023.

1064. Branche AR, Rouphael NG, Diemert DJ, et al. SARS-CoV-2 Variant Vaccine Boosters Trial: Preliminary Analyses. *medRxiv* 2022.

1065. Brasu N, Elia I, Russo V, et al. Memory CD8(+) T cell diversity and B cell responses correlate with protection against SARS-CoV-2 following mRNA vaccination. *Nat Immunol* 2022; **23**(10): 1445-56.

1066. Briggs J, Takahashi S, Nayebare P, et al. Reconstructing the SARS-CoV-2 epidemic in eastern Uganda through longitudinal serosurveillance in a malaria cohort. *medRxiv* 2022.

1067. Brogna B, Capasso C, Fontanella G, Bignardi E. A severe presentation of breakthrough infection caused by the Omicron variant with radiological findings of COVID-19 pneumonia in an elderly woman. *Radiol Case Rep* 2022; **17**(9): 3326-30.

1068. Bronstein Y, Avivi I, Cohen YC, Feigin E, Perry C, Herishanu Y. REGEN-COV antibody combination in patients with lymphoproliferative malignancies and SARS-CoV-2 infection. *EJHaem* 2022; **3**(2): 471-4.

1069. Brooks J, Montgomery A, Dalbeth N, et al. Omicron variant infection in inflammatory rheumatological conditions - outcomes from a COVID-19 naive population in Aotearoa New Zealand. *Lancet Reg Health West Pac* 2023; **38**: 100843.

1071. Buonsenso A, Murri A, Centorbi M, et al. Psychological Wellbeing and Perceived Fatigue in Competitive Athletes after SARS-CoV-2 Infection 2 Years after Pandemic Start: Practical Indications. *J Funct Morphol Kinesiol* 2022; **8**(1).

1072. Buonsenso D, Pazukhina E, Gentili C, et al. The Prevalence, Characteristics and Risk Factors of Persistent Symptoms in Non-Hospitalized and Hospitalized Children with SARS-CoV-2 Infection Followed-Up for up to 12 Months: A Prospective, Cohort Study in Rome, Italy. *J Clin Med* 2022; **11**(22).

1073. Burns JC. MIS-C: myths have been debunked, but mysteries remain. *Nat Rev Rheumatol* 2023; **19**(2): 70-1.

1074. Burns MD, Boribong BP, Bartsch YC, et al. Durability and cross-reactivity of SARS-CoV-2 mRNA vaccine in adolescent children. *medRxiv* 2022.

1075. Burns MD, Boribong BP, Bartsch YC, et al. Durability and Cross-Reactivity of SARS-CoV-2 mRNA Vaccine in Adolescent Children. *Vaccines (Basel)* 2022; **10**(4).

1076. Byazrova M, Gattinger P, Astakhova E, et al. Dissection of Antibody Responses of Gam-COVID-Vac-Vaccinated Subjects Suggests Involvement of Epitopes Outside RBD in SARS-CoV-2 Neutralization. *Int J Mol Sci* 2023; **24**(6).

1077. Cai J, Deng X, Yang J, et al. Modeling transmission of SARS-CoV-2 Omicron in China. *Nat Med* 2022; **28**(7): 1468-75.

1078. Campos GRF, Almeida NBF, Filgueiras PS, et al. Booster dose of BNT162b2 after two doses of CoronaVac improves neutralization of SARS-CoV-2 Omicron variant. *Commun Med (Lond)* 2022; **2**: 76.

1079. Campos GRF, Almeida NBF, Filgueiras PS, et al. Booster dose of BNT162b2 in a CoronaVac primary vaccination protocol improves neutralization of SARS-CoV-2 Omicron variant. *medRxiv* 2022.

1080. Cao R, Lai J, Fu X, Qiu P, Chen J, Liu W. Association between psychological stress, anxiety and oral health status among college students during the Omicron wave: a cross-sectional study. *BMC Oral Health* 2023; **23**(1): 470.

1081. Cao X, Li Y, Zi Y, Zhu Y. The shift of percent excess mortality from zero-COVID policy to living-with-COVID policy in Singapore, South Korea, Australia, New Zealand and Hong Kong SAR. *Front Public Health* 2023; **11**: 1085451.

1082. Cao Z, Gao W, Bao H, et al. VV116 versus Nirmatrelvir-Ritonavir for Oral Treatment of Covid-19. *N Engl J Med* 2023; **388**(5): 406-17.

1083. Caputo V, Calvino G, Strafella C, et al. Tracking the Initial Diffusion of SARS-CoV-2 Omicron Variant in Italy by RT-PCR and Comparison with Alpha and Delta Variants Spreading. *Diagnostics (Basel)* 2022; **12**(2).

1084. Castro GM, Sicilia P, Bolzon ML, et al. Tracking SARS-CoV-2 Variants Using a Rapid Typification Strategy: A Key Tool for Early Detection and Spread Investigation of Omicron in Argentina. *Front Med (Lausanne)* 2022; **9**: 851861.

1085. Cautilli F, Feleppa M, Valeriani M, et al. Case report: A case of acute disseminated encephalomyelitis after SARS-CoV-2 infection in pediatric patients. *Front Neurol* 2023; **14**: 1099458.

1086. Cavalcante TF, Barboza WS, Martins-Filho PR. The vaccination status of COVID-19 hospitalized patients during the Omicron BQ.1.1 wave in Northeast Brazil suggests the need for a fifth booster dose in the elderly, with a time since the last dose of more than 6 months. *Excli j* 2023; **22**: 169-72.

1087. Cegolon L, Mastrangelo G, Emanuelli E, Camerotto R, Spinato G, Frezza D. Early Negativization of SARS-CoV-2 Infection by Nasal Spray of Seawater plus Additives: The RENAISSANCE Open-Label Controlled Clinical Trial. *Pharmaceutics* 2022; **14**(11).

1088. Cegolon L, Pol R, Simonetti O, Larese Filon F, Luzzati R. Molnupiravir, Nirmatrelvir/Ritonavir, or Sotrovimab for High-Risk COVID-19 Patients Infected by the Omicron Variant: Hospitalization, Mortality, and Time until Negative Swab Test in Real Life. *Pharmaceuticals (Basel)* 2023; **16**(5).

1089. Chadeau-Hyam M, Tang D, Eales O, et al. Omicron SARS-CoV-2 epidemic in England during February 2022: A series of cross-sectional community surveys. *Lancet Reg Health Eur* 2022; **21**: 100462.

1090. Chadwick VL, Saich F, Freeman J, Martiniuk A. Media discourse regarding COVID-19 vaccinations for children aged 5 to 11 in Australia, Canada, the United Kingdom and the United States of America: a comparative analysis using the Narrative Policy Framework. *JMIR Form Res* 2022.

1091. Chanda D, Hines JZ, Itoh M, et al. COVID-19 Vaccine Effectiveness Against Progression to In-Hospital Mortality in Zambia, 2021-2022. *Open Forum Infect Dis* 2022; **9**(9): ofac469.

1092. Chandrasingh S, George CE, Inbaraj LR, Maddipati T. Antibody titres in fully vaccinated healthcare workers with and without breakthrough infection during the Delta and Omicron waves. *J Family Med Prim Care* 2023; **12**(7): 1298-302.

1093. Chang A, Akhtar A, Linderman SL, et al. Humoral Responses Against SARS-CoV-2 and Variants of Concern After mRNA Vaccines in Patients With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia. *J Clin Oncol* 2022; **40**(26): 3020-31.

1094. Chang SL, Nguyen QD, Martiniuk A, Sintchenko V, Sorrell TC, Prokopenko M. Persistence of the Omicron variant of SARS-CoV-2 in Australia: The impact of fluctuating social distancing. *PLOS Glob Public Health* 2023; **3**(4): e0001427.

1095. Charvet B, Brunel J, Pierquin J, et al. SARS-CoV-2 awakens ancient retroviral genes and the expression of proinflammatory HERV-W envelope protein in COVID-19 patients. *iScience* 2023; **26**(5): 106604.

1096. Chatzilena A, Hyams C, Challen R, et al. Effectiveness of BNT162b2 COVID-19 vaccination in prevention of hospitalisations and severe disease in adults with SARS-CoV-2 Delta (B.1.617.2) and Omicron (B.1.1.529) variant between June 2021 and July 2022: A prospective test negative case-control study. *Lancet Reg Health Eur* 2023; **25**: 100552.

1097. Cheah FC, Thong MK, Zulkifli I, et al. COVID-19 vaccination for children in Malaysia - A position statement by the College of Paediatrics, Academy of Medicine of Malaysia. *Malays J Pathol* 2022; **44**(2): 177-85.

1098. Chen B, Yu X, Zhang L, et al. Clinical efficacy of Jingyin granules, a Chinese patent medicine, in treating patients infected with coronavirus disease 2019. *Phytomedicine* 2023; **108**: 154496.

1099. Chen C, Li P, Chen J, et al. Plasma 25(OH)D Level is Associated with the Nucleic Acid Negative Conversion Time of COVID-19 Patients: An Exploratory Study. *Infect Drug Resist* 2023; **16**: 937-47.

1100. Chen C, Xing Z, Xi Y, Tiong R. Ensuring sufficient cabin hospital beds for curbing the spread of COVID-19 - Findings from petri net analysis. *Heliyon* 2022; **8**(10): e11202.

1101. Chen CY, Zhang W, Xu XR, et al. Efficacy and Safety of Huashi Baidu Granules in Treating Patients with SARS-CoV-2 Omicron Variant: A Single-Center Retrospective Cohort Study. *Chin J Integr Med* 2023: 1-8.

1102. Chen J, Qiu Y, Shi Y, et al. Uncovering the Impact of Control Strategies on the Transmission Pattern of SARS-CoV-2 - Ruili City, Yunnan Province, China, February-March 2022. *China CDC Wkly* 2022; **4**(46): 1032-8.

1103. Chen J, Tang Q, Zhang B, et al. Huashi baidu granule in the treatment of pediatric patients with mild coronavirus disease 2019: A single-center, open-label, parallel-group randomized controlled clinical trial. *Front Pharmacol* 2023; **14**: 1092748.

1104. Chen K, Fan N, Huang H, et al. mRNA Vaccines Against SARS-CoV-2 Variants Delivered by Lipid Nanoparticles Based on Novel Ionizable Lipids. *Adv Funct Mater* 2022; **32**(39): 2204692.

1105. Chen L, Qi X, Liang D, et al. Human Fc-Conjugated Receptor Binding Domain-Based Recombinant Subunit Vaccines with Short Linker Induce Potent Neutralizing Antibodies against Multiple SARS-CoV-2 Variants. *Vaccines (Basel)* 2022; **10**(9).

1106. Chen MZ, Tay YK, Teoh WM, et al. Melbourne colorectal collaboration: a multicentre review of the impact of COVID-19 on colorectal cancer in Melbourne, Australia. *ANZ J Surg* 2022; **92**(5): 1110-6.

1107. Chen SL, Jen GH, Hsu CY, et al. A new approach to modeling pre-symptomatic incidence and transmission time of imported COVID-19 cases evolving with SARS-CoV-2 variants. *Stoch Environ Res Risk Assess* 2023; **37**(1): 441-52.

1108. Chen X, Hong J, Deng L, et al. Association between levels of IgG antibodies from vaccines and Omicron symptomatic infection among children and adolescents in China. *Front Med (Lausanne)* 2023; **10**: 1240340.

1109. Chen Y, Feng L, Han Y, et al. Performance evaluation of SARS-CoV-2 antigen detection in the post-pandemic era: multi-laboratory assessment. *Clin Chem Lab Med* 2023.

1110. Chen Y, Mason GH, Scourfield DO, et al. Structural definition of HLA class II-presented SARS-CoV-2 epitopes reveals a mechanism to escape pre-existing CD4(+) T cell immunity. *Cell Rep* 2023; **42**(8): 112827.

1111. Chen Y, Song H, Liu S. Evaluations of COVID-19 epidemic models with multiple susceptible compartments using exponential and non-exponential distribution for disease stages. *Infect Dis Model* 2022; **7**(4): 795-810.

1112. Chen YC, Wang X, Teng YS, Jia DS, Li L, Pan HG. Otolaryngology-related symptoms of COVID-19 in children in the post-epidemic era: a cross-sectional web-based survey study. *Front Pediatr* 2023; **11**: 1190734.

1113. Chen Z, Li J, Li T, et al. A CRISPR/Cas12a-empowered surface plasmon resonance platform for rapid and specific diagnosis of the Omicron variant of SARS-CoV-2. *Natl Sci Rev* 2022; **9**(8): nwac104.

1114. Cheng A, Ren H, Ma Z, Alam N, Jia L, Liu E. Trends and characteristics of COVID-19 and cardiovascular disease related studies. *Front Pharmacol* 2023; **14**: 1105459.

1115. Cheng CC, Platen L, Christa C, et al. Improved SARS-CoV-2 Neutralization of Delta and Omicron BA.1 Variants of Concern after Fourth Vaccination in Hemodialysis Patients. *Vaccines (Basel)* 2022; **10**(8).

1116. Cheng M, Qian C, Zhou H, et al. The Use of SARS-CoV-2-Positive Donors in Hematopoietic Stem Cell Transplantation. *Transplant Proc* 2023.

1117. Cherkaoui D, Heaney J, Huang D, et al. Clinical Validation of a Rapid Variant-Proof RT-RPA Assay for the Detection of SARS-CoV-2. *Diagnostics (Basel)* 2022; **12**(5).

1118. Chinnadurai R, Wu HHL, Cox E, et al. Humoral Response in Hemodialysis Patients Following COVID-19 Vaccination and Breakthrough Infections during Delta and Omicron Variant Predominance. *Vaccines (Basel)* 2022; **10**(4).

1119. Chiu MC, Li C, Liu X, et al. A bipotential organoid model of respiratory epithelium recapitulates high infectivity of SARS-CoV-2 Omicron variant. *Cell Discov* 2022; **8**(1): 57.

1120. Chiuppesi F, Zaia JA, Faircloth K, et al. Vaccine-induced spike- and nucleocapsid-specific cellular responses maintain potent cross-reactivity to SARS-CoV-2 Delta and Omicron variants. *iScience* 2022; **25**(8): 104745.

1121. Chivu-Economescu M, Vremera T, Ruta SM, et al. Assessment of the Humoral Immune Response Following COVID-19 Vaccination in Healthcare Workers: A One Year Longitudinal Study. *Biomedicines* 2022; **10**(7).

1122. Christensen PA, Olsen RJ, Long SW, et al. Signals of Significantly Increased Vaccine Breakthrough, Decreased Hospitalization Rates, and Less Severe Disease in Patients with Coronavirus Disease 2019 Caused by the Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2 in Houston, Texas. *Am J Pathol* 2022; **192**(4): 642-52.

1123. Chrysostomou AC, Aristokleous A, Rodosthenous JH, Christodoulou C, Stathi G, Kostrikis LG. Detection of Circulating SARS-CoV-2 Variants of Concern (VOCs) Using a Multiallelic Spectral Genotyping Assay. *Life (Basel)* 2023; **13**(2).

1124. Chung H, Austin PC, Brown KA, et al. Effectiveness of COVID-19 Vaccines Over Time Prior to Omicron Emergence in Ontario, Canada: Test-Negative Design Study. *Open Forum Infect Dis* 2022; **9**(9): ofac449.

1125. Cicaloni V, Costanti F, Pasqui A, Bianchini M, Niccolai N, Bongini P. A Bioinformatics Approach to Investigate Structural and Non-Structural Proteins in Human Coronaviruses. *Front Genet* 2022; **13**: 891418.

1126. Ciesla AA, Wiegand RE, Smith ZR, et al. Effectiveness of Booster Doses of Monovalent mRNA COVID-19 Vaccine Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Children, Adolescents, and Adults During Omicron Subvariant BA.2/BA.2.12.1 and BA.4/BA.5 Predominant Periods. *Open Forum Infect Dis* 2023; **10**(5): ofad187.

1127. Cluff E, Bellusci L, Golding H, Khurana S. Immune Response to SARS-CoV-2 Vaccine and Following Breakthrough Omicron Infection in an Autoimmune Patient with Hashimoto's Thyroiditis, Pernicious Anemia, and Chronic Atrophic Autoimmune Gastritis: A Case Report. *Vaccines (Basel)* 2022; **10**(3).

1128. Cocchio S, Zabeo F, Tremolada G, et al. COVID-19 Vaccine Effectiveness against Omicron Variant among Underage Subjects: The Veneto Region's Experience. *Vaccines (Basel)* 2022; **10**(8).

1129. Cohen JA, Stuart RM, Panovska-Griffiths J, et al. The changing health impact of vaccines in the COVID-19 pandemic: A modeling study. *Cell Rep* 2023; **42**(4): 112308.

1130. Cornette M, Decaesteker B, Martens GA, Vandecandelaere P, Jonckheere S. From Delta to Omicron SARS-CoV-2 variant: Switch to saliva sampling for higher detection rate. *J Clin Virol Plus* 2022; **2**(3): 100090.

1131. Corominas J, Garriga C, Prenafeta A, et al. Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial. *Lancet Reg Health Eur* 2023; **28**: 100613.

1132. Cutrupi F, Cadonna M, Manara S, et al. The wave of the SARS-CoV-2 Omicron variant resulted in a rapid spike and decline as highlighted by municipal wastewater surveillance. *Environ Technol Innov* 2022; **28**: 102667.

1133. Dahu BM, Khan S, Li WS, et al. Demographic and Time Trend Analysis of COVID-19 Test Results of Boone County, Missouri. *AMIA Jt Summits Transl Sci Proc* 2023; **2023**: 91-100.

1134. Dai EY, Lee KA, Nathanson AB, et al. Viral Kinetics of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Omicron Infection in mRNA-Vaccinated Individuals Treated and Not Treated with Nirmatrelvir-Ritonavir. *medRxiv* 2022.

1135. Dai H, Zhao B. Association between the infection probability of COVID-19 and ventilation rates: An update for SARS-CoV-2 variants. *Build Simul* 2023; **16**(1): 3-12.

1136. Damman E, Trecourt A, de la Fournière B, et al. Predictive factors for severe placental damage in pregnant women with SARS-CoV-2 infection. *Placenta* 2023; **136**: 1-7.

1137. Das B, Kutsal M, Das R. A geometric deep learning model for display and prediction of potential drug-virus interactions against SARS-CoV-2. *Chemometr Intell Lab Syst* 2022; **229**: 104640.

1138. Dayan GH, Rouphael N, Walsh SR, et al. Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 Protein Vaccine. *medRxiv* 2023.

1139. de Bruyn G, Wang J, Purvis A, et al. Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3, parallel-group study. *EClinicalMedicine* 2023; **62**: 102109.

1140. De Luca R, Pollicino P, Rifici C, et al. Psycho-Emotional Well-Being in Caregivers of People with Acquired Brain Injury: An Exploratory Study on the Human Immersion Model during the Omicron Wave. *Clin Pract* 2023; **13**(2): 487-96.

1141. de Meijere G, Valdano E, Castellano C, et al. Attitudes towards booster, testing and isolation, and their impact on COVID-19 response in winter 2022/2023 in France, Belgium, and Italy: a cross-sectional survey and modelling study. *Lancet Reg Health Eur* 2023; **28**: 100614.

1142. Debes AK, Xiao S, Egbert ER, et al. Comparison of total and neutralizing SARS-CoV-2 spike antibodies against omicron and other variants in paired samples after two or three doses of mRNA vaccine. *medRxiv* 2022.

1143. Demers J, Fagan WF, Potluri S, Calabrese JM. The relationship between controllability, optimal testing resource allocation, and incubation-latent period mismatch as revealed by COVID-19. *Infect Dis Model* 2023; **8**(2): 514-38.

1144. Dergaa I, Musa S, Romdhani M, et al. FIFA World Cup 2022: What can we learn from the inspiring Tokyo 2020 Olympic Games held in COVID-19 times? *Biol Sport* 2022; **39**(4): 1073-80.

1145. Deshpande A, Schormann N, Piepenbrink MS, Martinez Sobrido L, Kobie JJ, Walter MR. Structure and epitope of a neutralizing monoclonal antibody that targets the stem helix of β coronaviruses. *Febs j* 2023; **290**(13): 3422-35.

1146. Di Chiara C, Mengato D, De Pieri M, et al. Early Use of Sotrovimab in Children: A Case Report of an 11-Year-Old Kidney Transplant Recipient Infected with SARS-CoV-2. *Children (Basel)* 2022; **9**(4).

1147. Dighe H, Sarkale P, Patil DY, et al. Differential Cell Line Susceptibility to the SARS-CoV-2 Omicron BA.1.1 Variant of Concern. *Vaccines (Basel)* 2022; **10**(11).

1148. Doan LH, Chu LW, Huang ZY, et al. Virofree, an Herbal Medicine-Based Formula, Interrupts the Viral Infection of Delta and Omicron Variants of SARS-CoV-2. *Front Pharmacol* 2022; **13**: 905197.

1149. Dobrynin D, Polishchuk I, Portal L, Zlotver I, Sosnik A, Pokroy B. Adsorption of SARS CoV-2 spike proteins on various functionalized surfaces correlates with the high transmissibility of Delta and Omicron variants. *Mater Today Bio* 2022; **14**: 100265.

1150. Dodge MC, Ye L, Duffy ER, et al. Kinetics of SARS-CoV-2 Serum Antibodies Through the Alpha, Delta, and Omicron Surges Among Vaccinated Health Care Workers at a Boston Hospital. *Open Forum Infect Dis* 2023; **10**(7): ofad266.

1151. Dolci M, Signorini L, Cason C, et al. Circulation of SARS-CoV-2 Variants among Children from November 2020 to January 2022 in Trieste (Italy). *Microorganisms* 2022; **10**(3).

1152. Domańska-Blicharz K, Orłowska A, Smreczak M, et al. SARS-CoV-2 Monitoring on Mink Farms in Poland. *J Vet Res* 2022; **66**(4): 449-58.

1153. Dong Q, Qiao H, Jiang H, et al. Jin-Zhen oral liquid for pediatric coronavirus disease (COVID-19): A randomly controlled, open-label, and non-inferiority trial at multiple clinical centers. *Front Pharmacol* 2023; **14**: 1094089.

1154. Dong Y, Zhai W, Fang B, et al. A retrospective study of Pupingqinghua prescription versus Lianhuaqingwen in Chinese participants infected with SARS-CoV-2 Omicron variants. *Front Pharmacol* 2022; **13**: 988524.

1155. Duangchaemkarn K, Boonchieng W, Wiwatanadate P, Chouvatut V. SARIMA Model Forecasting Performance of the COVID-19 Daily Statistics in Thailand during the Omicron Variant Epidemic. *Healthcare (Basel)* 2022; **10**(7).

1157. Earnest R, Chen C, Chaguza C, Hahn AM, Grubaugh ND, Wilson MS. Daily Rapid Antigen Exit Testing to Tailor University COVID-19 Isolation Policy. *Emerg Infect Dis* 2022; **28**(12): 2455-62.

1158. Eltayb WA, Abdalla M, Rabie AM. Novel Investigational Anti-SARS-CoV-2 Agent Ensitrelvir "S-217622": A Very Promising Potential Universal Broad-Spectrum Antiviral at the Therapeutic Frontline of Coronavirus Species. *ACS Omega* 2023; **8**(6): 5234-46.

1159. Engels G, Oechsle AL, Schlegtendal A, et al. SARS-CoV-2 sero-immunity and quality of life in children and adolescents in relation to infections and vaccinations: the IMMUNEBRIDGE KIDS cross-sectional study, 2022. *Infection* 2023: 1-9.

1160. Engjom HM, Ramakrishnan R, Vousden N, et al. Severity of maternal SARS-CoV-2 infection and perinatal outcomes of women admitted to hospital during the omicron variant dominant period using UK Obstetric Surveillance System data: prospective, national cohort study. *BMJ Med* 2022; **1**(1): e000190.

1161. Entzminger KC, Fleming JK, Entzminger PD, et al. Rapid engineering of SARS-CoV-2 therapeutic antibodies to increase breadth of neutralization including BQ.1.1, CA.3.1, CH.1.1, XBB.1.16, and XBB.1.5. *Antib Ther* 2023; **6**(2): 108-18.

1162. Eom G, Yun S, Byeon H. Predicting the sentiment of South Korean Twitter users toward vaccination after the emergence of COVID-19 Omicron variant using deep learning-based natural language processing. *Front Med (Lausanne)* 2022; **9**: 948917.

1163. Erol Ç, Kuloğlu ZE, Kayaaslan B, et al. BNT162b2 or CoronaVac as the Third Dose against Omicron: Neutralizing Antibody Responses among Transplant Recipients Who Had Received Two Doses of CoronaVac. *Viruses* 2023; **15**(7).

1164. Esman A, Cherkashina A, Mironov K, et al. SARS-CoV-2 Variants Monitoring Using Real-Time PCR. *Diagnostics (Basel)* 2022; **12**(10).

1165. Evering TH, Chew KW, Giganti MJ, et al. Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19. *Ann Intern Med* 2023; **176**(5): 658-66.

1166. Fabiani M, Mateo-Urdiales A, Sacco C, et al. Protection against severe COVID-19 after second booster dose of adapted bivalent (original/Omicron BA.4-5) mRNA vaccine in persons ≥ 60 years, by time since infection, Italy, 12 September to 11 December 2022. *Euro Surveill* 2023; **28**(8).

1167. Facciuolo A, Van Kessel J, Kroeker A, et al. Longitudinal analysis of SARS-CoV-2 reinfection reveals distinct kinetics and emergence of cross-neutralizing antibodies to variants of concern. *Front Microbiol* 2023; **14**: 1148255.

1168. Fall A, Eldesouki RE, Sachithanandham J, et al. A Quick Displacement of the SARS-CoV-2 variant Delta with Omicron: Unprecedented Spike in COVID-19 Cases Associated with Fewer Admissions and Comparable Upper Respiratory Viral Loads. *medRxiv* 2022.

1169. Fang Z, Peng L, Filler R, et al. Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2. *bioRxiv* 2022.

1170. Farman M, Amin M, Akgül A, Ahmad A, Riaz MB, Ahmad S. Fractal-fractional operator for COVID-19 (Omicron) variant outbreak with analysis and modeling. *Results Phys* 2022; **39**: 105630.

1171. Fass E, Zizelski Valenci G, Rubinstein M, et al. HiSpike Method for High-Throughput Cost Effective Sequencing of the SARS-CoV-2 Spike Gene. *Front Med (Lausanne)* 2021; **8**: 798130.

1172. Favre G, Maisonneuve E, Pomar L, et al. Maternal and perinatal outcomes following pre-Delta, Delta, and Omicron SARS-CoV-2 variants infection among unvaccinated pregnant women in France and Switzerland: a prospective cohort study using the COVI-PREG registry. *Lancet Reg Health Eur* 2023; **26**: 100569.

1173. Fayngersh A, Sudyn A, Jain N, et al. Learning in the Pandemic: Medical Students' Perceived Effects of COVID-19 on Their Clinical Experiences and Career Choices During the Internal Medicine Clerkship. *Med Sci Educ* 2022; **32**(4): 907-15.

1174. Feng Y, Liu Y, Liu L, et al. Real-world effectiveness of Yindan Jiedu granules-based treatment on patients infected with the SARS-CoV-2 Omicron variants BA.2 combined with high-risk factors: A cohort study. *Front Pharmacol* 2022; **13**: 978979.

1175. Feng Y, Shao H, Gong X, et al. 'Dynamic zero-COVID' policy and viral clearance during an omicron wave in Tianjin, China: a city-wide retrospective observational study. *BMJ Open* 2022; **12**(12): e066359.

1176. Feng Y, Zhang Y, Ding X, Fan Y, Ge J. Multi-scale risk assessment and mitigations comparison for COVID-19 in urban public transport: A combined field measurement and modeling approach. *Build Environ* 2023; **242**: 110489.

1177. Feng Y, Zhao X, Chen Z, et al. Genomic Surveillance for SARS-CoV-2 Variants of Concern from Imported COVID-19 Cases - the Mainland of China, 2021. *China CDC Wkly* 2022; **4**(31): 680-4.

1178. Ferrara P, Ponticelli D, Magliuolo R, Borrelli M, Schiavone B, Mantovani LG. Time-Varying Effect of Hybrid Immunity on the Risk of Breakthrough Infection after Booster Dose of mRNA COVID-19 Vaccine: The MOSAICO Study. *Vaccines (Basel)* 2022; **10**(8).

1179. Fiedler S, Devenish SRA, Morgunov AS, et al. Serological fingerprints link antiviral activity of therapeutic antibodies to affinity and concentration. *Sci Rep* 2022; **12**(1): 19791.

1180. Fischer C, Maponga TG, Yadouleton A, et al. RETRACTED: Gradual emergence followed by exponential spread of the SARS-CoV-2 Omicron variant in Africa. *Science* 2022; **378**(6623): eadd8737.

1181. Fisher CB, Bragard E, Jaber R, Gray A. COVID-19 Vaccine Hesitancy among Parents of Children under Five Years in the United States. *Vaccines (Basel)* 2022; **10**(8).

1182. Fishman B, Goitein O, Berkovitch A, Rahav G, Matetzky S. First report of myocarditis in two patients with COVID-19 Omicron variant: case report. *Eur Heart J Case Rep* 2022; **6**(10): ytac407.

1183. Francesconi M, Giovanetti M, De Florio L, et al. Genomic Epidemiology Unveil the Omicron Transmission Dynamics in Rome, Italy. *Pathogens* 2022; **11**(9).

1184. Franch-Llasat D, Bellaubí-Pallarés N, Pérez-Moreno MO, Chamarro-Martí E, García-Rodríguez E, Roche-Campo F. Pneumococcal meningitis secondary to otitis media in two patients with COVID-19 omicron variant. *Int J Emerg Med* 2022; **15**(1): 50.

1185. Frankcombe D, Gauri N, Satchithanandha V, et al. Management of acute appendicitis during the COVID-19 pandemic: a retrospective cohort study. *BMC Surg* 2022; **22**(1): 393.

1186. Frankel AE, Capozzola T, Andrabi R, et al. The Effects of an mRNA Covid-19 Vaccine Booster on Immune Responses in Cancer-Bearing Veterans. *Med Res Arch* 2022; **10**(7).

1187. Fratty IS, Reznik-Balter S, Nemet I, et al. Outbreak of Influenza and Other Respiratory Viruses in Hospitalized Patients Alongside the SARS-CoV-2 Pandemic. *Front Microbiol* 2022; **13**: 902476.

1188. Frediani JK, Parsons R, McLendon KB, et al. The New Normal: Delayed Peak SARS-CoV-2 Viral Loads Relative to Symptom Onset and Implications for COVID-19 Testing Programs. *medRxiv* 2023.

1189. Freeman ML, Oyebanji OA, Moisi D, et al. Association of Cytomegalovirus Serostatus With Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Responsiveness in Nursing Home Residents and Healthcare Workers. *Open Forum Infect Dis* 2023; **10**(2): ofad063.

1190. Friedman C. Financial hardship experienced by people with disabilities during the COVID-19 pandemic. *Disabil Health J* 2022; **15**(4): 101359.

1191. Fu D, He G, Li H, et al. Effectiveness of COVID-19 Vaccination Against SARS-CoV-2 Omicron Variant Infection and Symptoms - China, December 2022-February 2023. *China CDC Wkly* 2023; **5**(17): 369-73.

1192. Fu N, Jiang Y, Xu Z, et al. The impact of Omicron pandemic and COVID-19 vaccination on the pancreatic adenocarcinoma patients. *Aging Cancer* 2022; **3**(3-4): 161-8.

1193. Fujibayashi K, Kajinami K. A Case of Myopericarditis After the Second Dose of mRNA COVID-19 Vaccine in a Patient With a History of Myopericarditis. *Clin Med Insights Case Rep* 2022; **15**: 11795476221138648.

1194. Fujita K, Otsuka Y, Sunada N, et al. Manifestation of Headache Affecting Quality of Life in Long COVID Patients. *J Clin Med* 2023; **12**(10).

1195. Gallen C, Dukes CW, Aldrich A, et al. Long-Term CD4(+) T-Cell and Immunoglobulin G Immune Responses in Oncology Workers following COVID-19 Vaccination: An Interim Analysis of a Prospective Cohort Study. *Vaccines (Basel)* 2022; **10**(11).

1196. Galloway S, Taunton C, Matysek R, Hempenstall A. Seeking to improve access to COVID-19 therapeutics in the remote Torres and Cape communities of Far North Queensland during the first COVID-19 omicron outbreak. *Rural Remote Health* 2022; **22**(4): 7657.

1197. García-Fernández S, Fernández-Morán E, López-Martínez C, Vivanco-Allende B, Costales-Álvarez C, Ordóñez-Álvarez FA. Tubulointerstitial nephritis and uveitis syndrome and SARS-CoV-2 infection in an adolescent: just a coincidence in time? *Pediatr Nephrol* 2023: 1-5.

1198. García-Pérez J, González-Pérez M, Castillo de la Osa M, et al. Immunogenic dynamics and SARS-CoV-2 variant neutralisation of the heterologous ChAdOx1-S/BNT162b2 vaccination: Secondary analysis of the randomised CombiVacS study. *EClinicalMedicine* 2022; **50**: 101529.

1199. Garcia-Valtanen P, Hope CM, Masavuli MG, et al. SARS-CoV-2 Omicron variant escapes neutralizing antibodies and T cell responses more efficiently than other variants in mild COVID-19 convalescents. *Cell Rep Med* 2022; **3**(6): 100651.

1200. Garnier M, Constantin JM, Cinotti R, et al. Association of preoperative COVID-19 and postoperative respiratory morbidity during the Omicron epidemic wave: the DROMIS-22 multicentre prospective observational cohort study. *EClinicalMedicine* 2023; **58**: 101881.

1201. Garzi G, Cinetto F, Firinu D, et al. Real-life data on monoclonal antibodies and antiviral drugs in Italian inborn errors of immunity patients during COVID-19 pandemic. *Front Immunol* 2022; **13**: 947174.

1202. Gáspár Z, Szabó BG, Ábrahám A, et al. Outcomes of high-risk adult outpatients treated with early remdesivir therapy during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) omicron era: experiences from the national centre of Hungary. *Naunyn Schmiedebergs Arch Pharmacol* 2023; **396**(8): 1857-62.

1203. Gelanew T, Mulu A, Abebe M, et al. A single dose ChAdOx1 nCoV-19 vaccine elicits high antibody responses in individuals with prior SARS-CoV-2 infection comparable to that of double dose vaccinated SARS-CoV-2 infection naïve individuals. *Res Sq* 2022.

1204. Geng Y, Fan Y, Deng X, et al. The Recent Outbreak of COVID-19 in China During the Omicron Variant Predominance: Clinical Features and Outcomes in Patients with Autoimmune Inflammatory Rheumatic Diseases. *Rheumatol Ther* 2023; **10**(4): 1039-53.

1205. Geng Y, Nie Q, Liu F, et al. Understanding clinical characteristics influencing adverse outcomes of Omicron infection: a retrospective study with propensity score matching from a Fangcang hospital. *Front Cell Infect Microbiol* 2023; **13**: 1115089.

1206. Gentile I, Scotto R, Schiano Moriello N, et al. Nirmatrelvir/Ritonavir and Molnupiravir in the Treatment of Mild/Moderate COVID-19: Results of a Real-Life Study. *Vaccines (Basel)* 2022; **10**(10).

1207. Georgakopoulou VE, Gkoufa A, Tsakanikas A, et al. Predictors of COVID‑19‑associated mortality among hospitalized elderly patients with dementia. *Exp Ther Med* 2023; **26**(2): 395.

1208. Ghosh AK, Landt O, Yeasmin M, et al. Clinical Presentation of COVID-19 and Antibody Responses in Bangladeshi Patients Infected with the Delta or Omicron Variants of SARS-CoV-2. *Vaccines (Basel)* 2022; **10**(11).

1209. Ghosh K, Ghosh AK. Study of COVID-19 epidemiological evolution in India with a multi-wave SIR model. *Nonlinear Dyn* 2022; **109**(1): 47-55.

1210. Giang TV, Hoa LNM, Hien TT, et al. Traditional Vietnamese Medicine Containing Garlic Extract for Patients With Non-severe COVID-19: A Phase-II, Double-Blind, Randomized Controlled Trial. *Cureus* 2023; **15**(7): e42484.

1211. Gibson GC, Woody S, James E, et al. Real time monitoring of COVID-19 intervention effectiveness through contact tracing data. *Sci Rep* 2023; **13**(1): 9371.

1212. Gilioli A, Bresciani P, Franceschini E, et al. COVID-19 omicron variant outbreak in a hematopoietic stem cell transplant unit. *Int J Hematol* 2023.

1213. Gillot C, Bayart JL, Closset M, et al. Peri-infection titers of neutralizing and binding antibodies as a predictor of COVID-19 breakthrough infections in vaccinated healthcare professionals: importance of the timing. *Clin Chem Lab Med* 2023; **61**(9): 1670-5.

1214. Girard B, Tomassini JE, Deng W, et al. mRNA-1273 Vaccine-elicited Neutralization of SARS-CoV-2 Omicron in Adolescents and Children. *medRxiv* 2022.

1215. Gjorgjievska M, Mehandziska S, Stajkovska A, et al. Case Report: Omicron BA.2 Subvariant of SARS-CoV-2 Outcompetes BA.1 in Two Co-infection Cases. *Front Genet* 2022; **13**: 892682.

1216. Goc A, Rath M, Niedzwiecki A. Composition of naturally occurring compounds decreases activity of Omicron and SARS-CoV-2 RdRp complex. *Eur J Microbiol Immunol (Bp)* 2022; **12**(2): 39-45.

1217. Goes LR, Siqueira JD, Garrido MM, et al. Evidence of recurrent selection of mutations commonly found in SARS-CoV-2 variants of concern in viruses infecting immunocompromised patients. *Front Microbiol* 2022; **13**: 946549.

1218. Gregory DA, Trujillo M, Rushford C, et al. Genetic Diversity and Evolutionary Convergence of Cryptic SARS-CoV-2 Lineages Detected Via Wastewater Sequencing. *medRxiv* 2022.

1219. Grikscheit K, Rabenau HF, Ghodratian Z, et al. Characterization of the Antibody and Interferon-Gamma Release Response after a Second COVID-19 Booster Vaccination. *Vaccines (Basel)* 2022; **10**(7).

1220. Grøsland M, Reme BA, Gjefsen HM. Impact of Omicron on sick leave across industries: A population-wide study. *Scand J Public Health* 2023; **51**(5): 759-63.

1221. Gu L, Chang J, Wang J, Feng P, Xu H. Stress load of Chinese nurses in Fangcang Shelter Hospitals during the COVID-19 pandemic: A latent profile analysis. *Front Public Health* 2022; **10**: 1048358.

1222. Gu Y, Wang Y, Liu G, et al. Effective multidimensional approach for practical management of the emergency department in a COVID-19 designated children's hospital in east China during the Omicron pandemic: a cross-sectional study. *Transl Pediatr* 2023; **12**(2): 113-24.

1223. Guo D, Duan H, Cheng Y, Wang Y, Hu J, Shi H. Omicron-included mutation-induced changes in epitopes of SARS-CoV-2 spike protein and effectiveness assessments of current antibodies. *Mol Biomed* 2022; **3**(1): 12.

1224. Guo S, Zheng Y, Gao Z, et al. Dosing interval regimen shapes potency and breadth of antibody repertoire after vaccination of SARS-CoV-2 RBD protein subunit vaccine. *Cell Discov* 2023; **9**(1): 79.

1225. Guo Y, Li T. Modeling the competitive transmission of the Omicron strain and Delta strain of COVID-19. *J Math Anal Appl* 2023; **526**(2): 127283.

1226. Guo Y, Su X, Wu K, Yong KT. Numerical Analysis of Three-dimensional Nanodisk Array-based Surface Plasmon Resonance Biosensors for SARS-CoV-2 Detection. *Plasmonics* 2023; **18**(2): 769-79.

1227. Gupta AK, Srinivasulu A, Hiran KK, Sreenivasulu G, Rajeyyagari S, Subramanyam M. Prediction of Omicron Virus Using Combined Extended Convolutional and Recurrent Neural Networks Technique on CT-Scan Images. *Interdiscip Perspect Infect Dis* 2022; **2022**: 1525615.

1228. Gupta I, Arguello Perez ES. Use of Sotrovimab in a Pregnant Patient With COVID-19 Infection. *Cureus* 2022; **14**(2): e22658.

1229. Ha KM. Targeting the Variants of COVID-19 via the Unlimited Approach. *Indian J Microbiol* 2023; **63**(1): 152-4.

1230. Ha TV, Asada T, Arimura M. Changes in mobility amid the COVID-19 pandemic in Sapporo City, Japan: An investigation through the relationship between spatiotemporal population density and urban facilities. *Transp Res Interdiscip Perspect* 2023; **17**: 100744.

1231. Hadley E, Yoo YJ, Patel S, et al. SARS-CoV-2 Reinfection is Preceded by Unique Biomarkers and Related to Initial Infection Timing and Severity: an N3C RECOVER EHR-Based Cohort Study. *medRxiv* 2023.

1232. Hakami AR. Targeting the RBD of Omicron Variant (B.1.1.529) with Medicinal Phytocompounds to Abrogate the Binding of Spike Glycoprotein with the hACE2 Using Computational Molecular Search and Simulation Approach. *Biology (Basel)* 2022; **11**(2).

1233. Hall VG, Sim BZ, Lim C, et al. COVID-19 infection among patients with cancer in Australia from 2020 to 2022: a national multicentre cohort study. *Lancet Reg Health West Pac* 2023: 100824.

1234. Hammad NM, Kadry HM, Malek MM, et al. Maintenance of Antibody Response in Egyptian Healthcare Workers Vaccinated with ChAdOx1 nCoV-19 Vaccine during Delta and Omicron Variants Pandemic: A Prospective Study. *Vaccines (Basel)* 2022; **10**(10).

1235. Hammer MM, Sodickson AD, Marshall AD, Faust JS. Prevalence of Pneumonia Among Patients Who Died with COVID-19 Infection in Ancestral Versus Omicron Variant Eras. *Acad Radiol* 2023.

1236. Han MJ, Heo JH, Hwang JS, Jang YT, Lee M, Kim SJ. Incidence of Febrile Seizures in Children with COVID-19. *J Clin Med* 2023; **12**(3).

1237. Han T, Chen L, Gu J, et al. Patients with advanced pancreatic and biliary cancer appear vulnerable to SARS-CoV-2 Omicron variant: An observational study during the COVID-19 outbreak in Shanghai. *Front Oncol* 2023; **13**: 1115293.

1238. Han X, Li X, Zhu B, et al. Effect of Lockdown and Mass Testing for the SARS-CoV-2 Omicron Epidemic on Reducing New Infections in Shenzhen, China. *Healthcare (Basel)* 2022; **10**(9).

1239. Hara M, Ohta Y, Fusazaki N, Hirota Y. Effectiveness of BNT162b2 vaccine against symptomatic SARS-CoV-2 infection in children aged 5-11 years in Japan during Omicron variant predominate periods. *J Epidemiol* 2023.

1240. Harthaller T, Falkensammer B, Bante D, et al. Retained avidity despite reduced cross-binding and cross-neutralizing antibody levels to Omicron after SARS-COV-2 wild-type infection or mRNA double vaccination. *Front Immunol* 2023; **14**: 1196988.

1241. He D, Cowling BJ, Ali ST, Stone L. Rapid global spread of variants of concern of SARS-CoV-2. *IJID Reg* 2023; **7**: 63-5.

1242. He Q, Sun S, Chen X, et al. The Bivalent COVID-19 Booster Immunization after Three Doses of Inactivated Vaccine Augments the Neutralizing Antibody Response against Circulating Omicron Sublineages. *J Clin Med* 2022; **12**(1).

1243. He Y, Yu H, Huffman A, et al. A comprehensive update on CIDO: the community-based coronavirus infectious disease ontology. *J Biomed Semantics* 2022; **13**(1): 25.

1244. He Y, Zhang F, Liu Y, et al. Clinical Characteristics of Mild Patients with Breakthrough Infection of Omicron Variant in China after Relaxing the Dynamic Zero COVID-19 Policy. *Vaccines (Basel)* 2023; **11**(5).

1245. Hentzien M, Owen A, Strub-Wourgaft N, Pérez-Casas C, Trøseid M, Calmy A. Rethinking treatment paradigms for the deployment of SARS-CoV-2 antiviral drugs on the shifting landscape of new variants. *Front Microbiol* 2022; **13**: 998287.

1246. Herman GA, O'Brien MP, Forleo-Neto E, et al. Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial. *Lancet Infect Dis* 2022; **22**(10): 1444-54.

1247. Heshin-Bekenstein M, Ziv A, Toplak N, et al. Safety and Immunogenicity Following the Second and Third Doses of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents with Juvenile-Onset Autoimmune Inflammatory Rheumatic Diseases: A Prospective Multicentre Study. *Vaccines (Basel)* 2023; **11**(4).

1248. Heudorf U, Domann E, Förner M, et al. Development of morbidity and mortality of SARS-CoV-2 in nursing homes for the elderly in Frankfurt am Main, Germany, 2020-2022: What protective measures are still required? *GMS Hyg Infect Control* 2023; **18**: Doc05.

1249. Hilal W, Chislett MG, Snider B, McBean EA, Yawney J, Gadsden SA. Use of AI to assess COVID-19 variant impacts on hospitalization, ICU, and death. *Front Artif Intell* 2022; **5**: 927203.

1250. Hill JA, Martens MJ, Young JH, et al. SARS-CoV-2 vaccination in the first year after allogeneic hematopoietic cell transplant: a prospective, multicentre, observational study. *EClinicalMedicine* 2023; **59**: 101983.

1251. Hirotsu Y, Kakizaki Y, Saito A, et al. Lung tropism in hospitalized patients following infection with SARS-CoV-2 variants from D614G to Omicron BA.2. *Commun Med (Lond)* 2023; **3**(1): 32.

1252. Hladish TJ, Pillai AN, Longini IM. Updated projections for COVID-19 omicron wave in Florida. *medRxiv* 2022.

1253. Hooper AT, Somersan-Karakaya S, McCarthy SE, et al. Casirivimab and Imdevimab Treatment Reduces Viral Load and Improves Clinical Outcomes in Seropositive Hospitalized COVID-19 Patients with Nonneutralizing or Borderline Neutralizing Antibodies. *mBio* 2022; **13**(6): e0169922.

1254. Hsu CY, Chang JC, Chen SL, et al. Primary and booster vaccination in reducing severe clinical outcomes associated with Omicron Naïve infection. *J Infect Public Health* 2023; **16**(1): 55-63.

1255. Hu R, Yang Y, Liu Y, et al. Multiplexed evaluation of immunity against SARS-CoV-2 variants using surface enhanced fluorescence from a nanostructured plasmonic chip. *J Nanobiotechnology* 2022; **20**(1): 533.

1256. Huang Q, Sun Y, Jia M, et al. Quantitative Analysis of the Effectiveness of Antigen- and Polymerase Chain Reaction-Based Combination Strategies for Containing COVID-19 Transmission in a Simulated Community. *Engineering (Beijing)* 2023.

1257. Huang SM, Wu CH, Yen TY, et al. Clinical characteristics and factors associated with severe COVID-19 in hospitalized children during the SARS-CoV-2 Omicron pandemic in Taiwan. *J Microbiol Immunol Infect* 2023.

1258. Hussein T, Hammad MH, Surakhi O, et al. Short-Term and Long-Term COVID-19 Pandemic Forecasting Revisited with the Emergence of OMICRON Variant in Jordan. *Vaccines (Basel)* 2022; **10**(4).

1259. Hussey H, Vreede H, Davies MA, et al. Epidemiology and outcomes of SARS-CoV-2 infection associated with anti-nucleocapsid seropositivity in Cape Town, South Africa. *medRxiv* 2022.

1260. Huy LD, Shih CL, Chang YM, et al. Comparison of COVID-19 Resilience Index and Its Associated Factors across 29 Countries during the Delta and Omicron Variant Periods. *Vaccines (Basel)* 2022; **10**(6).

1261. Hvidt AK, Baerends EAM, Søgaard OS, et al. Comparison of vaccine-induced antibody neutralization against SARS-CoV-2 variants of concern following primary and booster doses of COVID-19 vaccines. *Front Med (Lausanne)* 2022; **9**: 994160.

1262. Hwang YM, Piekos S, Sorensen T, Hood L, Hadlock J. Adoption of a National Prophylactic Anticoagulation Guideline for Hospitalized Pregnant Women With COVID-19: Retrospective Cohort Study. *JMIR Public Health Surveill* 2023; **9**: e45586.

1263. Ijaz MK, Nims RW, McKinney J. Emerging SARS-CoV-2 Mutational Variants of Concern Should Not Vary in Susceptibility to Microbicidal Actives. *Life (Basel)* 2022; **12**(7).

1264. Imbrechts M, Maes W, Ampofo L, et al. Potent neutralizing anti-SARS-CoV-2 human antibodies cure infection with SARS-CoV-2 variants in hamster model. *iScience* 2022; **25**(8): 104705.

1265. Isgrò MA, Trillò G, Russo L, et al. Bimodal antibody-titer decline following BNT162b2 mRNA anti-SARS-CoV-2 vaccination in healthcare workers of the INT - IRCCS "Fondazione Pascale" Cancer Center (Naples, Italy). *Infect Agent Cancer* 2022; **17**(1): 40.

1266. Ishigaki H, Yasui F, Nakayama M, et al. An attenuated vaccinia vaccine encoding the severe acute respiratory syndrome coronavirus-2 spike protein elicits broad and durable immune responses, and protects cynomolgus macaques and human angiotensin-converting enzyme 2 transgenic mice from severe acute respiratory syndrome coronavirus-2 and its variants. *Front Microbiol* 2022; **13**: 967019.

1267. Islam MA, Shahi S, Marzan AA, et al. Variant-specific deleterious mutations in the SARS-CoV-2 genome reveal immune responses and potentials for prophylactic vaccine development. *Front Pharmacol* 2023; **14**: 1090717.

1268. Islam S, Islam T, Islam MR. New Coronavirus Variants are Creating More Challenges to Global Healthcare System: A Brief Report on the Current Knowledge. *Clin Pathol* 2022; **15**: 2632010x221075584.

1269. Ison MG, Popejoy M, Evgeniev N, et al. Efficacy and Safety of Adintrevimab (ADG20) for the Treatment of High-Risk Ambulatory Patients With Mild or Moderate Coronavirus Disease 2019: Results From a Phase 2/3, Randomized, Placebo-Controlled Trial (STAMP) Conducted During Delta Predominance and Early Emergence of Omicron. *Open Forum Infect Dis* 2023; **10**(6): ofad279.

1270. Ison MG, Weinstein DF, Dobryanska M, et al. Prevention of COVID-19 Following a Single Intramuscular Administration of Adintrevimab: Results From a Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial (EVADE). *Open Forum Infect Dis* 2023; **10**(7): ofad314.

1271. Jain S, Agarwal A, Bhardwaj A, et al. Remote Monitoring and Holistic Care of Home-Isolated COVID-19 Positive Healthcare Workers Through Digital Technology During the Omicron (B1.1.529) Wave: A Prospective Cohort Study From India. *Front Public Health* 2022; **10**: 936000.

1272. Jang EJ, Choe YJ, Choe SA, et al. Presumed population immunity to SARS-CoV-2 in South Korea, April 2022. *Osong Public Health Res Perspect* 2022; **13**(5): 377-81.

1273. Jara A, Undurraga EA, Flores JC, et al. Effectiveness of an inactivated SARS-CoV-2 vaccine in children and adolescents: a large-scale observational study. *Lancet Reg Health Am* 2023; **21**: 100487.

1274. Jassat W, Abdool Karim SS, Ozougwu L, et al. Trends in Cases, Hospitalizations, and Mortality Related to the Omicron BA.4/BA.5 Subvariants in South Africa. *Clin Infect Dis* 2023; **76**(8): 1468-75.

1275. Jayachandran AK, Nelson V, Shajahan ME. Chest CT severity score as a predictor of mortality and short-term prognosis in COVID-19. *J Family Med Prim Care* 2022; **11**(8): 4363-7.

1276. Jiang M, Yin H, Zhang S, Meng G, Wu G. Mathematical appraisal of SARS-CoV-2 Omicron epidemic outbreak in unprecedented Shanghai lockdown. *Front Med (Lausanne)* 2022; **9**: 1021560.

1277. Jimbo H, Horimoto Y, Hiki M, et al. Successful treatment with steroid pulse therapy for a COVID-19 case with progressive respiratory failure during treatment for pleural metastasis of breast cancer. *Surg Case Rep* 2022; **8**(1): 96.

1278. Jin S, Luo J, Wu X, Wang D, Zhang W, Li Z. A case of multiple thrombosis and septic shock in a critically ill patient with Omicron infection. *J Infect Public Health* 2022; **15**(11): 1321-5.

1279. Johnston M, Ceren Ates H, Glatz RT, et al. Multiplexed biosensor for point-of-care COVID-19 monitoring: CRISPR-powered unamplified RNA diagnostics and protein-based therapeutic drug management. *Mater Today (Kidlington)* 2022; **61**: 129-38.

1280. Juarez R, Kang Z, Okihiro M, Garcia BK, Phankitnirundorn K, Maunakea AK. Dynamics of Trust and Consumption of COVID-19 Information Implicate a Mechanism for COVID-19 Vaccine and Booster Uptake. *Vaccines (Basel)* 2022; **10**(9).

1281. Jugulete G, Luminos M, Pavelescu C, Merișescu MM. Remdesivir Efficacy and Tolerability in Children with COVID-19-Associated Allergic Comorbidities such as Asthma, Allergic Rhinitis, and Atopic Dermatitis. *Children (Basel)* 2023; **10**(5).

1282. Junker D, Becker M, Wagner TR, et al. Antibody Binding and Angiotensin-Converting Enzyme 2 Binding Inhibition Is Significantly Reduced for Both the BA.1 and BA.2 Omicron Variants. *Clin Infect Dis* 2023; **76**(3): e240-e9.

1283. Kaabi NA, Yang YK, Liang Y, et al. Safety and immunogenicity of a mosaic vaccine booster against Omicron and other SARS-CoV-2 variants: a randomized phase 2 trial. *Signal Transduct Target Ther* 2023; **8**(1): 20.

1284. Kairov U, Amanzhanova A, Karabayev D, et al. A high scale SARS-CoV-2 profiling by its whole-genome sequencing using Oxford Nanopore Technology in Kazakhstan. *Front Genet* 2022; **13**: 906318.

1286. Kanakan A, Mehta P, Devi P, et al. Clinico-Genomic Analysis Reiterates Mild Symptoms Post-vaccination Breakthrough: Should We Focus on Low-Frequency Mutations? *Front Microbiol* 2022; **13**: 763169.

1287. Karaba AH, Johnston TS, Aytenfisu TY, et al. A Fourth Dose of COVID-19 Vaccine Does Not Induce Neutralization of the Omicron Variant Among Solid Organ Transplant Recipients With Suboptimal Vaccine Response. *Transplantation* 2022; **106**(7): 1440-4.

1288. Karaoğlu Ö, Serhatlı M, Pelvan E, et al. Chewable tablet with herbal extracts and propolis arrests Wuhan and Omicron variants of SARS-CoV-2 virus. *J Funct Foods* 2023; **105**: 105544.

1289. Kashiwado Y, Kimoto Y, Oku K, et al. Prognostic improvement and treatment of COVID-19 in patients with rheumatic diseases until December 2022: Analysis of the JCR COVID-19 registry in Japan. *Mod Rheumatol* 2023.

1290. Katz Sand I, Gnjatic S, Krammer F, et al. Evaluation of immunological responses to third COVID-19 vaccine among people treated with sphingosine receptor-1 modulators and anti-CD20 therapy. *Mult Scler Relat Disord* 2023; **70**: 104486.

1291. Kawano Y, Patel NJ, Wang X, et al. Temporal trends in COVID-19 outcomes among patients with systemic autoimmune rheumatic diseases: from the first wave through the initial Omicron wave. *Ann Rheum Dis* 2022; **81**(12): 1742-9.

1292. Kawano Y, Patel NJ, Wang X, et al. Temporal trends in COVID-19 outcomes among patients with systemic autoimmune rheumatic diseases: From the first wave to Omicron. *medRxiv* 2022.

1293. Keloth VK, Zhou S, Lindemann L, et al. Mining of EHR for interface terminology concepts for annotating EHRs of COVID patients. *BMC Med Inform Decis Mak* 2023; **23**(Suppl 1): 40.

1294. Keshaviah A, Huff I, Hu XC, et al. Separating signal from noise in wastewater data: An algorithm to identify community-level COVID-19 surges in real time. *Proc Natl Acad Sci U S A* 2023; **120**(31): e2216021120.

1295. Khalid ET, Salah Khalefa M, Yassen W, Adil Yassin A. Omicron virus emotions understanding system based on deep learning architecture. *J Ambient Intell Humaniz Comput* 2023; **14**(7): 9497-507.

1296. Khamis F, Al Awaidy S, Ba'Omar M, et al. The Impact of Demographic, Clinical Characteristics and the Various COVID-19 Variant Types on All-Cause Mortality: A Case-Series Retrospective Study. *Diseases* 2022; **10**(4).

1298. Khan SA, Khan A, Zia K, Shawish I, Barakat A, Ul-Haq Z. Cheminformatics-Based Discovery of Potential Chemical Probe Inhibitors of Omicron Spike Protein. *Int J Mol Sci* 2022; **23**(18).

1299. Kienast P, Prayer D, Binder J, et al. SARS-CoV-2 variant-related abnormalities detected by prenatal MRI: a prospective case-control study. *Lancet Reg Health Eur* 2023; **26**: 100587.

1300. Kienbacher CL, Tanzer JR, Wei G, Rhodes JM, Roth D, Williams KA. Increases in Ambulance Call Volume Are an Early Warning Sign of Major COVID-19 Surges in Children. *Int J Environ Res Public Health* 2022; **19**(23).

1301. Kim JM, Kim D, Lee NJ, et al. Increased viral load in patients infected with severe acute respiratory syndrome coronavirus 2 Omicron variant in the Republic of Korea. *Osong Public Health Res Perspect* 2023; **14**(4): 272-8.

1302. Kim JM, Park EG, Lee JY, et al. Characteristics of febrile seizures with SARS-CoV-2 infection in the Omicron era. *Transl Pediatr* 2023; **12**(5): 807-15.

1303. Kim JY, Săndulescu O, Preotescu LL, et al. A Randomized Clinical Trial of Regdanvimab in High-Risk Patients With Mild-to-Moderate Coronavirus Disease 2019. *Open Forum Infect Dis* 2022; **9**(8): ofac406.

1304. Kim PY, Kim AY, Newman JJ, et al. A collaborative approach to improve representation in viral genomic surveillance. *bioRxiv* 2022.

1305. Kim T, Min KI, Yang JS, et al. Relative infectivity of the SARS-CoV-2 Omicron variant in human alveolar cells. *iScience* 2022; **25**(12): 105571.

1306. Kim TH, Ji E, Song MJ, Lim SY, Lee YJ, Cho YJ. Negative Conversion of Polymerase Chain Reaction and Clinical Outcomes according to the SARS-CoV-2 Variant in Critically Ill Patients with COVID-19. *Tuberc Respir Dis (Seoul)* 2023; **86**(2): 142-9.

1307. Kim Y, Jacobsen H, Fuerholzner B, et al. Long-term immune protection against SARS-CoV-2 escape variants upon a single vaccination with murine cytomegalovirus expressing the spike protein. *bioRxiv* 2022.

1308. Kim Y, Kim BI, Tak S. Time-series comparison of COVID-19 case fatality rates across 21 countries with adjustment for multiple covariates. *Osong Public Health Res Perspect* 2022; **13**(6): 424-34.

1309. Kimata M, Watanabe A, Yanagida Y, Kinoshita D, Maekawa S. Safety and Effectiveness of Molnupiravir (LAGEVRIO(®)) Capsules in Japanese Patients with COVID-19: Interim Report of Post-marketing Surveillance in Japan. *Infect Dis Ther* 2023; **12**(4): 1119-36.

1310. Kinikar AA, Vartak S, Dawre R, et al. Clinical Profile and Outcome of Hospitalized Confirmed Cases of Omicron Variant of SARS-CoV-2 Among Children in Pune, India. *Cureus* 2022; **14**(4): e24629.

1311. Kirsebom FCM, Andrews N, Stowe J, Ramsay M, Lopez Bernal J. Duration of protection of ancestral-strain monovalent vaccines and effectiveness of bivalent BA.1 boosters against COVID-19 hospitalisation in England: a test-negative case-control study. *Lancet Infect Dis* 2023.

1312. Kiruba Daniel SCG, Pai PS, Sabbella HR, et al. Handheld, Low-Cost, Aptamer-Based Sensing Device for Rapid SARS-CoV-2 RNA Detection Using Novelly Synthesized Gold Nanoparticles. *IEEE Sens J* 2022; **22**(19): 18437-45.

1313. Klaassen F, Chitwood MH, Cohen T, et al. Changes in population immunity against infection and severe disease from SARS-CoV-2 Omicron variants in the United States between December 2021 and November 2022. *medRxiv* 2022.

1314. Kogoj R, Korva M, Knap N, et al. Comparative Evaluation of Six SARS-CoV-2 Real-Time RT-PCR Diagnostic Approaches Shows Substantial Genomic Variant-Dependent Intra- and Inter-Test Variability, Poor Interchangeability of Cycle Threshold and Complementary Turn-Around Times. *Pathogens* 2022; **11**(4).

1315. Koh K, Tang KC, Axhausen K, Loo BPY. A metropolitan-scale, three-dimensional agent-based model to assess the effectiveness of the COVID-19 Omicron wave interventions in a hyperdense city: a case study of Hong Kong. *Int J Infect Dis* 2022; **122**: 534-6.

1316. Koh SWC, Tan HM, Lee WH, Mathews J, Young D. COVID-19 Vaccine Booster Hesitancy among Healthcare Workers: A Retrospective Observational Study in Singapore. *Vaccines (Basel)* 2022; **10**(3).

1317. Korogiannou M, Vallianou K, Xagas E, et al. Disease Course, Management and Outcomes in Kidney Transplant Recipients with SARS-CoV-2 Infection during the Omicron-Variant Wave: A Single-Center Experience. *Vaccines (Basel)* 2023; **11**(3).

1318. Kouamen AC, Da Cruz H, Hamidouche M, et al. Rapid investigation of BA.4/BA.5 cases in France. *Front Public Health* 2022; **10**: 1006631.

1319. Kreye J, Reincke SM, Edelburg S, et al. Preclinical safety and efficacy of a therapeutic antibody that targets SARS-CoV-2 at the sotrovimab face but is escaped by Omicron. *iScience* 2023; **26**(4): 106323.

1320. Krystallaki D, Kavakioti CA, Gkova M, et al. COVID-19 Burden in Long-Term Care Facilities in the Omicron Era: Public Health Action Not Yet Redundant. *Viruses* 2023; **15**(3).

1321. Kumar NP, Banurekha VV, Kumar CPG, et al. Inactivated COVID-19 vaccines: durability of Covaxin/BBV152 induced immunity against variants of concern. *J Travel Med* 2022; **29**(6).

1322. Kumar P, Mathayan M, Smieszek SP, et al. Identification of potential COVID-19 treatment compounds which inhibit SARS Cov2 prototypic, Delta and Omicron variant infection. *Virology* 2022; **572**: 64-71.

1323. Kumar S, Lomash A, Faruq M, et al. Amplicon-Based Nanopore Sequencing of Patients Infected by the SARS-CoV-2 Omicron (B.1.1.529) Variant in India. *Adv Exp Med Biol* 2023; **1412**: 271-83.

1324. La Maestra S, Garibaldi S, Balansky R, D'Agostini F, Micale RT, De Flora S. Inhibition of the Cell Uptake of Delta and Omicron SARS-CoV-2 Pseudoviruses by N-Acetylcysteine Irrespective of the Oxidoreductive Environment. *Cells* 2022; **11**(20).

1325. Lai FTT, Yan VKC, Ye X, et al. Booster vaccination with inactivated whole-virus or mRNA vaccines and COVID-19-related deaths among people with multimorbidity: a cohort study. *Cmaj* 2023; **195**(4): E143-e52.

1326. Lang J. NanoCoV19: An analytical pipeline for rapid detection of severe acute respiratory syndrome coronavirus 2. *Front Genet* 2022; **13**: 1008792.

1327. Lapa D, Grousova DM, Matusali G, et al. Retention of Neutralizing Response against SARS-CoV-2 Omicron Variant in Sputnik V-Vaccinated Individuals. *Vaccines (Basel)* 2022; **10**(5).

1328. Lapointe HR, Mwimanzi F, Cheung PK, et al. People With Human Immunodeficiency Virus Receiving Suppressive Antiretroviral Therapy Show Typical Antibody Durability After Dual Coronavirus Disease 2019 Vaccination and Strong Third Dose Responses. *J Infect Dis* 2023; **227**(7): 838-49.

1329. Laracy JC, Yan J, Steiger SN, et al. Predictors of SARS-CoV-2 Omicron breakthrough infection after receipt of AZD7442 (tixagevimab-cilgavimab) for pre-exposure prophylaxis among hematologic malignancy patients. *Haematologica* 2023.

1330. Latreche A, Kelaiaia R, Chemori A, Kerboua A. A New Home-Based Upper- and Lower-Limb Telerehabilitation Platform with Experimental Validation. *Arab J Sci Eng* 2023: 1-16.

1331. Lauring AS, Tenforde MW, Chappell JD, et al. Clinical Severity and mRNA Vaccine Effectiveness for Omicron, Delta, and Alpha SARS-CoV-2 Variants in the United States: A Prospective Observational Study. *medRxiv* 2022.

1332. Lavinio A, Cammarano C. Perioperative fatal thrombotic complication after elective meningioma resection in asymptomatic SARS-CoV-2 BA.5.2 (Omicron variant) infection. *BJA Open* 2023; **6**: 100131.

1333. Le Rutte EA, Shattock AJ, Chitnis N, Kelly SL, Penny MA. Modelling the impact of Omicron and emerging variants on SARS-CoV-2 transmission and public health burden. *Commun Med (Lond)* 2022; **2**: 93.

1334. Lee NY, Lee YW, Hong SM, et al. SARS-CoV-2 Omicron variant causes brain infection with lymphoid depletion in a mouse COVID-19 model. *Lab Anim Res* 2023; **39**(1): 8.

1335. Lendacki FR, Forst L, Weber E, Mehta SD, Kerins JL. COVID-19 Clusters and Outbreaks Among Non-Health Care, Noncongregate Workers in Chicago, Illinois: Surveillance Through the First Omicron Wave. *J Occup Environ Med* 2023; **65**(4): e211-e8.

1336. Leonardi AA, Sciuto EL, Lo Faro MJ, et al. Molecular Fingerprinting of the Omicron Variant Genome of SARS-CoV-2 by SERS Spectroscopy. *Nanomaterials (Basel)* 2022; **12**(13).

1337. Leung NHL, Cheng SMS, Martín-Sánchez M, et al. Immunogenicity of a Third Dose of BNT162b2 to Ancestral Severe Acute Respiratory Syndrome Coronavirus 2 and the Omicron Variant in Adults Who Received 2 Doses of Inactivated Vaccine. *Clin Infect Dis* 2023; **76**(3): e299-e307.

1338. Leuva H, Zhou M, Brau N, et al. Influence of Cancer on COVID-19 Incidence, Outcomes, and Vaccine Effectiveness: A Prospective Cohort Study of U.S. Veterans. *Semin Oncol* 2022; **49**(5): 363-70.

1339. Leventopoulos M, Michou V, Kyprianidou C, et al. Performance characteristics of the boson rapid SARS-cov-2 antigen test card vs RT-PCR: Cross-reactivity and emerging variants. *Heliyon* 2023; **9**(2): e13642.

1340. Li H, He J, Chen J, Pan S, Feng J, Liu S. The governance of imported 2019-nCov infections: What can be learned from China's experience? *Glob Health Res Policy* 2022; **7**(1): 8.

1341. Li H, Zhu M, Zhang P, et al. Milder symptoms and shorter course in patients with re-positive COVID-19: A cohort of 180 patients from Northeast China. *Front Microbiol* 2022; **13**: 989879.

1342. Li H, Zhu X, Yu R, et al. The effects of vaccination on the disease severity and factors for viral clearance and hospitalization in Omicron-infected patients: A retrospective observational cohort study from recent regional outbreaks in China. *Front Cell Infect Microbiol* 2022; **12**: 988694.

1343. Li J. Prevention is Key to Reducing the Spread of COVID-19 in Long-Term Care Facilities. *Infect Drug Resist* 2022; **15**: 6689-93.

1344. Li J, Wu J, Long Q, et al. Comprehensive Humoral and Cellular Immune Responses to SARS-CoV-2 Variants in Diverse Chinese Population. *Research (Wash D C)* 2022; **2022**: 9873831.

1345. Li J, Xie H, Chen W, et al. Immune Persistence against SARS-CoV-2 after Primary and Booster Immunization in Humans: A Large-Scale Prospective Cohort Study. *Vaccines (Basel)* 2022; **10**(10).

1346. Li M, Beck EJ, Laeyendecker O, et al. Convalescent plasma with a high level of virus-specific antibody effectively neutralizes SARS-CoV-2 variants of concern. *Blood Adv* 2022; **6**(12): 3678-83.

1347. Li M, Weng S, Wang Q, et al. Reduced binding activity of vaccine serum to omicron receptor-binding domain. *Front Immunol* 2022; **13**: 960195.

1348. Li M, Wu Z, Bian X, et al. Clinical and psychological status analysis of children and parents infected with familial aggregation omicron variant in Shanghai in parent-child ward. *Heliyon* 2022; **8**(12): e12151.

1349. Li S, Xu Q, Lv Y, Yuan D. Public attention, oil and gold markets during the COVID-19: Evidence from time-frequency analysis. *Resour Policy* 2022; **78**: 102868.

1350. Li T, Chen Y, Chen Z, et al. Early and Sensitive Detection of Pathogens for Public Health and Biosafety: An Example of Surveillance and Genotyping of SARS-CoV-2 in Sewage Water by Cas12a-Facilitated Portable Plasmonic Biosensor. *Research (Wash D C)* 2023; **6**: 0205.

1351. Li T, Han M, Wang J, Zhou C, Mu H. Clinical characteristics and risks of the convalescent COVID-19 patients with re-detectable positive RNA test: a 430 patients with Omicron infected cross-sectional survey in Tianjin, China. *J Infect Public Health* 2022; **15**(12): 1409-14.

1352. Li X, Li R, Lian Q, Wang Y, Gu W, Meng Q. A Small Surge in Incidence of SARS-CoV-2 Omicron Variant in the "Dynamic Zero" Period. *Can J Infect Dis Med Microbiol* 2023; **2023**: 5262117.

1353. Li X, Yin Y, Cui Q, Huang W, Zou Q, Shen T. Long-term variations and potency of neutralizing antibodies against Omicron subvariants after CoronaVac-inactivated booster: A 7-month follow-up study. *J Med Virol* 2023; **95**(1): e28279.

1354. Li Y, Guo T, Zhong J, et al. Effect of Vaccination Time Intervals on SARS-COV-2 Omicron Variant Strain Infection in Guangzhou: A Real-World Matched Case-Control Study. *Vaccines (Basel)* 2022; **10**(11).

1355. Li Y, Liu Y, Wen L, et al. Clinical efficacy analysis of paxlovid in children with hematological diseases infected with the omicron SARS-CoV-2 new variant. *Front Pediatr* 2023; **11**: 1160929.

1356. Li Z, Liang T, Zhang J, et al. Characteristics and Occurrence Scenarios of Staff Exposed to SARS-CoV-2 Omicron in Shanghai Lingang Fangcang Shelter Hospital, CHINA. *Infect Drug Resist* 2023; **16**: 1619-28.

1357. Li Z, Zhou J, Wang C, Liu R, Hu J, Lv Y. Isotope-encoded tetrahedral DNA for multiple SARS-CoV-2 variant diagnosis. *Chem Sci* 2023; **14**(24): 6654-62.

1358. Liang D, Zhang G, Huang M, et al. Progress of the COVID-19: Persistence, Effectiveness, and Immune Escape of the Neutralizing Antibody in Convalescent Serum. *Pathogens* 2022; **11**(12).

1359. Liang H, Nian X, Wu J, et al. COVID-19 vaccination boosts the potency and breadth of the immune response against SARS-CoV-2 among recovered patients in Wuhan. *Cell Discov* 2022; **8**(1): 131.

1360. Liang Y, Gong Z, Guo J, Cheng Q, Yao Z. Spatiotemporal analysis of the morbidity of global Omicron from November 2021 to February 2022. *J Med Virol* 2022; **94**(11): 5354-62.

1361. Liang Y, Peng C, You Q, et al. Estimating Changes in Contact Patterns in China Over the First Year of the COVID-19 Pandemic: Implications for SARS-CoV-2 Spread - Four Cities, China, 2020. *China CDC Wkly* 2023; **5**(5): 113-9.

1363. Lieber CM, Cox RM, Sourimant J, et al. SARS-CoV-2 variant of concern type and biological sex affect efficacy of molnupiravir in dwarf hamster model of severe COVID-19. *bioRxiv* 2022.

1364. Liew F, Talwar S, Cross A, et al. SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination. *EBioMedicine* 2023; **87**: 104402.

1365. Lim J, Stavins R, Kindratenko V, et al. Microfluidic point-of-care device for detection of early strains and B.1.1.7 variant of SARS-CoV-2 virus. *Lab Chip* 2022; **22**(7): 1297-309.

1366. Lin DY, Xu Y, Gu Y, et al. Effects of COVID-19 vaccination and previous SARS-CoV-2 infection on omicron infection and severe outcomes in children under 12 years of age in the USA: an observational cohort study. *Lancet Infect Dis* 2023.

1367. Lin FJ, Doss AMA, Davis-Adams HG, et al. SARS-CoV-2 booster vaccination rescues attenuated IgG1 memory B cell response in primary antibody deficiency patients. *Front Immunol* 2022; **13**: 1033770.

1368. Lin XQ, Lv L, Chen Y, et al. The impact of the Omicron epidemic on the health behavior in Cape Town, South Africa. *One Health* 2022; **14**: 100395.

1369. Lin YJ, Evans DH, Robbins NF, et al. Diminished Neutralization Capacity of SARS-CoV-2 Omicron BA.1 in Donor Plasma Collected from January to March 2021. *Microbiol Spectr* 2023; **11**(4): e0525622.

1370. Ling TC, Chen PL, Li NY, et al. Trajectory of Humoral Responses to Two Doses of ChAdOx1 nCoV-19 Vaccination in Patients Receiving Maintenance Hemodialysis. *Microbiol Spectr* 2023; **11**(2): e0344522.

1371. Lingani M, Cissé A, Tialla D, et al. Coinfections with SARS-CoV-2 variants and influenza virus during the 2019 Coronavirus disease pandemic in Burkina Faso: A surveillance study. *Health Sci Rep* 2023; **6**(1): e1041.

1372. Lippi G, Henry BM, Plebani M. A Simple Epidemiologic Model for Predicting Impaired Neutralization of New SARS-CoV-2 Variants. *Vaccines (Basel)* 2023; **11**(1).

1373. Liu B, Xie Y, Liu W, et al. Nanophotonic reservoir computing for COVID-19 pandemic forecasting. *Nonlinear Dyn* 2023; **111**(7): 6895-914.

1374. Liu C, Wu X, Yang H, et al. A retrospective study of Reyanning mixture in elderly patients infected with SARS-CoV-2 Omicron variant. *Front Pharmacol* 2023; **14**: 1185122.

1375. Liu H, Wang S, Yang S, et al. Characteristics of the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron BA.2 Subvariant in Jilin, China from March to May 2022. *J Transl Int Med* 2022; **10**(4): 349-58.

1376. Liu J, Liu M, Liang W. Persevere in the Dynamic COVID-Zero Strategy in China to Gain a Precious Time Window for the Future. *China CDC Wkly* 2022; **4**(18): 393-4.

1377. Liu J, Lu S, Lu C. What Motivates People to Receive Continuous COVID-19 Vaccine Booster Shots? An Expectation Confirmation Theory Perspective. *Healthcare (Basel)* 2022; **10**(12).

1378. Liu J, Wei H, He D. Differences in case-fatality-rate of emerging SARS-CoV-2 variants. *Public Health Pract (Oxf)* 2023; **5**: 100350.

1379. Liu L, Wang C, Xie S, Su L, Wang C. Effect of Nasal Irrigation in Children With Omicron Variant of COVID-19 Infection. *Ear Nose Throat J* 2023: 1455613231172337.

1380. Liu LT, Tsai JJ, Chu JJH, et al. The identification and phylogenetic analysis of SARS-CoV-2 delta variants in Taiwan. *Kaohsiung J Med Sci* 2023; **39**(6): 624-36.

1381. Liu Y, Kumblathan T, Joyce MA, et al. Multiplex Assays Enable Simultaneous Detection and Identification of SARS-CoV-2 Variants of Concern in Clinical and Wastewater Samples. *ACS Meas Sci Au* 2023; **3**(4): 258-68.

1382. Liu Y, Lu J, Zhan H, et al. Inactivated SARS-CoV-2 booster vaccine enhanced immune responses in patients with chronic liver diseases. *Virol Sin* 2023.

1383. Liu YX, Wang LH, Zhu C, Zha QF, Yu YT. A comparative bibliometric analysis of Omicron and Delta variants during the COVID-19 pandemic. *Ann Palliat Med* 2023; **12**(1): 60-9.

1384. Loconsole D, Bisceglia L, Centrone F, et al. Autochthonous Outbreak of SARS-CoV-2 Omicron Variant in Booster-Vaccinated (3 Doses) Healthcare Workers in Southern Italy: Just the Tip of the Iceberg? *Vaccines (Basel)* 2022; **10**(2).

1385. Loconsole D, Centrone F, Sallustio A, et al. Characteristics of the First 284 Patients Infected with the SARS-CoV-2 Omicron BA.2 Subvariant at a Single Center in the Apulia Region of Italy, January-March 2022. *Vaccines (Basel)* 2022; **10**(5).

1386. Loke J, Upasani V, Gaskell C, et al. Defective T-cell response to COVID-19 vaccination in acute myeloid leukaemia and myelodysplastic syndromes. *Br J Haematol* 2023; **202**(3): 498-503.

1387. López-Muñoz I, Torrella A, Pérez-Quílez O, et al. SARS-CoV-2 Secondary Attack Rates in Vaccinated and Unvaccinated Household Contacts during Replacement of Delta with Omicron Variant, Spain. *Emerg Infect Dis* 2022; **28**(10): 1999-2008.

1388. Lowthian E, Abbasizanjani H, Bedston S, et al. Trends in SARS-CoV-2 infection and vaccination in school staff, students and their household members from 2020 to 2022 in Wales, UK: an electronic cohort study. *J R Soc Med* 2023: 1410768231181268.

1389. Lu G, Ling Y, Jiang M, et al. Primary assessment of the diversity of Omicron sublineages and the epidemiologic features of autumn/winter 2022 COVID-19 wave in Chinese mainland. *Front Med* 2023: 1-10.

1390. Lu G, Zhang Y, Zhang H, et al. Geriatric risk and protective factors for serious COVID-19 outcomes among older adults in Shanghai Omicron wave. *Emerg Microbes Infect* 2022; **11**(1): 2045-54.

1391. Lu JY, Buczek A, Fleysher R, et al. Characteristics of COVID-19 patients with multiorgan injury across the pandemic in a large academic health system in the Bronx, New York. *Heliyon* 2023; **9**(4): e15277.

1392. Lu L, Qin J, Chen J, et al. Recent computational drug repositioning strategies against SARS-CoV-2. *Comput Struct Biotechnol J* 2022; **20**: 5713-28.

1393. Lu X, Chen Y, Zhang G. Functional evolution of SARS-CoV-2 spike protein: Maintaining wide host spectrum and enhancing infectivity via surface charge of spike protein. *Comput Struct Biotechnol J* 2023; **21**: 2068-74.

1394. Lu Z, Kuang Z, Li B, Song Z, Huang L. Understanding the viral shedding time of Omicron variant BA.2 infection in Shanghai: A population-based observational study. *Heliyon* 2023; **9**(6): e17173.

1395. Lubin JH, Markosian C, Balamurugan D, et al. Structural models of SARS-CoV-2 Omicron variant in complex with ACE2 receptor or antibodies suggest altered binding interfaces. *bioRxiv* 2021.

1396. Ludwikowska KM, Popiel A, Matkowska-Kocjan A, et al. COVID-19 mRNA BNT162b2 vaccine immunogenicity among children with a history of paediatric multisystem inflammatory syndrome temporally associated with COVID-19 (PIMS-TS). *Vaccine* 2023; **41**(21): 3317-27.

1397. Luo Y, Zhou Q, Huang X, et al. Effect of inactivated COVID-19 vaccine on the negative conversion of nucleic acid in asymptomatic or mild patients with COVID-19. *BMC Infect Dis* 2023; **23**(1): 443.

1398. Lustig G, Ganga Y, Rodel H, et al. SARS-CoV-2 evolves increased infection elicited cell death and fusion in an immunosuppressed individual. *medRxiv* 2022.

1399. Lyke KE, Atmar RL, Dominguez Islas C, et al. Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants. *NPJ Vaccines* 2023; **8**(1): 98.

1400. Lyke KE, Atmar RL, Islas CD, et al. Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant. *Cell Rep Med* 2022; **3**(7): 100679.

1401. Lyu H, Zhong X, Huang Q, Zheng L, Chen H, Cai S. High-rise buildings: A risk factor in the COVID-19 Omicron epidemic period. *Public Health Pract (Oxf)* 2023; **5**: 100389.

1402. Ma E, Ai J, Zhang Y, et al. Omicron infections profile and vaccination status among 1881 liver transplant recipients: a multi-centre retrospective cohort. *Emerg Microbes Infect* 2022; **11**(1): 2636-44.

1403. Ma L, Fan Y, Kong X, et al. Fast and Sensitive Detection of SARS-CoV-2 Nucleic Acid Using a Rapid Detection System Free of RNA Extraction. *Int J Anal Chem* 2023; **2023**: 8053524.

1404. Ma S, Wang H, Zhu K, Chen H, Xie J, Huang Y. Risk Factors and Disease Profile Associated with the Nucleic Acid Conversion Time of COVID-19 Patients Infected with the SARS-CoV-2 Omicron Variant in Fangcang Shelter Hospitals. *Infect Drug Resist* 2023; **16**: 3945-54.

1405. Ma T, Suryawanshi RK, Miller SR, et al. Post-acute immunological and behavioral sequelae in mice after Omicron infection. *bioRxiv* 2023.

1406. Mahalingam G, Periyasami Y, Arjunan P, et al. Omicron infection increases IgG binding to spike protein of predecessor variants. *J Med Virol* 2023; **95**(2): e28419.

1407. Mai F, Volzke J, Reisinger EC, Müller-Hilke B. Vaccine-Induced T-Cell and Antibody Responses at 12 Months after Full Vaccination Differ with Respect to Omicron Recognition. *Vaccines (Basel)* 2022; **10**(9).

1408. Maida CM, Tramuto F, Giammanco GM, et al. Wastewater-Based Epidemiology as a Tool to Detect SARS-CoV-2 Circulation at the Community Level: Findings from a One-Year Wastewater Investigation Conducted in Sicily, Italy. *Pathogens* 2023; **12**(6).

1409. Maier BF, Burdinski A, Wiedermann M, et al. Modeling the impact of the Omicron infection wave in Germany. *Biol Methods Protoc* 2023; **8**(1): bpad005.

1410. Malato J, Ribeiro RM, Fernandes E, et al. Rapid waning of protection induced by prior BA.1/BA.2 infection against BA.5 infection. *medRxiv* 2022.

1411. Malhotra S, Mani K, Lodha R, et al. COVID-19 infection, and reinfection, and vaccine effectiveness against symptomatic infection among health care workers in the setting of omicron variant transmission in New Delhi, India. *Lancet Reg Health Southeast Asia* 2022; **3**: 100023.

1412. Mamurova B, Akan G, Mogol E, et al. Strong Association between Vitamin D Receptor Gene and Severe Acute Respiratory Syndrome coronavirus 2 Infectious Variants. *Glob Med Genet* 2023; **10**(1): 27-33.

1413. Manchanda V, Mitra S, Rafique I, et al. Is Omicron really mild? - Comparative analysis of comorbidities and disease outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) and Delta (B.1.617.2) variants. *Indian J Med Microbiol* 2023; **45**: 100391.

1414. Mandal S, Wiesenfeld BM, Mann D, et al. Evidence for Telemedicine's Ongoing Transformation of Health Care Delivery Since the Onset of COVID-19: Retrospective Observational Study. *JMIR Form Res* 2022; **6**(10): e38661.

1415. Mangukia N, Rao P, Patel K, Pandya H, Rawal RM. Unveiling the nature's fruit basket to computationally identify Citrus sinensis csi-mir169-3p as a probable plant miRNA against Reference and Omicron SARS-CoV-2 genome. *Comput Biol Med* 2022; **146**: 105502.

1416. Manica M, De Bellis A, Guzzetta G, et al. Intrinsic generation time of the SARS-CoV-2 Omicron variant: An observational study of household transmission. *Lancet Reg Health Eur* 2022; **19**: 100446.

1417. Mao S, Li S, Zhang Y, et al. A highly efficient needle-free-injection delivery system for mRNA-LNP vaccination against SARS-CoV-2. *Nano Today* 2023; **48**: 101730.

1418. Mapanga W, Craig A, Mtintsilana A, et al. The Effects of COVID-19 Pandemic Lockdowns on Alcohol Consumption and Tobacco Smoking Behaviour in South Africa: A National Survey. *Eur Addict Res* 2023; **29**(2): 127-40.

1419. Marcacci G, Coppola N, Madonna E, et al. Post-exposure prophylaxis with sotrovimab for Omicron (B.1.1.529) SARS-CoV-2 variant during the aplastic phase of autologous stem cell transplantation. *Infect Agent Cancer* 2022; **17**(1): 41.

1420. Marinelli TM, Dolan L, Jenkins F, et al. The role of real-time, on-site, whole-genome sequencing of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) in guiding the management of hospital outbreaks of coronavirus disease 2019 (COVID-19). *Infect Control Hosp Epidemiol* 2022: 1-5.

1421. Marot S, Bocar Fofana D, Flandre P, et al. SARS-CoV-2 Neutralizing Responses in Various Populations, at the Time of SARS-CoV-2 Variant Virus Emergence: Evaluation of Two Surrogate Neutralization Assays in Front of Whole Virus Neutralization Test. *Life (Basel)* 2022; **12**(12).

1422. Marra AR, Miraglia JL, Malheiro DT, et al. Longer-term effectiveness of a heterologous coronavirus disease 2019 (COVID-19) vaccine booster in healthcare workers in Brazil. *Antimicrob Steward Healthc Epidemiol* 2023; **3**(1): e104.

1424. Martin-Onraët A, Barrientos-Flores C, Vilar-Compte D, Pérez-Jimenez C, Alatorre-Fernandez P. Use of remdesivir for COVID-19 in patients with hematologic cancer. *Clin Exp Med* 2022: 1-8.

1425. Maruyama S, Wada D, Oishi T, et al. A descriptive study of abdominal complications in patients with mild COVID-19 presenting to the emergency department: a single-center experience in Japan during the omicron variant phase. *BMC Gastroenterol* 2023; **23**(1): 43.

1426. Marzi R, Bassi J, Silacci-Fregni C, et al. Maturation of SARS-CoV-2 Spike-specific memory B cells drives resilience to viral escape. *bioRxiv* 2022.

1428. Masthi Nr R, Brahmajosyula A, Khamar A, Acharya N, Bilichod LP, Kondath D. Coverage of Coronavirus Disease-2019 (COVID-19) Booster Dose (Precautionary) in the Adult Population: An Online Survey. *Cureus* 2022; **14**(7): e26912.

1429. Mateo-Urdiales A, Sacco C, Fotakis EA, et al. Relative effectiveness of monovalent and bivalent mRNA boosters in preventing severe COVID-19 due to omicron BA.5 infection up to 4 months post-administration in people aged 60 years or older in Italy: a retrospective matched cohort study. *Lancet Infect Dis* 2023.

1430. Mathew M, Sebastian J, Doddaiah N, Thomas A, Narayanappa S. Clinico-epidemiological profile and outcome of infected health care workers during the three consecutive waves of COVID-19 pandemic: a longitudinal cohort study. *Ther Adv Vaccines Immunother* 2023; **11**: 25151355231181744.

1431. Mathioudakis N, Zachiotis M, Papadakos S, et al. Onodera's prognostic nutritional index: Comparison of its role in the severity and outcomes of patients with COVID‑19 during the periods of alpha, delta and omicron variant predominance. *Exp Ther Med* 2022; **24**(5): 675.

1432. Matsuura R, Maeda K, Hagiwara K, et al. WO(3) Photocatalyst Containing Copper Inactivates SARS-CoV-2 Pango Lineage A and Omicron BA.2 Variant in Visible Light and in Darkness. *Pathogens* 2022; **11**(8).

1433. Matthews ZK, Cybulski DJ, Frankel DN, et al. Sensitivity of Symptom-Based Screening for COVID-19 in Active Duty Basic Trainees. *Mil Med* 2023.

1434. Mazzaferri F, Mirandola M, Savoldi A, et al. Exploratory data on the clinical efficacy of monoclonal antibodies against SARS-CoV-2 Omicron variant of concern. *Elife* 2022; **11**.

1435. Mazzotta V, Cozzi-Lepri A, Colavita F, et al. Emulation of a Target Trial From Observational Data to Compare Effectiveness of Casirivimab/Imdevimab and Bamlanivimab/Etesevimab for Early Treatment of Non-Hospitalized Patients With COVID-19. *Front Immunol* 2022; **13**: 868020.

1436. Md Yusof MY, Arnold J, Saleem B, et al. Breakthrough SARS-CoV-2 infections and prediction of moderate-to-severe outcomes during rituximab therapy in patients with rheumatic and musculoskeletal diseases in the UK: a single-centre cohort study. *Lancet Rheumatol* 2023; **5**(2): e88-e98.

1437. Meier N, Perner A, Plovsing R, et al. Long-term outcomes in COVID-19 patients admitted to intensive care in Denmark: A nationwide observational study. *Acta Anaesthesiol Scand* 2023.

1438. Meletis G, Tychala A, Ntritsos G, et al. Variant-Related Differences in Laboratory Biomarkers among Patients Affected with Alpha, Delta and Omicron: A Retrospective Whole Viral Genome Sequencing and Hospital-Setting Cohort Study. *Biomedicines* 2023; **11**(4).

1439. Mendes D, Chapman R, Aruffo E, et al. Public health impact of UK COVID-19 booster vaccination programs during Omicron predominance. *Expert Rev Vaccines* 2023; **22**(1): 90-103.

1440. Messiah SE, Swartz MD, Abbas RA, et al. SARS-CoV-2 Serostatus and COVID-19 Illness Characteristics by Variant Time Period in Non-Hospitalized Children and Adolescents. *Children (Basel)* 2023; **10**(5).

1441. Meyer-Rath G, Hounsell RA, Pulliam JR, et al. The role of modelling and analytics in South African COVID-19 planning and budgeting. *PLOS Glob Public Health* 2023; **3**(7): e0001063.

1442. Michlmayr D, Hansen CH, Gubbels SM, et al. Observed protection against SARS-CoV-2 reinfection following a primary infection: A Danish cohort study among unvaccinated using two years of nationwide PCR-test data. *Lancet Reg Health Eur* 2022; **20**: 100452.

1443. Milojkovic D, Reynolds CJ, Sandoval DM, et al. COVID-19 vaccine boosted immunity against Omicron in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. *Leukemia* 2023; **37**(1): 244-7.

1444. Miron VD, Bar G, Filimon C, Craiu M. From COVID-19 to Influenza-Real-Life Clinical Practice in a Pediatric Hospital. *Diagnostics (Basel)* 2022; **12**(5).

1445. Miyamoto S, Arashiro T, Ueno A, et al. Non-Omicron breakthrough infection with higher viral load and longer vaccination-infection interval improves SARS-CoV-2 BA.4/5 neutralization. *iScience* 2023; **26**(2): 105969.

1446. Miyamoto S, Kuroda Y, Kanno T, et al. Saturation time of exposure interval for cross-neutralization response to SARS-CoV-2: Implications for vaccine dose interval. *iScience* 2023; **26**(5): 106694.

1447. Mizoue T, Yamamoto S, Oshiro Y, et al. Cumulative and undiagnosed SARS-CoV-2 infection among the staff of a medical research centre in Tokyo after the emergence of variants. *Epidemiol Infect* 2023; **151**: e48.

1448. Mndala L, Monk EJM, Phiri D, et al. Comparison of maternal and neonatal outcomes of COVID-19 before and after SARS-CoV-2 omicron emergence in maternity facilities in Malawi (MATSurvey): data from a national maternal surveillance platform. *Lancet Glob Health* 2022; **10**(11): e1623-e31.

1449. Mnguni AT, Schietekat D, Ebrahim N, et al. The clinical and epidemiological characteristics of a series of patients living with HIV admitted for COVID-19 in a district hospital. *BMC Infect Dis* 2023; **23**(1): 123.

1450. Moghnieh R, El Hajj C, Abdallah D, Jbeily N, Bizri AR, Sayegh MH. Immunogenicity and Effectiveness of Primary and Booster Vaccine Combination Strategies during Periods of SARS-CoV-2 Delta and Omicron Variants. *Vaccines (Basel)* 2022; **10**(10).

1451. Molteni E, Canas LS, Kläser K, et al. Post-vaccination infection rates and modification of COVID-19 symptoms in vaccinated UK school-aged children and adolescents: A prospective longitudinal cohort study. *Lancet Reg Health Eur* 2022; **19**: 100429.

1452. Monin MB, Gorny JG, Berger M, et al. Impaired immunogenicity after vaccination for SARS-CoV-2 in patients with gastrointestinal cancer: does tumor entity matter? *J Gastrointest Oncol* 2023; **14**(3): 1218-34.

1453. Montalbano M, Piccolo P, Lionetti R, et al. Third dose of SARS-CoV2 mRNA vaccination produces robust persistent cellular and humoral immune responses in liver transplant recipients. *Liver Int* 2023; **43**(5): 1120-5.

1454. Montez-Rath ME, Garcia P, Han J, et al. SARS-CoV-2 infection during the Omicron surge among patients receiving dialysis: the role of circulating receptor-binding domain antibodies and vaccine doses. *medRxiv* 2022.

1455. Morello W, Vianello FA, Bulgaro C, Montini G. Epidemiology, severity, and risk of SARS-CoV-2-related relapse in children and young adults affected by idiopathic nephrotic syndrome: a retrospective observational cohort study. *Pediatr Nephrol* 2023; **38**(4): 1159-66.

1456. Mori H, Yoshida H, Mori H, Shiraki T, Kawakami K. Stealth Omicron: A Novel SARS-CoV-2 Variant That Is Insensitive to RT-qPCR Using the N1 and N2 Primer-Probes. *Cureus* 2023; **15**(3): e36373.

1457. Morris CP, Eldesouki RE, Fall A, et al. Sequence Proven Reinfections with SARS-CoV-2 at a Large Academic Center. *medRxiv* 2022.

1459. Morsi SA, Alzahrani ME. Advanced Computing Approach for Modeling and Prediction COVID-19 Pandemic. *Appl Bionics Biomech* 2022; **2022**: 6056574.

1460. Mosconi G, Fantini M, Righini M, et al. Efficacy of SARS-CoV-2 Vaccination in Dialysis Patients: Epidemiological Analysis and Evaluation of the Clinical Progress. *J Clin Med* 2022; **11**(16).

1461. Moutombi Ditombi BC, Pongui Ngondza B, Manomba Boulingui C, et al. Malaria and COVID-19 prevalence in a population of febrile children and adolescents living in Libreville. *S Afr J Infect Dis* 2022; **37**(1): 459.

1462. Muhammad LJ, Haruna AA, Sharif US, Mohammed MB. CNN-LSTM deep learning based forecasting model for COVID-19 infection cases in Nigeria, South Africa and Botswana. *Health Technol (Berl)* 2022; **12**(6): 1259-76.

1463. Müller GC, Ferreira LS, Mesias Campos FE, et al. Modeling the impact of child vaccination (5-11 y) on overall COVID-19 related hospitalizations and mortality in a context of omicron variant predominance and different vaccination coverage paces in Brazil. *Lancet Reg Health Am* 2023; **17**: 100396.

1464. Mullins A, O'Donnell R, Morris H, et al. The effect of My Health Record use in the emergency department on clinician-assessed patient care: results from a survey. *BMC Med Inform Decis Mak* 2022; **22**(1): 178.

1465. Muñoz FM, Sher LD, Sabharwal C, et al. Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age. *N Engl J Med* 2023; **388**(7): 621-34.

1466. Muñoz-Alía M, Nace RA, Balakrishnan B, et al. Surface-modified measles vaccines encoding oligomeric, fusion-stabilized SARS-CoV-2 spike glycoproteins bypass measles seropositivity, boosting neutralizing antibody responses to omicron and historical variants. *bioRxiv* 2022.

1467. Murakami K, Iwasaki S, Oguri S, et al. SARS-CoV-2 Omicron detection by antigen tests using saliva. *J Clin Virol Plus* 2022; **2**(4): 100109.

1468. Murari TB, Fonseca L, Pereira HBB, et al. Retrospective Cohort Study of COVID-19 in Patients of the Brazilian Public Health System with SARS-CoV-2 Omicron Variant Infection. *Vaccines (Basel)* 2022; **10**(9).

1469. Murugadoss K, Niesen MJM, Raghunathan B, et al. Continuous genomic diversification of long polynucleotide fragments drives the emergence of new SARS-CoV-2 variants of concern. *PNAS Nexus* 2022; **1**(1): pgac018.

1470. Mutesa L, Misbah G, Remera E, et al. Use of trained scent dogs for detection of COVID-19 and evidence of cost-saving. *Front Med (Lausanne)* 2022; **9**: 1006315.

1471. Muwonge A, Wee BA, Mugerwa I, et al. An open-source digital contact tracing system tailored to haulage. *Front Digit Health* 2023; **5**: 1199635.

1472. Mwimanzi F, Lapointe HR, Cheung PK, et al. Impact of Age and Severe Acute Respiratory Syndrome Coronavirus 2 Breakthrough Infection on Humoral Immune Responses After Three Doses of Coronavirus Disease 2019 mRNA Vaccine. *Open Forum Infect Dis* 2023; **10**(3): ofad073.

1473. Naggie S. Ivermectin for Treatment of Mild-to-Moderate COVID-19 in the Outpatient Setting: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial. *medRxiv* 2022.

1474. Naggie S. Inhaled Fluticasone for Outpatient Treatment of Covid-19: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial. *medRxiv* 2022.

1475. Nair MS, Ribeiro RM, Wang M, et al. Changes in serum-neutralizing antibody potency and breadth post-SARS-CoV-2 mRNA vaccine boost. *iScience* 2023; **26**(4): 106345.

1476. Nam BH, English AS. Trauma-Informed Care: A Transcendental Phenomenology of the Experiences of International Faculty during the Delta and Omicron Variant Outbreaks in East China. *Int J Environ Res Public Health* 2022; **19**(17).

1477. Naruse H, Doi Y, Iwata M, Ishikawa K. An early return-to-work program for COVID-19 close contacts in healthcare during the Omicron wave in Japan. *J Infect Chemother* 2023; **29**(1): 102-4.

1478. Nasrallah GK, Ali F, Younes S, Al Khatib HA, Al-Thani AA, Yassine HM. Enhancing the sensitivity of rapid antigen detection test (RADT) of different SARS-CoV-2 variants and lineages using fluorescence-labeled antibodies and a fluorescent meter. *Heliyon* 2023; **9**(6): e17179.

1480. Nejatifar F, Hesni E, Samadani AA. A Novel Case Report of Severe Aplastic Anemia with COVID Infection. *Ethiop J Health Sci* 2023; **33**(1): 177-81.

1481. Nerlich B, Jaspal R. From danger to destination: changes in the language of endemic disease during the COVID-19 pandemic. *Med Humanit* 2023.

1482. Ngonghala CN, Taboe HB, Safdar S, Gumel AB. Unraveling the dynamics of the Omicron and Delta variants of the 2019 coronavirus in the presence of vaccination, mask usage, and antiviral treatment. *Appl Math Model* 2023; **114**: 447-65.

1483. Nguyen LH. The impact of the resumption of in-person school attendance on COVID-affected child abuse and neglect trends in Florida. *Child Abuse Negl* 2022; **129**: 105658.

1484. Nikam C, Suraweera W, Fu SHH, Brown PE, Nagelkerke N, Jha P. PCR Test Positivity and Viral Loads during Three SARS-CoV-2 Viral Waves in Mumbai, India. *Biomedicines* 2023; **11**(7).

1485. Nill F. Endemic oscillations for SARS-CoV-2 Omicron-A SIRS model analysis. *Chaos Solitons Fractals* 2023; **173**: 113678.

1486. Ning S, Chang HC, Fan KC, et al. A point-of-care biosensor for rapid detection and differentiation of COVID-19 virus (SARS-CoV-2) and influenza virus using subwavelength grating micro-ring resonator. *Appl Phys Rev* 2023; **10**(2): 021410.

1487. Ning X, Jia L, Wei Y, Li XA, Chen F. Epi-DNNs: Epidemiological priors informed deep neural networks for modeling COVID-19 dynamics. *Comput Biol Med* 2023; **158**: 106693.

1488. Nocini R, Henry BM, Mattiuzzi C, Lippi G. Improving Nasal Protection for Preventing SARS-CoV-2 Infection. *Biomedicines* 2022; **10**(11).

1489. Nordström P, Ballin M, Nordström A. Effectiveness of a fourth dose of mRNA COVID-19 vaccine against all-cause mortality in long-term care facility residents and in the oldest old: A nationwide, retrospective cohort study in Sweden. *Lancet Reg Health Eur* 2022; **21**: 100466.

1490. Odriozola Herrán A, Fortea Ormaechea JI, Cuadrado A, et al. Protective measures against Omicron could be more effective than Evusheld® in liver transplant recipients. *Rev Esp Enferm Dig* 2022; **114**(12): 769-70.

1491. Oh BLZ, Tan N, de Alwis R, et al. Enhanced BNT162b2 vaccine-induced cellular immunity in anti-CD19 CAR T cell-treated patients. *Blood* 2022; **140**(2): 156-60.

1492. Oh J, Apio C, Park T. Mathematical modeling of the impact of Omicron variant on the COVID-19 situation in South Korea. *Genomics Inform* 2022; **20**(2): e22.

1493. Oh J, Lee W, Kim CJ, et al. COVID-19, maternal, and neonatal outcomes: National Mother-Child Cohort (NMCC) of K-COV-N cohort in South Korea. *PLoS One* 2023; **18**(4): e0284779.

1494. Oh SJ, O SW, Choi YJ, et al. Neutralizing antibody responses in vaccinated and unvaccinated individuals infected with Omicron BA.1 variant. *J Clin Virol* 2022; **155**: 105253.

1495. Okada Y, Yamasaki S, Nishida A, Shibasaki R, Nishiura H. Night-time population consistently explains the transmission dynamics of coronavirus disease 2019 in three megacities in Japan. *Front Public Health* 2023; **11**: 1163698.

1496. Oliveira CF, Neto WFF, Silva CPD, et al. Absence of Anti-RBD Antibodies in SARS-CoV-2 Infected or Naive Individuals Prior to Vaccination with CoronaVac Leads to Short Protection of Only Four Months Duration. *Vaccines (Basel)* 2022; **10**(5).

1497. Ooms C, Mossong J, Vergison A, et al. Multisystem inflammatory syndrome in children during the first two years of the COVID-19 pandemic in Luxembourg. *Front Pediatr* 2023; **11**: 1141074.

1498. Otunuga OM. Analysis of multi-strain infection of vaccinated and recovered population through epidemic model: Application to COVID-19. *PLoS One* 2022; **17**(7): e0271446.

1499. Overduin M, Kervin TA, Tran A. Progressive membrane-binding mechanism of SARS-CoV-2 variant spike proteins. *iScience* 2022; **25**(8): 104722.

1500. Oyibo K, Morita PP. COVID Alert: Factors Influencing the Adoption of Exposure Notification Apps Among Canadian Residents. *Front Digit Health* 2022; **4**: 842661.

1501. Ozgur-Buyukatalay E, Demirbas YS, Bozdayi G, Kismali G, Ilhan MN. Is diagnostic performance of SARS-CoV-2 detection dogs reduced -due to virus variation- over the time? *Appl Anim Behav Sci* 2023; **258**: 105825.

1502. Pal S, Mehta P, Pandey A, et al. Molecular determinants associated with temporal succession of SARS-CoV-2 variants in Uttar Pradesh, India. *Front Microbiol* 2023; **14**: 986729.

1503. Palanisamy S, Lee LY, Kao CF, et al. One-step-one-pot hydrothermally derived metal-organic-framework-nanohybrids for integrated point-of-care diagnostics of SARS-CoV-2 viral antigen/pseudovirus utilizing electrochemical biosensor chip. *Sens Actuators B Chem* 2023; **390**: 133960.

1504. Palatnik-de-Sousa I, Wallace ZS, Cavalcante SC, et al. A novel vaccine based on SARS-CoV-2 CD4(+) and CD8(+) T cell conserved epitopes from variants Alpha to Omicron. *Sci Rep* 2022; **12**(1): 16731.

1505. Palmieri B, Manenti A, Galotti F, Vadalà M. Innate Immunity Stimulation during the COVID-19 Pandemic: Challenge by Parvulan. *J Immunol Res* 2022; **2022**: 4593598.

1506. Pan Z, Wan Z, Wang Y, et al. An open-label randomized controlled trial of leflunomide in patients with acute SARS-CoV-2 omicron variant infection. *Front Med (Lausanne)* 2023; **10**: 1218102.

1507. Papaioannou O, Karampitsakos T, Tsiri P, et al. Clinical outcomes in vaccinated and unvaccinated patients with COVID-19: a population-based analysis. *Eur Rev Med Pharmacol Sci* 2022; **26**(20): 7705-12.

1508. Papathanasiou J, Kashilska Y, Bozov H, Petrov I, Masiero S. The outbreak of the SARS-CoV-2 Omicron variant make imperative the adoption of telerehabilitation in the Bulgarian health care system. *Eur J Transl Myol* 2022; **32**(1).

1509. Parai D, Choudhary HR, Dash GC, et al. Dynamicity and persistence of severe acute respiratory syndrome coronavirus-2 antibody response after double dose and the third dose with BBV-152 and AZD1222 vaccines: A prospective, longitudinal cohort study. *Front Microbiol* 2022; **13**: 942659.

1510. Park H, Park YJ, Lee HY, et al. The effectiveness of Paxlovid treatment in long-term care facilities in South Korea during the outbreak of the Omicron variant of SARS-CoV-2. *Osong Public Health Res Perspect* 2022; **13**(6): 443-7.

1511. Park S, You J, Lee J, Park E. Two Case Reports of Life-Threatening Croup Caused by the SARS-CoV-2 Omicron BA.2 Variant in Pediatric Patients. *J Korean Med Sci* 2022; **37**(24): e192.

1512. Parn S, Savsani K, Dakshanamurthy S. SARS-CoV-2 Omicron (BA.1 and BA.2) specific novel CD8+ and CD4+ T cell epitopes targeting spike protein. *Immunoinformatics (Amst)* 2022; **8**: 100020.

1513. Partakusuma LG, Budiailmiawan L, Budiman, et al. The Single-Nucleotide Polymorphism (SNP) Validity to Detect Omicron Variants. *Adv Virol* 2023; **2023**: 6618710.

1514. Patro KK, Allam JP, Hammad M, Tadeusiewicz R, Pławiak P. SCovNet: A skip connection-based feature union deep learning technique with statistical approach analysis for the detection of COVID-19. *Biocybern Biomed Eng* 2023; **43**(1): 352-68.

1515. Pavliuk O, Kolesnyk H. Machine-learning method for analyzing and predicting the number of hospitalizations of children during the fourth wave of the COVID-19 pandemic in the Lviv region. *J Reliab Intell Environ* 2023; **9**(1): 17-26.

1516. Pei H, Gan X, Guo F, et al. A survey of health status of healthcare providers in a square cabin hospital during the new corona omicron outbreak: A cross-sectional study. *Front Psychol* 2022; **13**: 1028631.

1517. Peled Y, Afek A, Nemet I, et al. Fourth BNT162b2 vaccination neutralization of omicron infection after heart transplantation. *J Heart Lung Transplant* 2022; **41**(9): 1210-3.

1518. Peng D, Huang H, Liu Z, Gao Y, Liu Y. Vitamin D levels and clinical outcomes of SARS-CoV-2 Omicron subvariant BA.2 in children: A longitudinal cohort study. *Front Nutr* 2022; **9**: 960859.

1519. Peng M, Hu M, Peng X, et al. What contributes to the re-positive nucleic acid test results for the omicron variant of SARS-CoV-2 in the shelter cabin hospital in Shanghai, China? *Heliyon* 2023; **9**(5): e15679.

1520. Perez MA, Hsiao HM, Chen X, et al. Serologic responses to COVID-19 vaccination in children with history of multisystem inflammatory syndrome (MIS-C). *Vaccine* 2023; **41**(17): 2743-8.

1521. Perkmann T, Springer DN, Mucher P, Wolzt M, Weseslindtner L, Haslacher H. Breakthrough infections with SARS-CoV-2 omicron efficiently boost antibodies from previous BNT162b2 vaccinations. *J Clin Virol Plus* 2023; **3**(3): 100157.

1523. Petat H, Hassani A, Dabaj I, et al. Ischemic stroke on SARS-CoV2 vasculitis in a healthy young girl. *Health Sci Rep* 2023; **6**(1): e1046.

1524. Petrou A, Zagaliotis P, Theodoroula NF, et al. Thiazole/Thiadiazole/Benzothiazole Based Thiazolidin-4-One Derivatives as Potential Inhibitors of Main Protease of SARS-CoV-2. *Molecules* 2022; **27**(7).

1525. Pham VH, Pham HT, Balzanelli MG, et al. Multiplex RT Real-Time PCR Based on Target Failure to Detect and Identify Different Variants of SARS-CoV-2: A Feasible Method That Can Be Applied in Clinical Laboratories. *Diagnostics (Basel)* 2023; **13**(8).

1526. Pierz AJ, Rauh L, Masoud D, et al. Supporting US healthcare providers for successful vaccine communication. *BMC Health Serv Res* 2023; **23**(1): 423.

1527. Poh XY, Tan CW, Lee IR, et al. Antibody Response of Heterologous vs Homologous Messenger RNA Vaccine Boosters Against the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant: Interim Results from the PRIBIVAC Study, a Randomized Clinical Trial. *Clin Infect Dis* 2022; **75**(12): 2088-96.

1528. Poli K, Kowarik M, Hamprecht K, et al. Recurrent Acute Disseminated Encephalomyelitis (ADEM) after COVID-19-vaccination and after subsequent COVID-19-infection: A case report (part II). *Front Neurol* 2023; **14**: 1149612.

1529. Pollock Star A, Bachner YG, Cohen B, Haglili O, O'Rourke N. Social Media Use and Well-being With Bipolar Disorder During the COVID-19 Pandemic: Path Analysis. *JMIR Form Res* 2022; **6**(8): e39519.

1530. Popovic M. Strain wars 3: Differences in infectivity and pathogenicity between Delta and Omicron strains of SARS-CoV-2 can be explained by thermodynamic and kinetic parameters of binding and growth. *Microb Risk Anal* 2022; **22**: 100217.

1531. Popovic M. Strain wars 5: Gibbs energies of binding of BA.1 through BA.4 variants of SARS-CoV-2. *Microb Risk Anal* 2022; **22**: 100231.

1532. Popovic M. SARS-CoV-2 strain wars continues: Chemical and thermodynamic characterization of live matter and biosynthesis of Omicron BN.1, CH.1.1 and XBC variants. *Microb Risk Anal* 2023; **24**: 100260.

1533. Prakash S, Dhanushkodi NR, Zayou L, et al. Cross-Protection Induced by Highly Conserved Human B, CD4 (+,) and CD8 (+) T Cell Epitopes-Based Coronavirus Vaccine Against Severe Infection, Disease, and Death Caused by Multiple SARS-CoV-2 Variants of Concern. *bioRxiv* 2023.

1534. Pramanik A, Mayer J, Sinha SS, et al. Human ACE2 Peptide-Attached Plasmonic-Magnetic Heterostructure for Magnetic Separation, Surface Enhanced Raman Spectroscopy Identification, and Inhibition of Different Variants of SARS-CoV-2 Infections. *ACS Appl Bio Mater* 2022.

1535. Pramanik MEA, Miah MMZ, Ahmed I, et al. Euphorbia neriifolia Leaf Juice on Mild and Moderate COVID-19 Patients: Implications in OMICRON Era. *Euroasian J Hepatogastroenterol* 2022; **12**(1): 10-8.

1536. Primorac D, Brlek P, Matišić V, et al. Cellular Immunity-The Key to Long-Term Protection in Individuals Recovered from SARS-CoV-2 and after Vaccination. *Vaccines (Basel)* 2022; **10**(3).

1537. Primorac D, Brlek P, Pavelić ES, et al. Importance of Cellular Immunity and IFN-γ Concentration in Preventing SARS-CoV-2 Infection and Reinfection: A Cohort Study. *Viruses* 2023; **15**(3).

1538. Prosperi M, Rife B, Marini S, Salemi M. Transmission cluster characteristics of global, regional, and lineage-specific SARS-CoV-2 phylogenies. *IEEE Int Conf Bioinform Biomed Workshops* 2022; **2022**: 2940-4.

1539. Prusinkiewicz MA, Sediqi S, Li YJ, et al. Effect of vaccine dosing intervals on Omicron surrogate neutralization after three doses of BNT162b2. *Heliyon* 2023; **9**(6): e17259.

1540. Pushpa SR, Sukumaran RK, Savithri S. Robustness of FTIR-Based Ultrarapid COVID-19 Diagnosis Using PLS-DA. *ACS Omega* 2022; **7**(50): 47357-71.

1541. Putri NK, Melania MKN, Fatmawati SMY, Lim YC. How does the work-life balance impact stress on primary healthcare workers during the COVID-19 pandemic? *BMC Health Serv Res* 2023; **23**(1): 730.

1542. Qassim SH, Chemaitelly H, Ayoub HH, et al. Population immunity of natural infection, primary-series vaccination, and booster vaccination in Qatar during the COVID-19 pandemic: an observational study. *EClinicalMedicine* 2023; **62**: 102102.

1543. Qi L, Tang W, Wang J, et al. An Outbreak of SARS-CoV-2 Omicron Subvariant BA.2.76 in an Outdoor Park - Chongqing Municipality, China, August 2022. *China CDC Wkly* 2022; **4**(46): 1039-42.

1544. Qian G, Wang X, Patel NJ, et al. Outcomes with and without outpatient SARS-CoV-2 treatment for patients with COVID-19 and systemic autoimmune rheumatic diseases: A retrospective cohort study. *medRxiv* 2022.

1545. Qiao S, Li Z, Liang C, Li X, Rudisill C. Three dimensions of COVID-19 risk perceptions and their socioeconomic correlates in the United States: A social media analysis. *Risk Anal* 2023; **43**(6): 1174-86.

1546. Qin Y, Chen R. Social Network Analysis of COVID-19 Research and the Changing International Collaboration Structure. *J Shanghai Jiaotong Univ Sci* 2022: 1-11.

1547. Qiu C, Wu Z, Liu X, et al. Efficacy and safety of Nirmatrelvir/Ritonavir for treating the Omicron variant of COVID-19. *Front Med (Lausanne)* 2023; **10**: 1161193.

1548. Qiu W, Shi Q, Chen F, Wu Q, Yu X, Xiong L. The derived neutrophil to lymphocyte ratio can be the predictor of prognosis for COVID-19 Omicron BA.2 infected patients. *Front Immunol* 2022; **13**: 1065345.

1549. Rabie AM, Abdalla M. A Series of Adenosine Analogs as the First Efficacious Anti-SARS-CoV-2 Drugs against the B.1.1.529.4 Lineage: A Preclinical Repurposing Research Study. *ChemistrySelect* 2022; **7**(46): e202201912.

1550. Rabie AM, Abdalla M. Forodesine and Riboprine Exhibit Strong Anti-SARS-CoV-2 Repurposing Potential: In Silico and In Vitro Studies. *ACS Bio Med Chem Au* 2022; **2**(6): 565-85.

1551. Rabie AM, Eltayb WA. Potent Dual Polymerase/Exonuclease Inhibitory Activities of Antioxidant Aminothiadiazoles Against the COVID-19 Omicron Virus: A Promising In Silico/In Vitro Repositioning Research Study. *Mol Biotechnol* 2023: 1-20.

1552. Rahman MS, Hoque MN, Chowdhury SR, et al. Temporal dynamics and fatality of SARS-CoV-2 variants in Bangladesh. *Health Sci Rep* 2023; **6**(4): e1209.

1553. Ramchandar N, Slayden T, Garcia-Rivera JA, et al. Management of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Onboard a U.S. Navy Hospital Ship Amid a Global Omicron Surge. *Mil Med* 2022.

1554. Rao CM, Mohapatra AK, Patnaik AK, Panda PS, Behera PR. An in-depth appraisal of clinico-biochemical and radiological findings of COVID-19 patients during the COVID-19 pandemic in a dedicated COVID Care Hospital in Eastern India and its outcome in relation to the COVAXIN vaccination status: A 2-year study. *J Family Med Prim Care* 2023; **12**(5): 971-8.

1555. Ravindran S, Gubbay JB, Cronin K, et al. Association Between Cycle Threshold Value and Vaccination Status Among Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant Cases in Ontario, Canada, in December 2021. *Open Forum Infect Dis* 2023; **10**(6): ofad282.

1556. Redd AD, Nardin A, Kared H, et al. Minimal cross-over between mutations associated with Omicron variant of SARS-CoV-2 and CD8+ T cell epitopes identified in COVID-19 convalescent individuals. *bioRxiv* 2021.

1557. Regenhardt E, Kirsten H, Weiss M, et al. SARS-CoV-2 Vaccine Breakthrough Infections of Omicron and Delta Variants in Healthcare Workers. *Vaccines (Basel)* 2023; **11**(5).

1558. Reinscheid M, Luxenburger H, Karl V, et al. COVID-19 mRNA booster vaccine induces transient CD8+ T effector cell responses while conserving the memory pool for subsequent reactivation. *Nat Commun* 2022; **13**(1): 4631.

1559. Reiter ER, Coelho DH, French E, Costanzo RM. COVID-19-Associated Chemosensory Loss Continues to Decline. *Otolaryngol Head Neck Surg* 2023.

1560. Rennert L, Ma Z. An epidemiological modeling framework to inform institutional-level response to infectious disease outbreaks: A Covid-19 case study. *Res Sq* 2023.

1561. Reyes-Velázquez A, Molgado A, Berra-Montiel J, Martinez-Gonzalez JA. A General Path-Integral Monte Carlo Method for Exact Simulations of Chemical Reaction Networks. *J Phys Chem A* 2023; **127**(19): 4363-74.

1562. Ribeiro Xavier C, Sachetto Oliveira R, da Fonseca Vieira V, Lobosco M, Weber Dos Santos R. Characterisation of Omicron Variant during COVID-19 Pandemic and the Impact of Vaccination, Transmission Rate, Mortality, and Reinfection in South Africa, Germany, and Brazil. *BioTech (Basel)* 2022; **11**(2).

1563. Richardson JR, Götz R, Mayr V, Lohse MJ, Holthoff HP, Ungerer M. SARS-CoV2 wild type and mutant specific humoral and T cell immunity is superior after vaccination than after natural infection. *PLoS One* 2022; **17**(4): e0266701.

1564. Richardson SI, Kgagudi P, Manamela NP, et al. Antibody-dependent cellular cytotoxicity against SARS-CoV-2 Omicron sub-lineages is reduced in convalescent sera regardless of infecting variant. *Cell Rep Med* 2023; **4**(1): 100910.

1565. Ridgway JP, Tideman S, Wright B, Robicsek A. Decreased Risk of Coronavirus Disease 2019-Related Hospitalization Associated With the Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2. *Open Forum Infect Dis* 2022; **9**(7): ofac288.

1566. Risk M, Hayek SS, Schiopu E, et al. COVID-19 vaccine effectiveness against omicron (B.1.1.529) variant infection and hospitalisation in patients taking immunosuppressive medications: a retrospective cohort study. *Lancet Rheumatol* 2022; **4**(11): e775-e84.

1567. Rochman ND, Faure G, Wolf YI, Freddolino PL, Zhang F, Koonin EV. Epistasis at the SARS-CoV-2 RBD Interface and the Propitiously Boring Implications for Vaccine Escape. *bioRxiv* 2021.

1568. Rodriguez-Rodriguez BA, Ciabattoni GO, Duerr R, et al. A neonatal mouse model characterizes transmissibility of SARS-CoV-2 variants and reveals a role for ORF8. *bioRxiv* 2023.

1569. Roe TL, Brady T, Schuko N, et al. Molecular Characterization of AZD7442 (Tixagevimab-Cilgavimab) Neutralization of SARS-CoV-2 Omicron Subvariants. *Microbiol Spectr* 2023; **11**(2): e0033323.

1570. Routhu NK, Stampfer SD, Lai L, et al. Efficacy of mRNA-1273 and Novavax ancestral or BA.1 spike booster vaccines against SARS-CoV-2 BA.5 infection in non-human primates. *Sci Immunol* 2023: eadg7015.

1571. Rowe BR, Canosa A, Meslem A, Rowe F. Increased airborne transmission of COVID-19 with new variants, implications for health policies. *Build Environ* 2022; **219**: 109132.

1572. Rui R, Tian M, Xiong W. Exploration of the impact of political ideology disparity on COVID-19 transmission in the United States. *BMC Public Health* 2022; **22**(1): 2163.

1573. Russell TW, Townsley H, Abbott S, et al. Within-host SARS-CoV-2 viral kinetics informed by complex life course exposures reveals different intrinsic properties of Omicron and Delta variants. *medRxiv* 2023.

1574. Rzymski P, Szuster-Ciesielska A. The COVID-19 Vaccination Still Matters: Omicron Variant Is a Final Wake-Up Call for the Rich to Help the Poor. *Vaccines (Basel)* 2022; **10**(7).

1575. Saade C, Pozzetto B, Yaugel-Novoa M, et al. Long-term humoral response following Delta and Omicron BA.1 co-infection. *NPJ Vaccines* 2023; **8**(1): 57.

1576. Saade M, Ghosh S, Banerjee M, Volpert V. An epidemic model with time delays determined by the infectivity and disease durations. *Math Biosci Eng* 2023; **20**(7): 12864-88.

1577. Sadowski MM. Hong Kong, the Virus and Illiberalism: Between Flattening the Curve and an Authoritarian Slide? *Int J Semiot Law* 2022; **35**(3): 961-76.

1578. Saharia KK, Husson JS, Niederhaus SV, et al. Humoral immunity against SARS-CoV-2 variants including omicron in solid organ transplant recipients after three doses of a COVID-19 mRNA vaccine. *Clin Transl Immunology* 2022; **11**(5): e1391.

1579. Saiag E, Alcalay Y, Marudi O, Orr-Urtreger A, Hagin D. Cellular and humoral immune response to the fourth Pfizer-BioNTech COVID-19 vaccine dose in individuals aged 60 years and older. *Vaccine* 2023; **41**(4): 914-21.

1580. Salimović-Bešić I, Dedeić-Ljubović A, Zahirović E, et al. The SARS-CoV-2 Delta (B.1.617.2) variant with spike N501Y mutation in the shadow of Omicron emergence. *Heliyon* 2022; **8**(12): e12650.

1581. Sánchez-Morales L, Sánchez-Vizcaíno JM, Pérez-Sancho M, Domínguez L, Barroso-Arévalo S. The Omicron (B.1.1.529) SARS-CoV-2 variant of concern also affects companion animals. *Front Vet Sci* 2022; **9**: 940710.

1583. Sangkachai N, Chaiwattanarungruengpaisan S, Thongdee M, et al. Serological and Molecular Surveillance for SARS-CoV-2 Infection in Captive Tigers (Panthera tigris), Thailand. *Animals (Basel)* 2022; **12**(23).

1584. Sano H, Yamazaki T, Kudo E, Hatakeyama K, Ito T. Posterior reversible encephalopathy syndrome associated with mild COVID-19 infection in a 9-year-old child: A case report and literature review. *IDCases* 2023; **31**: e01699.

1585. Santos C, Valiati NCM, Noronha TG, et al. The effectiveness of COVID-19 vaccines against severe cases and deaths in Brazil from 2021 to 2022: a registry-based study. *Lancet Reg Health Am* 2023; **20**: 100465.

1586. Sarkar A, Roy KK, Zangmo R, et al. Gynaecological Laparoscopic Surgeries in the Omicron Era: Improvising the Management Skills After Lessons Learnt From the Delta Wave. *Cureus* 2022; **14**(10): e29904.

1587. Sarkar P, Banerjee S, Chakrabarti S, et al. Genome characterization, phylogenomic assessment and spatio-temporal dynamics study of highly mutated BA variants from India. *Indian J Med Microbiol* 2023; **43**: 66-72.

1588. Schmidt MM, Despres HW, Shirley DJ, et al. Viral infectivity in pediatric SARS-CoV-2 clinical samples does not vary by age. *medRxiv* 2022.

1589. Schmiege D, Kraiselburd I, Haselhoff T, et al. Analyzing community wastewater in sub-sewersheds for the small-scale detection of SARS-CoV-2 variants in a German metropolitan area. *Sci Total Environ* 2023; **898**: 165458.

1590. Schultz BM, Melo-González F, Duarte LF, et al. A booster dose of an inactivated SARS-CoV-2 vaccine increases neutralizing antibodies and T cells that recognize Delta and Omicron variants of concern. *medRxiv* 2022.

1591. Schwenk GR, Glass AM, Ji HF, et al. Surfactant-Impregnated MOF-Coated Fabric for Antimicrobial Applications. *ACS Appl Bio Mater* 2023; **6**(1): 238-45.

1592. Scott LE, Hsiao NY, Dor G, et al. How South Africa Used National Cycle Threshold (Ct) Values to Continuously Monitor SARS-CoV-2 Laboratory Test Quality. *Diagnostics (Basel)* 2023; **13**(15).

1593. Seaman MS, Siedner MJ, Boucau J, et al. Vaccine Breakthrough Infection with the SARS-CoV-2 Delta or Omicron (BA.1) Variant Leads to Distinct Profiles of Neutralizing Antibody Responses. *medRxiv* 2022.

1594. Seetha D, Ravikumar A, Nair RR. Comparative performance of CDC-modified SARS-CoV-2 real-time PCR assay with four different commercial assays: laboratory-based study. *Comp Clin Path* 2022; **31**(3): 355-63.

1595. Semeraro M, Pinson P, Populaire M, et al. Analysis of the impact of the SARS-CoV-2 infection on the pediatric population hospitalized during the pandemic in the Greater Paris University Hospitals. *Front Pediatr* 2023; **11**: 1044352.

1596. Sener T, Haenen W, Smits P, Hans GH. Large-scale real-life implementation of technology-enabled care to maximize hospitals' medical surge preparedness during future infectious disease outbreaks and winter seasons: a viewpoint. *Front Public Health* 2023; **11**: 1149247.

1597. Sepulveda K, Issa T, Dubrocq G. Cerebral fat embolism syndrome in a patient with homozygous sickle cell disease in the setting of multisystem inflammatory syndrome in children. *Proc (Bayl Univ Med Cent)* 2023; **36**(2): 266-8.

1598. Shafaati M, Bagherzadeh K, Lotfinia M, et al. The protection quest is a primary key to sharing the neutralizing antibody response to cover against all emerging VOCs based on BIV1-CovIran studies. *Heliyon* 2023; **9**(3): e14108.

1599. Shah M, Shin JY, Woo HG. Rational strategies for enhancing mAb binding to SARS-CoV-2 variants through CDR diversification and antibody-escape prediction. *Front Immunol* 2023; **14**: 1113175.

1600. Shahab M, Akter S, Sarkar MMH, et al. Computational design of medicinal compounds to inhibit RBD-hACE2 interaction in the Omicron variant: unveiling a vulnerable target site. *Inform Med Unlocked* 2023; **40**: 101281.

1601. Shahan JL, Collins RH, Patel P, Madanat YF, Vusirikala M. Anti-Spike Antibody Responses in Allogeneic Stem Cell Transplant Recipients to Two Doses of COVID-19 mRNA Vaccination: A Retrospective, Single-Center Analysis. *J Adv Pract Oncol* 2023; **14**(5): 367-71.

1602. Shan D, Liu C, Li S, Zheng Y. Corrigendum: Increased anxiety from fear of Omicron in China as compared to North America and Western Europe: A cross-sectional Kendall's tau-b analysis using the generalized anxiety disorder 7-item questionnaire. *Front Psychiatry* 2022; **13**: 1038966.

1603. Shan Y, Ji M, Xie W, et al. Use of Health Care Chatbots Among Young People in China During the Omicron Wave of COVID-19: Evaluation of the User Experience of and Satisfaction With the Technology. *JMIR Hum Factors* 2022; **9**(2): e36831.

1604. Shao J, Fan R, Hu J, et al. Clinical Progression and Outcome of Hospitalized Patients Infected with SARS-CoV-2 Omicron Variant in Shanghai, China. *Vaccines (Basel)* 2022; **10**(9).

1605. Shapiro JR, Sitaras I, Park HS, et al. Association of Frailty, Age, and Biological Sex With Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccine-Induced Immunity in Older Adults. *Clin Infect Dis* 2022; **75**(Suppl 1): S61-s71.

1606. Sharma P, Basu S, Mishra S, et al. SARS-CoV-2 Seroprevalence in Delhi, India, During September-October 2021: A Population-Based Seroepidemiological Study. *Cureus* 2022; **14**(7): e27428.

1607. Sharma RP, Gautam S, Sharma P, et al. Genomic profile of SARS-CoV-2 Omicron variant and its correlation with disease severity in Rajasthan. *Front Med (Lausanne)* 2022; **9**: 888408.

1608. Shen J, Wu L, Wang P, et al. Clinical characteristics and short-term recovery of hyposmia in hospitalized non-severe COVID-19 patients with Omicron variant in Shanghai, China. *Front Med (Lausanne)* 2022; **9**: 1038938.

1609. Shen Y, Ai J, Lin N, et al. An open, prospective cohort study of VV116 in Chinese participants infected with SARS-CoV-2 omicron variants. *Emerg Microbes Infect* 2022; **11**(1): 1518-23.

1610. Shen Y, Freeman JA, Holland J, et al. Multiple COVID-19 vaccine doses in CLL and MBL improve immune responses with progressive and high seroconversion. *Blood* 2022; **140**(25): 2709-21.

1611. Shen Y, Huo D, Yu T, Wang Q. Bubble Strategy - A Practical Solution to Return to Regular Life in the Intertwined Era of Vaccine Rollouts and Virus Mutation. *China CDC Wkly* 2022; **4**(4): 71-3.

1612. Shi X, Ling GHT, Leng PC, Rusli N, Matusin A. Associations between institutional-social-ecological factors and COVID -19 case-fatality: Evidence from 134 countries using multiscale geographically weighted regression (MGWR). *One Health* 2023; **16**: 100551.

1613. Shin IS, Lee YP, Lee SH, Lee JY, Park JH, Chung YS. Effectiveness of the COVID-19 vaccine in the Honam region of the Republic of Korea. *Osong Public Health Res Perspect* 2023; **14**(3): 197-206.

1614. Shrivastava S, Carmen JM, Lu Z, et al. SARS-CoV-2 spike-ferritin-nanoparticle adjuvanted with ALFQ induces long-lived plasma cells and cross-neutralizing antibodies. *NPJ Vaccines* 2023; **8**(1): 43.

1615. Si S, Jin C, Li J, et al. Safety and Effectiveness of SA58 Nasal Spray Against COVID-19 Infection in Medical Personnel: An Open-Label, Blank-Controlled Study - Hohhot City, Inner Mongolia Autonomous Region, China, 2022. *China CDC Wkly* 2023; **5**(10): 218-22.

1616. Silva Júnior JVJ, Durães-Carvalho R, de Souza JR, Ramos Janini LM, Weiblen R, Flores EF. Emergence of SARS-CoV-2 serotype(s): Is it a matter of time? *Virology* 2023; **585**: 78-81.

1617. Simard M, Boiteau V, Fortin É, et al. Impact of chronic comorbidities on hospitalization, intensive care unit admission and death among adult vaccinated and unvaccinated COVID-19 confirmed cases during the Omicron wave. *J Multimorb Comorb* 2023; **13**: 26335565231169567.

1618. Sindu D, Razia D, Grief K, et al. Pre-exposure Prophylaxis with Tixagevimab-cilgavimab did not Reduce Severity of COVID-19 in Lung Transplant Recipients with Breakthrough Infection. *Transplant Direct* 2023; **9**(6): e1485.

1619. Singh P, Sharma K, Shaw D, Bhargava A, Negi SS. Mutational characterization of Omicron SARS-CoV-2 lineages circulating in Chhattisgarh, a central state of India. *Front Med (Lausanne)* 2022; **9**: 1082846.

1620. Sintusek P, Buranapraditkun S, Khunsri S, et al. Safety and Humoral and Cellular Immunogenicity of the BNT162b2 SARS-CoV-2 Vaccine in Liver-Transplanted Adolescents Compared to Healthy Adolescents. *Vaccines (Basel)* 2022; **10**(8).

1621. Sit BHM, Po KHL, Cheung YY, et al. Detection of SARS-CoV-2 VOC-Omicron using commercial sample-to-answer real-time RT-PCR platforms and melting curve-based SNP assays. *J Clin Virol Plus* 2022; **2**(3): 100091.

1622. Sobczak M, Pawliczak R. Which Factors Were Related to the Number of COVID-19 Cases in the 2022/2023 Season Compared to the 2021/2022 Season in Europe? *J Clin Med* 2023; **12**(13).

1623. Sokhansanj BA, Zhao Z, Rosen GL. Interpretable and Predictive Deep Neural Network Modeling of the SARS-CoV-2 Spike Protein Sequence to Predict COVID-19 Disease Severity. *Biology (Basel)* 2022; **11**(12).

1624. Somersan-Karakaya S, Mylonakis E, Mou J, et al. Effectiveness of Casirivimab and Imdevimab Antibody Combination in Immunocompromised Hospitalized Patients With Coronavirus Disease 2019: A Post Hoc Analysis in a Phase 1/2/3 Double-Blind Trial. *Open Forum Infect Dis* 2023; **10**(5): ofad211.

1625. Sominina A, Danilenko D, Komissarov A, et al. Resurgence of Influenza Circulation in the Russian Federation during the Delta and Omicron COVID-19 Era. *Viruses* 2022; **14**(9).

1626. Song J, Zhang L, Zeng L, Xu X. Visualized Lateral Flow Assay for Dual Viral RNA Fragment Detection. *Anal Chem* 2023; **95**(30): 11187-92.

1627. Song Y, Hu H, Xiao K, et al. A Synthetic SARS-CoV-2-Derived T-Cell and B-Cell Peptide Cocktail Elicits Full Protection against Lethal Omicron BA.1 Infection in H11-K18-hACE2 Mice. *Microbiol Spectr* 2023; **11**(2): e0419422.

1628. Soriano V, de-Mendoza C, Edagwa B, et al. Oral antivirals for the prevention and treatment of SARS-CoV-2 infection. *AIDS Rev* 2022; **24**(1): 41-9.

1629. Stafylis C, Pernet O, Hernandez-Tamayo C, et al. Surveillance of Severe Acute Respiratory Syndrome Coronavirus 2 and Variants Using Digital Droplet Polymerase Chain Reaction at a Large University and Healthcare System in California. *Open Forum Infect Dis* 2023; **10**(4): ofad147.

1630. Stirrup O, Shrotri M, Adams NL, et al. Clinical Effectiveness of SARS-CoV-2 Booster Vaccine Against Omicron Infection in Residents and Staff of Long-term Care Facilities: A Prospective Cohort Study (VIVALDI). *Open Forum Infect Dis* 2023; **10**(1): ofac694.

1631. Stoll S, Desai S, Levit E. A retrospective evaluation of seroconversion after COVID-19 during the early Omicron wave in fully vaccinated multiple sclerosis patients receiving anti-CD20 therapies. *Mult Scler Relat Disord* 2023; **71**: 104574.

1632. Stuempfig ND, Toulouie S, Durant EJ, Nadir NA. Comparison of the Characteristics of Intubation Airway Barrier Devices Using a Simulated Airway Task Trainer. *Cureus* 2022; **14**(3): e22817.

1633. Stupica D, Collinet-Adler S, Kejžar N, Poljak M, Štamol T. SARS-CoV-2 Vaccination and Clinical Presentation of COVID-19 in Patients Hospitalized during the Delta- and Omicron-Predominant Periods. *J Clin Med* 2023; **12**(3).

1634. Subhash Walinjkar R, Kumbhar M, Harihar Shinde R, Chaurasia E. Real-world effect of casirivimab and imdevimab cocktail in patients infected with SARS-CoV-2 delta and omicron variants. *J Infect Dev Ctries* 2023; **17**(3): 293-301.

1635. Sun J, Li Y, Xiao LF, Shao NY, Liu M. Flattening the Curve after the Initial Outbreak of Coronavirus Disease 2019: A Data-Driven Modeling Analysis for the Omicron Pandemic in China. *Vaccines (Basel)* 2023; **11**(5).

1637. Sun P, Balinsky CA, Jiang L, et al. Antibody Responses to the SARS-CoV-2 Ancestral Strain and Omicron Variants in Moderna mRNA-1273 Vaccinated Active-Duty US Navy Sailors and Marines. *J Infect Dis* 2023; **228**(2): 149-59.

1638. Sun P, Ramos I, Coelho CH, et al. Asymptomatic or symptomatic SARS-CoV-2 infection plus vaccination confers increased adaptive immunity to variants of concern. *iScience* 2022; **25**(10): 105202.

1639. Sun Y, Wang Z, Qiu Z, Zhou C. Multi-Impacts of Spatial Self-Policing during COVID-19: Evidence from a Chinese University. *Int J Environ Res Public Health* 2022; **19**(19).

1640. Suntronwong N, Yorsaeng R, Puenpa J, et al. COVID-19 Breakthrough Infection after Inactivated Vaccine Induced Robust Antibody Responses and Cross-Neutralization of SARS-CoV-2 Variants, but Less Immunity against Omicron. *Vaccines (Basel)* 2022; **10**(3).

1641. Swart M, van der Lubbe J, Schmit-Tillemans S, et al. Booster vaccination with Ad26.COV2.S or an Omicron-adapted vaccine in pre-immune hamsters protects against Omicron BA.2. *NPJ Vaccines* 2023; **8**(1): 40.

1642. Swed S, Kashkash F, Shoib S, et al. Anxiety and depression among patient's companions during admission to the ICU in the Omicron wave of COVID-19: A cross-sectional study in Aleppo University Hospital. *PLoS One* 2022; **17**(10): e0273900.

1643. Szanyi J, Wilson T, Howe S, et al. Epidemiologic and economic modelling of optimal COVID-19 policy: public health and social measures, masks and vaccines in Victoria, Australia. *Lancet Reg Health West Pac* 2023; **32**: 100675.

1644. Tada T, Dcosta BM, Minnee J, Landau NR. Vectored Immunoprophylaxis and Treatment of SARS-CoV-2 Infection. *bioRxiv* 2023.

1645. Tadmor T, Alapi H, Rokach L. Effectiveness of nirmatrelvir plus ritonavir treatment for patients with chronic lymphocytic leukemia during the Omicron surge. *Blood* 2023; **141**(18): 2239-44.

1646. Takemae N, Doan YH, Momose F, Saito T, Kageyama T. Development of New SNP Genotyping Assays to Discriminate the Omicron Variant of SARS-CoV-2. *Jpn J Infect Dis* 2022; **75**(4): 411-4.

1647. Tan C, Wang J, Cao G, et al. Psychological changes in athletes infected with Omicron after return to training: fatigue, sleep, and mood. *PeerJ* 2023; **11**: e15580.

1648. Tan C, Wang J, Yin J, et al. The effect of prolonged closed-loop management on athletes' sleep and mood during COVID-19 pandemic: Evidence from the 2022 Shanghai Omicron Wave. *PLoS One* 2023; **18**(4): e0284858.

1649. Tan NH, Sablerolles RSG, Rietdijk WJR, et al. Analyzing the immunogenicity of bivalent booster vaccinations in healthcare workers: The SWITCH ON trial protocol. *Front Immunol* 2022; **13**: 1067749.

1650. Tang J, Randolph AG, Novak T, et al. Systemic and Lower Respiratory Tract Immunity to SARS-CoV-2 Omicron and Variants in Pediatric Severe COVID-19 and Mis-C. *Vaccines (Basel)* 2022; **10**(2).

1651. Tang S, Wang X, Tang B, et al. Threshold conditions for curbing COVID-19 with a dynamic zero-case policy derived from 101 outbreaks in China. *BMC Public Health* 2023; **23**(1): 1084.

1652. Tatsi EB, Filippatos F, Dellis C, Dourdouna MM, Syriopoulou V, Michos A. Kinetics of SARS-CoV-2 Spike Antibodies after the Second and Third Dose of the BNT162b2 COVID-19 Vaccine and Association with Epidemiological Characteristics and Breakthrough Infection in a Cohort Study of Healthcare Workers. *Microorganisms* 2023; **11**(8).

1653. Tauzin A, Gong SY, Chatterjee D, et al. A boost with SARS-CoV-2 BNT162b2 mRNA vaccine elicits strong humoral responses independently of the interval between the first two doses. *Cell Rep* 2022; **41**(4): 111554.

1654. Taytard J, Prevost B, Schnuriger A, et al. SARS-CoV-2 B.1.1.529 (Omicron) Variant Causes an Unprecedented Surge in Children Hospitalizations and Distinct Clinical Presentation Compared to the SARS-CoV-2 B.1.617.2 (Delta) Variant. *Front Pediatr* 2022; **10**: 932170.

1655. Tayyar R, Wong LK, Dahlen A, Shu E, Pandey S, Liu AY. High-titer post-vaccine COVID-19 convalescent plasma for immunocompromised patients during the first omicron surge. *Transpl Infect Dis* 2023; **25**(2): e14055.

1656. Tegally H, Wilkinson E, Martin D, et al. Global Expansion of SARS-CoV-2 Variants of Concern: Dispersal Patterns and Influence of Air Travel. *medRxiv* 2022.

1657. Tennøe S, Gheorghe M, Stratford R, Clancy T. The T Cell Epitope Landscape of SARS-CoV-2 Variants of Concern. *Vaccines (Basel)* 2022; **10**(7).

1658. Terbsiri V, Putcharoen O, Suwanpimolkul G, et al. Long-term immunogenicity in previously vaccinated healthcare workers with inactivated virus vaccine after SARS-CoV-2 infection or booster vaccination. *Vaccine X* 2023; **14**: 100334.

1659. Theparod T, Kreabkhontho P, Teparos W. Booster Dose Vaccination and Dynamics of COVID-19 Pandemic in the Fifth Wave: An Efficient and Simple Mathematical Model for Disease Progression. *Vaccines (Basel)* 2023; **11**(3).

1660. Thomas K, Grigoropoulos I, Alexopoulou P, et al. Sustained cell-mediated but not humoral responses in rituximab-treated rheumatic patients after vaccination against SARS-CoV-2. *Rheumatology (Oxford)* 2023.

1661. Tian B, Ning Z, Tu P. Temporary COVID-19 Specialized Hospital: Management Strategies for Public Health Emergencies. *J Multidiscip Healthc* 2023; **16**: 1699-704.

1662. Tiantian C, Jing Z, Yiwen M, et al. COVID-19 causing death in a rheumatoid arthritis patient who retested positive for SARS-CoV-2 RNA: A case report. *Int J Rheum Dis* 2023; **26**(5): 957-9.

1663. Tong CK, Chan YH, Leung CCD, et al. Use of high flow nasal cannula oxygen therapy for patients infected with SARS-CoV-2 outside intensive care setting. *J Thorac Dis* 2023; **15**(7): 3699-707.

1664. Tong X, McNamara RP, Avendaño MJ, et al. Waning and boosting of functional humoral immunity to SARS-CoV-2. *bioRxiv* 2022.

1665. Torres AR, Silva S, Kislaya I, et al. Impact of Lifting Mask Mandates on COVID-19 Incidence and Mortality in Portugal: An Ecological Study. *Acta Med Port* 2023.

1666. Torti C, Olimpieri PP, Bonfanti P, et al. Real-life comparison of mortality in patients with SARS-CoV-2 infection at risk for clinical progression treated with molnupiravir or nirmatrelvir plus ritonavir during the Omicron era in Italy: a nationwide, cohort study. *Lancet Reg Health Eur* 2023; **31**: 100684.

1667. Tran TT, Vaage EB, Mehta A, et al. Titers of antibodies against ancestral SARS-CoV-2 correlate with levels of neutralizing antibodies to multiple variants. *NPJ Vaccines* 2022; **7**(1): 174.

1668. Trigger SA, Ignatov AM. Strain-stream model of epidemic spread in application to COVID-19. *Eur Phys J B* 2022; **95**(11): 194.

1669. Trottier C, La J, Li LL, et al. Maintaining the Utility of COVID-19 Pandemic Severity Surveillance: Evaluation of Trends in Attributable Deaths and Development and Validation of a Measurement Tool. *Clin Infect Dis* 2023.

1670. Tsai DY, Wang CH, Schiro PG, Chen N, Tseng JY. Tracking B Cell Memory to SARS-CoV-2 Using Rare Cell Analysis System. *Vaccines (Basel)* 2023; **11**(4).

1671. Tuccori M, Convertino I, Ferraro S, et al. Preclinical discovery and development of the casirivimab + imdevimab cocktail for the treatment of novel coronavirus infection: the rise and fall. *Expert Opin Drug Discov* 2022; **17**(6): 531-46.

1672. Uday U, Tadi LJ, Islam Z, et al. Zika, Nipah and Kala-azar: Emerging lethal infectious diseases amid COVID-19 as an escalating public health threat in South India. *Ann Med Surg (Lond)* 2022; **79**: 103972.

1673. Upasani V, Townsend K, Wu MY, et al. Commercial immunoglobulin products contain neutralising antibodies against SARS-CoV-2 spike protein. *Clin Infect Dis* 2023.

1674. Uschner D, Bott M, Lagarde WH, et al. Breakthrough SARS-CoV-2 Infections after Vaccination in North Carolina. *Vaccines (Basel)* 2022; **10**(11).

1675. Utzon AN, Johansen IS, Bang LL, Pedersen RM, Andersen TE, Madsen LW. Viral dynamics of SARS-CoV-2 in immunocompromised patients. *Clin Microbiol Infect* 2023; **29**(8): 1087.e1-.e3.

1676. Vaira LA, Lechien JR, Deiana G, et al. Prevalence of olfactory dysfunction in D614G, alpha, delta and omicron waves: a psychophysical case-control study. *Rhinology* 2023; **61**(1): 32-8.

1677. Valério M, Borges-Araújo L, Melo MN, Lousa D, Soares CM. SARS-CoV-2 variants impact RBD conformational dynamics and ACE2 accessibility. *Front Med Technol* 2022; **4**: 1009451.

1678. Van Egeren D, Stoddard M, Malakar A, et al. No magic bullet: Limiting in-school transmission in the face of variable SARS-CoV-2 viral loads. *Front Public Health* 2022; **10**: 941773.

1679. van Iersel S, McDonald SA, de Gier B, et al. Number of COVID-19 hospitalisations averted by vaccination: Estimates for the Netherlands, January 6, 2021 through August 30, 2022. *Vaccine* 2023; **41**(26): 3847-54.

1680. Van Poelvoorde LAE, Picalausa C, Gobbo A, et al. Development of a Droplet Digital PCR to Monitor SARS-CoV-2 Omicron Variant BA.2 in Wastewater Samples. *Microorganisms* 2023; **11**(3).

1681. Vanmechelen B, Logist AS, Wawina-Bokalanga T, et al. Identification of the First SARS-CoV-2 Lineage B.1.1.529 Virus Detected in Europe. *Microbiol Resour Announc* 2022; **11**(2): e0116121.

1682. Vardhan S, Sahoo SK. Computational studies on the interaction of Omicron subvariants (BA.1, BA.2, and BA.3) with ACE2 and polyphenols. *Phytochem Anal* 2023.

1683. Vattiato G, Maclaren O, Lustig A, Binny RN, Hendy SC, Plank MJ. An assessment of the potential impact of the Omicron variant of SARS-CoV-2 in Aotearoa New Zealand. *Infect Dis Model* 2022; **7**(2): 94-105.

1684. Verma DK, Kapoor S, Das S, Thakur KG. Potential Inhibitors of SARS-CoV-2 Main Protease (M(pro)) Identified from the Library of FDA-Approved Drugs Using Molecular Docking Studies. *Biomedicines* 2022; **11**(1).

1685. Vihta KD, Pouwels KB, Peto TE, et al. Omicron-associated changes in SARS-CoV-2 symptoms in the United Kingdom. *Clin Infect Dis* 2022; **76**(3): e133-41.

1686. Vimercati A, De Nola R, Battaglia S, et al. Adverse Maternal Outcomes in Pregnant Women Affected by Severe-Critical COVID-19 Illness: Correlation with Vaccination Status in the Time of Different Viral Strains' Dominancy. *Vaccines (Basel)* 2022; **10**(12).

1687. Volle R, Murer L, Petkidis A, et al. Methylene blue, Mycophenolic acid, Posaconazole, and Niclosamide inhibit SARS-CoV-2 Omicron variant BA.1 infection of human airway epithelial organoids. *Curr Res Microb Sci* 2022; **3**: 100158.

1688. Wakiguchi H, Kaneko U, Sato S, Imagawa T, Narazaki H, Miyamae T. Clinical Features of COVID-19 in Pediatric Rheumatic Diseases: 2020-2022 Survey of the Pediatric Rheumatology Association of Japan. *Viruses* 2023; **15**(5).

1689. Wallace B, Chang D, O'Malley Olsen E, et al. Critical care among newborns with and without a COVID-19 diagnosis, May 2020-February 2022. *J Perinatol* 2023; **43**(6): 766-74.

1690. Wallace ZS, Davis J, Niewiadomska AM, et al. Early detection of emerging SARS-CoV-2 variants of interest for experimental evaluation. *Front Bioinform* 2022; **2**: 1020189.

1691. Wang CY, Hwang KP, Kuo HK, et al. A multitope SARS-CoV-2 vaccine provides long-lasting B cell and T cell immunity against Delta and Omicron variants. *J Clin Invest* 2022; **132**(10).

1692. Wang H, Gan M, Wu B, et al. Humoral and cellular immunity of two-dose inactivated COVID-19 vaccination in Chinese children: A prospective cohort study. *J Med Virol* 2023; **95**(1): e28380.

1693. Wang H, Wang Z, Ma L, et al. S Trimer Derived from SARS-CoV-2 B.1.351 and B.1.618 Induced Effective Immune Response against Multiple SARS-CoV-2 Variants. *Vaccines (Basel)* 2023; **11**(1).

1694. Wang H, Yuan Y, Wu B, et al. Neutralization against SARS-CoV-2 Delta/Omicron variants and B cell response after inactivated vaccination among COVID-19 convalescents. *Front Med* 2023: 1-11.

1695. Wang J, Chen Y, Huang J, et al. Prevalence of taste and smell dysfunction in mild and asymptomatic COVID-19 patients during Omicron prevalent period in Shanghai, China: a cross-sectional survey study. *BMJ Open* 2023; **13**(3): e067065.

1696. Wang J, Hu W, Wang K, Yu R, Chang L, Rong Z. Case report: Acute hepatitis in neonates with COVID-19 during the Omicron SARS-CoV-2 variant wave: a report of four cases. *Front Pediatr* 2023; **11**: 1179402.

1697. Wang J, Jiang W, Wu X, Yang M, Shao W. Role of vaccine in fighting the variants of COVID-19. *Chaos Solitons Fractals* 2023; **168**: 113159.

1698. Wang L, Berger NA, Kaelber DC, Davis PB, Volkow ND, Xu R. COVID infection severity in children under 5 years old before and after Omicron emergence in the US. *medRxiv* 2022.

1699. Wang L, Berger NA, Kaelber DC, Davis PB, Volkow ND, Xu R. COVID infection rates, clinical outcomes, and racial/ethnic and gender disparities before and after Omicron emerged in the US. *medRxiv* 2022.

1700. Wang L, Berger NA, Kaelber DC, Davis PB, Volkow ND, Xu R. Comparison of outcomes from COVID infection in pediatric and adult patients before and after the emergence of Omicron. *medRxiv* 2022.

1701. Wang L, Kainulainen MH, Jiang N, et al. Differential neutralization and inhibition of SARS-CoV-2 variants by antibodies elicited by COVID-19 mRNA vaccines. *Nat Commun* 2022; **13**(1): 4350.

1702. Wang L, Volkow ND, Davis PB, Berger NA, Kaelber DC, Xu R. COVID-19 rebound after Paxlovid treatment during Omicron BA.5 vs BA.2.12.1 subvariant predominance period. *medRxiv* 2022.

1703. Wang M, Shi J, Zhang K, et al. Efficacy and Safety of Longyizhengqi Granule in Treatment of Mild COVID-19 Patients Caused by SARS-CoV-2 Omicron Variant: A Prospective Study. *Infect Drug Resist* 2023; **16**: 1611-8.

1704. Wang Q, Jia M, Jiang M, et al. Seesaw Effect Between COVID-19 and Influenza From 2020 to 2023 in World Health Organization Regions: Correlation Analysis. *JMIR Public Health Surveill* 2023; **9**: e44970.

1705. Wang Q, Wang Y, Wang Y, Bi Q, Zhang Q, Wang F. Impact of improved stroke green channel process on the delay of intravenous thrombolysis in patients with acute cerebral infarction during the COVID-19 pandemic: An observational study. *Front Neurol* 2022; **13**: 998134.

1706. Wang RC, Gottlieb M, Montoy JCC, et al. Association Between SARS-CoV-2 Variants and Frequency of Acute Symptoms: Analysis of a Multi-institutional Prospective Cohort Study-December 20, 2020-June 20, 2022. *Open Forum Infect Dis* 2023; **10**(7): ofad275.

1707. Wang S, Li J, Wang S, et al. Impacts of delta and omicron variants on inactivated SARS-CoV-2 vaccine-induced T cell responses in patients with autoimmune diseases and healthy controls. *Clin Transl Med* 2023; **13**(1): e1171.

1708. Wang S, Niu P, Su Q, et al. Genomic Surveillance for SARS-CoV-2 - China, September 26, 2022 to January 29, 2023. *China CDC Wkly* 2023; **5**(7): 143-51.

1709. Wang X, Han M, Fuentes LR, et al. SARS-CoV-2 neutralizing antibody response after three doses of mRNA1273 vaccine and COVID-19 in hemodialysis patients. *Front Nephrol* 2022; **2**.

1710. Wang Y, Chen Y, Gu L, Lou L, Zhang J, Zhang K. The clinical characteristics and risk factors for severe COVID-19 in patients with COVID-19 and tuberculosis coinfection. *Front Microbiol* 2022; **13**: 1061879.

1711. Wang Y, Li J, Zhang W, et al. Extending the dosing interval of COVID-19 vaccination leads to higher rates of seroconversion in people living with HIV. *Front Immunol* 2023; **14**: 1152695.

1712. Wang Y, Yan A, Song D, et al. Biparatopic antibody BA7208/7125 effectively neutralizes SARS-CoV-2 variants including Omicron BA.1-BA.5. *Cell Discov* 2023; **9**(1): 3.

1713. Wang Z, Liu S. Internet of things (IoT) imbedded point-of-care SARS-CoV-2 testing in the pandemic and post-pandemic era. *Biosaf Health* 2022; **4**(6): 365-8.

1714. Wang Z, Wang R, Wu P, et al. Optimization of Population-Level Testing, Contact Tracing, and Isolation in Emerging COVID-19 Outbreaks: a Mathematical Modeling Study - Tonghua City and Beijing Municipality, China, 2021-2022. *China CDC Wkly* 2023; **5**(4): 82-9.

1715. Wang Z, Yang X, Mei X, et al. SARS-CoV-2-specific CD4(+) T cells are associated with long-term persistence of neutralizing antibodies. *Signal Transduct Target Ther* 2022; **7**(1): 132.

1716. Ward JL, Harwood R, Kenny S, et al. Pediatric Hospitalizations and ICU Admissions Due to COVID-19 and Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2 in England. *JAMA Pediatr* 2023; **177**(9): 947-55.

1717. Wee LE, Pang D, Chiew C, et al. Long-term real-world protection afforded by third mRNA doses against symptomatic SARS-COV-2 infections, COVID-19-related emergency attendances and hospitalizations amongst older Singaporeans during an Omicron XBB wave. *Clin Infect Dis* 2023.

1718. Wei GW. Topological AI forecasting of future dominating viral variants. *ArXiv* 2022.

1719. Wei Q, Mease PPJ, Chiorean M, et al. Risk factors for severe COVID-19 outcomes: a study of immune-mediated inflammatory diseases, immunomodulatory medications, and comorbidities in a large US healthcare system. *medRxiv* 2023.

1720. Wei-Wen Hsiao W, Sharma N, Le TN, et al. Fluorescent nanodiamond-based spin-enhanced lateral flow immunoassay for detection of SARS-CoV-2 nucleocapsid protein and spike protein from different variants. *Anal Chim Acta* 2022; **1230**: 340389.

1721. Weigert M, Beyerlein A, Katz K, Schulte R, Hartl W, Küchenhoff H. Vaccine-Induced or Hybrid Immunity and COVID-19-Associated Mortality During the Omicron Wave. *Dtsch Arztebl Int* 2023; **120**(13): 213-20.

1722. Wells CR, Pandey A, Gokcebel S, et al. Quarantine and serial testing for variants of SARS-CoV-2 with benefits of vaccination and boosting on consequent control of COVID-19. *PNAS Nexus* 2022; **1**(3): pgac100.

1723. Wen R, Li J, Wang X, et al. Pre-Existing Allergies Patients with Higher Viral Load and Longer Recovery Days Infected by SARS-CoV-2 Omicron BA.2 in Shanghai, China, 2022. *J Asthma Allergy* 2023; **16**: 903-13.

1724. Weng C, Xie R, Han G, et al. Safety and Efficacy of Paxlovid Against Omicron Variants of Coronavirus Disease 2019 in Elderly Patients. *Infect Dis Ther* 2023; **12**(2): 649-62.

1725. Werzowa J, Behanova M, Handisurya A, et al. Response to Immunization against SARS-CoV-2 and Risk of Omicron Infection in Dialysis Patients: A Prospective Cohort Study. *J Clin Med* 2023; **12**(15).

1726. White LA, McCorvie R, Crow D, Jain S, León TM. Assessing the accuracy of California county level COVID-19 hospitalization forecasts to inform public policy decision making. *BMC Public Health* 2023; **23**(1): 782.

1727. Wilks SH, Muhlemann B, Shen X, et al. Mapping SARS-CoV-2 antigenic relationships and serological responses. *bioRxiv* 2023.

1728. Wilson C. Long covid risk with omicron may be half that of delta. *New Sci* 2022; **254**(3392): 12.

1729. Wong JY, Cheung JK, Lin Y, et al. Intrinsic and effective severity of COVID-19 cases infected with the ancestral strain and Omicron BA.2 variant in Hong Kong. *J Infect Dis* 2023.

1730. Wong SM, Chen EY, Suen YN, et al. Increased psychological distress among young people before and during the fifth wave of COVID-19 after two years of pandemic in Hong Kong: a 6-month longitudinal study. *BMC Psychiatry* 2023; **23**(1): 433.

1731. Wood DA, Aleem A, Davis D. Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2023, StatPearls Publishing LLC.; 2023.

1732. Wu H, Liao K, Yang C, et al. Psychological experience of Juvenile patients' parents in Fangcang shelter hospital during the Omicron wave of COVID-19 pandemic in Shanghai, China: a qualitative study. *BMC Public Health* 2022; **22**(1): 2203.

1733. Wu Q, Chan SC, Lee TT, et al. Evaluating the Patient Boarding during Omicron Surge in Hong Kong: Time Series Analysis. *J Med Syst* 2023; **47**(1): 76.

1734. Wu S, Li Y, Mishra S, et al. Effect of the incremental protection of previous infection against Omicron infection among individuals with a hybrid of infection- and vaccine-induced immunity: a population-based cohort study in Canada. *Int J Infect Dis* 2023; **127**: 69-76.

1735. Xing Y, Li Y, Feng L, et al. Predictors of COVID-19 Severity in Elderly Patients Infected by Omicron in China, 18 December 2022-5 February 2023. *Infect Drug Resist* 2023; **16**: 4505-18.

1736. Xiong X, Li J, Huang B, et al. Economic Value of Vaccines to Address the COVID-19 Pandemic in Hong Kong: A Cost-Effectiveness Analysis. *Vaccines (Basel)* 2022; **10**(4).

1737. Xu J, Cao Z, Miao C, Zhang M, Xu X. Predicting omicron pneumonia severity and outcome: a single-center study in Hangzhou, China. *Front Med (Lausanne)* 2023; **10**: 1192376.

1738. Xu N, Pan J, Sun L, et al. Interferon α-2b spray shortened viral shedding time of SARS-CoV-2 Omicron variant: An open prospective cohort study. *Front Immunol* 2022; **13**: 967716.

1739. Xu XR, Zhou S, Jin GQ, et al. Reyanning Mixture on Asymptomatic or Mild SARS-CoV-2 Infection in Children and Adolescents: A Randomized Controlled Trial. *Chin J Integr Med* 2023.

1740. Xu Y, Li H, Kirui B, et al. Effectiveness of COVID-19 Vaccines over 13 Months Covering the Period of the Emergence of the Omicron Variant in the Swedish Population. *Vaccines (Basel)* 2022; **10**(12).

1741. Yadav O, Kumar M, Mittal H, Yadav K, Seidel V, Ansari A. Theoretical exploration on structures, bonding aspects and molecular docking of α-aminophosphonate ligated copper complexes against SARS-CoV-2 proteases. *Front Pharmacol* 2022; **13**: 982484.

1742. Yadav PD, Mohandas S, Shete A, et al. Protective efficacy of COVAXIN® against Delta and Omicron variants in hamster model. *iScience* 2022; **25**(10): 105178.

1743. Yaesoubi R, You S, Xi Q, et al. Simple decision rules to predict local surges in COVID-19 hospitalizations during the winter and spring of 2022. *medRxiv* 2021.

1744. Yamagishi H, Tamura D, Aoyagi J, et al. Impact of the omicron phase on a highly advanced medical facility in Japan. *Front Pediatr* 2023; **11**: 1201825.

1745. Yan J, Cai H, Wang J, et al. Nirmatrelvir/ritonavir for patients with SARS-CoV-2 infection and impaired kidney function during the Omicron surge. *Front Pharmacol* 2023; **14**: 1147980.

1746. Yan J, Steiger SN, Kodama R, et al. Predictors of Coronavirus Disease 2019 Hospitalization After Sotrovimab in Patients With Hematologic Malignancy During the BA.1 Omicron Surge. *Clin Infect Dis* 2023; **76**(8): 1476-82.

1747. Yan L, Wu J, Fan X, et al. Analysis of risk factors and short-term prognostic factors of arrhythmia in patients infected with mild/moderate SARS-CoV-2 Omicron variant. *Front Med (Lausanne)* 2023; **10**: 1186200.

1748. Yang H, Chen Y, Jiang D, et al. Preclinical evaluation of ISH0339, a tetravalent broadly neutralizing bispecific antibody against SARS-CoV-2 with long-term protection. *Antib Ther* 2023; **6**(2): 97-107.

1749. Yang H, Wang Z, Zhang Y, et al. Clinical characteristics and factors for serious outcomes among outpatients infected with the Omicron subvariant BF.7. *J Med Virol* 2023; **95**(8): e28977.

1750. Yang W, Yan J, Liu R, et al. Ultra-sensitive specific detection of nucleic acids in pathogenic infections by Ta(2)C-MXene sensitization-based ultrafine plasmon spectroscopy combs. *Sens Actuators B Chem* 2023; **387**: 133785.

1751. Yang X, Hou C, Shen Y, et al. Two-Year Health Outcomes in Hospitalized COVID-19 Survivors in China. *JAMA Netw Open* 2022; **5**(9): e2231790.

1752. Yang Y. How the emergence of the omicron variant may change people's attitudes toward the COVID-19 pandemic. *Front Psychol* 2022; **13**: 922470.

1753. Yang Y, Wu Y, Zhang W, et al. Infection with the SARS-CoV-2 Omicron variant in children with congenital heart disease: A case series study during Shanghai epidemic. *Front Cardiovasc Med* 2022; **9**: 1001780.

1754. Yang Y, Zhao R, Wang Y, et al. Rapid and universal detection of SARS-CoV-2 and influenza A virus using a reusable dual-channel optic fiber immunosensor. *J Med Virol* 2022; **94**(11): 5325-35.

1755. Yao X, Zhang Z, Mei Q, et al. A highly sensitive bead-based flow cytometric competitive binding assay to detect SARS-CoV-2 neutralizing antibody activity. *Front Immunol* 2022; **13**: 1041860.

1756. Ye F, Huang B, Zhao L, Deng Y, Ren J, Tan W. Novaferon Effectively Inhibits Ancestral SARS-CoV-2 and Omicron Variant in Vitro, 2022. *China CDC Wkly* 2022; **4**(23): 509-12.

1757. Ye J, Shao X, Yang Y, Zhu F. Predicting the negative conversion time of nonsevere COVID-19 patients using machine learning methods. *J Med Virol* 2023; **95**(4): e28747.

1758. Yi Y, Han X, Cui X, et al. Safety and Immunogenicity of the Inactivated COVID-19 Vaccine Booster in People Living with HIV in China. *Vaccines (Basel)* 2023; **11**(6).

1759. Yin J, Cong X, Wang N, et al. Thrombosis and lymphocyte subsets of COVID-19 omicron BA.2 variant patients with cancer. *Front Oncol* 2022; **12**: 1048999.

1760. Yogurtcu ON, Funk PR, Forshee RA, Anderson SA, Marks PW, Yang H. Benefit-risk assessment of Covid-19 vaccine, MRNA (MRNA-1273) for males age 18-64 years. *Vaccine X* 2023; **14**: 100325.

1761. Yorsaeng R, Atsawawaranunt K, Suntronwong N, et al. SARS-CoV-2 Antibody Dynamics after COVID-19 Vaccination and Infection: A Real-World Cross-Sectional Analysis. *Vaccines (Basel)* 2023; **11**(7).

1762. You SD, Kim JH, You J. Clinical characteristics and short-term outcomes of multisystem inflammatory syndrome in a country with a high prevalence of KD. *Front Pediatr* 2023; **11**: 1088529.

1763. Yousaf Z, Khan MA, Asghar MS, Zaman M, Ahmed M, Tahir MJ. COVID-19 Omicron variant - Time for airborne precautions. *Ann Med Surg (Lond)* 2022; **78**: 103919.

1764. Yu B, Li Q, Chen J, He D. The impact of COVID-19 vaccination campaign in Hong Kong SAR China and Singapore. *Infect Dis Model* 2023; **8**(1): 101-6.

1765. Yu B, Li S, Tabata T, et al. Accelerating PERx reaction enables covalent nanobodies for potent neutralization of SARS-CoV-2 and variants. *Chem* 2022; **8**(10): 2766-83.

1766. Yu B, Xu C, Huang S, et al. Development of a universal real-time RT-PCR assay for detection of pan-SARS-coronaviruses with an RNA-based internal control. *Front Microbiol* 2023; **14**: 1181097.

1767. Yu H, Liu H, Yang Y, Guan X. Development and Evaluation of a Rapid Neutralizing Antibody Assay for COVID-19 Vaccination. *ACS Omega* 2022; **7**(41): 36254-62.

1768. Yu P, Bian X, Xie Z, et al. Risk factor analysis of omicron patients with mental health problems in the Fangcang shelter hospital based on psychiatric drug intervention during the COVID-19 pandemic in Shanghai, China. *Front Psychiatry* 2023; **14**: 1100849.

1769. Yu SY, Xie JR, Luo JJ, et al. Liver test abnormalities in asymptomatic and mild COVID-19 patients and their association with viral shedding time. *World J Hepatol* 2022; **14**(11): 1953-63.

1770. Yu T, Dong J, Qi Q, et al. A Nomogram for Predicting Delayed Viral Shedding in Non-Severe SARS-CoV-2 Omicron Infection. *Infect Drug Resist* 2023; **16**: 2487-500.

1771. Yu Y, Zhou JXY, Li B, et al. A quantitative RT-qLAMP for the detection of SARS-CoV-2 and human gene in clinical application. *Microb Biotechnol* 2022; **15**(10): 2619-30.

1772. Yuan A, Atanasov V, Parra PNB, et al. Understanding COVID-19 Vaccine Effectiveness Against Death Using a Novel Measure: COVID Excess Mortality Percentage. *Res Sq* 2022.

1773. Zachrdla M, Savastano A, Ibáñez de Opakua A, Cima-Omori MS, Zweckstetter M. Contributions of the N-terminal intrinsically disordered region of the severe acute respiratory syndrome coronavirus 2 nucleocapsid protein to RNA-induced phase separation. *Protein Sci* 2022; **31**(9): e4409.

1774. Zahradník J, Nunvar J, Schreiber G. Perspectives: SARS-CoV-2 Spike Convergent Evolution as a Guide to Explore Adaptive Advantage. *Front Cell Infect Microbiol* 2022; **12**: 748948.

1775. Zambrano LD, Newhams MM, Olson SM, et al. BNT162b2 mRNA Vaccination Against Coronavirus Disease 2019 is Associated With a Decreased Likelihood of Multisystem Inflammatory Syndrome in Children Aged 5-18 Years-United States, July 2021 - April 2022. *Clin Infect Dis* 2023; **76**(3): e90-e100.

1776. Zaqout A, Almaslamani MA, Chemaitelly H, et al. Effectiveness of the neutralizing antibody sotrovimab among high-risk patients with mild-to-moderate SARS-CoV-2 in Qatar. *Int J Infect Dis* 2022; **124**: 96-103.

1777. Zee ST, Kwok LF, Kee KM, et al. Impact of COVID-19 Vaccination on Healthcare Worker Infection Rate and Outcome during SARS-CoV-2 Omicron Variant Outbreak in Hong Kong. *Vaccines (Basel)* 2022; **10**(8).

1778. Zelenkov Y, Reshettsov I. Analysis of the COVID-19 pandemic using a compartmental model with time-varying parameters fitted by a genetic algorithm. *Expert Syst Appl* 2023; **224**: 120034.

1779. Zeng G, Wang X. Ending the COVID-19 pandemic: We still have a long way to go. *J Med Virol* 2022; **94**(11): 5075-6.

1780. Zeng QL, Lv YJ, Liu XJ, et al. Clinical Characteristics of Omicron SARS-CoV-2 Variant Infection After Non-mRNA-Based Vaccination in China. *Front Microbiol* 2022; **13**: 901826.

1781. Zhai Q, Wang X, Hu C, Zhu L, Zhang C, Dai L. Label-free electrochemical immunosensor for highly sensitive COVID-19 spike protein detection. *Sens Actuators Rep* 2022; **4**: 100124.

1782. Zhang D, Zhong J, Xiong H, et al. Protective Effect of Inactivated COVID-19 Vaccines against Omicron BA.2 Infection in Guangzhou: A Test-Negative Case-Control Real-World Study. *Vaccines (Basel)* 2023; **11**(3).

1783. Zhang H, Chen W, Ye X, et al. Clinical characteristics of patients infected with novel coronavirus wild strain, Delta variant strain and Omicron variant strain in Quanzhou: A real‑world study. *Exp Ther Med* 2023; **25**(1): 62.

1784. Zhang J, Chen N, Zhao D, Zhang J, Hu Z, Tao Z. Clinical Characteristics of COVID-19 Patients Infected by the Omicron Variant of SARS-CoV-2. *Front Med (Lausanne)* 2022; **9**: 912367.

1785. Zhang J, Wang C, Huang L, Zhang J. Continuous care needs in patients with cancer receiving chemotherapy during the recent omicron wave of COVID-19 in Shanghai: A qualitative study. *Front Psychol* 2022; **13**: 1067238.

1786. Zhang P, Cai Z, He Z, et al. Analysis of 394 COVID-19 cases infected with Omicron variant in Shenzhen: impact of underlying diseases to patient's symptoms. *Eur J Med Res* 2022; **27**(1): 291.

1787. Zhang P, Luo S, Zou P, et al. Vaccination of cats with Sad23L-nCoV-S vaccine candidate against major variants of SARS-CoV-2. *Mol Ther Methods Clin Dev* 2022; **26**: 181-90.

1788. Zhang Q, Feng Z, Hao Y, et al. Dynamic Changes of ORF1ab and N Gene Ct Values in COVID-19 Omicron Inpatients of Different Age Groups - Beijing Municipality, China, November-December 2022. *China CDC Wkly* 2023; **5**(8): 180-3.

1789. Zhang S, Liu L, Meng Q, Zhang Y, Yang H, Xu G. Spatiotemporal Patterns of the Omicron Wave of COVID-19 in the United States. *Trop Med Infect Dis* 2023; **8**(7).

1790. Zhang Y, Han J, Sun F, et al. A practical scoring model to predict the occurrence of critical illness in hospitalized patients with SARS-CoV-2 omicron infection. *Front Microbiol* 2022; **13**: 1031231.

1791. Zhang Y, Li X, Zhang S, et al. Clinical Features and Predictive Nomogram of Acute Kidney Injury in Aging Population Infected with SARS-CoV-2 Omicron Variant. *J Inflamm Res* 2023; **16**: 2967-78.

1792. Zhang Y, Ma X, Yan G, et al. Immunogenicity, durability, and safety of an mRNA and three platform-based COVID-19 vaccines as a third dose following two doses of CoronaVac in China: A randomised, double-blinded, placebo-controlled, phase 2 trial. *EClinicalMedicine* 2022; **54**: 101680.

1793. Zhang Z, He Q, Zhao W, et al. A Heterologous V-01 or Variant-Matched Bivalent V-01D-351 Booster following Primary Series of Inactivated Vaccine Enhances the Neutralizing Capacity against SARS-CoV-2 Delta and Omicron Strains. *J Clin Med* 2022; **11**(14).

1794. Zhao F, Zhang S, Zhang D, et al. Illuminated border: Spatiotemporal analysis of COVID-19 pressure in the Sino-Burma border from the perspective of nighttime light. *Int J Appl Earth Obs Geoinf* 2022; **109**: 102774.

1795. Zhao J, Li Y, Chen R, et al. Real-world experience of arbidol for Omicron variant of SARS-CoV-2. *J Thorac Dis* 2023; **15**(2): 452-61.

1796. Zheng J, Hong W, Zhou C, Hong D, Yan H, Shen Y. A retrospective analysis of factors associated with the length of hospital stay in COVID-19 patients treated with Nirmatrelvir / Ritonavir. *Front Pharmacol* 2023; **14**: 1146938.

1797. Zhong W, Jiang X, Yang X, et al. The efficacy of paxlovid in elderly patients infected with SARS-CoV-2 omicron variants: Results of a non-randomized clinical trial. *Front Med (Lausanne)* 2022; **9**: 980002.

1798. Zhong Y, Sun Z, Xu P, Bai Y, Zhang Z, Wang G. The value of non-contrast chest CT in the prediction of myocardial injury in patients with the COVID-19 Omicron variant. *Sci Rep* 2023; **13**(1): 10321.

1799. Zhou K, Hu B, Zhao X, et al. Longitudinal observation of viral load in patients infected with Omicron variant and its relationship with clinical symptoms. *Front Microbiol* 2022; **13**: 1037733.

1800. Zhou R, Liu N, Li X, et al. Three-dose vaccination-induced immune responses protect against SARS-CoV-2 Omicron BA.2: a population-based study in Hong Kong. *Lancet Reg Health West Pac* 2023; **32**: 100660.

1801. Zhou SH, Zhang RY, You ZW, et al. pH-Sensitive and Biodegradable Mn(3)(PO(4))(2)·3H(2)O Nanoparticles as an Adjuvant of Protein-Based Bivalent COVID-19 Vaccine to Induce Potent and Broad-Spectrum Immunity. *ACS Appl Mater Interfaces* 2023.

1802. Zhou W, Zhang X, Zheng Y, Gao T, Liu X, Liang H. Psychological Impact of COVID-19 Lockdown and Its Evolution: A Case Study Based on Internet Searching Data during the Lockdown of Wuhan 2020 and Shanghai 2022. *Healthcare (Basel)* 2023; **11**(3).

1803. Zhou Y, Huang Y, Wu C, Yang H, Shan C, Zhou Z. Epidemiological and Clinical Characteristics of COVID-19 Outbreak in a Mental Hospital in Wenzhou, China, December 2022-January 2023. *Infect Drug Resist* 2023; **16**: 5719-28.

1804. Zhu KL, Jiang XL, Zhan BD, et al. Durability of neutralization against Omicron subvariants after vaccination and breakthrough infection. *Cell Rep* 2023; **42**(2): 112075.

1805. Zhu X, Jiang Q, Lu J, et al. COVID-19 infection in patients with haematological malignancies: A single-centre survey in the latest Omicron wave in China. *Br J Haematol* 2023; **202**(1): 31-9.

1806. Zhu XY, Lu YF, Xue F, et al. SARS-CoV-2 BA.2 (Omicron) variant infection in pediatric liver transplanted recipients and cohabitants during 2022 Shanghai outbreak: a prospective cohort. *Virol J* 2023; **20**(1): 28.

1807. Zou R, Peng L, Shu D, et al. Antiviral Efficacy and Safety of Molnupiravir Against Omicron Variant Infection: A Randomized Controlled Clinical Trial. *Front Pharmacol* 2022; **13**: 939573.

1808. Zwetsloot PP, Smit WL, Van der Kaaij NP, et al. Pre-Operative SARS-CoV-2 Testing in Asymptomatic Heart Transplantation Recipients. *Biomedicines* 2023; **11**(8).

1809. Erratum to: The health impact of long COVID during the 2021-2022 Omicron wave in Australia: A quantitative burden of disease study (International Journal of Epidemiology (dyad033) DOI: 10.1093/ije/dyad033). *International Journal of Epidemiology* 2023; **52**(3): 967.

1811. Ameratunga R, Woon ST, Steele R, Lehnert K, Leung E, Brooks AES. Severe COVID-19 is a T cell immune dysregulatory disorder triggered by SARS-CoV-2. *Expert Review of Clinical Immunology* 2022; **18**(6): 557-65.

1812. Amir O, Goldberg Y, Mandel M, et al. Initial protection against Omicron in children and adolescents by BNT162b2. 2022.

1814. Ayoubkhani D, Bosworth ML, King S, et al. Risk of Long Covid in people infected with SARS-CoV-2 after two doses of a COVID-19 vaccine: community-based, matched cohort study. 2022.

1816. Beukenhorst AL, Koch CM, Hadjichrysanthou C, et al. SARS-CoV-2 elicits non-sterilizing immunity and evades vaccine-induced immunity: implications for future vaccination strategies. *European Journal of Epidemiology* 2023; **38**(3): 237-42.

1817. Blain H, Tuaillon E, Gamon L, Pisoni A, Miot S, Picot MC. Strong Decay of SARS-CoV-2 Spike Antibodies after 2 BNT162b2 Vaccine Doses and High Antibody Response to a Third Dose in Nursing Home Residents. *Journal of the American Medical Directors Association* 2022; **23**(5): 750-3.

1818. Brasseler M, Schönecker A, Steindor M, et al. Development of restrictive eating disorders in children and adolescents with long-COVID-associated smell and taste dysfunction. *Frontiers in Pediatrics* 2022; **10**.

1819. Brown M, Gerrard J, McKinlay L, Marquess J, Sparrow T, Andrews R. Ongoing symptoms and functional impairment 12 weeks after testing positive to SARS-CoV-2 or influenza in Australia: an observational cohort study. 2023.

1820. Buchhorn R. Dysautonomia in Children with Post-Acute Sequelae of Coronavirus 2019 Disease and/or Vaccination. *Vaccines* 2022; **10**(10).

1824. Cloherty APM, Rader AG, Patel KS, et al. Berbamine suppresses intestinal SARS-CoV-2 infection via a BNIP3-dependent autophagy blockade. *Emerging Microbes and Infections* 2023; **12**(1).

1825. de Bruijn S, van Hoek AJ, Mutubuki EN, et al. Lower prevalence of Post-Covid-19 Condition following Omicron SARS-CoV-2 infection. 2023.

1826. De Rooij LPMH, Becker LM, Carmeliet P. A Role for the Vascular Endothelium in Post-Acute COVID-19? *Circulation* 2022; **145**(20): 1503-5.

1827. Dhaliwal M, Small R, Webb D, et al. Covid-19 as a long multiwave event: implications for responses to safeguard younger generations. *The BMJ* 2022; **376**.

1830. Durstenfeld MS, Peluso MJ, Lin F, et al. Association of Nirmatrelvir/Ritonavir Treatment with Long COVID Symptoms in an Online Cohort of Non-Hospitalized Individuals Experiencing Breakthrough SARS-CoV-2 Infection in the Omicron Era. 2023.

1832. Dwyer KM, Sum C, Johnson DW. Impact of COVID-19 on the worsening crisis of chronic kidney disease: the imperative to fund early detection is now. *Internal Medicine Journal* 2022; **52**(4): 680-2.

1833. Dyer AH, Fallon A, Noonan C, et al. Managing the Impact of COVID-19 in Nursing Homes and Long-Term Care Facilities: An Update. *Journal of the American Medical Directors Association* 2022; **23**(9): 1590-602.

1835. Habet V, Oliveira CR. Clinical Epidemiology of Pediatric Coronavirus Disease 2019 and its Postacute Sequelae. *Seminars in Respiratory and Critical Care Medicine* 2023; **44**(1): 66-74.

1837. Hirahata K, Nawa N, Fujiwara T. Characteristics of Long COVID: Cases from the First to the Fifth Wave in Greater Tokyo, Japan. *Journal of Clinical Medicine* 2022; **11**(21).

1839. James-Pemberton PH, Kohli S, Westlake AC, et al. Fully Quantitative Measurements of Differential Antibody Binding to a Spectrum of SARS-CoV-2 Spike Proteins: Wuhan, Alpha, Beta, Gamma, Delta, Omicron BA.1, BA.4, BA.5, BA.2.75 and BA.2.12.1. 2023.

1840. Jin X, Xu L, Lu C, et al. Traditional Chinese medicine for the COVID-19 pandemic: An online cross-sectional survey among health care workers. *European Journal of Integrative Medicine* 2023; **61**.

1842. Li Z, Chen X, Dan J, et al. Innate immune imprints in SARS-CoV-2 Omicron variant infection convalescents. *Signal Transduction and Targeted Therapy* 2022; **7**(1).

1843. Limoges MA, Quenum AJI, Chowdhury MMH, et al. SARS-CoV-2 spike antigen-specific B cell and antibody responses in pre-vaccination period COVID-19 convalescent males and females with or without post-covid condition. 2023.

1847. Marra AR, Sampaio VS, Ozahata MC, et al. Risk factors for long COVID among healthcare workers, Brazil, 2020–2022. 2023.

1849. Mirin AA. A preliminary estimate of the economic impact of long COVID in the United States. *Fatigue: Biomedicine, Health and Behavior* 2022; **10**(4): 190-9.

1852. Pacheco-Romero J. The coronavirus conundrum - Countries better prepared to face the pandemic - The Omicron variant and mutations - New vaccines? - The pregnant woman, the placenta, the fetus and the neonate. *Revista Peruana de Ginecologia y Obstetricia* 2022; **68**(1).

1856. Pongkunakorn T, Manosan T, Surawit A, et al. Immune response after SARS-CoV-2 infection with residual post COVID symptoms. 2022.

1860. Russell JA, Walley KR, Kalil AC, Fowler R. The Potential for Increasing Risk of Consent Refusal in COVID-19 Trials Considering Underlying Reasons and Responses. *Annals of the American Thoracic Society* 2022; **19**(9): 1446-7.

1861. Shamabadi A, Akhondzadeh S. Protection against the Omicron and Subsequent Coronavirus Variants: Medical-grade Masking, Third Dose Vaccination, Updating Vaccines, and Pursuing Universal Vaccine. *Avicenna Journal of Medical Biotechnology* 2022; **14**(1): 1-2.

1862. Spiliopoulos L, Vedel Sørensen AI, Bager P, et al. Post-acute symptoms four months after SARS-CoV-2 infection during the Omicron period: a nationwide Danish questionnaire study. 2022.

1863. Wadman M. Coronavirus, adenovirus, or both? Hepatitis poses mystery. *Science* 2022; **376**(6596): 906-7.

1864. Ward B, Yombi JC, Balligand JL, et al. HYGIEIA: HYpothesizing the Genesis of Infectious Diseases and Epidemics through an Integrated Systems Biology Approach. *Viruses* 2022; **14**(7).

1865. Yamamoto S, Matsuda K, Maeda K, et al. Pre-infection neutralizing antibodies, Omicron BA.5 breakthrough infection, and long COVID: a propensity score-matched analysis. 2023.